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Abstract	
Streptococcus	 pneumoniae	 is	 an	 important	bacterial	 pathogen	 causing	 significant	morbidity	and	 mortality.	 	 The	 host	 inflammatory	 response	 to	 S.	 pneumoniae	 plays	 a	 critical	 role	 in	escalating	 the	host	defence	 response	 to	deal	with	 large	bacterial	numbers,	 however	 excess	inflammation	 can	 cause	 bystander	 damage.	 	 Macrophages	 are	 a	 key	 immune	 cell	 that	mediates	recognition	of	pathogens	and	initiates	inflammatory	responses.		The	polysaccharide	capsule	 and	 toxin	 pneumolysin	 are	 important	 virulence	 factors	 that	 affect	 multiple	components	of	the	immune	system.			
	The	S.	pneumoniae	capsule	increases	inflammatory	responses	in	vitro	tissue	culture	models,	with	macrophages	providing	the	main	response.		This	was	not	dependent	on	TLR2	signalling,	phagocytosis,	 lectin	 signalling,	 or	 scavenger	 receptor	 function.	 	 Mouse	 pneumonia	 and	 rat	septic	 shock	modelling	showed	 that	 this	had	 in	vivo	correlates.	 	This	data	was	extended	by	examining	 the	 extent	 capsule	 affects	 inflammatory	 responses	 by	 using	 other	 bacteria	expressing	serotype	4	capsule,	and	serotype	4	expressing	other	serotypes’	capsules.		
Pneumolysin	decreases	inflammatory	responses	 in	vitro,	this	was	found	to	be	dependent	on	phagocytosis	 and	 partially	 by	 its	 pore	 forming	 ability.	 	 This	 was	 reflected	 by	 the	 TNF	response	 in	 mouse	 bronchoalveolar	 lavage	 fluid	 in	 a	 mouse	 model.	 	 Blockade	 of	 TNF	abrogated	differences	between	wild-type	bacteria	and	pneumolysin	deficient	mutants.	 	TNF	administration	 to	mice	 increased	 the	 ability	 of	 bronchoalveolar	 lavage	 fluid	 to	 restrict	 the	growth	of	S.	pneumoniae.	
In	 conclusion,	 capsule	 and	 pneumolysin	 have	 opposing	 roles	 in	 their	 effect	 on	 the	inflammatory	response.		The	inflammation	promoting	effects	of	capsule	impact	on	virulence,	and	 may	 increase	 morbidity	 during	 infection.	 	 The	 inflammation	 dampening	 effects	 of	pneumolysin	may	 be	 an	 important	 immune	 evasion	 strategy	 that	 explains	 its	 evolutionary	conservation	in	S.	pneumoniae.	
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1	Introduction		
1.1	Background	
1.1.1	Microbiology	
Streptococcus	 pneumoniae	 (or	 pneumococcus)	 is	 a	 Gram-positive	 lancet	 shaped	 bacterium	that	usually	grows	as	diplococci,	but	can	also	form	short	chains.	Individual	cells	are	between	0.5	 and	 1.25	 µm	 in	 diameter.	 They	 do	 not	 form	 spores	 and	 are	 non-motile.	 Like	 other	streptococci,	they	lack	catalase	and	ferment	glucose	to	lactic	acid.		When	cultured	aerobically	on	blood	agar,	 they	are	α-haemolytic,	giving	a	characteristic	green	colour	(due	to	hydrogen	peroxide	causing	the	reduction	of	haemoglobin	to	methaemoglobin).	This	is	a	trait	they	share	with	 other	 α-haemolytic	 streptococci	 such	 as	 the	 viridans	 species,	 which	 also	 colonise	 the	oropharynx.	 	 Tests	 such	 as	 optochin	 sensitivity	 or	 susceptibility	 to	 bile	 salt	 induced	 lysis	(Garcia-Suarez	Mdel,	 Vazquez	 et	 al.	 2006)	may	 be	 required	 to	 differentiate	 S.	 pneumoniae	from	 these	 commensals.	 	 However	 under	 anaerobic	 conditions,	 β-haemolysis	 (lysis	 of	 red	cells	 resulting	 in	 transparent	 agar)	may	 become	 evident	 due	 to	 the	 action	 of	 pneumolysin	(Ply),	which	is	an	oxygen	labile	cytotoxin.		S.	pneumoniae	grows	best	in	culture	at	37°C	in	5%	CO2,	 and	 clinical	 isolates	 harbour	 an	 enzyme	 named	 LytA,	 which	 induces	 autolysis	 once	culture	 has	 reached	 a	 stationary	 phase.	 	 To	 grow	 in	 culture	 the	 S.	 pneumoniae	 requires	 a	source	of	catalase	(e.g.	from	blood)	to	neutralise	the	hydrogen	peroxide	it	produces.		
The	 structure	 of	 S.	 pneumoniae	 consists	 of	 a	 cell	membrane	 that	 contains	 the	 intracellular	material	including	free	circular	DNA,	and	is	surrounded	by	a	complex	cell	wall	that	allows	the	bacterium	to	maintain	shape	and	not	lyse	due	to	osmotic	pressure.		This	is	then	surrounded	by	 a	 polysaccharide	 capsule.	 	 There	 are	 multiple	 proteins	 that	 are	 attached	 to	 the	 cell	membrane	and	cell	wall	that	contribute	to	virulence	(see	chapter	1.5	and	table	1.8).	
S.	pneumoniae	cell	wall	consists	of	peptidoglycan	(PG),	 lipoproteins,	wall	 teichoic	acid	(TA),	and	 lipoteichoic	 acid	 (LTA).	 	 Wall	 TA	 is	 covalently	 bonded	 to	 PG,	 whereas	 LTA	 is	 non-covalently	 anchored	 to	 the	 cell	 membrane	 via	 a	 diacylglycerol-containing	 lipid	 anchor	
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Figure 1.3: Basic structure of S. pneumoniae cell surface. 
Basic schematic of S. pneumoniae surface structure including the lipid cell membrane, peptidoglycan 
cell wall, polysaccharide capsule and three classes of surface protein (Jedrzejas, 2004).  
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(Weidenmaier	 and	 Peschel	 2008).	 	 Both	 TA	 and	 LTA	 contain	 phosphorylcholine	 (PCho),	which	serves	as	an	anchor	for	surface-exposed	choline-binding	proteins.				  	
	
	
	
	
	
	
	
	
	
	
Figure	1.1:	Basic	S.	pneumoniae	surface	structure	(Jedrzejas,	2004)		Schematic	of	how	S.	pneumoniae	cell	membrane	and	cell	wall	are	structured.	
	
The	first	published	S.	pneumoniae	genome	was	for	TIGR4,	a	capsular	serotype	4	strain.		This	has	 a	 circular	 genome	 containing	 2,160,837	 base	 pairs,	 with	 4-6	 ribosomal	 RNA	 operons	depending	on	strain,	and	5%	content	made	up	of	insertion	sequences	(Tettelin,	Nelson	et	al.	2001).	 The	 genomes	 of	 other	 strains	 sequenced	 demonstrate	 significant	 genomic	heterogeneity	between	strains,	with	a	core	genome	of	around	50%	of	the	genome	(Dopazo,	Mendoza	et	al.	2001,	Barocchi,	Censini	et	al.	2007,	Lanie,	Ng	et	al.	2007,	Donkor,	Stabler	et	al.	2012).			
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S.	pneumoniae	is	genetically	and	phenotypically	closely	related	to	commensal	species	such	as	
Streptococcus	 mitis,	 Streptococcus	 oralis,	 and	 Streptococcus	 infantis.	 	 Population	 genetic	analysis	suggests	 that	S.	mitis	has	evolved	 from	a	common	ancestor	of	S.	pneumoniae	 (very	similar	to	the	current	pneumococcus)	but	the	loss	of	15%	of	its	genome	including	virulence	factors	 results	 in	 a	 harmonious	 existence	 with	 its	 host.	 	 Horizontal	 transfer	 of	 genetic	material	by	S.	pneumoniae	is	common,	with	evidence	of	periodic	transfer	of	genetic	material	from	S.	mitis	to	S.	pneumoniae	(Kilian,	Riley	et	al.	2014).	Due	to	its	different	epidemiological	behaviour	compared	to	other	commensals,	with	frequent	short-lived	colonisation	episodes,	S.	
pneumoniae	 is	 exposed	 to	 a	 greater	 number	 of	 potential	 recombination	 partners.	 	 It	 is	possible	 that	a	very	 small	population	of	humans	 living	over	100,000	years	ago	 represent	a	bottleneck	for	S.	pneumoniae	and	that	the	recent	expansion	of	the	human	population	allowed	lineage-specific	expansion	of	S.	pneumoniae	(Kilian,	Poulsen	et	al.	2008).	
1.1.2	Infection	&	Disease		
1.1.2.1	Colonisation	
S.	pneumoniae	 is	a	ubiquitous	nasopharyngeal	commensal	that	occasionally	spreads	beyond	its	 usual	 ecological	 niche	 to	 cause	 disease.	 	 Over	 half	 of	 children	 under	 the	 age	 of	 2	 are	colonised,	 reducing	 to	 approximately	 8%	 of	 adults	 (Hussain,	 Melegaro	 et	 al.	 2005).		Colonisation	frequently	occurs	without	disease,	and	asymptomatic	carriage	induces	acquired	B	cell	immunity,	as	evidenced	by	circulating	serotype	specific	antibodies	(Musher,	Groover	et	al.	1997).		However,	nasopharyngeal	carriage	is	necessary	to	progress	to	disease.		In	addition,	colonisation	 is	 thought	 to	 be	 important	 in	 horizontal	 spread,	 as	 transmission	 is	 via	aerosolised	 droplet.	 	 Duration	 of	 colonisation	 reduces	 with	 age,	 likely	 due	 to	 improved	immunological	 memory	 through	 exposure	 to	 multiple	 strains,	 as	 previous	 colonisation	extends	 time	 to	 subsequent	 nasopharyngeal	 carriage	 by	 any	 strain	 (Turner,	 Turner	 et	 al.	2012).			
As	 the	 nasopharynx	 is	 the	 natural	 ecological	 niche	 for	S.	 pneumoniae,	 it	 is	 likely	 that	most	evolutionary	 pressure	 is	 dependent	 on	 successful	 colonisation	 strategies.	 	 Competition	
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between	bacterial	species	(both	pathogenic	and	non-pathogenic)	may	be	the	most	important	factor	 that	 drives	 the	 genetic	 make-up	 of	 S.	 pneumoniae,	 e.g.	 the	 production	 of	 hydrogen	peroxide	 from	 S.	 pneumoniae	 inhibits	 Neisseria	 meningitidis	 and	 Staphylococcus	 aureus	growth	(Pericone,	Overweg	et	al.	2000).		
1.1.2.2	Disease	
S.	pneumoniae	causes	a	variety	of	disease	phenotypes	including	non-invasive	disease	such	as	otitis	media	and	infective	exacerbations	of	chronic	obstructive	pulmonary	disease.	 	Invasive	disease	 phenotypes	 include	 pneumonia,	 meningitis,	 and	 septicaemia.	 	 S.	 pneumoniae	 is	responsible	for	over	800,000	deaths	a	year	in	children	under	5	(O'Brien,	Wolfson	et	al.	2009),	and	overall	 is	 likely	to	cause	well	over	a	million	deaths	a	year	worldwide,	 leaving	 it	second	only	 to	 tuberculosis	 as	 a	 cause	 of	 bacterial	 mortality	 (Walker,	 Rudan	 et	 al.	 2013).	 	 S.	
pneumoniae	 is	 responsible	 for	 almost	 half	 of	 pneumonia	 cases,	 causing	 38%	 of	 outpatient	treated	 community	 acquired	 pneumonia	 (CAP),	 27%	 of	 hospital	 treated,	 and	 27%	 of	intensive	care	unit	treated	CAP	(Welte,	Torres	et	al.	2012).			
Once	S.	pneumoniae	are	aspirated	into	the	respiratory	tract,	if	they	do	not	get	cleared	by	the	host	 immune	 response,	 bacteria	 multiple	 rapidly	 in	 the	 alveolus	 and	 spread	 through	 the	pores	 of	 Kohn	 to	 cause	 lobar	 infection.	 	 As	 a	 result	 of	 local	 inflammation	 there	 is	 the	accumulation	 of	 protein-rich	 fluid	 in	 the	 alveolar	 compartment,	 this	 is	 accompanied	 by	migration	 of	 leukocytes.	 	 This	 thick	 exudative	 fluid	 can	 solidify	 to	 form	 consolidation	 and	impair	gas	exchange.	 	Fortunately,	 if	 the	bacterial	 infection	is	cleared,	the	consolidation	can	resolve,	often	without	long-term	sequelae.	
Invasive	 pneumococcal	 disease	 (IPD)	 requires	 the	 movement	 of	 bacteria	 from	 mucosal	surfaces	through	epithelium	into	regions	of	the	body	that	are	largely	sterile.		Less	than	1%	of	
S.	pneumoniae	infections	achieve	invasive	bacteraemia,	however	at	this	stage	mortality	rates	approach	10%,	with	rates	as	high	as	25%	in	patients	with	predisposing	risk	factors	which	are	outlined	below	(Naucler,	Darenberg	et	al.	2013).			 	
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1.1.2.3	Risk	factors	for	disease	Host	 factors	 can	 increase	 the	 risk	 of	 serious	 S.	 pneumoniae	 infection;	 including	 immune	deficiency	(Lynch	and	Zhanel	2010)	(HIV,	innate	immune	signalling	defects,	immunoglobulin	(Ig)	 deficiencies,	 complement	 deficiencies,	 myeloma,	 post	 organ	 transplant),	 splenic	dysfunction	(e.g.	asplenia,	sickle	cell	disease),	and	chronic	organ	dysfunction	(Table	1.1).	The	extremes	of	age	(Table	1.2),	smoking,	alcohol	abuse,	and	influenza	increase	the	risk	of	disease	mortality.		
1.1.2.4	Diagnosis	and	Treatment	Diagnosis	 of	 S.	 pneumoniae	 infection	 is	 reliant	 on	 culturing	 the	 organism,	 urine	 antigen	testing,	or	PCR.		The	BinaxNOW	antigen	test	is	a	rapid	immunochromatographic	test	for	the	use	on	urine	 and	 cerebrospinal	 fluid	 that	 detects	TA	 (Sinclair,	 Xie	 et	 al.	 2013).	 	 The	 test	 is	rapid	 and	may	 be	 positive	 in	 culture	 negative	 patients	who	 have	 already	 been	 exposed	 to	antibiotics.	 	Novel	multiplex	urine	capsular	antigen	 tests	are	also	useful	 (Huijts,	Pride	et	al.	2013).	Nucleic	acid	amplification	is	also	widely	available;	lytA	quantitative	real-time	PCR	had	a	sensitivity	of	82.2%	and	a	specificity	of	92.0%	in	respiratory	samples	(Albrich,	Madhi	et	al.	2012).	 	 All	 these	 techniques	 pick	 up	 culture	 negative	 infection,	 suggesting	 epidemiological	estimates	of	disease	based	on	culture	are	likely	to	be	underestimates.			
Antibiotic	therapy	is	the	mainstay	of	treatment	for	established	infection	with	S.	pneumoniae.		The	 mortality	 rates	 from	 S.	 pneumoniae	 pneumonia	 have	 dropped	 from	 50%	 in	 the	 pre-antibiotic	 era	 to	 <20%	 now.	 	 Delay	 of	 as	 little	 as	 4	 hours	 in	 antibiotic	 administration	 is	associated	 with	 increased	 mortality	 (Lujan,	 Gallego	 et	 al.	 2006).	 	 In	 the	 clinical	 setting	antibiotics	are	given	empirically	for	the	clinical	syndrome	before	an	organism	identified,	with	guidelines	tailored	for	local	antibiotic	resistant	patterns.		If	there	is	no	suggestion	of	β-lactam	resistance,	first	line	treatment	is	with	a	penicillin	or	a	cephalosporin.	
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Table	1.1:	Odds	Ratios	 for	 IPD	compared	 to	 individuals	with	no	risk	 factors,	adapted	
from	(van	Hoek,	Andrews	et	al.	2012)	
Chronic	
disease	
Acquisition	
of	IPD	in		
2-15	year	
olds	
IPD	
mortality	
in	2-15	
year	olds	
Acquisition	
of	IPD	in	
16-65	year	
olds	
IPD	
mortality	
in	16-65	
year	olds	
Acquisition	
of	IPD	>65	
year	olds	
IPD	
mortality	
in	IPD	in	
>65	year	
olds	
Splenic	
dysfunction	 4.7	 20.9	 2.3	 2.0	 0.7	 0.3	
Chronic	
respiratory	
disease	
12.7	 6.6	 16.8	 3.9	 5.1	 1.2	
Chronic	
heart	
disease	
4.1	 6.5	 6.9	 4.3	 3.0	 1.4	
Chronic	
kidney	
disease	
11.7	 1.7	 6.5	 6.2	 0.9	 1.9	
Chronic	liver	
disease	 29.6	 7.0	 33.3	 10.3	 7.2	 2.8	
Diabetes	
mellitus	 3.8	 Unknown	 4.6	 3.2	 2.3	 1.0	
Immunosup
pression	
(not	HIV)	
41	 2.0	 17.1	 3.2	 11.7	 1.0	
HIV	 100.8	 Unknown	 61.2	 1.6	 5.3	 Unknown	
Table	 1.2:	 Odds	 Ratios	 for	 30-day	 mortality	 due	 to	 IPD,	 adapted	 from	 (Naucler,	
Darenberg	et	al.	2013)	
Host	Factor	 Adjusted	odds	
ratio	(OR)	
Age			 >85	 29.4	75-84	 11.3	65-74	 7.1	55-64	 4.8	45-54	 2.6	<45	 1	(reference)	
Sex	 Male	 1.55	Female	 1	(reference)	
Smoking	 Yes	 1.79	No	 1	(reference)	
Alcohol	
abuse	 Yes	 3.82	No	 1	(reference)	
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1.1.2.5	Vaccine	prevention	Vaccination	 is	widely	 used	 to	 reduce	 the	 burden	 of	 S.	 pneumoniae	 disease.	 	 Vaccines	were	initially	based	on	a	whole	cell	killed	vaccine	that	did	not	protect	against	pneumonia	for	more	than	2	months	(Grabenstein	and	Klugman,	2012),	then	more	recently	on	the	polysaccharide	capsule,	 which	 was	 the	 first	 non-protein	 antigen	 described.	 	 A	 23-valent	 vaccine	(Pneumovax)	 covers	23	 common	disease-causing	 serotypes	 (1,	 2,	 3,	 4,	 5,	 6B,	 7F,	 8,	 9N,	 9V,	10A,	 11A,	 12F,	 14,	 15B,	 17F,	 18C,	 19F,	 19A,	 20,	 22F,	 23F,	 and	 33F).	 	 This	 induces	 B	lymphocytes	 to	 create	 appropriate	 antibodies	 by	multipoint	 recognition	 of	 polysaccharide.		As	children	have	relatively	immature	B	cells	this	vaccine	is	not	effective	in	this	critical	group	who	 host	 the	 most	 colonisation	 events	 and	 facilitate	 horizontal	 infection.	 	 Conjugating	capsular	 polysaccharide	 to	 a	 carrier	 protein	 elicits	 a	more	 effective	 response,	 and	 this	 has	become	the	mainstay	of	childhood	vaccination	programmes.		The	most	recent	pneumococcal	conjugated	polyvalent	vaccine	(PCV,	Prevenar)	covers	13	serotypes	(1,	3,	4,	5,	6A,	6B,	7F,	9V,	14,	 18C,	 19A,	 19F,	 and	 23F),	 though	 the	 preceding	 10	 valent	 vaccine	 is	 still	 widely	 used	(covering	serotypes	1,	4,	5,	6B,	7F,	9V,	14,	18C,	19F	and	23F).		The	capsular	polysaccharides	are	individually	conjugated	to	CRM197,	a	non-toxic	diphtheria	toxoid	(Song,	Dagan	et	al.	2012)	which	is	expensive	and	does	not	afford	cover	to	the	other	80	serotypes	currently	known.		
1.1.3	Molecular	epidemiology	Given	 the	 enormous	 genetic	 variation	 evident	 in	 S.	 pneumoniae	 molecular	 epidemiology,	techniques	 have	 been	 developed	 to	 identify	 subtypes	 and	 categorise	 cultured	 isolates,	allowing	for	surveillance	and	tracking	of	outbreaks.			
1.1.3.1	Capsular	Serotypes	Variations	in	capsule	composition	have	led	to	the	identification	of	at	least	93	serotypes	of	S.	
pneumoniae,	 grouped	 into	 46	 antigenically	 similar	 serogroups	 (Table	 1.3),	 which	 exhibit	different	 propensities	 for	 causing	 disease.	 	 The	 differential	 virulence	 of	 the	 serotypes	 is	thought	 largely	 to	 be	 due	 to	 variation	 in	 capsule	 structure.	 	 Invasive	 disease	 potential	 of	different	 serotypes	 can	 be	 calculated	 from	 rates	 of	 invasive	 disease	 compared	 to	 the	
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frequency	of	nasopharyngeal	carriage	in	the	population.		Serotypes	1,	4,	7F,	18C	and	14	have	greater	 invasive	 disease	 potential	whereas	 serotypes	 6A,	 6B,	 23F,	 9V,	 and	 3	 are	 relatively	poor	at	causing	IPD.		These	data	are	taken	from	children	in	Finland	(Hanage,	Kaijalainen	et	al.	2005),	 when	 comparing	 children	 nasopharyngeal	 carriage	 with	 all	 invasive	 isolates	 in	Sweden	(Sandgren,	Albiger	et	al.	2004)	and	Oxford,	UK	(Brueggemann,	Griffiths	et	al.	2003).		However,	all	3	groups	found	different	serotypes	were	overrepresented	in	the	invasive	group.		This	may	reflect	 local	prevalence	data	 that	could	skew	the	overall	 interpretation	of	 results.		Some	authors	have	also	found	significant	variation	in	disease	induction	within	serotype,	with	the	 same	 studies	 noting	more	 similarities	 in	 invasive	 potential	 associated	with	 clonal	 type	but	varying	serotype,	due	to	serotype	switch	events.		The	mouse	studies	also	noted	variation	in	 disease	 susceptibility	 by	 mouse	 strain,	 implicating	 host	 factors	 being	 as,	 if	 not	 more	important	than	serotype	(Sandgren,	Albiger	et	al.	2005).	
Some	serotypes	are	overrepresented	in	fatal	cases	of	infection	(serotypes	3,	6A,	6B,	9N,	19F,	23F,	 31)	 (Harboe,	 Thomsen	 et	 al.	 2009,	 Weinberger,	 Harboe	 et	 al.	 2010).	 	 Serotype	prevalence	varies	widely	by	geographical	region	(Figure	1.2).		Serotypes	associated	with	high	carriage	prevalence	and	reduced	invasiveness	are	more	heavily	encapsulated.		Paradoxically	invasive	 serotypes	 (1,	 7F,	 14)	 have	 relatively	 reduced	mortality	 rates.	 	 	 This	 suggests	 that	‘invasive	 serotypes’	 act	 as	primary	pathogens;	more	 likely	 to	 affect	 the	 immunocompetent,	whereas	 less	 invasive	 serotypes	 cause	 infection	 in	 patients	 with	 underlying	 disease	 i.e.	causing	‘opportunistic	infection’	(Sjostrom,	Spindler	et	al.	2006).			
In	a	UK	study	serotypes	14,	1,	8,	3,	19A,	5,	7F,	4	and	6A/C	were	the	commonest	causes	of	CAP,	with	less	invasive	serotypes	causing	more	disease	and	mortality	with	increasing	age	(Bewick,	Sheppard	et	al.	2012).		Serotype	5	and	14	were	overrepresented	in	non-invasive	disease.		In	American	 studies	 serotype1,	 7F,	 19A	 and	 3	 are	 overrepresented	 as	 causes	 of	 complicated	pneumonia	(Fletcher,	Schmitt	et	al.	2014).		Serotype	1	was	also	the	commonest	cause	of	CAP	in	Spain,	whereas	19A	was	more	prominent	in	the	Asia-Pacific	region.	 	In	the	UK,	serotype1	predominated	 in	 causing	 empyema	 (McKee,	 Ives	 et	 al.	 2011),	 and	 serotype3	 caused	 most	
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bronchopleural	 fistulas.	 	 In	 another	 Spanish	 study	 serotype1,	 5,	 7F,	 and	 14	 caused	 most	empyemas	 (Fletcher,	 Schmitt	 et	 al.	 2014).	 	 Overall	 cases	 of	 complicated	 S.	 pneumoniae	pneumonia	and	empyema	have	increased	over	the	past	few	decades.		Though	these	data	may	change	as	all	the	above	serotypes	are	covered	by	the	PCV13	vaccine.	 	There	is	less	serotype	variation	in	meningitis	mortality,	suggesting	that	host	factors	may	be	more	important	in	this	disease	 setting,	 though	 serotypes	 6	 and	 14	 are	 the	 most	 frequently	 isolated	 from	cerebrospinal	 fluid	 (CSF)	 (Hausdorff,	 Bryant	 et	 al.	 2000).	 	 Risk	 factors	 for	 IPD	 associated	respiratory	 failure	 include:	 age	 >50	 years,	 chronic	 heart	 or	 lung	 disease,	 and	 infections	 by	serotypes	3,	19A,	and	19F,	all	of	which	are	heavily	encapsulated	(Burgos,	Lujan	et	al.	2014).	However	 serotype	 8	 has	 a	 thick	 capsule	 and	 no	 increase	 in	 risk	 of	 respiratory	 failure,	indicating	 that	 the	 degree	 of	 encapsulation	 is	 not	 the	 sole	 factor	 that	 is	 associated	 with	serotype	dependent	disease.		
1.1.3.2	Sequence	Typing	
S.	 pneumoniae	 can	 also	 be	 categorised	 based	 on	 its	 genetic	 sequence	 type.	 	 Multi-locus	sequence	 typing	 (MLST)	 classifies	 S.	 pneumoniae	 based	 on	 the	 sequence	 of	 seven	 core	housekeeping	gene	fragments	(Hanage,	Kaijalainen	et	al.	2005).		By	tracking	polymorphisms	in	these	genes,	closely	related	isolates	can	be	identified.		A	number	of	isolates	responsible	for	invasive	disease	from	different	countries	were	of	the	same	sequence	type,	but	not	necessarily	the	 same	 serotype	 (Coffey,	 Daniels	 et	 al.	 1999),	 suggesting	 clonal	 expansion	 with	 the	acquisition	of	differing	capsular	polysaccharides	by	horizontal	gene	transfer,	explaining	the	variety	 within	 serotypes.	 	 S.	 pneumoniae	 strains	 of	 different	 sequence	 type	may	 therefore	have	 distinct	 virulence	 phenotypes	 independent	 of	 capsular	 polysaccharide	 (Sjostrom,	Spindler	et	al.	2006).	 	 It	has	been	suggested	that	clonal	expansion	of	S.	pneumoniae	may	be	more	 important	 in	 isolates	 responsible	 for	 invasive	 disease	 than	 isolates	 responsible	 for	nasopharyngeal	colonisation	(Donkor,	Stabler	et	al.	2012).			 	
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Table	1.3:	Serotypes	and	serogroups	adapted	from	(Henrichsen	1995)	
Type	 Cross	reactions	by	capsular	reaction	 Type	 Cross	reactions	by	capsular	reaction	1	 1a	 19C	 	19a,	19c,	19f,	7h	2	 2a	 20	 	20a,	20b,	7g	3	 3a	 21	 21a	4	 4a	 22F		 22a,	22b	5	 5a	 22A		 22a,	22c	6A	 6a,	6b	 23F		 23a,	23b,	18b	6B	 6a,	6c	 23A		 23a,	23c,	15a	6C	 6a,	6b	 23B		 23a,	23b,	23d	7F		 7a,	7b	 24F	 24a,	24b,	24d,	7h	7A	 7a,	7b,	7c	 24A	 24a,	24c,	24d	7B	 7a,	7d,	7e,	7h	 24B	 24a,	24b,	24e,	7h	7C	 7a,	7d,	7f,	7g,	7h	 25F		 25a,	25b	8	 8a	 25A		 25a,	25c,	38a	9A	 9a,	9c,	9d	 27	 27a,	27b	9L		 9a,	9b,	9c,	9f	 28F	 28a,	28b,	16b,	23d	9N		 9a,	9b,	9e	 28A		 28a,	28c,	23d	9V		 9a,	9c,	9d,	9g	 29	 29a,	29b,	13b	10F	 10a,	10b	 31	 31a,	20b	10A	 10a,	10c,	10d	 32F	 32a,	27b	10B	 10a,	10b,	10c,	10d,	10e	 32A		 32a,	32b,	27b	10C	 10a,	10b,	10c,	10f	 33F		 33a,	33b,	33d	11F		 11a,	11b,	11e,	11g	 33A		 33a,	33b,	33d,	20b	11A	 11a,	11c,	11d,	11e	 33B		 33a,	33c,	33d,	33f	11B	 11a,	11b,	11f,	11g	 33C		 33a,	33c,	33e	11C		 11a,	11b,	11c,	11d,	11f	 33D		 33a,	33c,	33d,	33f,	6a	11D		 11a,	11b,	11c,	11e	 34	 34a,	34b	12F		 12a,	12b,	12d	 35F		 35a,	35b,	34b	12A	 12a,	12c,	12d	 35A	 35a,	35c,	20b	12B	 12a,	12b,	12c,	12e	 35B		 35a,	35c,	29b	13	 13a,	13b	 35C		 35a,	35c,	20b,	42a	14	 14a	 36	 36a,	9e	15F	 15a,	15b,	15c,	15f	 37	 37a	15A	 15a,	15c,	15d,	15g	 38	 38a,	25b	15B	 15a,	15b,	15d,	15e,	15h	 39	 39a,	10d	15C	 15a,	15d,	15e	 40	 40a,	7g,	7h	16F		 16a,	16b,	11d	 41F		 41a,	41b	16A	 16a,	16c	 41A		 41a	17F		 17a,	17b	 42	 42a,	20b,	35c	17A	 17a,	17c	 43	 43a,	43b	18F		 18a,	18b,	18c,	18f	 44	 44a,	44b,	12b,	12d	18A	 18a,	18b,	18d	 45	 45a	18B	 18a,	18b,	18e,	18g	 46	 46a,	12c,	44b	18C	 18a,	18b,	18c,	18e	 47F	 	47a,	35a,	35b	19F		 19a,	19b,	19d	 47A		 47a,	43b	19A	 19a,	19c,	19d	 48	 48a	19B		 19a,	19c,	19e,	7h	 	 	
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Figure	 1.2	 Cumulative	 distribution,	 by	 global	 region,	 of	 serotypes	 causing	 paediatric	
IPD	for	the	13	serotypes	in	PCV13	and	an	aggregate	estimate	for	other	serotypes,	prior	
to	 PCV7	 introduction	 (McIntosh	 and	 Reinert	 2011);	 a	 –	 serotype	 present	 in	 PCV	 7,	 b	 –	serotype	present	in	PCV	10,	c	–	serotype	present		in	PCV	13.		 	
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1.1.3.3	Effect	of	Vaccines	on	Epidemiology	Multiple	studies	have	examined	the	effect	of	the	PCV	7	vaccine	(which	preceded	the	current	13-valent	vaccine)	on	S.	pneumoniae	infections.		While	undoubtedly	effective	in	reducing	the	total	burden	of	pneumococcal	disease	(by	>40%),	vaccination	has	resulted	in	an	increase	in	nasopharyngeal	 carriage	 and	 disease	 caused	 by	 non-vaccine	 serotypes	 (e.g.	 11A,	 16F,	 19A,	22F,	35B)	(Hsu,	Shutt	et	al.	2009,	Weinberger,	Malley	et	al.	2011).	Genetic	analysis	has	shown	that	existing	subpopulations	of	S.	pneumoniae	have	expanded	to	fill	the	ecological	niche	of	the	vaccine	serotypes	(Croucher,	Harris	et	al.	2011).			
Macrolide	 resistance	 has	 increased	 in	 both	 PCV13	 and	 non	 PCV	 13	 serotypes	 by	 2011	 in	North	America,	 and	 similarly	 penicillin	 non-susceptibility	 has	 increased	 from	3.2	 to	 11.7%	between	1998	and	2011	(Song	2012).		There	has	been	particular	concern	with	the	expansion	of	19A,	which	accounted	for	28-53%	of	penicillin	non-susceptible	isolates,	and	86%	of	which	are	macrolide	resistant.		Fortunately	19A	is	covered	by	PCV13,	but	there	is	potential	for	other	non-vaccine	serotypes	to	acquire	drug	resistance	and	then	spread	rapidly.			
PCV7	in	USA	since	2000	has	reduced	vaccine	type	invasive	disease	in	young	children	(by	551	per	100,000	infants)	as	well	as	unvaccinated	adults	(by	1300	per	100,000)	(Griffin,	Zhu	et	al.	2013).	 	 By	 2004	 hospitalisations	 from	 all	 cause	 pneumonia	 had	 also	 reduced	 in	 young	children.		In	2009,	decline	in	hospital	admissions	for	children	and	adults	have	continued,	with	an	estimated	168,000	fewer	hospitalisations	than	would	have	been	expected	pre	PCV.	
The	 introduction	 of	 the	 PCV13	 conjugate	 vaccine	 has	 reduced	 rates	 of	 nasopharyngeal	carriage	of	serotypes	contained	within	the	vaccine,	but	not	overall	carriage	rates	in	children,	suggesting	replacement	by	non-vaccine	serotypes	(van	Hoek,	Sheppard	et	al.	2014).		The	use	of	 the	 PCV13	 vaccine	 in	 over	 65s	 has	 reduced	 rates	 of	 CAP	 due	 to	 S.	 pneumoniae,	 but	 not	overall	CAP	rates,	over	the	subsequent	year	(Bonten,	Huijts	et	al.	2015).		However,	PCV13	roll	out	to	children	in	the	USA	has	reduced	overall	rates	of	CAP	in	adults	as	well	as	S.	pneumoniae	CAP	 in	 children	 and	 adults,	 suggesting	 that	 there	 are	 herd	 protective	 effects	 of	 reducing	
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nasopharyngeal	colonisation	(Simonsen,	Taylor	et	al.	2014).		PCV13	serotypes	have	a	higher	incidence	 of	 causing	 IPD	 compared	 to	 non-vaccine	 serotypes,	 so	 PCV13	 has	 had	 a	 greater	impact	on	IPD	than	CAP.			
PCV13	roll	out	in	the	UK	(2010)	has	coincided	with	a	decrease	in	incidence	rate	ratios	of	total	and	pneumococcal	hospitalised	CAP	by	0.96	and	0.84	respectively	from	an	incidence	in	2008	of	 79.9	 and	 23.4	 per	 100,000	 respectively	 (Rodrigo,	 Bewick	 et	 al.	 2015).	 	 S.	 pneumoniae	meningitis	 admission	 rates	 have	 reduced	 from	 4.45	 to	 2.03	 per	 100,000	 in	 the	 UK,	septicaemia	rates	have	reduced	from	2.81	to	1.12	(Martin,	Sadarangani	et	al.	2014),	and	the	overall	 incidence	 of	 IPD	 in	 the	UK	has	 decreased	 from	15.63	 to	 6.85	per	 100,000	 (Waight,	Andrews	 et	 al.	 2015).	 	 However,	 there	 is	 evidence	 of	 a	 slight	 increase	 in	 non-vaccine	serotypes	causing	invasive	disease	(Waight,	Andrews	et	al.	2015).	
Given	 the	 spectre	 of	 serotype	 replacement	 there	 continues	 to	 be	 work	 on	 S.	 pneumoniae	vaccines,	 ideally	that	will	act	across	all	serotypes.	 	As	such	there	is	interest	in	using	protein	antigens	that	are	expressed	by	all	S.	pneumoniae	for	example,	Ply	and	PspA	(Daniels,	Rogers	et	 al.	 2016).	 	Alternative	 strategies	 are	 also	being	 investigated,	 such	as	whole	 cell	 vaccines	using	killed	or	attenuated	bacteria	(Chimalapati,	Cohen	et	al.	2011).		 	
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1.2	Overview	of	the	Innate	Immune	Response	to	S.	pneumoniae	
1.2.1	Mucociliary	escalator	Successful	 adhesion	 to	 epithelium	 is	 a	 prerequisite	 for	 S.	 pneumoniae	 causing	 both	colonisation	 and	disease.	 	 The	 initial	 obstacle	 is	 the	mucus	 layer,	 produced	by	 goblet	 cells,	covering	 the	 ciliated	 pseudostratified	 columnar	 epithelial	 surfaces	 of	 nasopharynx	 or	 the	proximal	 bronchial	 tree.	 	 The	 viscous	 gel	 layer	 entraps	 pathogens,	 which	 are	 then	transported	by	ciliary	beating	and	coughing	 into	 the	oropharynx.	 	The	mucus	also	contains	antimicrobial	 compounds	 and	 mucins,	 which	 are	 glycoproteins	 coated	 with	 negatively	charged	sialic	acid,	 that	serve	to	bind	positively	charged	bacteria.	 	S.	pneumoniae	expresses	several	 enzymes	 that	 cleave	 sialic	 acid,	 e.g.	 NanA.	 	 Inhibition	 of	 mucociliary	 function	 by	cigarette	 smoke	 (Nuorti,	Butler	 et	 al.	 2000)	or	viral	 co-infection	 (Pittet,	Hall-Stoodley	et	 al.	2010)	increases	the	ability	of	invading	bacteria	to	establish	infection	within	the	lungs.	
1.2.2	Epithelial	Adhesion	&	Invasion	
S.	 pneumoniae	 adheres	 to	 cell	 surface	 carbohydrates,	 N-acetyl-glycosamine	 (GlcNAc),	 on	resting	 epithelium.	 	 This	 is	mediated	 by	 cell	 surface	 proteins	 on	 S.	 pneumoniae	 binding	 to	receptors	on	 the	epithelium	and	also	 contributing	 to	hydrophobic	and	electrostatic	 surface	characteristics	 contributing	 to	 physiochemical	 interactions	 (Bogaert,	De	Groot	 et	 al.	 2004).		The	adhesin	PspC	expressed	on	the	S.	pneumoniae	surface	binds	to	laminin	receptor,	which	is	expressed	on	a	variety	of	cell	 types	including	nasopharyngeal	epithelium	(Zhang,	Mostov	et	al.	2000).		
The	epithelium	acts	as	a	barrier,	preventing	pathogens	from	invading	into	tissue	and	blood.		Damage	 to	 the	 epithelium,	 in	 particular	 through	 viral	 infection,	 increases	 likelihood	of	 IPD	(Kash,	Walters	 et	 al.	 2011).	 	S.	 pneumoniae	 only	 enters	 activated	 epithelial	 and	 endothelial	cells;	 this	 is	 mediated	 by	 upregulation	 of	 cells	 surface	 platelet	 activating	 factor	 receptor	(PAFr)	and	GlcNAc	expression,	induced	by	pro-inflammatory	cytokines	(Cundell,	Weiser	et	al.	1995).	 	Adhesion	to	activated	host	cells	is	enhanced	by	PAFr,	which	recognises	PCho	on	the	
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bacterial	surface	(Cundell,	Gerard	et	al.	1995,	Ring,	Weiser	et	al.	1998).		PCho	bound	to	PAFr	has	 different	 effects	 depending	 on	 the	 cell	 involved;	 epithelial	 cells	 have	 an	 inflammatory	response	but	no	uptake	whereas	endothelial	cells	internalise	S.	pneumoniae	(Fillon,	Soulis	et	al.	2006).		
There	 are	 2	 routes	 by	 which	 S.	 pneumoniae	 has	 been	 described	 as	 invading	 through	epithelium.	 	 It	 is	 likely	 that	 both	 occur	 in	 parallel.	 	 There	 is	 evidence	 that	 binding	 to	 the	polymeric	 Ig	 receptor	 also	 facilitates	 bacterial	 uptake,	while	 the	majority	 of	S.	 pneumoniae	are	 destroyed	 in	 phagolysosomes,	 a	 few	 undergo	 trancytosis	 via	 recycling	 endosomes	through	 the	 epithelial	 layer	 (Asmat,	 Agarwal	 et	 al.	 2014).	 	 S.	 pneumoniae	 also	 translocates	across	 epithelium	by	moving	 through	 tight	 junctions	 between	 cells	 (Clarke,	 Francella	 et	 al.	2011).		Toll-like	receptor	(TLR)	stimulation	induced	upregulation	of	the	transcription	factor	SNAIL1,	which	 downregulated	 transcription	 of	 claudins	 (7	 and	 10	 particularly),	 which	 are	important	 components	 of	 tight	 junctions	 between	 epithelial	 cells.	 In	 vitro,	 polarised	 HBEC	monolayers	 had	 reduced	 transepithelial	 electrical	 resistance	 after	 incubation	 with	 S.	
pneumoniae.	 	 The	host	 evolutionary	 imperative	 for	 this	 process	 is	 likely	 to	be	 to	 allow	 the	egress	of	host	immune	cells	to	the	mucosal	surface.			
1.2.3	Antibacterial	peptides	Antibacterial	 products	 are	 found	 in	 alveolar	 lining	 fluid	 that	 assist	 in	 bacterial	 killing.		Respiratory	secretions	inhibit	the	growth	of	bacteria,	though	this	is	inhibited	by	the	addition	of	divalent	cations,	as	cationic	peptides	have	an	electrostatic	attraction	to	anionic	microbial	surfaces.	 	 Treatment	 of	 mice	 with	 aerosolised	 killed	 non	 typeable	Haemophilus	 influenzae	protected	 mice	 from	 subsequent	 challenge	 with	 aerosolised	 S.	 pneumoniae	 by	 increasing	levels	 of	 multiple	 proteins	 with	 antimicrobial	 properties	 in	 bronchoalveolar	 lavage	 fluid	(BALF)	(Clement,	Evans	et	al.	2008).		
Antibacterial	 compounds	 include	 (a)	 lactoferrin,	 which	 sequesters	 free	 iron	 required	 for	bacterial	growth	and	oxidises	bacterial	cell	membranes,	(b)	lysozyme,	which	breaks	down	PG	
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in	 bacterial	 cell	 walls;	 and	 (c)	 a	 wide	 range	 of	 antimicrobial	 peptides	 (e.g.	 defensins	 and	cathelicidin)	 that	 form	 pores	 in	 bacterial	 cell	 surfaces	 thereby	 lysing	 invading	 pathogens.		The	efficacy	of	these	soluble	components	of	mucosal	defences	against	S.	pneumoniae	has	been	poorly	defined.		
Lactoferrin	is	an	iron	binding	protein	found	in	neutrophil	granules	and	epithelial	secretions.		It	sequesters	 iron	that	 is	essential	 for	bacterial	respiration,	but	also	has	direct	microbicidal	effects.	 	S.	 pneumoniae	 is	 relatively	 resistant	 to	 lactoferrin	 as	 it	 is	 bound	 by	 pneumococcal	surface	protein	A	(PspA),	which	blocks	its	activity	(Shaper,	Hollingshead	et	al.	2004).			
Similarly,	while	 lysozyme	can	restrict	 the	growth	of	S.	pneumoniae,	modifications	 to	 its	 cell	wall	 structure	render	 it	 relatively	resistant	 to	degradation	(Lee,	Andalibi	et	al.	2004,	Davis,	Akinbi	 et	 al.	 2008).	 	 Lysozyme	 breaks	 down	 the	 glycosidic	 bond	 between	 N-acetylglucosamine	(NAG)	and	N-acetylmuramic	acid	(NAM),	which	make	up	PG.	 	 It	 is	highly	effective	 against	 Gram-positive	 organisms.	 	 Although	 it	 is	 produced	 by	 neutrophils,	 in	respiratory	 fluids	 the	 major	 source	 is	 probably	 airway	 epithelium	 and	 associated	 glands.	Both	 lysozyme	 and	 lactoferrin	 restrict	 S.	 pneumoniae	 in	 vitro,	 but	 have	 more	 effect	 in	combination	(Andre,	Politano	et	al.	2015).			
The	 α	 defensins	 1-4	 also	 known	 as	 human	 neutrophil	 peptides	 (HNP)	 are	 small	 peptides	found	in	neutrophil	azurophilic	granules	whereas	5&6	are	found	in	the	secretory	granules	of	Paneth	 cells,	 and	 are	 important	 in	 neutrophil	 mediated	 killing	 of	 S.	 pneumoniae	 (Beiter,	Wartha	et	al.	2008).		The	β	defensins	(hBD)	1-4	are	all	found	in	respiratory	fluids,	with	hBD2	release	stimulated	by	direct	activation	of	epithelial	cells,	as	well	as	by	the	cytokines	such	as	interleukin	(IL)	1β	and	tumour	necrosis	factor	(TNF)	(Kota,	Sabbah	et	al.	2008,	Kim,	Min	et	al.	2010).	 	They	act	by	permeabilising	membranes	rich	 in	anionic	phospholipids	(with	relative	sparing	 of	 cholesterol	 and	 neutral	 membranes	 found	 in	 humans),	 and	 have	 antimicrobial	activity	 against	 bacteria,	 fungi	 &	 viruses.	 	 Their	 effects	 are	 inhibited	 by	 increasing	 salt	concentrations.		They	may	also	act	by	inducing	secretory	leukocyte	protease	inhibitor	(SLPI)	
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and	CXCL8	secretion	by	bronchial	epithelial	cells.	 	hBD1-3	are	the	most	extensively	studied;	hBD3	appears	to	be	the	most	potent.		Respiratory	epithelial	cells	constitutively	express	hBD1,	whereas	hBD2	&	3	are	 inducible	by	S.	pneumoniae,	 and	both	restrict	S.	pneumoniae	 growth	and	induce	its	lysis	in	vitro	(Lee,	Andalibi	et	al.	2004,	Scharf,	Zahlten	et	al.	2012).	
Cathelicidins	 are	 mammalian	 peptides	 with	 a	 varied	 C	 terminal	 peptide	 sequence	 that	undergo	extracellular	proteolytic	cleavage.		LL37	is	the	only	known	human	member	and	are	found	 in	 specific	 granules	 of	 neutrophils	 and	 from	 alveolar	 epithelium	 and	 exhibit	 broad	spectrum	microbicidal	activities	 (Ganz	2004).	 	Bactericidal/permeability-increasing	protein	(BPI)	is	a	cationic	protein	from	azurophilic	granules	in	neutrophils	and	expressed	in	mucosal	epithelium,	and	recombinant	BPI	binds	to	S.	pneumoniae.		While	the	addition	of	recombinant	BPI	 has	no	 effect	 on	 growth	of	S.	 pneumoniae,	 it	 increased	 the	 association	of	 bacteria	with	mouse	macrophages,	increased	apoptosis	and	was	protective	against	pneumonia	in	a	mouse	model	(Srivastava,	Casey	et	al.	2007).	
Surfactant	protein	A	&	D	(SP-A	&	D	respectively)	are	constitutively	synthesised	and	secreted	into	 alveolar	 lining	 fluid	by	 type	 II	 pneumocytes	 and	non-ciliated	bronchial	 epithelial	 cells.		SP-A	&	D	bind	to	exposed	mannose	and	glucose	residues	on	the	surface	of	bacteria,	leading	to	agglutination	 of	 pathogens,	 inhibition	 of	 microbial	 growth,	 and	 increase	 recruitment	 of	phagocytes.		SP-A	also	functions	as	an	opsonin	that	increases	macrophage	phagocytosis	of	S.	
pneumoniae	(Sano,	Kuronuma	et	al.	2006).	
1.2.4	Alveolar	macrophage	Macrophages	 are	 tissue	 resident	 phagocytes	 that	 play	 an	 important	 role	 in	 orchestrating	innate	 immune	 responses	 to	 pathogens.	 	 They	 are	 characterised	 by	 surface	 expression	 of	multiple	proteins,	few	of	which	are	unique	to	macrophages;	a	combination	of	CD14,	CD68	and	CD163	have	been	used	to	 identify	human	tissue	macrophages	 in	 the	past	(Murray	&	Wynn,	2011).	 	 They	 are	 able	 to	 phagocytose	 foreign	 material,	 coordinate	 a	 cytokine	 response	 to	organisms	 and	 act	 as	 antigen	presenting	 cells.	 	Macrophages	 kill	 pathogens	by	 a	 variety	 of	
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mechanisms.	 	 Chief	 among	 these	 are	 inducible	 nitric	 oxide	 synthase	 and	 nicotinamide	adenine	dinucleotide	phosphate	 (NADPH)	oxidase,	which	 enable	 the	 generation	of	 reactive	oxygen	species	(ROS).		There	appear	to	be	subgroups	of	activated	macrophages	that	display	different	phenotypes	though	this	may	be	more	akin	to	a	spectrum	of	phenotypes.		Classically	activated	or	M1	macrophages	are	induced	by	exposure	to	interferon	gamma	(IFNγ)	and	TNF	from	 Th1	 lymphocytes,	 antigen	 presenting	 cells	 and	 natural	 killer	 (NK)	 cells.	 	 These	 cells	appear	to	be	primed	towards	microbicidal	functions,	i.e.	to	produce	more	ROS	and	more	pro-inflammatory	cytokines,	as	well	as	IL12	and	IL23.		M2	or	alternatively	activated	macrophages	are	induced	by	IL4	released	from	Th2	cells.	 	Their	primary	role	appears	to	be	tissue	repair,	with	 increased	 arginase	 activity	 resulting	 in	 ornithine,	 a	 precursor	 of	 collagen	 thereby	contributing	 to	 extracellular	 matrix	 production.	 	 They	 are	 also	 induced	 by	 chitinase	 from	parasites	 and	 appear	 to	 have	 a	 role	 in	 parasite	 clearance.	 	 A	 third	 subset,	 regulatory	macrophages,	are	induced	by	IL10	from	regulatory	T	cells,	as	well	as	immune	complexes	and	apoptotic	cells	(Mosser	and	Edwards	2008).		Their	function	appears	to	be	anti-inflammatory	by	 secreting	 more	 IL10	 and	 reducing	 IL12	 secretion,	 and	 they	 express	 more	 scavenger	receptors	and	 lectins.	 	There	appears	 to	be	some	plasticity	 in	macrophage	phenotype,	with	the	ability	to	switch	phenotypes	by	changes	in	stimuli.	
Foetal	 monocyte	 derived	 alveolar	 macrophages	 (AM)	 make	 up	 most	 of	 the	 resident	macrophage	 population	 in	 the	 lung	 (Hussell	 and	Bell	 2014),	 and	 recognised	 by	 expressing	lots	of	CD11c,	little	CD11b,	and	little	MHC	II	on	their	surface,	as	well	as	high	amounts	of	Siglec	F,	 macrophage	 receptor	 with	 collagenous	 structure	 (MARCO),	 mannose	 receptor	 (MR),	dectin-1	and	galectin	3	(Davies,	Jenkins	et	al.	2013,	Findlay	&	Hussell,	2012,	Hussell	and	Bell,	2014).	 	Though,	surface	expression	varies	by	stimulation	state,	and	some	of	these	receptors	are	more	closely	 related	 to	M1	or	M2	phenotype	 than	AM	per	se.	 	They	are	predominantly	derived	 from	a	 low	 level	 of	 replication	within	 the	 lung	 and	have	 a	 long	 life	 span	 (Murphy,	Summer	et	al.	2008).		While	only	1	in	3	alveoli	contain	AM,	they	make	up	90-95%	of	cellular	material	 within	 the	 alveoli,	 and	 AM	 can	 traverse	 alveoli	 by	 pores	 of	 Kohn.	 	 AM	 have	
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characteristics	of	both	classically	and	alternatively	activated	phenotypes	and	can	have	their	phenotype	altered	by	the	addition	of	cytokines.		AM	exhibit	relatively	little	phagocytic	activity	and	 respiratory	 burst	 and	 present	 antigens	 relatively	 poorly.	 	 They	 lack	 CD86,	 so	 are	 less	likely	to	stimulate	T	cells,	promoting	tolerance	to	innocuous	antigens.	 	In	addition	they	may	drive	differentiation	of	T	cells	 into	a	regulatory	phenotype	by	the	secretion	of	transforming	growth	factor	β	(TGFβ)	and	prostaglandins	(Gwyer	Findlay,	Danks	et	al.	2014).	
AM	can	contain	small	numbers	of	bacteria	by	phagocytosis,	with	depletion	of	AM	 in	mouse	pneumonia	models	decreasing	bacterial	clearance,	but	more	so	at	 low	 inocula	(Camberlein,	Cohen	 et	 al.	 2015).	 	 Once	 their	 phagocytic	 capabilities	 are	 overcome	 they	 institute	 an	inflammatory	response	that	results	in	leukocyte	chemotaxis	(Dockrell,	Marriott	et	al.	2003).		If	 the	 neutrophils	 are	 able	 to	 clear	 the	 infection,	 macrophages	 then	 remove	 apoptotic	neutrophils.	 	 	 If	 the	 neutrophils	 are	 not	 cleared,	 they	 undergo	 necrosis	 with	 subsequent	release	of	ROS	and	proteases	that	cause	tissue	injury	and	inflammation.			
1.2.5	Cytokines	After	cellular	recognition	of	S.	pneumoniae	by	PRRs,	an	inflammatory	response	is	generated	by	 the	 production	 of	 cytokines	 and	 chemokines	 (Table	 1.4	 and	 1.5).	 	 In	mouse	models	 of	intranasal	S.	pneumoniae	infection,	levels	of	the	pro-inflammatory	cytokine	TNF	are	elevated	in	BALF	within	an	hour	of	infection	followed	by	IL1β,	particularly	in	lung	homogenates,	and	then	 IL6	 (Calbo	 and	 Garau	 2010).	 	 IL6	 is	 also	 rapidly	 elevated	 in	 serum.	 	 These	 cytokine	responses	 are	 associated	 with	 neutrophil	 infiltrate	 starting	 from	 2	 hours	 onwards,	 with	 a	later	influx	of	inflammatory	monocytes.	 	In	meningitis	models	there	is	a	similar	time	course	of	inflammatory	cytokine	levels	in	CSF:	TNF	followed	by	IL1β,	then	IL6.		Mice	deficient	in	any	of	 these	 cytokines	 have	 increased	 mortality	 rates	 (van	 der	 Poll,	 Keogh	 et	 al.	 1997,	Zwijnenburg,	van	der	Poll	et	al.	2003,	Gerber,	Bottcher	et	al.	2004).		These	pro-inflammatory	cytokines	 also	 induce	 the	 acute	 phase	 response,	 and	 upregulate	 adhesion	 molecules	 to	facilitate	transmigration	of	leukocytes	from	the	blood;	this	may	also	lead	to	downregulation	
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of	 the	 tight	 junctions	 between	 epithelial	 cells,	 facilitating	 S.	 pneumoniae	 invasion	 (Clarke,	Francella	et	al.,	2011).				
The	key	cytokines	that	are	important	in	S.	pneumoniae	responses	are	discussed	in	individual	sections	below.	
1.2.5.1	Tumour	Necrosis	Factor	TNF	 is	 one	 of	 the	 cardinal	 cytokines	 involved	 in	 the	 inflammatory	 response.	 	 TNF	 is	synthesised	 in	 the	 endoplasmic	 reticulum	 (ER)	 and	TNF	 containing	 vesicles	 from	 the	 golgi	complex	fuse	with	recycling	endosomes,	which	migrate	to	the	cell	membrane	(Arango	Duque	and	Descoteaux	 2014).	 	 TNF	 is	 expressed	 by	 activated	macrophages,	 lymphocytes,	 natural	killer	 (NK)	 cells,	 and	 epithelial	 cells;	 and	 is	 generated	 in	 its	 transmembrane	 form	as	 a	233	amino	acid	polypeptide	(26kDa)	and	aggregates	into	homotrimers.		TNFα	converting	enzyme	cleaves	 the	 transmembrane	 form	 to	 release	 soluble	TNF	 and	 the	 residual	 portion	migrates	back	 to	 the	 nucleus.	 	 It	 exerts	 effects	 when	 in	 either	 transmembrane	 or	 soluble	 forms.		Soluble	TNF	then	acts	at	distant	sites	by	binding	to	type	I	and	II	TNF	receptors	(TNF	–	R1	and	R2),	 whereas	 the	 transmembrane	 form	 acts	 in	 a	 juxtacrine	 fashion	 as	 a	 ligand	 of	 TNFR2	(Horiuchi,	Mitoma	et	al.	2010).	
The	TNF	 receptor	 family	 contains	29	members	 that	 can	be	placed	 into	3	groups:	 a)	 induce	apoptosis,	 b)	 induce	 inflammatory	 signalling	 cascades,	 and	 c)	 act	 as	 ‘decoys’.	 	 Apoptosis	 is	induced	by	activating	caspase	8,	which	processes	downstream	caspases	(Dempsey,	Doyle	et	al.	 2003).	 	Nuclear	 factor	kappa	B	 (NFκB)	 actively	 inhibits	 the	death	 function	of	TNFR1	by	upregulating	anti-apoptotic	genes	such	as	Bcl-2	and	TNF	receptor	associated	factor	(TRAF)	1	&	2	(Figure	1.2).	TNFR2	does	not	contain	a	death	domain	(DD)	but	can	recruit	Fas	associated	protein	 with	 DD	 (FADD)	 and/or	 receptor-interacting	 serine/threonine-protein	 kinases	(RIPK)	to	induce	apoptosis	(Rahman	and	McFadden	2006).			
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Table	1.4:	Cytokines	involved	in	the	immune	response	to	S.	pneumoniae	
Cytokine	 Function	during	S.	pneumoniae	infection	 Reference	IFN	α/β		 Upregulate	tight	junctions	and	downregulate	PAFr	in	murine	pneumonia	models	 (Parker,	Martin	et	al.	2011,	LeMessurier,	Hacker	et	al.	2013)	IFNγ	 Induces	inflammatory	monocyte	infiltrate	in	murine	meningitis	model.		Induces	neutrophil	infiltrate	by	stimulating	chemokines	in	a	murine	pneumonia	model	
(Mitchell,	Yau	et	al.	2012)	(Sun,	Salmon	et	al.	2007)	
IL1β		 Endogenous	pyrogen,	potentiates	inflammatory	responses	in	murine	pneumonia	models		
(Marriott,	Gascoyne	et	al.	2012,	Zwijnenburg,	van	der	Poll	et	al.	2003,	Jones,	Simms	et	al.	2005)	
IL6		 Induces	acute	phase	response	and	potentiates	inflammatory	responses	in	murine	pneumonia	model		
(Quinton,	Jones	et	al.	2009,	van	der	Poll,	Keogh	et	al.	1997)	
IL10		 Inhibits	inflammatory	responses	and	inhibits	neutrophil	recruitment	by	affecting	chemokine	expression	 (Williams,	Jose	et	al.	2015)	IL12		 Induces	IFNγ	secretion	in	murine	pneumonia	models		 (Sun,	Salmon	et	al.	2007Yamamoto,	Kawakami	et	al.	2004)	IL17		 Potentiates	inflammatory	responses	including	neutrophil	recruitment,	and	increases	mucosal	immunity	in	murine	pneumonia	and	human	colonisation	models	
(Zhang,	Clarke	et	al.	2009,	Li,	Moltedo	et	al.	2012,	Wright,	Bangert	et	al.	2013)	
IL23		 Stimulates	T	cells,	increases	IFNγ	and	IL17	in	murine	pneumonia	models	 (Kim,	Lee	et	al.	2013)	IL27		 Inhibits	IL17	production,	so	increasing	susceptibility	in	a	murine	pneumonia	model	 (Cao,	Wang	et	al.	2014)	TNF		 Endogenous	pyrogen,	and	potentiates	inflammatory	responses	in	murine	pneumonia	and	meningitis	models	 (Takashima,	Tateda	et	al.	1997,	van	der	Poll,	Keogh	et	al.	1997,	Gerber,	Bottcher	et	al.	2004,	Jones,	Simms	et	al.	2005)		
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In	the	hypothalamus	TNF	stimulates	corticotropin	releasing	hormones,	suppresses	appetite,	and	 induces	 fever.	 	 It	 stimulates	 the	 acute	 phase	 response	 from	 the	 liver,	 vasodilation	 and	increased	 vascular	 permeability,	 and	 helps	 regulate	 chemokine	 release	 including	 inducing	CXCL1,	 2,	 and	 5	 and	 increasing	 cell	 adhesion	 molecule	 expression	 as	 well	 as	 CXCR2	dependent	neutrophil	migration.			
	
	
	
Figure	 1.3:	 Apoptosis	 v	 inflammatory	 pathways	 downstream	 of	 TNF	 receptor	
activation	(Dempsey,	Doyle	et	al.	2003)			TNFR1	 labelled	 in	 red,	 upon	 binding	 to	 ligand,	 induces	 activation	 of	 signalling	 molecules,	such	as	members	of	the	TRAF	family.		Signalling	cascades	induce	two	main	effects;	apoptosis	or	inflammation	&	differentiation.		Anti-apoptotic	signalling	is	labelled	in	green,	whereas	pro-apoptotic	are	in	red.				
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TNF	is	important	in	the	host	response	to	S.	pneumoniae.		In	vitro	TNF	increased	the	oxidative	burst	produced	by	neutrophils	in	response	to	S.	pneumoniae	(Kragsbjerg	and	Fredlund	2001).		In	addition,	TNF	deficient	mice	had	poorer	bacterial	clearance	and	survival	in	pneumonia	and	meningitis	models	 (Gerber,	 Bottcher	 et	 al.	 2004,	 Jeong,	 Seo	 et	 al.	 2015)	 and	TNF	 blockade	decreased	mouse	survival	in	a	pneumonia	model	(van	der	Poll,	Keogh	et	al.	1997).		This	was	associated	 with	 greater	 bacteraemia,	 relative	 neutropenia,	 and	 the	 development	 of	 solid	lobar	consolidation	and	pulmonary	haemorrhage	(Takashima,	Tateda	et	al.	1997).			
1.2.5.2	Interleukin	1β	The	IL1	gene	family	consists	of	the	agonists	IL1α	and	IL1β,	and	the	antagonist	IL1	receptor	antagonist	(IL1RA).		IL1RA	binding	to	the	IL1R	fails	to	recruit	an	accessory	protein,	therefore	inhibiting	the	agonists.	 	IL1β	is	released	primarily	by	monocytes	and	macrophages,	but	also	NK	cells,	B	cells,	DCs,	and	epithelial	cells.		IL1β	is	synthesised	as	a	precursor	that	is	cleaved	by	caspase-1	after	 inflammasome	activation.	 	Release	of	 IL1β	 is	usually	 thought	 to	require	cell	membrane	 permeabilisation,	 and	 occur	 as	 a	 part	 of	 the	 process	 of	 subsequent	 cell	 death	(Martín-Sánchez,	Diamond	et	al.	2016).		In	neuronal	cells,	a	process	of	active	transport	out	of	the	cell	by	ATP	binding	cassette	(ABC)	transporters	has	been	described	(Marty	V,	Medina	C	et	al.	2005).		IL1β	acts	to	induce	the	acute	phase	response,	fever,	prostaglandin	release	from	the	hypothalamus,	 and	 histamine	 release	 from	 mast	 cells	 to	 elicit	 vasodilation.	 	 It	 is	 also	 a	chemoattractant	for	granulocytes,	 induces	expansion	of	CD4	T	cells,	and	increases	adhesion	molecules	on	endothelium	and	leucocytes.	 	IL1α	is	active	as	an	intracellular	precursor	or	as	its	 membrane-associated	 form.	 	 It	 is	 synthesised	 de	 novo	 and	 can	 be	 actively	 secreted	 or	passively	 released	 from	apoptotic	 cells	 and	 functions	 similarly	 to	 IL1β	 (Arango	Duque	 and	Descoteaux	2014).	
IL1R	 deficient	mice	 were	more	 susceptible	 to	 S.	 pneumoniae	 colonisation,	 pneumonia	 and	meningitis	 (Zwijnenburg,	 van	 der	 Poll	 et	 al.	 2003,	 Lemon,	 Miller	 et	 al.	 2015).	 	 This	 was	associated	with	higher	levels	of	TNF,	IL6,	CCL2	and	IFNγ	in	BALF	and	increased	lung	bacterial	load,	but	comparable	 levels	of	keratinocyte	chemoattractant	 (KC),	 the	mouse	homologue	of	
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CXCL8,	 to	 infection	 in	 wild-type	 mice.	 	 Neutrophil	 and	 macrophage	 numbers	 and	phagocytosis	 function	were	 also	 similar.	 	 In	 contrast,	 deficient	mice	 had	 reduced	 levels	 of	fibrinogen.	 	 Supplementing	 IL1R	knockout	mice	with	 exogenous	 fibrinogen	 improved	 their	survival	to	S.	pneumoniae	challenge	(Yang,	Ko	et	al.	2013).	 	 In	a	colonisation	model,	 in	IL1R	deficient	mice	there	was	reduced	neutrophil	infiltrate	at	early	timepoints,	and	later	reduced	macrophage	numbers	due	to	less	CCL6	compared	to	wild-type	(Lemon,	Miller	et	al.	2015).	
After	 murine	 intranasal	 infection	 IL1β	 deficient	 mice	 had	 reduced	 neutrophil	 numbers	 in	blood	compared	to	wild-type,	and	worse	lung	damage	on	histology,	increased	bacterial	load	in	lungs,	and	reduced	survival	(Kafka,	Ling	et	al.	2008).		Administration	of	recombinant	IL1β	improved	knock	out	mice	survival	to	equivalence	with	wild-type.	
CXCL8	 release	 from	A549	AEC	by	 conditioned	media	 from	THP-1	monocytes	 exposed	 to	S.	
pneumoniae	 was	 inhibited	 by	 IL1RA	 suggesting	 that	 IL1β	 is	 central	 to	 chemokine	 release	from	epithelial	 cells.	 	 IL1R	deficient	mice	had	 less	neutrophil	 recruitment	after	 low	dose	S.	
pneumoniae	 infection	 than	 wild-type,	 associated	 with	 less	 CXCL1	 in	 BAL	 at	 24	 hours,	supporting	the	functional	role	of	the	IL1	family	in	inducing	leukocyte	recruitment	(Marriott,	Gascoyne	et	al.	2012).			
1.2.5.3	Interleukin	6	IL6	 is	 a	 soluble	 protein	 synthesised	 in	 the	 ER,	 that	 accumulates	 in	 the	 golgi	 and	 exits	 via	tubulovesicular	carriers	(Arango	Duque	and	Descoteaux	2014).	 	 IL6	has	both	pro-	and	anti-inflammatory	functions;	inducing	the	acute	phase	response	and	fever	as	well	as	promoting	B	cell	 differentiation	 into	 plasma	 cells	 and	 activation	 of	 CD8	 cells.	 	 IL6	 signalling	 occurs	 via	soluble	 receptors	 binding	 to	 the	 ubiquitous	 gp130,	 leading	 to	 monocyte	 recruitment,	promoting	Th17	cell	formation,	and	inhibiting	Treg	formation.		Anti-inflammatory	properties	occur	via	classical	signalling	through	the	IL6	receptor	(expressed	on	very	few	cells)	to	inhibit	apoptosis	 and	 increase	 insulin	 sensitivity.	 	 Polymorphisms	 in	 IL6	 are	 associated	 with	increased	 incidence	 of	 otitis	 media,	 and	 limiting	 extrapulmonary	 spread	 in	 S.	 pneumoniae	
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infection	(Schaaf,	Rupp	et	al.	2005).	 	 IL6	deficient	mice	are	unable	to	mount	an	acute	phase	response	to	S.	pneumoniae	pneumonia.		This	is	dependent	on	IL6	inducing	STAT3	activation	in	 hepatocytes	 (Quinton,	 Jones	 et	 al.	 2009).	 	 In	 a	 pneumonia	model	 IL6	deficient	mice	 had	reduced	 survival,	 reduced	 bacterial	 clearance,	 but	 increased	 levels	 of	 both	 pro-	 and	 anti-	inflammatory	cytokines	(van	der	Poll,	Keogh	et	al.	1997).	
1.2.5.4	Interleukin	17	The	 cytokine	 IL17	 is	 involved	 in	 maintaining	 mucosal	 immunity	 against	 S.	 pneumoniae	(Zhang,	 Clarke	 et	 al.	 2009).	 	 Polymorphisms	 in	 IL17A	 are	 associated	 with	 increased	colonisation	and	 lung	 infection	 in	humans	 (Nakada,	Russell	 et	al.	2011).	 	Functions	 include	increasing	 neutrophil	 recruitment,	 β	 defensin	 production,	 and	 expression	 of	 polymeric	 Ig	receptor	expression	on	alveolar	epithelial	cells,	which	is	required	for	transport	of	antibodies	into	 epithelial	 lining	 fluid.	 	 In	 addition,	AM	 from	healthy	 volunteers	have	 increased	uptake	and	 killing	 of	 S.	 pneumoniae	 if	 incubated	 with	 recombinant	 IL17A	 (Wright,	 Bangert	 et	 al.	2013).	 	 IL17	 levels	peak	24	hours	after	S.	pneumoniae	 infection	and	 flow	cytometry	of	 lung	homogenate	suggests	that	γδT	cells	are	the	primary	source	of	IL17	(Cao,	Wang	et	al.	2014).		IL17	 neutralisation	 reduced	 neutrophil	 recruitment	 and	 decreased	 survival	 in	 a	 murine	pneumonia	model	 (Cao,	Wang	 et	 al.	 2014);	 conversely	 administration	of	 recombinant	 IL17	reduced	 bacterial	 counts.	 	 This	 was	 associated	with	 increased	 inflammatory	 cell	 infiltrate,	increased	CCL3	and	hBD2	gene	expression	in	lung	homogenate,	and	increased	IFNγ	in	BALF,	supporting	the	central	role	of	IL17	in	mucosal	immunity	in	the	lung	(Chen,	Guo	et	al.	2014).	
1.2.5.5	Type	I	Interferon	Type	 I	 IFNs	 consist	 of	 multiple	 IFNα	 forms	 and	 one	 IFNβ	 that	 bind	 to	 a	 heterodimeric	receptor;	the	interferon	α/β	receptor	(IFNAR).	 	IFNβ	mRNA	is	upregulated	in	lungs	after	24	hours	 after	 S.	 pneumoniae	 infection.	 	 IFNAR	 deficient	mice	 had	 prolonged	 nasopharyngeal	carriage	and	increased	mortality	in	lung	infection	models	(Parker,	Martin	et	al.	2011).		Type	I	IFN	 release	 from	 macrophages	 occurred	 after	 phagocytosis	 and	 release	 of	 bacterial	constituents	(Kafka,	Ling	et	al.	2008).	 	IFNβ	transcription	is	associated	with	upregulation	of	
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tight	 junction	 proteins	 and	 downregulation	 of	 PAFr.	 	 This	 was	 associated	 with	 reduced	bacterial	 transmigration	 across	 epithelial	 and	 endothelial	 layers	 in	 transwell	 systems.		Administration	 of	 IFNβ	 protected	 mice	 against	 systemic	 disease	 in	 a	 pneumonia	 model,	whereas	using	blocking	antibody	to	IFNAR	increased	bacteraemia	(LeMessurier,	Hacker	et	al.	2013).		This	may	be	strain	dependent,	as	an	invasive	serotype1	strain	upregulated	more	type	1	IFN	genes	compared	to	a	non-invasive	strain	(Hughes,	Harvey	et	al.	2014).		In	this	context	IFNAR1	blockade	significantly	reduced	invasion	into	pleura	and	blood,	i.e.	the	opposite	effect.	
1.2.5.6	Interferon	γ	IFNγ,	secreted	by	Natural	Killer	cells	and	Th1	cells	after	intracellular	PRR	activation	(Olliver,	Hiew	 et	 al.	 2011),	 activates	 macrophages.	 	 This	 usually	 improves	 phagocytosis	 and	intracellular	 killing.	 	 However,	 IFNγ	 decreased	mouse	AM	binding	 and	 internalisation	 of	 S.	
pneumoniae	in	vitro	(Mina,	Brown	et	al.	2015).		Data	on	the	role	of	IFNγ	during	S.	pneumoniae	infection	 is	 contradictory;	 it	 was	 largely	 protective	 in	 S.	 pneumoniae	 pneumonia	 models	(Rubins	 and	 Pomeroy	 1997,	Weber,	 Tian	 et	 al.	 2011),	 but	 influenza	 infection	 in	 a	 murine	model	 induced	 IFNγ	 that	 increased	 susceptibility	 to	 subsequent	 S.	 pneumoniae	 infection	 a	week	 later	 by	 reducing	 phagocytosis	 by	 AM	 (Sun	 and	 Metzger	 2008).	 	 In	 addition,	neutralisation	of	IFNγ	was	protective	in	a	meningitis	model	in	terms	of	survival	and	bacterial	clearance	due	to	reduced	inflammatory	monocyte	infiltrate	(Mitchell,	Yau	et	al.	2012).		Some	studies	 suggest	 that	 recruited	 neutrophils	 are	 also	 an	 important	 source	 of	 IFNγ	 (Gomez,	Yamada	et	al.	2015).			
1.2.5.7	Other	Important	Cytokines		IL12	is	produced	primarily	by	macrophages	and	DCs.		It	synergises	with	TNF	to	stimulate	Th1	cells	by	 inducing	 IFNγ	and	 increasing	cytotoxicity	of	NK	cells	and	CD8	cells	 (Arango	Duque	and	 Descoteaux	 2014).	 	 IL12	 deficiency	 in	 humans	 increases	 risk	 of	 S.	 pneumoniae	 lung	infection	 (Haraguchi,	 Day	 et	 al.	 1998).	 	 IL12	 deficient	 mice	 had	 reduced	 survival	 in	 a	pneumonia	 model	 (Yamamoto,	 Kawakami	 et	 al.	 2004),	 and	 supplementary	 IL12	
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administration	 was	 protective	 against	 subsequent	 S.	 pneumoniae	 pneumonia	 in	 a	 murine	model	(Sun,	Salmon	et	al.	2007).	
IL22,	 from	 Th17	 cells,	 is	 involved	 in	 the	 induction	 of	 inflammation	 as	 well	 as	 promoting	mucosal	immunity.		S.	pneumoniae	pneumonia	induced	IL22	production	in	the	lungs	of	mice,	and	IL22	production	was	protective	against	S.	pneumoniae	 in	primary	infection	(Van	Maele,	Carnoy	 et	 al.	 2014)	 as	well	 as	 in	 the	 context	 of	 prior	 sublethal	 influenza	 infection	 (Ivanov,	Renneson	et	al.	2013).	
IL23	is	closely	related	to	IL12,	and	is	released	from	DCs	and	macrophages.		It	induces	IFNγ	as	well	 as	 augmenting	 IL10	 and	 IL17	 production	 by	 T	 cells	 and	 chemokine	 upregulation	 by	respiratory	 epithelial	 cells	 (Arango	 Duque	 and	 Descoteaux	 2014).	 	 In	 a	mouse	 pneumonia	model,	 IL23	 deficient	 mice	 had	 earlier	 bacteraemia,	 associated	 with	 lower	 neutrophil	numbers	 in	 lungs	up	 to	24	hours	 after	 infection.	 	Mononuclear	 cells	 isolated	 from	 lungs	of	IL23	deficient	mice	secreted	less	IL17A	and	IFNγ	in	response	to	S.	pneumoniae,	and	the	mice	had	lower	levels	of	IL6	and	IL12	in	BALF	(Kim,	Lee	et	al.	2013).	
IL27	 is	 a	 heterodimeric	 cytokine	 that	 signals	 via	 a	 receptor	 complex	 of	 T	 cell	 cytokine	receptor,	WSX-1	and	gp130	and	seems	to	play	a	role	 in	regulating	Th1/2/17	depending	on	context.	 	 It	 is	produced	early	by	macrophages	 in	response	 to	pathogens,	and	acts	 to	 induce	IFNγ	 and	 Th1	 differentiation,	 as	 well	 as	 inhibit	 Th17	 differentiation	 (Arango	 Duque	 and	Descoteaux	2014).	 	 Influenza	 infection	 induces	a	 type	 I	 IFN	mediated	 increase	 in	 IL27	 that	decreases	production	of	 IL17	 from	γδT	cells,	 and	 thus	 increases	 susceptibility	of	mice	 to	S.	
pneumoniae.		IL27	receptor	deficient	mice	had	faster	S.	pneumoniae	clearance	than	wild-type	mice	but	this	was	only	associated	with	reduced	mortality	if	pre-infected	with	influenza	(Cao,	Wang	et	al.	2014).		
The	 largely	 anti-inflammatory	 cytokine,	 IL10,	 plays	 an	 important	 role	 in	 regulating	inflammation	during	S.	pneumoniae	infections.		Deficiency	of	IL10	in	murine	models	results	in	increased	 inflammation	 that	 is	 associated	with	 improved	bacterial	 clearance,	but	 increased	
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mortality	(van	Der	Poll,	Marchant	et	al.	1997,	Penaloza,	Nieto	et	al.	2015).		In	murine	models,	IL10	 levels	 were	 reduced	 in	 the	 lungs	 of	 infected	 aged	 mice,	 suggesting	 that	 immune	dysregulation	 and	 enhanced	 inflammation	 in	 these	 mice	 is	 partly	 due	 to	 loss	 of	 this	 anti-inflammatory	 cytokine	 resulting	 in	 increased	 levels	 of	 chemokines	 (Williams,	 Jose	 et	 al.	2015).	 Furthermore	 the	 administration	 of	 IL10	 in	 combination	 with	 antibiotics	 improves	survival	 of	 mice	 infected	 with	 S.	 pneumoniae	 compared	 to	 infected	 mice	 treated	 with	antibiotics	alone	(Wang,	Bergeron	et	al.,	2005).	
1.2.6	Chemokines	The	 pro-inflammatory	 cytokines	 act	 in	 concert	 with	 chemokines	 (Table	 1.5)	 to	 recruit	leukocytes	to	the	site	of	infection.		Chemokines	are	grouped	as	families	by	their	structure;	CC	chemokines	have	 two	adjacent	cysteines,	and	CXC	chemokines	have	cysteines	separated	by	another	 amino	 acids.	 	 Chemokine	 relationships	 to	 their	 receptors	 are	 variable	 with	 some	redundancy;	 several	 chemokines	 bind	 to	 the	 same	 receptor,	 and	 many	 receptors	 bind	multiple	 chemokines.	 In	 particular,	 inhibition	 of	 CXCR2	 (activated	 by	 CXCL	1-3,	 CXCL	5-8),	which	 is	 expressed	 on	 neutrophils	 and	 macrophages,	 appeared	 to	 be	 protective	 in	 non-infective	acute	lung	injury	and	chronic	inflammation	(Tomankova,	Kriegova	et	al.	2015),	but	the	absence	of	CXCR2	also	compromised	host	defence	(Herbold,	Maus	et	al.	2010).		Targeting	individual	 chemokines	may	prove	 to	be	beneficial	at	attenuating	neutrophilic	 inflammation	without	compromising	host	defence	(Jose,	Williams	et	al.	2015).		
1.2.6.1	CCL	Family	CCL2	 is	 upregulated	 at	 mRNA	 and	 protein	 level	 in	 respiratory	 epithelial	 cell	 lines	 after	exposure	to	S.	pneumoniae	lysates,	this	is	reflected	in	transcriptional	responses	in	mouse	lung	homogenate	 after	 inoculation	with	bacterial	 lysate	 (Shin,	Yoo	et	 al.	 2010).	 	 The	 inability	of	infant	mice	to	upregulate	CCL2	in	the	nasopharynx	in	response	to	S.	pneumoniae	colonisation	resulted	in	reduced	macrophage	recruitment	and	delayed	clearance	(Siegel,	Tamashiro	et	al.	2015).	 	 CCL2	 deficient	 mice	 infected	 with	 serotype19F,	 which	 results	 in	 a	 resolving	
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pneumonia	 phenotype,	 had	 reduced	 survival	 compared	 to	 wild-type,	 associated	 with	increased	bacteraemia.		While	there	was	an	equivalent	neutrophilic	infiltrate,	CCL2	deficient	mice	had	reduced	numbers	of	parenchymal	DCs	and	 inflammatory	monocytes	and	reduced	subsequent	 AM	 repopulation.	 	 This	 suggests	 that	 in	 less	 virulent	 infection,	 monocyte	recruitment	 is	 important	 in	 preventing	 bacterial	 dissemination,	 that	 this	 effect	 is	independent	 of	 neutrophil	 recruitment,	 and	 CCL7	 and	 CCL12	 cannot	 fully	 compensate	 for	lack	of	CCL2	(Winter,	Herbold	et	al.	2009).	
CCL5	 is	 secreted	by	 epithelial	 cells,	 lymphocytes	 and	platelets	 and	acts	 as	 a	 chemokine	 for	monocytes,	NK	cells,	eosinophils,	memory	T	cells,	DCs	and	basophils	by	acting	on	CCR1,	3,	4	&	5.		The	expression	of	CCL5	in	nasal	associated	lymphoid	tissue	was	increased	in	response	to	colonisation	with	 S.	 pneumoniae,	 and	was	 associated	with	 an	 increase	 in	 CCR5	 expressing	leukocytes,	 usually	Th1	 cells.	 	 CCL5	blockade	 reduced	 transcription	 of	 IL4,	 IL12,	 IFNγ,	 and	CCR5,	 which	 correlated	 with	 increased	 bacterial	 counts	 in	 nasopharynx	 and	 lungs	 and	correspondingly	low	levels	of	leukocytes	in	lymphoid	tissue	and	lungs.		This	protective	effect	was	 mediated	 by	 increased	 antibody	 responses	 and	 increased	 IFNγ	 from	 T	 cells	(Palaniappan,	Singh	et	al.	2006).		CCL7	is	closely	related	to	CCL2	and	is	primarily	known	as	a	monocyte	 chemoattractant,	 acting	by	binding	 to	CCR	1-3,	 and	CCR5.	 	However	 in	 a	murine	pneumonia	 model,	 alveolar	 inhibition	 of	 CCL7	 inhibited	 neutrophil	 recruitment	 and	ameliorated	lung	injury	without	affecting	bacterial	clearance	(Jose,	Williams	et	al.	2015).	
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Table	1.5:	Chemokines	involved	in	the	immune	response	to	S.	pneumoniae	
Chemokine	 Function	during	S.	pneumoniae	
infection	
Reference	
CCL2	(MCP-1)	 Monocyte	chemoattractant	in	a	murine	pneumonia	model	 (Winter,	Herbold	et	al.	2009)	CCL5	(RANTES)	
	
Th1	cell	chemoattractant	 (Palaniappan,	Singh	et	al.	2006)	CCL7	
	
Neutrophil	chemoattractant	in	a	murine	pneumonia	model	 (Jose,	Williams	et	al.	2015)	CXCL1	(GRO-1)		
	
Neutrophil	chemoattractant	in	a	murine	pneumonia	model	 (Jose,	Williams	et	al.	2015)	CXCL8	(IL8)	
	
Neutrophil	chemoattractant	in	an	in	vitro	macrophage/epithelial	cell	co-culture	mouse	pneumonia	model	(KC)	 (Marriott,	Gascoyne	et	al.	2012)	CXCR3	(receptor	for	CXCL9/CXCL10	(IP-10)/CXCL11)	
Neutrophil	recruitment	and	lung	inflammation	in	a	murine	pneumonia	model	 (Seyoum,	Yano	et	al.	2011)	
	
1.2.6.2	CXC	Family	CXCR2	 is	 a	 receptor	 for	multiple	 chemokines,	 and	 CXCR2	 deficient	mice	 have	 significantly	greater	mortality	 than	wild-type	 in	 a	murine	 pneumonia	model,	 associated	with	 increased	bacterial	outgrowth	in	BALF	and	lungs	(Herbold,	Maus	et	al.	2010).		The	knockout	mice	had	reduced	 inflammatory	monocyte	 and	 neutrophil	 recruitment,	 greater	 levels	 of	 CXCL1	 &	 2,	CCL2	&	12	suggesting	that	CXCR2	is	important	in	both	neutrophil	and	monocyte	recruitment.		In	addition	neutralisation	of	systemic	CXCL1	inhibited	neutrophil	recruitment	to	the	lung	in	a	murine	pneumonia	model	(Jose,	Williams	et	al.	2015).	
CXCL9,	10,	11	bind	to	CXCR3,	which	is	expressed	on	Th1	and	NK	cells.	CXCR3	deficient	mice	infected	 with	 S.	 pneumoniae	 had	 better	 survival,	 less	 bacteraemia,	 less	 lung	 neutrophilic	infiltrate,	more	lung	AM,	and	less	 lung	inflammation	on	histological	analysis	(Seyoum,	Yano	et	 al.	 2011).	 	 This	 suggests	 that	 these	 chemokines	 may	 be	 involved,	 although	 possibly	indirectly,	in	excessive	neutrophil	infiltrate.	
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There	is	diurnal	variation	in	neutrophil	response	to	S.	pneumoniae,	as	mice	infected	at	dusk	had	greater	neutrophil	 infiltrate	at	24	hours	 than	 those	 infected	at	dawn	(Gibbs,	 Ince	et	al.	2014).		This	correlated	with	lower	bacterial	counts	at	48	hours	in	lungs	and	blood.		Knocking	out	expression	of	clock	genes	in	pulmonary	epithelial	cells	of	mice	caused	greater	neutrophil	infiltrate	 and	 loss	 of	 circadian	 variation;	 this	 was	 associated	 with	 CXCL5	 upregulation.		Human	bronchial	 epithelial	 cells	 expressed	CXCL5	 in	 response	 to	 IL1β.	 	 The	 glucocorticoid	receptor	binds	to	the	promoter	sequence	of	CXCL5,	which	may	explain	why	steroids	inhibit	the	neutrophil	response	to	S.	pneumoniae.			
1.2.7	Inflammatory	Response	to	S.	pneumoniae	Transcriptional	analysis	of	mouse	 lungs	after	 infection	with	S.	pneumoniae	 shows	that	 IL17	signalling,	 and	NFκB	 signalling	 are	 upregulated	 at	 early	 timepoints	 in	 association	with	 the	most	overrepresented	cell	types,	 i.e.	granulocytes	and	macrophages.	 	By	48	hours,	IL17	and	NFκB	pathways	are	still	upregulated	but	less	so,	while	IFN	signalling	is	also	now	upregulated	(Scicluna,	Van	Lieshout	et	al.	2015).	
1.2.7.1	Epithelial	Cells	As	well	as	secreting	soluble	antibacterial	 factors,	epithelial	cells	express	PRR	that	recognise	conserved	molecular	 patterns	 found	 on	 the	 surface	 of	 S.	 pneumoniae.	 	 While	 activation	 of	epithelial	 PRRs	 can	 contribute	 towards	 the	 inflammatory	 response	 to	 S.	 pneumoniae	(Sorrentino,	de	Souza	et	al.	2008),	these	responses	can	be	also	be	increased	by	macrophages	in	mice,	 in	vitro	co-culture	models	(Marriott,	Gascoyne	et	al.	2012),	and	human	ex	vivo	lung	biopsies	(Xu,	Droemann	et	al.	2008).		BALF	from	infected	mice	induced	IκB	degradation	(pro-inflammatory	 cell	 signalling)	 in	 AECs,	 but	 S.	 pneumoniae	 itself	 did	 not.	 	 This	 epithelial	 cell	activation	 was	 inhibited	 by	 combined	 IL1β	 and	 TNF	 blockade	 (Yamamoto,	 Ferrari	 et	 al.	2012).	 	 CXCL8	 release	 from	 an	AEC	 line,	 A549s,	 in	 response	 to	S.	 pneumoniae	was	 greater	when	in	co-culture	with	a	human	monocyte	cell	line,	THP-1	or	with	conditioned	media	from	infected	 THP-1.	 	 This	 was	 inhibited	 by	 the	 presence	 of	 an	 IL1	 receptor	 (IL1R)	 antagonist	suggesting	that	IL1β	is	key	in	this	communication.		This	was	seen	in	an	in	vivo	setting,	as	IL1R	
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deficient	mice	had	 less	neutrophil	 recruitment	 after	 low	dose	S.	 pneumoniae	 infection	 than	wild-type,	 associated	with	 less	CXCL1	 in	BALF	 (Marriott,	Gascoyne	et	 al.	 2012).	 	 Culture	of	primary	type	II	AEC	and	AM	(approximately	5:1	ratio	 in	human	lung)	from	the	same	donor	indicate	 differential	 cytokine	 and	 chemokine	 responses	 in	 response	 to	 lipopolysaccharide	(LPS):	AM	released	more	IL1β	and	TNF,	but	less	IL6	and	chemokines	than	AEC	(Thorley,	Ford	et	 al.	 2007).	 	 TNF	blockade	 inhibited	 the	 release	of	 IL6	 and	CCL2	 from	AECs.	 	 Conditioned	media	 from	 either	 cell	 type	 was	 able	 to	 induce	 migration	 of	 monocytes	 and	 neutrophils	across	 a	 transwell.	 	 CXCL1	 appeared	 to	 be	 the	most	 important	 chemokine	 in	 this	 context,	though	CCL2	was	more	important	 in	AM	conditioned	media,	and	CXCL8	in	AEC	conditioned	media.	 	 However,	 a	 bronchial	 epithelial	 cell	 line,	 BEAS2B,	 secreted	 CXCL8	 in	 response	 to	unencapsulated	S.	pneumoniae	in	a	dose	dependent	manner	after	16	hours	(Schmeck,	Huber	et	 al.	 2006).	 These	 data	 suggests	 that,	 while	 epithelial	 cells	 are	 able	 to	 recognise	 S.	
pneumoniae,	 AM	 primarily	 recognise	 S.	 pneumoniae,	 and	 then	 stimulate	 the	 alveolar	epithelium	by	paracrine	or	juxtacrine	mechanisms	to	amplify	the	inflammatory	response.	
1.2.7.2	Macrophages		AMs	must	be	able	 to	 clear	debris	and	 limit	 inflammation	 for	most	of	 the	 time,	but	elicit	 an	inflammatory	 response	 to	 pathogens.	 This	 may	 be	 mediated	 by	 juxtaregulation	 from	 the	alveolar	 epithelium	 such	 that	when	damaged,	 there	 is	 loss	 of	 negative	 regulators,	 allowing	the	AM	to	respond	in	an	inflammatory	manner.		Sessile	AM	communicate	with	each	other	via	the	alveolar	epithelium;	a	subset	of	AM	form	gap	junctions	with	alveolar	epithelial	cells	(AEC)	via	connexin	43	hemichannels.		Stimulation	of	AM	induces	cyclical	synchronised	Ca2+	release	that	serves	to	inhibit	excess	inflammatory	response	(Westphalen,	Gusarova	et	al.	2014).		AM	suppress	immune	responses	by	inhibiting	dendritic	cell	(DC)	mediated	T	cell	activation,	and	by	secreting	TGFβ.		αVβ6	integrins	on	AEC	are	critical	in	the	activation	of	secreted	non-active	TGFβ	 (Kopf,	 Schneider	 et	 al.	 2015).	 CD200L	on	 epithelial	 cells	 interacting	with	CD200R	on	AM	negatively	regulates	inflammatory	responses,	as	does	signal	regulatory	protein	α	(SIRPα)	
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on	AM	interacting	with	SP-	A	and	D.	 	These	negative	inhibitory	signals	are	overcome	by	the	combined	ligation	of	multiple	pattern	recognition	receptors	(PRR).		
In	 mouse	 models,	 depleting	 AM	 reduced	 inflammation	 in	 low	 inoculum	 infection	 models.		This	was	 associated	with	 increased	bacterial	 counts	 in	 the	 lung,	 and	 as	 this	was	 simulated	with	 caspase	 inhibition,	macrophages	 apoptosis	 is	 important	 in	bacterial	 control	 (Dockrell,	Marriott	et	al.	2003,	Sun	and	Metzger	2008).		Depleting	AM	in	mice,	then	infecting	them	with	
S.	pneumoniae,	induced	increased	neutrophil	infiltrate	along	with	pro-inflammatory	cytokine	profile	 and	 reduced	 IL10	 at	 20	 and	 48	 hours	 post	 infection	 (Knapp,	 Leemans	 et	 al.	 2003).		This	is	supportive	evidence	that	eventually	there	will	be	a	pro-inflammatory	response	from	other	 airway	 cells,	 and	 epithelial	 cells	 are	 the	 likely	 candidates.	 	 In	 addition	macrophages	play	 a	 role	 in	 clearance	 of	 apoptotic	 neutrophils	 as	 increased	 numbers	 of	 apoptotic	neutrophils	are	seen	in	lungs	after	macrophage	depletion.	
1.2.7.3	Non	conventional	T	cells	Non-conventional	 T	 cells	 have	 T	 cell	 receptors	 (TCR)	 that	 only	 recognise	 conserved	 non-peptide	 antigens	 and	 secrete	 cytokines	 in	 response.	 	Invariant	 natural	 killer	 T	 cells	 (iNKT)	cells	express	invariant	TCR	and	NK	receptors	and	recognise	glycolipid	antigens	presented	by	CD1d	 on	 antigen	 presenting	 cells	 and	 produce	 IFNγ	 and	 IL17A	 in	 response	 to	 α-glucosyldiacylgycerol	 from	 S.	 pneumoniae	 cell	 wall	 in	 vitro	 (Kinjo,	 Illarionov	 et	 al.	 2011).		They	 express	 costimulatory	molecules	 such	 as	 CD40L,	 activate	 DCs	 and	NK	 cells	 and	 have	cytolytic	abilities	by	secreting	granzyme	B	and	contribute	 to	FAS	 ligand	 induced	apoptosis.		iNKT	cells	are	found	in	mucosal	sites;	making	up	0.1-0.2%	of	T	cells	in	BAL	or	sputum.		Jα18	deficient	 mice,	 which	 lack	 iNKT	 had	 higher	 bacterial	 counts	 and	 worse	 survival	 in	 S.	
pneumoniae	 pneumonia(Kawakami,	 Yamamoto	 et	 al.	 2003).	 	 .	 	 This	 was	 associated	 with	reduced	TNF,	CXCL2	and	neutrophil	recruitment	The	phenotype	was	rescued	by	transfer	of	cells	 from	wild-type	mice,	 but	 not	 for	 IFNγ	 knockout	mice,	 suggesting	 that	 the	 IFNγ	 from	iNKT	cells	was	 important	 in	the	protective	effect	(Nakamatsu,	Yamamoto	et	al.	2007).	They	
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may	also	 increase	antigen	presentation	by	DCs	and	enhance	CD4	T	cells	ability	 to	 induce	B	cell	production	of	Ig	(Ivanov,	Paget	et	al.	2014).		
Mucosal	associated	Invariant	T	(MAIT)	cells,	which	account	for	1-10%	of	circulating	T	cells,	are	 found	 in	 lung	mucosa	and	secrete	 IFNγ	and	TNF	(Ivanov,	Paget	et	al.	2014).	 	Their	TCR	are	 restricted	 to	 antigens	 presented	 by	Major	 Histocompatibility	 Complex	 (MHC)	 I	 related	molecule	 (MR1).	 	They	 recognise	 riboflavin	metabolites	 that	 aren't	 produced	 by	mammals.		Genome	 analysis	 of	 S.	 pneumoniae	 suggests	 it	may	 express	 enzymes	 involved	 in	 riboflavin	metabolism.		MAIT	cells	are	also	stimulated	by	IL1β,	IL12	and	IL23.		
γδT	 cells	 appear	 to	 modulate	 the	 inflammatory	 response	 to	 other	 organisms	 in	 the	respiratory	 tract	 despite	 being	 present	 in	 low	 numbers.	 	 They	 recognise	 stress	 signals	 via	damage	 associated	 molecular	 patterns	 (DAMPs)	 through	 their	 TCRs,	 activated	 via	 non-classical	 MHC	molecules	 such	 as	 CD1,	 as	 well	 as	 recognition	 of	 other	 stress	 molecules	 by	PRRs,	NK	 receptors,	 and	 cytokines.	 	Their	 functions	 include	 cytokine	 release,	perforins	 and	granzymes	 for	 direct	 toxicity,	 and	 the	 induction	 of	 apoptosis	 via	 Fas	 and	TRAIL.	 	γδT	 cells	numbers	 increased	 by	 30	 fold	 following	 S.	 pneumoniae	 intranasal	 inoculation	 of	 mice,	peaking	at	7-10	days	(Ivanov,	Paget	et	al.	2014).	 	Compared	to	wild-type,	γδT	cells	deficient	mice	had	worse	survival	associated	with	reduced	CXCL2,	TNF,	and	IL17	with	poor	neutrophil	recruitment	 to	 the	 lungs	after	S.	pneumoniae	 infection.	 	The	γδ	T	cells	of	 influenza	 infected	mice	were	less	able	to	produce	IL17	in	response	to	S.	pneumoniae	and	therefore	contribute	to	influenza	induced	S.	pneumoniae	 infection	(Li,	Moltedo	et	al.	2012).	 	γδ	T	cells	are	probably	also	 involved	 in	 the	 resolution	 of	 inflammation	 by	 inducing	 cytotoxic	 cell	 death	 of	inflammatory	monocytes	(Kirby,	Newton	et	al.	2007).		However,	the	mechanism	by	which	S.	
pneumoniae	induces	their	activation	remains	unclear.	
1.2.7.4	Neutrophils		Neutrophils	 are	 the	 first	 cells	 recruited	 to	 sites	 of	 injury	 and	 infection,	 primarily	 by	responding	 to	 CXCL1,	 2,	 and	 8,	 and	 upregulating	 integrins	 to	 allow	 directed	 migration	
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(Kadioglu,	De	Filippo	et	al.	2011).	 	The	anatomy	of	the	narrow	pulmonary	microvasculature	means	that	neutrophils	have	slow	intra-pulmonary	transit	times	and	hence	can	respond	very	rapidly	 to	 pulmonary	 inflammation.	 	 Neutrophils	 primarily	 engage	 with	 pathogens	 via	phagocytosis	 and	 intracellular	 killing	 in	 phagolysosomes.	 	 They	 also	 produce	 neutrophil	extracellular	 traps	 by	 extruding	 their	 chromatin,	 entrapping	 pathogens	 and	 then	 exposing	them	 to	 antimicrobial	 compounds.	 	 While	 required	 for	 bacterial	 clearance	 in	 murine	pneumonia	models,	they	also	induced	bystander	alveolar	epithelial	barrier	disruption	(Jose,	Williams	et	al.	2015).	
Neutropenic	patients	have	increased	rates	of	bacteraemia	with	pneumonia,	and	while	they	do	not	have	increased	rates	of	S.	pneumoniae	infection	they	have	very	high	mortality	both	after	chemotherapy	(Carratalà,	Marron	et	al.	1997)	and	after	haematopoetic	stem	cell	 transplant	(Engelhard,	Cordonnier	et	al.	2002).	 	 Steroids	also	reduce	neutrophil	 function	and	 increase	rates	 of	 IPD,	 but	 have	 complex	 effects	 on	 the	 immune	 system	 apart	 from	 this.	 	 The	 main	mechanism	of	neutrophil	antimicrobial	function	is	by	the	oxidative	burst	that	generates	ROS	via	NADPH	oxidase.	However,	humans	with	chronic	granulomatous	disease	(exhibit	failure	of	ROS	 production)	 don’t	 have	 excessive	 rates	 of	 S.	 pneumoniae	 infection.	 	 Neutrophils	 also	contain	granules	with	antimicrobial	compounds.	 	Azurophilic	(or	primary)	granules	contain	defensins,	 myeloperoxidase,	 BPI	 and	 serine	 proteases	 such	 as	 elastase,	 cathepsin	 G	 and	proteinase	 3.	 	 BPI	 and	 defensins	 disrupt	 anionic	 bacterial	 surface,	 and	 serine	 proteases	degrade	bacterial	proteins.		Specific	(or	secondary)	granules	contain	microbicidal	agents	like	lactoferrin	(Kumar	and	Sharma	2010).			
Patients	with	Chediak-Higashi	syndrome	have	a	non-functional	lysosomal	trafficking	protein,	leading	 to	 failure	of	phagolysosome	 formation	and	reduced	 lysosomal	degranulation.	 	They	have	 increased	 incidence	 of	 S.	 pneumoniae	 infections	 amongst	 other	 disease	 forming	pathogens.	 	In	vitro	studies	suggest	that	the	serine	proteases	appear	to	be	the	predominant	method	by	which	neutrophils	kill	S.	pneumoniae	(Standish	and	Weiser	2009).	 	Studies	with	cathepsin	 G	 deficient	 and	 cathepsin	 G/neutrophil	 elastase	 double	 knockout	 mice	 showed	
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increased	mortality	and	shorter	survival	with	a	non-invasive	19F	S.	pneumoniae	pneumonia.		This	was	 associated	with	 bacterial	 outgrowth	 in	 the	 lung,	 and	 increased	 lung	 permeability	and	 poorer	 oxygenation	 in	 the	 knockout	mice,	 though	 this	 was	 not	 related	 to	 numbers	 of	recruited	neutrophils	(Hahn,	Klaus	et	al.	2011).	
Neutrophils	 have	 a	 short	 lifespan	 due	 to	 encoded	 apoptosis	 that	 is	 regulated	 by	 external	signals;	 cross-linking	 of	 β2	 integrins	 during	 the	 process	 of	 transmigration	 into	 tissue	increases	 their	 life	 span.	 	 Other	 factors	 that	 promote	 survival	 include	 IL6,	 CXCL8,	 and	 the	complement	component	C5a,	whereas	TNF	and	IL10	induce	apoptosis.		S.	pneumoniae	causes	neutrophil	necrosis	within	24	hours,	though	the	mechanisms	are	not	fully	understood	(Zysk,	Bejo	et	al.	2000).		Neutrophils	also	release	CXCL8,	TNF,	CCL3	&	4,	and	IFNγ	that	act	to	recruit	monocytes	and	activate	macrophages.	 	Myeloperoxidase	released	 from	neutrophils	 is	 taken	up	by	macrophages	and	lead	to	ROS	release	and	inflammatory	cytokine	secretion	(Kumar	and	Sharma	2010).			
1.2.7.5	Monocytes		Monocytes	 make	 up	 1-6%	 of	 circulating	 blood	 cells.	 	 They	 are	 generated	 as	 part	 of	 the	inflammatory	 response	 and	 can	 be	 split	 into	 2	 broad	 groups.	 	 ‘Patrolling’	 non-classical	monocytes	remain	amongst	the	vascular	endothelium	expressing	CD16,	CX3CR1	and	CXCR1.		Non-classical	 monocytes	 are	 effectively	 ‘vascular	 macrophages’,	 and	 mainly	 respond	 via	TLR7	 (and	 are	 hyporesponsive	 to	 LPS).	 	 The	 other	 ‘inflammatory’	 classical	 monocytes	express	CD14	and	CCR2	(and	Ly6c	in	mice)	and	are	rapidly	mobilised	from	the	subcapsular	red	 pulp	 and	 bone	 marrow.	 	 After	 exiting	 the	 circulatory	 system,	 they	 differentiate	 into	inflammatory	 macrophages.	 	 Their	 main	 function	 is	 to	 phagocytose	 foreign	 organisms,	particulate	 matter,	 apoptotic	 cells,	 and	 also	 recycling	 nutrients	 (Arango	 Duque	 and	Descoteaux	 2014).	 	 Classical	monocytes	 infiltrate	 inflamed	 tissue	more	 robustly	 than	 non-classical,	 though	 after	 efferocytosis	 they	 become	 less	 ‘classical’	 and	 are	 involved	 in	 tissue	repair	(Italiani	and	Boraschi	2014).	
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Recruited	 inflammatory	macrophages	 undergo	 Fas-ligand	mediated	 apoptosis,	 though	 they	may	 also	 undergo	 phenotypic	 conversion	 to	 tissue	 resident	 macrophages.	 	 Monocyte/	macrophage	development	is	controlled	by	macrophage	colony	stimulating	factor	(or	CSF-1),	granulocyte	 macrophage	 colony	 stimulating	 factor	 is	 also	 involved	 under	 inflammatory	conditions.		
Intranasal	 infection	 of	 mice	 with	 S.	 pneumoniae	 results	 in	 a	 ‘disappearing	 macrophage’	phenomenon	(Taut,	Winter	et	al.	2008).		After	24	hours,	60%	of	the	macrophage	pool	in	BALF	originates	 from	 inflammatory	monocytes;	 this	 reaches	80%	by	7	days	 (alongside	 a	 10	 fold	expansion	 in	 total	macrophage	numbers).	 	The	decline	 in	numbers	of	original	AM	 is	due	 to	apoptosis	 and	 necrosis,	 with	 an	 even	 higher	 rate	 of	 cell	 death	 in	 the	 recruited	 monocyte	derived	 macrophages	 (MDM).	 	 Studies	 inhibiting	 chemotaxis	 of	 monocytes	 indicate	 that	monocytes	play	an	important	role	in	amplifying	inflammation	as	well	as	providing	increased	phagocytic	capability	(Winter,	Herbold	et	al.	2009).	
1.2.7.6	The	Acute	Phase	Response	The	 local	 inflammatory	 response	 to	 S.	 pneumoniae	 infection	 in	 the	 lungs	 stimulates	 a	systemic	response	characterised	by	increased	production	of	multiple	proteins	from	the	liver,	many	of	which	play	a	role	in	host	defence	(Gabay	and	Kushner	1999)	(Table	1.6).		This	acute	phase	 response	 is	 vital	 for	 effective	 host	 defence	 against	 S.	 pneumoniae,	 and	 is	 largely	mediated	 by	 the	 cytokine	 IL6,	which	 is	 produced	 in	 large	 quantities	 during	 S.	 pneumoniae	pneumonia	and	reaches	the	liver	via	the	circulation	(Quinton,	Jones	et	al.	2009).	It	is	not	clear	how	 the	 acute	phase	 response	boosts	 immunity;	 the	 large	 increases	 in	 circulating	 levels	 of	complement	 proteins	 and	 pentraxins	 may	 improve	 recognition	 of	 S.	 pneumoniae	 and	therefore	 neutrophil	 phagocytosis.	 	 In	 addition	 induction	 of	 fever	 may	 inhibit	 optimal	bacterial	 growth.	 	 Furthermore,	 increased	permeability	 of	 the	 endothelium	 allows	 some	of	these	 plasma	 constituents	 and	 cellular	 infiltrate	 into	 affected	 tissues,	 thereby	 promoting	immune	clearance	within	the	lung	during	S.	pneumoniae	infection.	
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Table	1.6	Components	of	the	acute	phase	response	that	play	a	role	in	host	defence		
Component	 Role	in	host	defence	Complement	components:	C3,C4,C9,	Mannose	binding	lectin	
Opsonisation	for	phagocytosis	Binding	 of	 antibody	 bound	 to	 pathogen	 to	 effect	 bacterial	agglutination	or	lysis	(Brown,	Hussell	et	al.	2002)	Opsonisation	for	phagocytosis	C	reactive	protein	 Binds	to	PCho	-	 increasing	agglutination,	allowing	complement	binding	and	phagocytosis	(Simons,	Loeffler	et	al.	2014)	Serum	amyloid	P	 Binds	 to	 negatively	 charged	 carbohydrates	 –	 allowing	complement	binding	and	phagocytosis		Granulocyte	Colony	Stimulating	Factor	 Increases	granulopoesis	and	activates	mature	granulocytes	Coagulation	components:	E.g.	Fibrinogen	 Involved	 in	 tissue	 repair	 and	 local	 containment	 of	 bacterial	infection	(Yang,	Ko	et	al.	2013)	α1	protease	inhibitor	 Inhibit	proteolytic	enzymes	and	reduces	inflammation-induced	damage		
Complement	 is	 a	 series	 of	 host	 proteins	 found	 in	 serum,	 epithelial	 lining	 fluid	 and	 cell	surfaces	 that	 form	 protease	 cascades.	 	When	 activated	 by	 C	 reactive	 protein	 (CRP),	 serum	amyloid	 P,	 antibody,	 or	 the	 complement	 component	 C1q	 binding	 to	 the	 S.	 pneumoniae	surface,	 these	 protease	 cascades	 result	 in	 the	 coating	 of	 the	 bacteria	 with	 C3b	 and	 iC3b	molecules,	 promoting	 phagocytosis	 via	 complement	 receptors	 (Brown,	 Hussell	 et	 al.	 2002,	Hyams,	Camberlein	et	al.	2010),	termed	the	classical	pathway.		This	is	important	in	early	lung	defence	 against	 S.	 pneumoniae	 (Kerr,	 Paterson	 et	 al.	 2005).	 	 The	 alternative	 pathway	 is	mediated	by	spontaneous	hydrolysis	of	C3	on	cell	surfaces,	which	is	inhibited	on	host	cells	by	host	proteins	such	as	factor	H.		S.	pneumoniae	subverts	this	by	PspC	binding	factor	H	(Dave,	Carmicle	 et	 al.	 2004).	 	 The	 proportion	 of	 S.	 pneumoniae	 bound	 by	 C3	 is	 dependent	 on	 the	classical	pathway,	with	 the	alternative	pathway	amplifying	 the	C3	deposition	once	 initiated	(Brown,	 Hussell	 et	 al.	 2002).	 	 The	 mannose	 binding	 lectin	 pathway	 also	 activates	 C3	 on	binding	directly	to	mannose	residues	on	pathogens,	though	its	role	in	S.	pneumoniae	infection	
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is	 contentious	 (Brown,	 Hussell	 et	 al.	 2002,	 Roy,	 Knox	 et	 al.	 2002).	 	 Downstream	 of	 C3	activation	there	is	also	the	cleavage	of	C5,	resulting	in	the	release	of	the	anaphylatoxin	C5a,	as	well	as	the	formation	of	the	membrane	attack	complex	(MAC).		The	pore	forming	function	of	MAC	does	not	seem	to	play	a	role	in	the	clearance	of	S.	pneumoniae	whereas	C5a	is	a	powerful	inflammatory	 mediator	 and	 effective	 chemoattractant	 for	 monocytes	 and	 neutrophils.	 	 A	polymorphism	 in	 C5	 is	 associated	 with	 worse	 outcome	 in	 S.	 pneumoniae	 meningitis	 in	humans	and	mice	(Woehrl,	Brouwer	et	al.	2011).		Neutralising	C5a	antibodies,	in	conjunction	with	dexamethasone	and	antibiotics,	had	an	additional	mortality	benefit	above	 that	of	each	individual	treatment	in	a	murine	meningitis	model	(Kasanmoentalib,	Valls	Seron	et	al.	2015).		
CRP,	which	is	named	after	its	interaction	with	S.	pneumoniae	c-polysaccharide	(also	known	as	TA),	 appears	 to	 have	 evolved	 in	 response	 to	 S.	 pneumoniae	 and	 similar	 bacteria.	 	 It	 binds	PCho	and	can	be	bactericidal	in	conjunction	with	complement.	There	is	no	known	deficiency	of	 CRP	 in	 humans	 suggesting	 it	 has	 important	 functions	 for	 human	 survival.	 	 Injection	 of	human	CRP	 into	mice	 at	 the	 time	 of	 infection	with	S.	 pneumoniae	 improved	 survival.	 	 CRP	deficient	mice	had	reduced	survival	after	intraperitoneal	infection	with	some	serotypes,	but	not	 with	 heavily	 encapsulated	 mucoid	 strains	 originating	 from	 patient	 blood	 cultures	(Simons,	Loeffler	et	al.	2014).	This	may	be	due	to	structural	changes	on	CRP	that	allow	it	to	bind	to	 factor	H	(or	possibly	 ficolins)	which	allow	activation	of	 the	alternative	complement	cascade	on	S.	pneumoniae	(Gang,	Hanley	et	al.	2015).	
No	natural	state	of	serum	amyloid	P	(SAP)	deficiency	has	been	recognised,	also	suggesting	a	non-redundant	 role	 in	host	 immune	 function.	 	 SAP	binds	 to	DNA,	 chromatin,	 and	apoptotic	cells	 to	aid	 clearance,	but	also	 stabilises	amyloid	 fibrils	 and	so	promotes	amyloidosis.	 	 SAP	binds	 to	C1q	and	prevents	 the	 inhibitory	 function	of	C4BP,	and	 thus	may	promote	classical	complement	pathway	activation.		SAP	binds	PCho	and	displays	calcium	dependent	binding	to	
S.	 pneumoniae	 (Yuste,	 Botto	 et	 al.	 2007).	 	 C3b	 deposition	 on	 S.	 pneumoniae	 is	 markedly	reduced	 in	 serum	 from	 SAP	 deficient	mice.	 	 SAP	 deficient	mice	 had	 impaired	 survival	 in	 a	
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murine	 pneumonia	 model	 compared	 to	 wild-type,	 associated	 with	 reduced	 bacterial	clearance,	underlining	its	importance	in	S.	pneumoniae	host	defence.			
Pulmonary	 infections	 initiate	 a	 pro-coagulant	 state	 by	 activating	 coagulation	 pathways,	components	 of	 which	 are	 upregulated	 by	 the	 acute	 phase	 response,	 and	 inhibiting	anticoagulant	and	 fibrinolysis	pathways.	 	The	 tissue	 factor	pathway	 is	 the	main	 initiator	of	inflammation-induced	activation	of	coagulation	and	the	abundance	of	coagulation	proteases	can	further	induce	inflammation	by	activating	proteinase-activated	receptor	(PAR)	signalling,	in	 particular	 PAR-1.	 	 PAR-1	 antagonism	 attenuates	 neutrophilic	 inflammation	 and	 alveolar	leak	in	murine	S.	pneumoniae	pneumonia	(Jose,	Williams	et	al.	2015).	 		In	rodent	studies	of	S.	
pneumoniae	pneumonia	the	use	of	various	anticoagulants	(anti-thrombin,	activated	protein	C,	tissue	factor	pathway	inhibitor)	is	beneficial	at	attenuating	inflammation	(Choi,	Hofstra	et	al.	2008,	Hofstra,	Cornet	et	al.	2009,	Schouten,	van	't	Veer	et	al.	2011,	Van	Den	Boogaard,	Brands	et	 al.	 2011),	 but	 in	 human	disease	 these	 agents	 have	 not	 improved	 outcomes	 (Wunderink,	Laterre	et	al.	2011)	and	are	associated	with	 increased	bleeding.	 	However,	 local	delivery	of	these	anti-coagulants,	limiting	systemic	effects,	may	be	beneficial	(Dixon,	Schultz	et	al.	2010,	van	den	Boogaard,	Hofstra	et	al.	2015).	 	Subgroup	analysis	of	 the	PROWESS	study	suggests	that	 activated	 protein	 C	 improved	 outcome	 in	 patients	 with	 sepsis	 secondary	 to	 S.	
pneumoniae	CAP	(Ely,	Laterre	et	al.	2003,	Laterre,	Garber	et	al.	2005).		So,	pathways	involved	in	 coagulation-inflammation	 crosstalk	may	be	 amenable	 to	 intervention	 to	 reduce	 the	 lung	damage	from	an	excessive	inflammatory	response	without	compromising	host	defence.	
1.3	Overview	on	adaptive	response	to	S.	pneumoniae	The	 innate	 immune	 response	 to	 invading	 pathogens	 is	 generic,	 able	 to	 target	 conserved	microbial	 structures	 without	 the	 host	 having	 had	 prior	 exposure	 to	 that	 pathogen.	 	 In	contrast,	 the	 adaptive	 response	 is	 highly	 specific,	 depending	 on	 recognition	 of	 antigens	expressed	by	pathogens.		Generating	an	adaptive	immune	response	can	take	days	after	initial	exposure	 to	 pathogen,	 but	 also	 generates	 memory	 cells,	 which	 enable	 a	 more	 rapid	 and	
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powerful	 response	 when	 that	 pathogen	 is	 subsequently	 re-encountered.	 	 S.	 pneumoniae	colonisation	of	 the	nasopharynx	elicits	an	adaptive	 immune	response	that	can	help	prevent	colonisation,	pneumonia	and	invasive	disease.		Immune	deficiencies	that	cause	defects	in	the	adaptive	immune	response	such	as	antibody	deficiency	(Martinot,	Oswald	et	al.	2014)	and	T	cell	 deficiencies	 (Klein,	 Lisowska-Grospierre	 et	 al.	 1993)	 lead	 to	 increased	 rates	 of	 S.	
pneumoniae	pneumonia.			
1.3.1	Dendritic	cells	DC	are	found	in	lamina	propria,	intercalating	between	epithelial	cells,	and	plasmacytoid	DCs	are	found	in	the	conducting	airways.		During	inflammation,	monocyte	derived	inflammatory	DCs	 are	 also	 found	 (Werner	 and	 Steele	 2014).	 	 Dendritic	 cells	 in	 the	 submucosa	 are	responsible	 for	 phagocytosing	 pathogens,	 migrating	 to	 regional	 lymphoid	 tissue,	 and	presenting	 antigens	 to	 naïve	 lymphocytes.	 	 S.	 pneumoniae	 phagocytosis	 stimulates	 DC	maturation	 as	 measured	 by	 expression	 of	 MHC,	 CD80,	 and	 CD86	 (Olliver,	 Spelmink	 et	 al.	2013).			
1.3.2	B	lymphocyte	and	antibody	Prior	 infection	 leads	 to	 induction	 of	 an	 antibody	 response	 by	 B	 lymphocytes	 to	 specific	bacterial	 antigens.	 	 The	 high	 incidence	 of	 lung	 infections	 in	 subjects	 with	 antibody	deficiencies	 and	 the	 efficacy	 of	 antibody-inducing	 vaccines	 at	 preventing	 S.	 pneumoniae	pneumonia	in	children	demonstrate	an	important	role	for	antibody	for	protection	against	S.	
pneumoniae.	 	 Antibody	 improves	 immunity	 to	 S.	 pneumoniae	 by	 activating	 complement	deposition,	 so	 promoting	 complement-mediated	 phagocytosis,	 and	 by	 increasing	 direct	phagocytosis	 by	 Fcγ	 receptor	 recognition	 of	 the	 antibody.	 	 They	 also	 cause	 bacterial	agglutination	(Roche,	Richard	et	al.	2015),	which	 is	 likely	to	be	how	the	conjugated	vaccine	prevents	nasopharyngeal	colonisation.		Adults	with	antibody	deficiencies	have	increased	risk	of	developing	IPD,	including	those	with	IgG	deficiency,	IgA	deficiency,	isolated	IgM	deficiency,	and	paraproteinaemias	(Martinot,	Oswald	et	al.	2014).	
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S.	 pneumoniae	 proteins	 and	 polysaccharide	 capsule	 are	 recognised	 as	 antigens	 by	 the	adaptive	 immune	 system.	 	 Polysaccharide	 antigens	 generate	 a	 poor	 adaptive	 immune	response	as	 these	 antigens	 are	unable	 to	 stimulate	T	 lymphocytes	 to	 assist	B	 cell	 antibody	responses.		This	type	II	T	cell-independent	activation	generates	rapid	B	cell	proliferation	and	antibody	production	(largely	IgM,	but	also	IgG)	by	crosslinking	of	multiple	B	cell	receptors	on	the	surface	of	B	lymphocyte.		While	there	is	some	class	switch	recombination	(IgA	and	IgG3)	and	somatic	hypermutation	(Krljanac,	Weih	et	al.	2014),	there	is	no	generation	of	a	memory	B	cell	population.	 	So	the	response	is	 largely	 limited	to	antibodies	of	relatively	poor	affinity	(Coutinho	and	Moller	1973),	and	as	a	result	vaccination	with	capsular	polysaccharide	alone	is	ineffective	 in	 infants.	 	T	cell-independent	responses	occur	primarily	 in	(i)	B	 lymphocytes	 in	the	marginal	zone	of	the	spleen	(Cerruti,	Cols	et	al.	2013),	and	(ii)	B-1	like	cells	(Verbinnen,	Covens	et	al.	2012)	which	reside	 in	pleural	and	peritoneal	cavities,	but	also	circulate	 in	 the	blood	and	lymphatics	(Vos,	Lees	et	al.	2000).		
Protein	 antigens	 stimulate	 a	 T-cell	 dependent	 B	 lymphocyte	 antibody	 response	 that	generates	a	memory	B	cell	population	and	can	therefore	lead	to	a	memory	response	and	are	effective	in	infants.		Polysaccharide	immunogenicity	has	been	improved	by	conjugation	with	carrier	protein	adjuvants	to	induce	a	T	cell	dependent	antibody	response	to	the	capsule.	IgG	and	 IgM	 titres	 to	 capsular	 polysaccharide	 are	 detectable	within	 6	 days	 of	 vaccination	 and	weeks	of	nasopharyngeal	colonisation	(Musher,	Groover	et	al.	1993,	Goldblatt,	Hussain	et	al.	2005).			
Patients	 who	 have	 undergone	 splenectomy	 have	 higher	 incidence	 of	 infections	 with	encapsulated	 bacteria,	 probably	 due	 to	 reduced	 levels	 of	 IgM	memory	 B	 cells	 to	 capsular	polysaccharide	 in	 the	blood.	 	The	presence	of	 IgM	memory	 cells	 correlates	with	protection	against	 IPD,	and	administration	of	capsule	specific	 IgM	is	protective	 in	a	mouse	pneumonia	model	 (Burns,	 Abadi	 et	 al.	 2005).	 	 A	 subgroup	 of	 patients	with	 common	 variable	 immune	deficiency	who	have	recurrent	IPD	have	normal	total	Ig	levels,	but	reduced	IgM	memory	cells	(Kruetzmann,	Rosado	et	al.	2003).	
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IgA	 is	 the	 most	 common	 antibody	 at	 mucosal	 surfaces	 where	 it	 primarily	 functions	 by	agglutinating	pathogens.	 	S.	pneumoniae	 IgA1	protease	removes	 the	Fc	domain	at	 the	hinge	region	 so	 it	 no	 longer	 has	 agglutination	 ability	 (Weiser,	 Bae	 et	 al.	 2003).	 	 In	 addition	 the	function	 of	 IgA	 is	 subverted	 as	 the	 cleavage	 of	 opsonising	 IgA	 allows	 a	 neutralisation	 of	surface	charge	and	increased	proximity	of	cell	wall	epithelial	membrane	receptors.			
1.3.3	T	lymphocytes	Cellular	 adaptive	 immune	 responses	 are	 driven	 by	 T	 lymphocytes,	 which	 recognise	internalised	antigen	presented	on	MHC	II	molecules.	 	CD4	expressing	helper	T	cells	secrete	cytokines	 to	 affect	 cells	 in	 the	 local	 milieu,	 while	 CD8	 expressing	 cytotoxic	 T	 cells	 induce	apoptosis	 of	 host	 cells	 infected	 with	 intracellular	 pathogens.	 	 In	 adaptive	 immunity,	 the	presentation	of	antigens	to	naïve	T	cells	in	lymph	nodes	by	DCs	drives	the	activation	of	T	cells	and	directs	their	development	into	specific	effector	T	cells.		
Studies	 with	 naïve	 CD4	 T	 cells	 have	 found	 conflicting	 roles	 in	 innate	 pulmonary	 S.	
pneumoniae	 infection.	 	 Prior	 colonisation	 with	 S.	 pneumoniae	 protects	 against	 subsequent	colonisation	 by	 both	 homologous	 and	 heterologous	 S.	 pneumoniae.	 	 Some	 authors	 have	shown	 that	 this	protection	 is	dependent	on	memory	CD4	 cells	 and	antibody	 responses	 are	dispensable	 (Kadioglu,	 Coward	 et	 al.	 2004),	 while	 other	 have	 shown	 increased	 survival	 in	mice	deficient	in	CD4	cells	(LeMessurier,	Hacker	et	al.	2010).		Depletion	of	CD4	cells	at	time	of	 infection	also	reduces	protection	 in	some	models,	suggesting	that	CD4	T	cells	need	to	be	present	at	time	of	challenge	to	have	a	protective	effect	(Malley,	Trzcinski	et	al.	2005).			
Th1	 cells	 are	 a	 subset	 of	 helper	 T	 lymphocytes	 that	 secrete	 IFNγ,	 the	 effect	 of	which	 is	 to	‘activate’	macrophages,	 increasing	phagocytosis	and	 intracellular	killing.	 	Furthermore,	Th1	cells	 induce	 B	 cell	 isotype	 switching	 to	 IgG2	 antibody,	 which	 correlates	 with	 increased	phagocytic	ability	in	mice	(Lefeber,	Benaissa-Trouw	et	al.	2003).		Live	S.	pneumoniae	interact	with	multiple	intracellular	receptors	to	induce	IL12	and	thus	a	Th1	response	(Olliver,	Hiew	et	
	 64	
al.	 2011),	 but	 it	 is	 not	 known	whether	Th1	 responses	 improve	 adaptive	 immune	mediated	protection	against	subsequent	infection.	
CD4	 Th17	 cells	 indirectly	 improve	 immunity	 against	 extracellular	 pathogens	 on	 mucosal	surfaces	via	secretion	of	IL17,	IL17F,	and	IL22.		IL17	induces	bronchial	epithelium	to	produce	CXCL8	 and	 β-defensins,	 resulting	 in	 neutrophil	 recruitment	 and	 increased	 mucosal	antimicrobial	activity	respectively.	 	Th17	responses	also	improve	epithelial	barrier	integrity	and	increase	export	of	Ig	to	mucosal	surfaces.		Patients	with	hyper	IgE	syndrome	have	defects	in	 Th17	 cell	 differentiation	 and	 have	 increased	 susceptibility	 to	 S.	 pneumoniae	 pneumonia	(Milner,	 Brenchley	 et	 al.	 2008),	 and	 experimental	 human	 colonisation	 with	 S.	 pneumoniae	resulted	 in	detectable	Th17	responses	 in	BALF	and	blood	(Wright,	Bangert	et	al.	2013).	 	 In	animal	 models	 Th17	 responses	 to	 colonisation	 or	 vaccination	 inhibit	 S.	 pneumoniae	colonisation	and	pneumonia	(Zhang,	Clarke	et	al.	2009,	Moffitt,	Gierahn	et	al.	2011,	Wilson,	Cohen	 et	 al.	 2014),	 and	 recombinant	 IL17F	 increases	CXCL2,	 β-defensin	 and	 IFNγ	 levels	 in	lung	 and	 reduces	 bacterial	 load	 (Chen,	 Guo	 et	 al.	 2014).	 	 External	 PRR	 engagement	 of	monocytes	with	S.	pneumoniae	or	 its	cell	wall	constituents	skews	towards	a	Th17	response	(Olliver,	Hiew	et	al.	2011).		
Regulatory	 T	 lymphocytes	 (Treg)	 are	 important	 in	 host	 resistance	 to	 S.	 pneumoniae	pneumonia	 in	mice.	 	Tregs	 cells	 limit	 excessive	 inflammation	by	 secreting	 IL10.	 	 In	murine	pneumonia	 models,	 CD25	 positive	 T	 cells	 migrate	 preferentially	 to	 sites	 of	 infection	(Kadioglu,	 Coward	 et	 al.	 2004).	 	Mice	 strains	 that	 are	 relatively	 resistant	 to	 infection	 have	more	Tregs,	TGFβ	(which	drives	the	differentiation	of	naïve	T	cells	into	Tregs)	and	IL10.	This	is	 probably	 because	 regulation	 of	 the	 inflammatory	 response	 during	 S.	 pneumoniae	pneumonia	 helps	 prevent	 the	 bacteria	 from	 penetrating	 the	 epithelial	 layers	 to	 cause	septicaemia	 (Neill,	 Fernandes	 et	 al.	 2012).	 S.	 pneumoniae	 induces	 TGFβ	 secretion	 from	human	fibroblasts	and	epithelial	cells,	suggesting	that	this	drives	T	cell	differentiation	in	the	nasopharynx	(Neill,	Coward	et	al.	2014).	
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CD8	cells	are	usually	associated	with	responses	to	intracellular	organisms.		However	genetic	mutations	in	humans	affecting	transporter	associated	with	antigen	processing	(TAP)	proteins	required	 for	 CD8	 function	 are	 associated	 with	 an	 increased	 incidence	 of	 S.	 pneumoniae	infection	(Gadola,	Moins-Teisserenc	et	al.	2000),	and	in	a	mouse	model	of	lung	infection	CD8	deficient	mice	had	greater	levels	of	bacteraemia	with	several	serotypes	of	S.	pneumoniae	and	poorer	 survival	 with	 serotype	 3.	 	 The	 mechanism	 appears	 to	 be	 the	 role	 of	 CD8	 cells	 in	inhibition	of	CD4	 (particularly	Th17)	mediated	 inflammation	 (Weber,	Tian	et	 al.	 2011),	 via	the	secretion	of	IL10	and	TGFβ	(Mertens,	Fabri	et	al.	2009).		The	role	of	CD8	cells	for	adaptive	immunity	to	S.	pneumoniae	requires	further	characterisation.				 	
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1.4	Macrophage	Biology		
1.4.1	Pattern	Recognition	Receptors	The	 host	 immune	 system	 recognises	 S.	 pneumoniae	 via	 PRR	 that	 recognise	 pathogen	associated	molecular	patterns	(PAMP)	such	as	bacterial	virulence	factors	or	DAMPs	released	by	endogenous	cells	as	a	result	of	 tissue	damage	(Figure	1.3	and	Table	1.7).	 	Stimulation	of	PRRs	results	in	cell	signalling	cascades	that	result	in	altered	gene	transcription	to	trigger	an	immune	response.	 	PRRs	are	often	situated	on	cell	surface	membranes,	but	are	also	present	on	endosomes	 to	 recognise	phagocytosed	PAMPs	and	 the	 cytosol	 to	 recognise	 intracellular	PAMPs.	Tissue	 resident	macrophages	 serve	 as	 the	 surveillance	 system	 for	 the	body	 and	 as	such	 express	 an	 array	 of	 receptors	 that	 act	 as	 PRR.	 	 They	 include	 opsonic	 phagocytic	receptors	 such	 as	 Fc	 receptors	 for	 Ig	 and	 complement	 receptors.	 	 Non-opsonic	 phagocytic	receptors	 include	 lectins	 such	 as	 dectin-1	 and	 dendritic	 cell-specific	 ICAM-3	 grabbing	 non	integrin	 (DC-SIGN),	 and	 scavenger	 receptors	 such	 as	 scavenger	 receptor	 A	 (SR-A)	 and	MARCO.	 	 Non-phagocytic	 receptors	 are	 expressed	 on	 cell	 surface	 and	 phagolysosome	membranes	 (toll	 like	 receptors	 [TLRs])	 or	 are	 found	 in	 the	 cytosol	 (nucleotide-binding	oligomerization	 domain	 receptors	 [NOD],	 retinoic	 acid-inducible	 gene	 1	 [RIG-I],	 and	 the	inflammasome).		 	
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Figure	1.4	Pattern	Recognition	Receptors	expressed	by	macrophages	Cell	 surface	 PRR	 such	 as	 TLR2	 and	 TLR4	 induce	 cell	 signalling	 cascades	 that	 culminate	 in	NFκB	translocating	to	the	nucleus	to	induce	pro-inflammatory	cytokine	transcription.	 	Non-opsonic	 PRR	 such	 as	 MARCO	 and	 DC-SIGN	 recognise	 pathogen	 constituents	 that	 induce	phagocytosis.	 	 Opsonic	 PRR	 such	 as	 Fcγ	 recognise	 antibody	 that	 results	 in	 phagocytosis.		Endosomal	 PRR	 such	 as	 TLR9	 function	 like	 cell	 surface	 PRR	 and	 initiate	 cytokine	transcription,	 including	pro-inflammatory	 cytokines	 and	 type	 I	 IFN.	 	 Cytosolic	PRR	 such	 as	NOD2	 and	 STING	 recognise	 PG	 and	 bacterial	 DNA	 respectively	 to	 initiate	 cytokine	transcription.	 	NLRP3	and	AIM2	 recognise	 the	K+	 ion	 shifts	 and	bacterial	DNA	 respectively	and	 form	part	 of	 the	 inflammasome;	 a	multicomponent	 protein	 complex	 that	 initiate	 post-translational	modifications	to	activate	cytokines	such	as	IL1β.	
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Table	1.7:	Macrophage	pattern	recognition	receptors	
PRR	
	
Cellular	
localisation	
S.	pneumoniae	
ligand	
Consequences	of	
activation	
References	
TLR	2		 Leucocyte	and	epithelial	cell	surface	 Lipoproteins	Cell	wall	constituents?	 Pro-inflammatory	cytokine	transcription	 (Tomlinson,	Chimalapati	et	al.	2014)	TLR	4		 Leucocyte	and	epithelial	cell	surface	 Pneumolysin?	 Pro-inflammatory	cytokine	transcription	 (Malley,	Henneke	et	al.	2003)	TLR	9		 Leucocyte	endosomes	 Unmethylated	CpG	DNA	fragments	 Pro-inflammatory	cytokine	transcription	Type	1	IFN	transcription	
(Albiger,	Dahlberg	et	al.	2007)	
NOD	2		 Leucocyte	cytoplasm	 Cell	wall	muramyl	dipeptide	 Pro-inflammatory	cytokine	transcription	 (Davis,	Nakamura	et	al.	2011)	AIM2		 Cytoplasm	 Bacterial	DNA	 Activation	of	pro	IL1β	and	IL18	 (Fang,	Tsuchiya	et	al.	2011)	NLRP3		 Cytoplasm	 Pore	forming	function	of	pneumolysin	 Activation	of	pro	IL1β	and	IL18	 McNeela	et	al.	2010	DC-SIGN	/	SIGN-R1		 Macrophages	and	dendritic	cells	(marginal	zone	of	spleen)	
Capsular	polysaccharide?	 Increased	phagocytosis	Complement	activation?	Improved	natural	IgM	production?	
(Koppel,	Wieland	et	al.	2005)	
Unknown		 Cytoplasm	 Bacterial	DNA	 Activation	of	STING	to	induce	Type	1	IFN	transcription	 (Parker	and	Prince	2011)	MARCO		 Macrophages	 Unknown	 Increased	phagocytosis	Amplification	of	other	PRR	signalling	
(Arredouani,	Yang	et	al.	2004)	
Scavenger	receptor	A		 Macrophages	 Unknown	 Increased	phagocytosis	 (Arredouani,	Yang	et	al.	2006)	SP-A	&	SP-D	surfactant	proteins		
Epithelial	lining	fluid		 Surface	mannose	&	glucose	residues	 Increased	phagocytosis	 (Jounblat,	Clark	et	al.	2005,	Sano,	Kuronuma	et	al.	2006)	
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1.4.1.1	Toll	Like	Receptors	Toll	 like	receptors	(TLR)	are	a	 family	of	single,	membrane-spanning,	non-catalytic	proteins.		There	 are	 10	 members	 in	 humans.	 	 TLR	 1,	 2,	 4,	 5,	 and	 6	 are	 situated	 on	 the	 cell	 surface	membrane	 and	 the	 rest	 reside	 on	 endosomes.	 	When	 they	 recognise	 PAMPs	 they	 activate	signalling	 pathways	 by	 a	 number	 of	 adaptor	 molecules.	 	 TLR2,	 4	 and	 9	 are	 probably	 the	dominant	 TLRs	 for	 driving	 inflammatory	 responses	 to	 S.	 pneumoniae	 and	 are	 discussed	 in	detail	below.		TLR3	recognises	double	stranded	RNA,	TLR5	recognises	flagellin,	and	TLR7	&	8	recognise	 single	 stranded	 RNA.	 	 The	 function	 of	 TLR10	 is	 not	 entirely	 clear,	 though	 it	 has	been	linked	to	recognition	of	influenza	strains	as	well	as	H.	pylori	LPS.	
TLR	2	heterodimerises	with	TLR6	 to	 recognise	diacylated	 lipoproteins	 from	S.	 pneumoniae	(Tomlinson,	Chimalapati	et	al.	2014),	and	heterodimerises	with	TLR1	to	recognise	triacylated	lipopetides	 from	 Gram-negative	 bacteria	 (Schenk,	 Belisle	 et	 al.	 2009).	 LTA	 may	 activate	inflammatory	cytokine	release	by	binding	 to	TLR2,	but	 is	enhanced	by	 the	presence	of	LPS	binding	 protein	 (LBP)	 and	 CD14	 (Schroder,	 Morath	 et	 al.	 2003).	 	 A	 human	 cell	 line	transfected	with	CD14	and	TLR2	had	increased	NFκB	translocation	in	response	to	purified	PG	or	 heat	 killed	 S.	 pneumoniae	 in	 a	 dose	 dependent	 manner	 (Yoshimura,	 Lien	 et	 al.	 1999).		However	the	identified	TLR2	responses	to	LTA	and	PG	may	be	caused	by	contamination	with	lipoproteins	 (Travassos,	 Girrardin	 et	 al.	 2004).	 	 A	 cell	 line	 transfected	 with	 TLR2	 were	activated	 by	 live	 or	 heat	 killed	 S.	 pneumoniae,	 and	 TLR2	 neutralising	 antibodies	 reduced	peripheral	 blood	 mononuclear	 cell	 secretion	 of	 TNF,	 IL6	 and	 CXCL8	 in	 response	 to	 S.	
pneumoniae	(Mogensen,	Paludan	et	al.	2006).	
There	was	 less	 IL1β,	 IL6,	and	KC	 in	 lung	homogenates	of	TLR2	deficient	mice	compared	 to	wild-type	 in	 a	 murine	 pneumonia	 model	 (Knapp,	 Wieland	 et	 al.	 2004).	 	 However	 the	mortality	 rate	 of	 the	mice	 and	 bacterial	 counts	within	 the	 lung	were	 similar.	 	 AM	 isolated	from	 knockout	 mice	 secreted	 less	 TNF	 and	 KC	 after	 being	 exposed	 to	 heat	 killed	 S.	
pneumoniae	compared	to	wild-type.	 	TLR2	deficient	mice	colonised	with	S.	pneumoniae	had	reduced	 IL6	 transcription	 in	 nasopharyngeal	 tissue	 compared	 to	 wild-type,	 and	 less	 non-
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secretory	 IgG	 in	 nasopharyngeal	 washes	 indicating	 less	 leakage	 from	 blood	 into	 mucosa.		Immunohistochemical	analysis	demonstrated	that	this	was	due	to	epithelial	cell	stimulation	resulting	in	Snail1	(downstream	of	TGFβ	signalling)	upregulation	after	infection	in	wild-type	mice,	but	not	TLR2	deficient	mice	(Beisswenger,	Lysenko	et	al.	2009).			
TLR4	is	best	known	as	a	specific	receptor	for	LPS,	but	requires	the	accessory	molecule	MD-2,	which	 binds	 to	 the	 ectodomain	 of	 TLR4	 and	 affects	 subcellular	 localisation.	 	 Some	 authors	report	that	TLR	4	recognises	Ply	(Srivastava,	Henneke	et	al.	2005).		TLR4	reporter	cells	were	stimulated	by	wild-type,	but	not	Ply	deficient	S.	pneumoniae.	 	Mice	 lacking	 functional	TLR4	were	 more	 susceptible	 to	 nasopharyngeal	 colonisation	 and	 had	 reduced	 survival	 in	 a	pneumonia	 model	 (Malley,	 Henneke	 et	 al.	 2003).	 	 Other	 authors	 report	 that	 HEK	 cells	transfected	with	TLR4	did	not	respond	to	S.	pneumoniae	(Mogensen,	Paludan	et	al.	2006),	and	that	TLR4	was	only	protective	in	a	low	dose	in	vivo	infection	(Branger,	Knapp	et	al.	2004).	
TLR9	 recognises	 the	 unmethylated	 CpG	 motifs	 of	 prokaryotic	 organisms.	 	 Some	polymorphisms	 in	 TLR9	 are	 associated	 with	 reduced	 production	 of	 CXCL8	 from	 AM	 in	response	 to	 S.	 pneumoniae	 (Berenson,	 Kruzel	 et	 al.	 2015).	 	 In	 a	 mouse	 S.	 pneumoniae	pneumonia	model,	TLR9	deficient	mice	had	reduced	survival,	increased	lung	bacterial	counts	and	 bacteraemia	 compared	 to	 wild-type.	 	 Primary	 AM	 and	 bone	 marrow	 derived	macrophages	 (BMDM)	 from	 TLR9	 deficient	 mice	 had	 reduced	 ability	 to	 phagocytose	 S.	
pneumoniae	 (Albiger,	Dahlberg	 et	 al.	 2007).	 	 This	 suggests	 that	TLR9	has	 a	 non-redundant	role	in	resident	airway	macrophage	killing	of	S.	pneumoniae.		HEK	cells	transfected	with	TLR9	are	activated	by	 live	but	not	heat	killed	S.	pneumoniae	 as	well	 as	DNA	 from	S.	pneumoniae.		Peripheral	 blood	mononuclear	 cell	 secretion	 of	 CXCL10	 in	 response	 to	 S.	 pneumoniae	 was	reduced	by	inhibition	of	TLR9	(Mogensen,	Paludan	et	al.	2006).		TLR9	recognition	of	CpG	also	stimulated	 signalling	 via	 myeloid	 differentiation	 primary	 response	 gene	 88	 (MyD88)	 and	interferon	 regulatory	 factor	 7	 (IRF7)	 to	 initiate	 type	 I	 IFN	 secretion	 (Moretti	 and	 Blander	2014).		
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1.4.1.2	NOD	NLRs	 (NOD	 like	 receptors)	 are	 a	 group	 of	 intracellular,	 primarily	 cytosol-based	 PRRs,	 of	which	 22	 have	 been	 identified	 in	 humans	 (Koppe,	 Suttorp	 et	 al.	 2012).	 	 They	 all	 contain	 a	centrally	 located	NOD,	a	C-terminal	 leucine	rich	repeat	(LRR)	that	recognises	 ligands,	and	a	variable	N-terminal	 interaction	domain	that	 initiates	signalling.	 	The	N-terminal	can	consist	of	 caspase	 activation	 and	 recruitment	 domain	 (CARD),	 pyrin	 domains,	 or	 acidic	transactivating	 domains	 (Mogensen	 2009)	 (Figure	 1.4).	 	 NOD	 1	 &	 2	 activation	 results	primarily	 in	 a	 pro-inflammatory	 response	 as	 a	 result	 of	 activation	 of	 the	 NFκB	 pathway.		NOD1	 recognises	 diaminopimelic	 acid,	 which	 are	 cell	 wall	 fragments	 from	 Gram-negative	bacteria,	 whereas	 NOD2	 recognises	 PG	 from	 all	 bacteria.	 	 NOD1	 is	 expressed	 in	many	 cell	types,	but	NOD2	 is	 largely	 restricted	 to	 leucocytes	and	epithelial	 cells	 (Opitz,	Puschel	 et	 al.	2004),	where	its	expression	is	upregulated	by	pro-inflammatory	cytokines.			
NOD2	recognises	muramyl	dipeptide	from	the	S.	pneumoniae	cell	wall,	activating	a	signalling	cascade	 via	 RIP2	 kinase	 that	 culminates	 in	 NFκB	 activation	 (Parker	 and	 Prince	 2011).	 	 S.	
pneumoniae	 is	 largely	resistant	to	 lysozyme	mediated	cell	 lysis	due	to	deacetylation	of	NAG	and	O-acetylation	of	NAM	(Davis,	Nakamura	et	al.	2011).		However,	the	activation	of	NOD2	in	mice	 was	 dependent	 on	 LysM	 (an	 isoform	 of	 lysozyme	 found	 on	 epithelium	 and	 in	phagosomes	of	macrophages	and	neutrophils),	with	release	of	NOD2	ligands	without	lysis	of	
S.	pneumoniae.	 	This	resulted	in	CCL2	release,	and	monocyte	recruitment	in	nasopharyngeal	colonisation.	 	 In	 mouse	 nasopharyngeal	 colonisation	 double	 knock	 out	 NOD2	 and	 TLR2	deficient	mice	 cleared	bacteria	 less	well	 than	 single	knockout	mice	 (Davis,	Nakamura	et	 al.	2011).	 	 Additionally,	 in	 rat	 S.	 pneumoniae	 meningitis	 NOD2	 mRNA	 and	 protein	 were	upregulated	 in	 brain,	 associated	 with	 elevated	 NFκB,	 TNF	 and	 IL6	 levels	 (Liu,	 Han	 et	 al.	2014),	 and	NOD2	deficient	mice	 had	 less	 inflammation	 than	wild-type	 (Liu,	 Chauhan	 et	 al.	2010).			
NOD1	stimulation	by	Gram-negative	organisms	 improved	neutrophil	 killing	of	 complement	opsonised	 S.	 pneumoniae	 (Lysenko,	 Clarke	 et	 al.	 2007).	 	 Similarly	 neutrophils	 from	 mice	
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raised	 in	 a	 germ-free	 environment	 exhibit	 reduced	 killing	 of	 S.	 pneumoniae	 compared	 to	conventionally	raised	mice,	implicating	the	microbiome	as	priming	neutrophil	killing	activity.		NOD1	deficient	mice	had	 increased	rates	of	early	sepsis	but	similar	mortality	rates	to	wild-type	mice	in	a	S.	pneumoniae	pneumonia	model	(Clarke,	Davis	et	al.	2010).			
	
	
	
	
Figure	1.5	Cytosolic	PRR	signalling	Cytosolic	 PRR	 recognise	 components	 of	 S.	 pneumoniae	 to	 induce	 cytokine	 responses.	 	 S.	
pneumoniae	DNA	is	recognised	by	an	unknown	PRR	to	induce	STING	activation,	that	activates	TBK1	 and	 then	 IRF3	 to	 induce	 interferon	 transcription.	 	 LRR	 are	 integral	 to	 NLRP3	recognition	 of	 K+	 efflux	 induced	 by	 Ply.	 	 NLRP3	 or	 AIM2	 activation	 (by	 bacterial	 DNA),	induces	 caspase	1	 activation,	which	 cleaves	 the	 zymogen	precursors	 to	 IL1β	 and	 IL18.	 	 PG	recognition	 by	 the	 LRR	 of	 NOD2	 induces	 RIP2	 phosphorylation,	 which	 stimulates	 MAPK	cascades	 by	 TAK1,	 and	 NFκB	 by	 NEMO,	 both	 of	 which	 induce	 pro-inflammatory	 cytokine	transcription.			 	
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1.4.1.3	Inflammasome	NLR	 family	 pyrin	 containing	 domain	 (NLRP)	 1	 and	 3,	 and	NLR	CARD	 containing	 domain	 4	form	 cytosolic	 protein	 complexes	 called	 inflammasomes	 that	 promote	 inflammation	 by	activating	 post-translational	 changes	 to	 activate	 IL1β	 and	 IL18	 by	 cleaving	 zymogenic	proforms	 (Figure	 1.4).	 	 They	 all	 contain	 caspase-1	 and	 the	 adaptor	 molecule	 apoptosis-associated	 speck-like	 protein	 containing	 a	 CARD	 (ASC),	 which	 is	 redistributed	 from	 the	nucleus	 to	 the	 cytoplasm	 in	activated	 inflammatory	cells	 (dos	Santos,	Kutuzov	et	 al.	2012).		CARD	–	CARD	interactions	between	the	 inactive	caspase-1	and	ASC	induce	the	activation	of	caspase-1.	 	NLRP3	and	pro-IL1β	are	expressed	minimally	in	macrophages,	but	are	inducible	by	inflammatory	stimuli;	hence	two	signals	are	required	for	inflammasome	activation.		
NLRP3	 knockout	 mice	 were	 more	 susceptible	 to	 pneumonia	 but	 have	 less	 pathological	sequelae	 in	 meningitis	 (Koppe,	 Suttorp	 et	 al.	 2012).	 	 NLRP3	 is	 activated	 by	 pore-forming	toxins	as	well	as	DAMPs	such	as	uric	acid,	adenosine	triphosphate	(ATP),	and	silica,	as	well	as	muramyl	 dipeptides.	 	 Absent	 in	 melanoma	 2	 (AIM2)	 is	 activated	 by	 cytosolic	 DNA	 (Fang,	Tsuchiya	 et	 al.	 2011).	 	 Humans	 with	 mutations	 to	 NLRP3	 exhibit	 a	 range	 of	 dominantly	inherited	 disorders	 (e.g.	Muckle-Wells	 syndrome,	 and	 Familial	 Cold	 Urticaria)	 that	 involve	constitutive	 activation	of	 the	 inflammasome	and	 consequent	hypersensitivity	 to	 exogenous	stimuli	(Martinon,	Agostini	et	al.	2004).	
S.	pneumoniae	stimulation	of	 the	 inflammasome	 is	dependent	on	an	 initial	 insult,	 e.g.	TLR2	activation,	to	 induce	transcription	and	synthesis	of	 inflammasome	constituents,	 i.e.	 two	hits	are	required	 for	 IL1β	secretion	 	While	ASC	 is	 the	most	critical	component,	NLRP3	deficient	BMDM	(McNeela,	Burke	et	al.	2010,	Witzenrath,	Pache	et	al.	2011),	and	AIM2	deficient	cells	also	 have	 reduced	 capacity	 to	 secrete	 IL1β	 (Fang,	 Tsuchiya	 et	 al.	 2011).	 	 In	 a	 pneumonia	model,	 NLRP3	 deficient	mice	 had	 greater	mortality	 and	 increased	 albumin	 leak	 into	 BALF,	though	 no	 significant	 difference	 in	 BAL	 cytokines	 were	 detected	 (Witzenrath,	 Pache	 et	 al.	2011).		Caspase-1	activation	is	ablated	in	a	high	K+	medium,	suggesting	K+	efflux	is	critical	in	activating	NLRP3	and	ASC	(Karmakar,	Katsnelson	et	al.	2015).	
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CARD8	is	implicated	in	negative	regulation	of	IL1β	secretion,	and	a	genome	wide	association	study	 of	 bacterial	 meningitis	 indicates	 worse	 outcomes	 were	 associated	 with	 a	polymorphism	 in	 CARD8	 that	 results	 in	 translation	 of	 a	 truncated	 form	 of	 the	 protein	(Geldhoff,	Mook-Kanamori	et	al.	2013).	 IL1β	and	IL18	 levels	are	elevated	 in	CSF	of	patients	with	 meningitis,	 and	 higher	 levels	 are	 associated	 with	 systemic	 and	 neurological	complications.		In	murine	S.	pneumoniae	meningitis,	ASC	deficient	mice	had	reduced	brain	KC,	CXCL2,	and	IL6	compared	to	wild	type;	conversely	NLRP3	deficient	mice	had	increased	brain	neutrophil	 infiltrate	and	haemorrhage	(Geldhoff,	Mook-Kanamori	et	al.	2013).	 	Additionally	inflammasome	 dependent	 IL18	 generation	 is	 important	 in	 NK	 cell	 stimulation	 and	subsequent	 release	 of	 IFNγ	 in	 murine	 meningitis,	 where	 the	 resulting	 inflammatory	monocyte	infiltrate	drives	pathology	(Mitchell,	Yau	et	al.	2012).		
1.4.1.4	Cytosolic	RNA/DNA	receptors	Cytosolic	DNA	sensing	may	be	a	means	by	which	a	phagocyte	distinguishes	live	bacteria	from	dead,	 and	 so	 scale	 inflammatory	 responses	 appropriately	 (Abdullah	 and	 Knolle	 2014).		Cytosolic	 receptors	 recognise	 non-self	 RNA	 via	 RIG-I-like	 receptors	 (RLRs),	 e.g.	 RIG-I	 and	melanoma	 differentiation-associated	 protein	 5	 (MDA5),	 resulting	 in	 release	 of	 type	 1	interferon	that	acts	in	a	para-	and	autocrine	manner	to	activate	IFNα/β	receptors	to	induce	transcription	of	interferon	stimulated	genes.		RNA	polymerase	III	converts	A:T	rich	cytosolic	DNA	 into	 RNA	 thus	 allowing	 bacterial	 DNA	 to	 be	 recognised	 by	 RLRs	 (Tam	 and	 Jacques	2014).	 	 RLR	 activation	 is	mediated	by	 the	 adaptor	molecule	 stimulator	 of	 interferon	 genes	(STING)	 (Figure	 1.4).	 	 Resting	 dimerised	 STING	 is	 located	 in	 the	 ER	 or	 the	 mitochondria	associated	 membrane,	 and	 when	 activated	 results	 in	 the	 transcription	 factor	 IRF3	 being	recruited	to	STING,	culminating	in	IRF3	mediated	transcription	of	IFNβ.			
S.	 pneumoniae	 or	 its	 DNA	 induces	 IFNβ	 transcription	 in	mouse	 BMDM.	 	 Inhibition	 studies	suggest	 that	 bacterial	 DNA	 is	 released	 into	 the	 cytosol	 downstream	 of	 phagocytosis	 or	phagolysosome	 acidification.	 	 siRNA	 knockdown	 of	 STING	 or	 IRF3	 in	 BMDM	 inhibited	 IFN	release	 (Koppe,	 Hogner	 et	 al.	 2012).	 	 IFNAR	 deficient	mice	 had	 reduced	 levels	 of	 CCL5	 in	
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BALF	 compared	 to	 wild-type	 in	 a	 pneumonia	 model	 suggesting	 that	 this	 chemokine	 is	dependent	on	IFN	release	(Koppe,	Hogner	et	al.	2012).		STING	also	localises	with	autophagy	proteins	such	as	autophagy	related	gene	9	(Atg9a).	The	increased	susceptibility	of	aged	mice	to	S.	pneumoniae	pneumonia	may	be	due	to	increased	acetylation	of	Atg9a,	and	so	decreased	STING	mediated	IFNβ	transcription	(Mitzel,	Lowry	et	al.	2014).	 	Other	DNA	sensors	such	as	cyclic	 GMP-AMP	 synthase	 are	 important	 in	 recognition	 of	 DNA	 viruses	 but	 have	 not	 been	implicated	in	S.	pneumoniae	infection.	
1.4.1.5	Lectins	Lectins	 are	 carbohydrate-binding	 proteins	 that	 recognise	 sugar	 moieties,	 and	 serve	 a	multitude	 of	 purposes	 from	 mediating	 cell	 adhesion	 to	 glycoprotein	 synthesis	 including	innate	 immunity	 (Geijtenbeek	 and	 Gringhuis	 2009).	 	 Primarily	 they	 recognise	 mannose,	fucose,	and	glucan	structures	(Werner	and	Steele	2014).	 	They	 largely	signal	via	a	common	adaptor	protein,	CARD9	(Osorio	and	Reis	e	Sousa	2011).	
DC-SIGN	is	a	human	C-type	(i.e.	it	has	a	carbohydrate	recognition	domain	[CRD]	that	requires	calcium	for	binding)	lectin,	which	binds	high	mannose	containing	ligands.		It	is	expressed	by	macrophages	and	DCs,	particularly	 in	 the	marginal	zone	of	 the	spleen.	 	SIGN-R1	 is	a	mouse	homologue	(Pluddemann,	Mukhopadhyay	et	al.	2011).		Intravenous	bacterial	inoculation	into	mice	led	to	S.	pneumoniae	association	with	SIGNR1	expressing	macrophages	in	the	marginal	zone	 of	 the	 spleen	 (Kang,	 Kim	 et	 al.	 2004).	 	 In	 addition,	 cells	 from	 an	 antigen	 presenting	murine	cell	line	transfected	with	SIGN-R1	internalised	capsular	polysaccharide	from	a	variety	of	S.	pneumoniae	serotypes	(Koppel,	Wieland	et	al.	2005).		In	murine	intraperitoneal	(Lanoue,	Clatworthy	 et	 al.	 2004)	 and	 intranasal	 infection	 (Koppel,	 Wieland	 et	 al.	 2005)	 SIGN-R1	deficient	mice	had	poorer	survival	than	wild-type	associated	with	increased	bacterial	counts	and	 increased	 levels	of	 IL1β,	TNF,	and	KC	 in	 lungs	 in	 the	pneumonia	setting.	 In	addition,	B	lymphocytes	 from	 SIGN-R1	 deficient	 mice	 produced	 less	 anti-PCho	 IgM	 than	 wild-type	(Koppel,	Litjens	et	al.	2008),	suggesting	that	B-lymphocytes	are	stimulated	by	macrophages	that	recognise	S.	pneumoniae	capsule	by	DC-SIGN	to	secrete	IgM.	 	In	rat	meningitis,	CD209b	
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(a	 homologue	 of	 SIGN-R1)	 is	 expressed	widely	 on	microglia,	 and	 uptake	 of	 S.	 pneumoniae	capsular	 polysaccharide	 is	 abolished	 by	 CD209	 blockade	 (Park,	 Choi	 et	 al.	 2009).		Furthermore,	 SIGN-R1	 mediates	 complement	 activation	 on	 splenic	 macrophages	 after	intravenous	S.	pneumoniae	infection	(Kang,	Do	et	al.	2006).	
Collectins	are	soluble	PRRs	that	increase	phagocytosis.		This	group	includes	SP-A	&	D	which	are	constitutively	synthesised	and	secreted	into	alveolar	lining	fluid	by	type	II	pneumocytes	and	non-ciliated	bronchial	epithelial	cells.	 	They	bind	mannose	and	glucose	residues	avidly,	thus	preferentially	 binding	microbial	 surface	 ligands	over	 eukaryote	 glycoproteins.	 	 In	 this	manner	they	agglutinate	pathogens,	 inhibit	microbial	growth,	and	recruit	phagocytes.	 	SP-A	increased	AM	phagocytosis	of	S.	pneumoniae,	mediated	by	increased	cell	trafficking	of	SR-A	to	the	 cell	 surface	 independently	 of	 SP-A	 binding	 to	 S.	 pneumoniae	 (Sano,	 Kuronuma	 et	 al.	2006).		SP-A	and	–D	modulate	inflammation	depending	on	the	orientation	of	their	binding	to	ligands.		If	the	CRD	binds	SIRPα,	a	transmembrane	protein,	there	is	inhibition	of	downstream	pro-inflammatory	 signals.	 	 However,	 if	 the	 CRD	 is	 bound	 to	 pathogen,	 the	 collagen	 region	binds	 to	 calreticulin/CD91,	 thus	 stimulating	 phagocytosis	 and	 pro-inflammatory	 responses	(Kishore,	Bernal	et	al.	2005)	with	SP-D	deficient	mice	having	reduced	neutrophil	recruitment	and	S.	pneumoniae	clearance	(Jounblat,	Clark	et	al.	2005).	
Dectin-1	 is	a	C	 type	 lectin	 that	 is	expressed	on	myeloid	cells	and	a	subset	of	γδ	T	cells	and	recognises	 the	 β	 glucan	 component	 of	 fungal	 cell	 walls	 (Osorio	 and	 Reis	 e	 Sousa	 2011).		Binding	 of	 its	 ligand	 induces	 activation	 of	 Syk	 and	 subsequently	 the	 NF𝜅B	 pathway,	 and	stimulates	a	calcium	flux	that	drives	Nuclear	factor	of	activated	T	cells	(NFAT)	activation.		It	also	signals	in	a	Syk	independent	manner	via	c-Raf	to	activate	NFκB	(Osorio	and	Reis	e	Sousa	2011).	 	 Dectin	 2	 recognises	 structures	 with	 high	 mannose	 concentrations	 and	 also	subsequently	 signals	 via	 Syk.	 	 Dectin-2	 deficient	mice	 had	 reduced	 survival	 in	 a	murine	 S.	
pneumoniae	pneumonia	model,	perhaps	due	to	reduced	activation	of	the	IL12-IFNγ	axis	and	subsequent	serotype	specific	antibody	production	(Akahori,	Miyasaka	et	al.	2016).		
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MR	 is	 a	 type	 I	 integral	membrane	glycoprotein	 expressed	on	macrophages	 and	endothelial	cells.		It	mediates	non-opsonic	phagocytic	uptake	of	a	variety	of	microbes	and	endocytosis	of	soluble	 glycoconjugates.	 	 It	 recognises	 mannose,	 fucose,	 glucose,	 and	 galactose.	 	 Direct	binding	assays	suggest	that	purified	polysaccharide	of	some	S.	pneumoniae	serotypes	bind	to	MR	 (Zamze,	Martinez-Pomares	 et	 al.	 2002),	 and	 rat	 Schwann	 cell	 uptake	 of	 S.	 pneumoniae	was	 inhibited	by	 competitive	 inhibition	of	MR	 (Macedo-Ramos,	Batista	 et	 al.	 2014).	 	MR	 is	upregulated	 by	 IL4	 and	 IL13	 and	 recognition	 of	 unopsonised	 bacteria	 by	 MR	 inhibits	 AM	inflammation,	 potentially	 reducing	 the	 inflammatory	 response	 to	 commensal	 bacteria.	 	MR	has	no	 recognised	 signalling	motifs,	 so	 it	 is	 unclear	how	downstream	communication	 after	ligand	binding	occurs	(Drummond	and	Brown	2013).	
1.4.1.6	Scavenger	Receptors	Scavenger	 receptors	 (SR)	 include	 SR-A	 and	 MARCO	 and	 recognise	 negatively	 charged	macromolecules,	and	are	best	known	for	binding	to	low	density	lipoproteins	that	have	been	modified	 by	 oxidation	 or	 acetylation.	 	 They	 can	 function	 as	 PRRs,	 this	 may	 be	 because	epitopes	 generated	 by	 peroxidation	 of	 endogenous	 proteins	 and	 lipoproteins	 resemble	pathogens	 (Canton,	 Neculai	 et	 al.	 2013).	 	 The	 structural	 features	 of	 SRs	 are	 varied	 and	membership	of	this	group	is	determined	by	functional	properties.		Overall	they	recognise	and	remove	 unwanted	 particles	 by	 uptake,	 and	 their	 ligand	 binding	 sites	 share	 similarities	 in	shape	 and	 electrostatic	 charge	 distribution,	 possibly	 explaining	 their	 preference	 for	polyanionic	 ligands	 (Canton,	Neculai	 et	 al.	 2013).	They	 are	 able	 to	 oligomerise	 and	usually	have	 short	 cytosolic	 domains	 without	 intrinsic	 signalling	 ability.	 	 It	 is	 likely	 that	heteromultimeric	signalling	complexes	form	and	that	the	co-receptors	may	vary	by	the	ligand	bound,	 resulting	 in	 specific	 downstream	 effects.	 	 CD36	 for	 example	 binds	 to	 diacylated	lipoproteins	 in	conjunction	with	TLR2/6	 leading	to	 inflammation,	but	also	mediates	uptake	of	Plasmodium	falciparum	without	cytokine	release	(Canton,	Neculai	et	al.	2013).		MARCO	and	SR-A	binding	leads	to	receptor	mediated	endocytosis.		One	effect	of	this	process	is	to	remove	ligands	 from	 the	 extracellular	 milieu,	 so	 reducing	 interaction	 with	 cell	 surface	 PRR,	 and	
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increasing	interaction	with	endosomal	and	cytosolic	PRR.		Expression	of	SRs	on	macrophages	vary	 by	 polarisation;	 classical	 macrophages	 tend	 to	 express	 MARCO	 whereas	 alternative	macrophages	have	more	SR-A	and	less	MARCO.			
MARCO	is	expressed	on	subsets	of	macrophages	as	well	as	endothelial	cells	and	astrocytes,	and	 is	 inducible	 by	 inflammation.	 	 MARCO	 binds	 to	 S.	 pneumoniae	 by	 non-opsonic	mechanisms	 (Arredouani,	 Palecanda	 et	 al.	 2005),	 and	 MARCO	 deficient	 mice	 had	 reduced	bacterial	 clearance	and	 reduced	pro-inflammatory	 cytokines	production	 compared	 to	wild-type	 in	 S.	 pneumoniae	 colonisation	 and	 pneumonia	 models	 (Arredouani,	 Yang	 et	 al.	 2004,	Dorrington,	 Roche	 et	 al.	 2013).	 	 Macrophages	 isolated	 from	 these	 knockout	 mice	 showed	reduced	 internalisation	of	S.	pneumoniae.	 	MARCO	activation	does	not	 induce	 inflammation	by	 itself,	but	appears	 to	amplify	 the	response	 from	TLR2	or	NOD2	stimulation	(Dorrington,	Roche	et	al.	2013).	This	is	probably	mediated	by	the	CD14/TLR2	complex	and	MARCO’s	role	in	 phagocytosis,	 for	 example	 MARCO	 appears	 to	 bind	 to	 M.	 tuberculosis	 cord	 factor	 and	present	it	to	TLR2	(Bowdish,	Sakamoto	et	al.	2009).	 	MARCO	expression	on	AMs	appears	to	be	 downregulated	 after	 influenza	 infection,	 contributing	 to	 secondary	 S.	 pneumoniae	infection	(Sun	and	Metzger	2008).	
SR-A	 also	 mediates	 non-opsonic	 uptake	 of	 a	 variety	 of	 pathogens	 and	 is	 expressed	 on	macrophages,	 and	 epithelial	 cells	 amongst	 others.	 	 SR-A	 enables	 phagocytic	 uptake	 of	apoptotic	 cells	 in	 conjunction	with	 the	 cell	 surface	 receptor	MER	 proto-oncogene	 tyrosine	kinase,	whereas	 interaction	with	LPS	 in	conjunction	with	TLR4	results	 in	pro-inflammatory	cytokine	release.	 	SR-A	binding	to	ligands	such	as	poly	I:C	can	induce	endocytosis-mediated	TNF	 production	 (Coller	 and	 Paulnock	 2001).	 	 In	 addition	 SR-A	 deficient	 macrophages	produced	 lower	 levels	 of	 inflammatory	 cytokines	 in	 response	 to	 TLR3,	 NOD1,	 and	inflammasome	stimulation	 (Mukhopadhyay,	Varin	et	 al.	 2011),	 suggesting	 that	 SR-A	allows	presentation	 of	 ligands	 to	 endosomal	 and	 cytosolic	 PRR.	 	 In	 a	 murine	 S.	 pneumoniae	pneumonia	model	BALF	from	SR-A	deficient	mice	had	reduced	levels	of	neutrophils	and	pro-inflammatory	cytokines	and	higher	bacterial	counts	(Arredouani,	Yang	et	al.	2006).	
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1.4.2	Cell	Signalling	Intracellular	 signalling	 pathways	 coordinate	 the	 macrophage	 response	 to	 PRR	 from	pathogens	like	S.	pneumoniae,	and	also	to	auto-,	para-,	and	juxtacrine	signalling	in	response	to	 cytokines.	 	 These	 networks	 are	 critical	 in	 the	 transcriptional	 and	 post	 translational	responses	that	generate	inflammation.		Understanding	how	they	work	is	complicated	by	the	fact	 that	 a	 few	 receptors	 stimulate	more	 than	one	pathway,	 and	multiple	 receptors	 initiate	signalling	events	that	converge	on	a	few	key	signalling	pathways.	
1.4.2.1	MyD88/IRAK4	The	binding	of	a	TLR	to	 its	 ligand	 induces	conformational	changes,	 such	 that	a	cytoplasmic	Toll/interleukin	 1	 receptor	 (TIR)	 domain	 is	 exposed,	 allowing	 the	 recruitment	 of	 TIR-containing	 adaptor	 proteins	 (Figure	 1.5).	 	 Apart	 from	 TLR3	 and	 endosomal	 TLR4,	 TLR	signalling	 involves	 the	 engagement	 of	 the	 adaptor	 protein	 MyD88,	 either	 directly	 or	 in	combination	with	Myelin	and	lymphocyte	protein	(MAL),	also	known	as	TIR	adaptor	protein	(TIRAP).	 	MyD88	also	has	a	DD	which	binds	to	the	DD	on	IL1R	associated	kinases	(IRAK)	4.		IRAK4	is	a	serine/threonine	kinase,	and	phosphorylation	induces	binding	to	IRAK1	&	2.		The	MyD88	and	IRAK	proteins	conglomerate	to	form	the	myddosome,	which	also	attracts	the	E3	ubiquitin	ligase	TNF	receptor-associated	factor	6	(TRAF6)	as	part	of	a	ubiquitin	conjugating	enzyme	 complex.	 	 This	 results	 in	 the	 ubiquitination	 of	 IκB	 kinase	 γ	 (IKKγ)	 also	 known	 as	NFκB	essential	modulator	 (NEMO),	 as	well	 as	 the	ubiquitination	of	TRAF6	 itself.	 	TRAF6	 is	then	 recruited	 to	 the	 TGFβ	 activated	 kinase	 (TAK1)	 complex	 by	 binding	 to	 TAK1	 binding	proteins	 (TAB)	 1	 &	 2,	 which	 then	 initiates	 the	 mitogen	 activated	 protein	 kinase	 (MAPK)	pathway	(Lee	and	Kim	2007,	Newton	and	Dixit	2012).		In	response	to	TLR1,	2	and	4,	TRAF6	also	 translocates	 to	 mitochondria	 where	 it	 associates	 with	 Evolutionarily	 Conserved	Signalling	Intermediate	in	Toll	pathways,	triggering	mitochondrial	production	of	ROS,	which	serves	to	increase	bacterial	killing	(Vogel,	Janssen	et	al.	2007).	
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Figure	1.6	TLR	signalling	TLR2	and	canonical	TLR4	signalling	induces	the	recruitment	of	adaptor	proteins	such	as	MAL	and	MyD88.	 	 These	 activate	 the	 IRAK	 kinases	 to	 form	 the	myddosome,	which	 recruits	 the	ubiquitin	ligase,	TRAF6	that	ubiquitinates	NEMO	to	activate	NFκB	and	the	TAK	proteins	that	induce	 the	 MAPK	 pathway,	 both	 of	 which	 are	 involved	 in	 pro-inflammatory	 cytokine	transcription.	 	Meanwhile,	 TLR3	and	 endosomal	TLR4	activation	 causes	 the	 recruitment	 of	the	 TRIF	 and	 TRAM	 adaptor	 proteins	 that	 cause	 the	 activation	 of	 TBK1,	 and	 consequently	IRF3,	which	is	implicated	in	IFN	transcription.									
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MyD88	deficient	mice	had	poorer	outcomes	 than	either	TLR2	or	TLR4	deficient	mice,	with	reduced	 survival	 and	 increased	 bacterial	 numbers	 in	 S.	 pneumoniae	 CNS	 infection,	nasopharyngeal	colonisation,	pneumonia	and	sepsis	models	(Koedel,	Rupprecht	et	al.	2004,	Albiger,	Sandgren	et	al.	2005).		Mice	with	IRAK4	deficiency	also	had	increased	susceptibility	to	 S.	 pneumoniae	 infection	 and	 a	 blunted	 pro-inflammatory	 cytokine	 secretion	 profile	(Pennini,	 Perkins	 et	 al.	 2013).	 	 In	 vitro,	 macrophages	 from	 mice	 with	 deficient	phosphorylation	 of	 IRAK4	 produced	 less	 pro-inflammatory	 cytokines	 in	 response	 to	 TLR2	agonists,	had	a	partial	 response	 to	TLR4	agonists	 compared	 to	wild-type,	 and	produced	no	inflammatory	cytokines	from	either	live	or	heat-killed	S.	pneumoniae.		
The	phenotype	of	humans	with	MyD88	deficiency	is	different	from	mice.		Mice	have	increased	susceptibility	to	many	bacteria,	as	well	as	some	viruses,	fungi	and	protozoa,	whereas	humans	are	 largely	 only	 susceptible	 to	 pyogenic	 bacterial	 infections,	 especially	 S.	 pneumoniae	 (von	Bernuth,	 Picard	 et	 al.	 2008).	 Examination	 of	 patients	 with	 IRAK4	 deficiency	 and	 MyD88	deficiency	 showed	 that	 the	 leading	 threat	 was	 invasive	 disease	 including	 meningitis,	septicaemia,	deep	seated	abscesses,	lymph	node	and	salivary	gland	infections	(von	Bernuth,	Picard	et	al.	2012).		S.	pneumoniae	caused	the	majority	of	infections,	followed	by	S.	aureus	and	
P.	aueruginosa.		Systemic	signs	of	inflammation	tended	to	be	weak	or	delayed	and	in	88%	the	first	infection	was	before	the	age	of	2	with	72%	having	recurrent	invasive	infections.		38%	of	patients	had	died	due	to	invasive	bacterial	disease	(primarily	IPD)	by	the	age	of	8,	but	after	the	 age	 of	 14	 there	were	 no	 documented	 cases	 of	 invasive	 disease	 though	 there	were	 still	incidences	of	non-invasive	disease.	 	Generally	there	was	reduced	fever	and	CRP	in	response	to	 invasive	disease	but	 in	some	cases	there	was	an	exaggerated	 inflammatory	response.	 	 In	children	there	was	a	significant	protective	effect	with	prophylactic	antibiotics	(von	Bernuth,	Picard	et	 al.	 2008,	Picard,	 von	Bernuth	et	 al.	 2010).	The	peripheral	blood	 transcriptome	of	IRAK4	deficient	patients	in	response	to	ex	vivo	stimulation	showed	diminished	inflammatory	cytokine	 and	 chemokine	 responses	 to	 synthetic	 lipoproteins,	 flagellin,	 IL1β,	 IL18,	 and	synthetic	 TLR7,	 8,	 and	 9	 agonists.	 	 However,	 exposure	 of	 heat	 killed	 S.	 pneumoniae	 still	
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generated	a	significant	albeit	reduced	response	of	inflammatory	genes	in	IRAK4	and	MyD88	deficient	 patients,	 suggesting	 further	 redundancy	 in	 recognition	 of	 bacteria.	 	 Unbiased	analysis	 suggests	 that	 this	may	 be	mediated	 by	 immunoreceptor	 tyrosine	 based	 activation	motif	 (ITAM)	 signalling	 (e.g.	 lectins,	 Fc	 receptors,	 integrins,	 and	 complement)	 (Alsina,	Israelsson	et	al.	2014).	
Several	 members	 of	 the	 IL1	 family,	 e.g.	 IL1β	 and	 IL18	 also	 signal	 by	 recruiting	 the	 same	adaptor	 proteins	 as	 TLRs,	 i.e.	 MyD88,	 IRAKs,	 and	 TRAF6.	 	 Some	 of	 the	 effects	 of	 adaptor	protein	deficiencies	may	be	therefore	linked	to	IL1	family	functions	in	addition	to	TLRs.		
1.4.2.2	TNF	receptor	The	binding	of	members	of	the	TNF	family	to	their	receptors	can	induce	both	inflammatory	responses	 and	 apoptotic	 responses,	 which	 are	 often	 associated	 with	 suppressing	inflammation.	 	 This	 depends	 on	 the	 signalling	molecules	 triggered	 and	 regulation	by	 other	signals	 received	 by	 receptors	 binding	 their	 ligands.	 	 TNF-R1	 activation	 usually	 activates	inflammatory	pathways	by	TNF	receptor	type	1	associated	DD	(TRADD)	activating	the	TRAFs	and	 RIPKs,	 whereas	 when	 protein	 synthesis	 is	 inhibited	 TRADD	 associates	 with	 FADD.		TRAFs	 are	 a	 major	 group	 of	 intracellular	 adaptors	 involved	 in	 TNF/IL1/TLR	 signalling	pathways.	 	 Distinct	 but	 overlapping	 parts	 of	 the	 protein	 are	 responsible	 for	 activating	differing	 pathways.	 	 This	 is	 probably	 regulated	 by	 the	 binding	 of	 differing	 proteins	 which	stabilise/destabilise	the	various	signalling	complexes	that	TRAF	can	form.			
While	 the	membrane	 associated	 complex	 of	 RIP1,	 TRADD	 and	TRAF2,	 induces	 rapid	NFκB	and	 activator	 protein	 1	 (AP-1)	 activation,	 the	 cytosolic	 complex	 of	 RIP1,	 TRADD,	 TRAF2,	FADD,	and	caspase	8	and	10	 is	pro-apoptotic.	 	Therefor	TNF	signalling	 leads	 to	rapid	NFκB	activation,	then	the	dissociation	of	the	complex	from	the	membrane	within	an	hour	leads	to	apoptotic	 signalling.	 	Apoptosis	 is	 only	 induced	when	 there	 is	 insufficient	 NFκB	 activation,	and	 therefore	 failure	 of	 induction	 of	 anti-apoptotic	 proteins.	 	TNFR,	 TRAIL	 and	 Fas	 also	induce	 necroptosis	 via	 RIP1	 and	 RIP3	 in	 association	 with	 FADD.	 	The	 deubiquitinase	
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cylindromatosis	 (CYLD)	 promotes	 apoptosis	 by	 increasing	 RIP1-FADD	 association;	suggesting	 that	 the	 ubiquitin	 status	 of	 RIP1K	 is	 critical	 to	 which	 pathway	 is	 dominant	(Dempsey,	Doyle	et	al.	2003).		
1.4.2.3	NFκB	NFκB	is	a	 family	of	5	proteins	that	exist	as	homo-	or	hetero-	dimers	 in	the	cytoplasm:	v-rel	avian	 reticuloendotheliosis	 viral	 oncogene	homolog	A	 (RelA)	 (also	 known	as	p65),	RelB,	 c-Rel,	p50/p105,	p52/p100.		RelA	mediates	the	pro-inflammatory	functions,	whereas	p50	has	inhibitory	effects	on	inflammation.	 	IκBs	bind	NFκB	to	retain	the	resulting	complexes	in	the	cytoplasm.		The	NFκB	pathway	can	be	stimulated	by	a	number	of	different	mechanisms.	The	canonical	pathway	of	NFκB	(Figure	1.6)	is	initiated	after	TNF,	IL1β,	TCR,	and	LPS	stimulation.		IκK	exists	as	a	complex	of	IκKα	and	IκKβ	catalytic	subunits	attached	to	a	regulatory	subunit,	IκKγ	 (also	 known	 as	 NEMO).	 	 IκK	 activation	 phosphorylates	 IκBα,	 which	 results	 in	 its	ubiquitin	mediated	degradation.	 	This	allows	NFκB	dimers,	primarily	RelA	bound	to	p50,	to	translocate	 to	 the	 nucleus	 and	 act	 as	 a	 transcription	 factor.	 	 IκBα	 bound	 to	 NFκB	 actually	translocates	to	the	nucleus	but	has	a	nuclear	export	sequence	such	that	it	shuttles	out	again	without	binding	to	DNA.				
The	non-canonical	pathway	occurs	downstream	of	specific	TNF	 family	members	(e.g.	B	cell	activating	factor,	CD40L,	lymphotoxin	beta)	binding	to	their	receptors.		These	cause	a	signal	transduction	 cascade	 that	 stimulates	 NFκB	 inducing	 kinase	 (NIK)	 to	 cleave	 p100	 into	 its	active	p52	form.		p52	heterodimerises	with	RelB,	and	translocates	into	the	nucleus	to	initiate	transcription.		Dectin-1	also	activates	NFκB	via	NIK2,	however	the	signalling	pathway	has	not	been	 completely	 elucidated	 (Osorio	 and	 Reis	 e	 Sousa	 2011).	 	 There	 are	 also	 atypical	 IκK	independent	pathways	that	result	in	the	dissociation	or	degradation	of	IκB	(e.g.	hypoxia	and	ultraviolet	light	stimuli).	
NFKBIA/B/E	 are	 the	 genes	 that	 encode	 for	 the	 α,	 β,	 and	 ε	 members	 of	 the	 IκB	 family	respectively.	 	6	nucleotide	polymorphisms	 in	NFKBIA	have	been	associated	with	protection	
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from	IPD,	and	one	polymorphism	 in	NFKBIE	has	been	associated	with	susceptibility	 to	 IPD	(Chapman,	Khor	et	al.	2007).	Patients	with	mutations	to	NEMO	or	IκBα	suffer	from	a	broad	range	 of	 infections	 with	 some	 predisposition	 to	 S.	 pneumoniae	 infection.	 	 X-linked	hypohydrotic	ectodermal	dysplasia	with	immunodeficiency	is	a	condition	with	hypomorphic	mutations	to	IKBKG	gene	that	codes	for	IKKγ,	impairing	its	translocation	to	the	nucleus.		They	suffer	 from	early	 life	pyogenic	 infections	and	have	a	humoral	defect	with	defective	 specific	antibody	 production,	 especially	 to	 polysaccharide	 antigens,	 and	 sometimes	hypogammaglobulinaemia.	 	This	 is	because	CD40	mediated	B	 cell	 stimulation	 is	dependent	on	NFκB.		Autosomal	dominant	hypohydrotic	ectodermal	dysplasia	with	immunodeficiency	is	due	 to	 a	 missense	 gain	 of	 function	 mutation	 in	 NFKBIA	 encoding	 IκBα,	 preventing	 its	degradation	 and	 therefore	 NFκB	 activation.	 	 Presentation	 is	 similar	 to	 IKBKG	 mutations,	except	for	the	additional	presence	of	T	cell	immune	defects	(Turvey	and	Hawn	2006).	
Mice	 deficient	 in	 RelA	 and	 TNF	 receptor	 had	 reduced	 cytokine	 translation,	 reduced	neutrophil	 recruitment,	 and	 100-fold	 more	 bacteria	 in	 the	 lungs	 after	 intranasal	 S.	
pneumoniae	infection	(Quinton,	Jones	et	al.	2007).		Dexamethasone	acts	on	peripheral	blood	mononuclear	 cells	 to	 inhibit	 S.	 pneumoniae	 mediated	 CXCL8	 secretion	 by	 inhibiting	 IκBα	(Mogensen,	 Berg	 et	 al.	 2008)	 partly	 explaining	 the	 inflammation	 dampening	 effects	 of	steroids.	
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Figure	1.7	NFκB	activation	The	 canonical	 pathway	 is	 activated	 when	 the	 IκK	 complex	 (NEMO,	 IKKα,	 and	 IKKβ)	 is	activated	to	phosphorylate	 IκBα,	allowing	 its	degradation	and	the	consequent	translocation	of	the	RelA-p50	dimer	into	the	nucleus	to	induce	transcriptional	events.	 	The	non-canonical	pathway	involves	NIK	activation	and	subsequent	cleavage	of	p100	into	the	active	p52	form.		The	p52-RelB	dimer	translocates	into	the	nucleus	to	act	as	a	transcription	factor.		 	
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1.4.2.4	MAPK	MAPK	pathways	are	critical	in	multiple	cellular	events	from	proliferation	and	metabolism	to	inflammation.	 	 They	 coordinate	 multiple	 receptor–ligand	 events	 into	 4	 conventional	signalling	 cascades	where	 a	MAPK	 kinase	 kinase	 (MAP3K)	 phosphorylates	 a	MAPK	 kinase	(MAP2K),	which	in	turn	phosphorylates	a	MAPK.		The	best	studied	pathways	are	extracellular	signal-regulated	kinases	1	&	2	(ERK	1/2)	which	are	often	stimulated	by	growth	factors,	c-Jun	N	terminal	kinases	(JNK)	1	&	2,	and	p38	MAPK	(in	particular	 isoform	α),	both	of	which	are	predominantly	 stimulated	by	stress	pathways	and	cytokines.	 	The	substrates	 for	 the	MAPK	are	shared	somewhat;	ribosomal	6S	kinase	(RSK)	1-4	are	activated	by	ERK	1/2,	whereas	MAP	kinase-interacting	serine/threonine-protein	kinase	(MNK	or	MKNK)	1	&	2	and	mitogen-	and	stress-activated	protein	kinase-1	(MSK)	1	&	2	are	activated	by	ERK	1/2	and	p38	MAPK,	and	MAPK-activated	protein	kinase	(MK)	2	&	3	are	stimulated	by	p38	MAPK	and	JNK	(Figure	1.7).			
The	RSK	proteins	are	able	to	phosphorylate	IκB,	and	so	induce	NFκB	activation.	 	The	MNKs	have	 been	 implicated	 in	 prostaglandin	 synthesis,	 regulate	 pro-inflammatory	 cytokine	transcription,	and	stabilise	TNF	mRNA.		The	MSKs	may	have	an	effect	on	acetylation	of	RelA,	and	 thus	 increase	 its	DNA	affinity,	 but	 also	 target	 IL10	and	 IL1RA,	 so	may	be	 important	 in	regulation	 of	 inflammation.	 	 MK2	 and	 the	 closely	 related	 MK3	 act	 to	 stabilise	 pro-inflammatory	cytokine	mRNA	as	well	as	induce	their	transcription	directly	(Moens,	Kostenko	et	 al.	 2013).	 	The	MSKs,	 and	ERK	directly,	 increase	 transcription	of	dual	 specificity	protein	phosphatases	(DUSP)	such	as	DUSP1,	which	inactivates	JNK	and	p38	MAPK.			
JNK	 deficient	 macrophages	 have	 reduced	 expression	 of	 classically	 activated	 M1	 genes	 in	response	 to	 LPS	 indicating	 that	 JNK	 has	 pro-inflammatory	 roles.	 	 ERK	 activation	 increases	production	of	TNF,	IL1β,	and	IL10,	but	reduces	production	of	IL12,	IFNγ,	and	inducible	nitric	oxide	 synthase	 (iNOS).	 	 P38	MAPK	 induces	 TNF,	 IL10,	 and	 type	 I	 IFN	 production,	 but	 also	initiates	 feedback	mechanisms	 by	 inhibiting	 TAK1	 effects	 on	NFκB	 activation.	 Some	 of	 the	MAPK	functions	are	also	by	direct	transcriptional	control;	translocation	of	ERK	to	the	nucleus		
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Figure	1.8	MAPK	signalling		MAPK	signalling	pathways	involve	at	least	3	kinases.		MAP3K	(in	green)	activate	MAP2K	(in	red),	 which	 then	 activate	 MAPK	 (in	 red).	 	 Raf	 is	 stimulated	 by	 growth	 factor	 and	 antigen	receptor	activation.	 	TLR,	TNFR1,	and	 IL1R	activation	 induces	TAK1	activation.	 	ROS	action	on	cell	membrane	liberates	apoptosis	signal-regulating	kinase	1	(ASK1).		The	terminal	MAPK	have	multiple	 isoforms;	 those	most	 involved	 in	 inflammatory	 signalling	 are	 shown	 above.		The	terminal	MAPK	then	activate	further	kinases	and	induce	transcriptional	effects.		
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induces	 the	 phosphorylation	 of	 Elk-1,	 stimulating	 the	 transcription	 of	 fos.	 	 JNK	 causes	phosphorylation	of	c-Jun,	which	translocates	to	the	nucleus	and	combines	with	c-Fos	to	form	the	 transcription	 factor	 AP-1.	 	 AP-1	 has	 pleiotropic	 effects,	 including	 transcription	 of	 pro-inflammatory	genes	and	chemokines	(Foletta,	Segal	et	al.	1998,	Whitmarsh	2007).		
S.	pneumoniae	is	known	to	induce	some	MAPK	activation.		When	incubated	in	vitro	with	AM,	
S.	pneumoniae	induced	phosphorylation	of	p38	MAPK	and	ERK	pathways	(Thorley,	Ford	et	al.	2007).	 	 In	 a	 bronchial	 epithelial	 cell	 line,	 defensin	 release	was	mediated	 by	 the	 JNK/AP-1	pathway	(Scharf,	Zahlten	et	al.	2012).				
1.4.2.5	IRF3	Type	1	 IFN	 are	primarily	 involved	 in	 antiviral	 immunity	 and	 also	mediate	 induction	of	 co-stimulatory	molecules	on	antigen	presenting	cells.		IRF	3	and	7	are	transcription	factors	that	regulate	 type	 1	 IFN	 transcription,	 with	 IRF3	 constitutively	 expressed	 in	 most	 cells.		Phosphorylation	 of	 a	 serine/threonine	 cluster	 at	 the	 C	 terminal	 of	 IRF3	 causes	conformational	 change	 allowing	 dimerisation	 of	 IRF3	 and	 DNA	 binding	 at	 the	 relevant	promoters.	 	This	change	also	allows	association	with	co-activators	cAMP	response	element-binding	protein	(CREB)	binding	protein	(CBP)	and	p300	to	prevent	export	of	IRF3	from	the	nucleus.	 	 IRF3	 effects	 transcription	of	 IFNβ	 in	 cooperation	with	 other	 transcription	 factors	such	as	NFκB.	 	 IFNβ	activates	 the	 IFN	 stimulated	gene	 factor	3	 complex	 (signal	 transducer	and	 activator	 of	 transcription	 [STAT]	 1,	 STAT2,	 IRF9),	 which	 in	 turn	 induces	 IRF7	transcription	-	and	thus	IFNα	and	β	transcription.			
Multiple	 receptors	 induce	 IRF	 functions,	 including	 TLR3	 and	 TLR4,	 when	 activated	 on	 an	endosomal	 membrane	 rather	 than	 at	 the	 cell	 surface.	 	 This	 occurs	 via	 activation	 of	 TIR-domain-containing	 adaptor	 inducing	 interferon-beta	 (TRIF).	 	 TLR3	 interacts	 directly	 with	TRIF	but	TLR4	requires	the	bridging	adaptor	TRIF	related	adaptor	molecule	(TRAM).	 	TRIF	activates	TRAF3	 to	 induce	 IKKε	and	TRAF	 family	member-associated	NF-kappa-B	activator	(TANK)	 binding	 kinase	 1	 (TBK1)	 mediated	 phosphorylation	 of	 IRF3.	 	 In	 addition,	 TRIF	
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activation	 of	 TRAF-6	 leads	 to	 delayed	 NFκB	 activation.	 	 RIG-I	 or	 MDA5	 recognition	 of	cytoplasmic	non-self	RNA	induces	IRF3	via	TRAF3	and	TBK1,	in	these	instances	the	adaptor	mitochondrial	 antiviral	 protein	 (MAVS)	 is	 also	 involved	 (Moynagh	2005,	Newton	 and	Dixit	2012).			
The	relationship	between	interferon	and	inflammatory	cytokine	induction	is	complex.		While	Rel	 A	 can	 form	 dimers	 with	 IRF3	 to	 act	 as	 cofactors	 in	 transcription	 of	 both	 NFκB	 and	interferon	 response	elements	 (IRE),	p50	homodimers	may	bind	 to	 IRE	 in	 competition	with	IRFs	so	inhibiting	their	transcription	(Oeckinghaus,	Hayden	et	al.	2011).		In	hepatocytes	IRF3	signalling	 inhibited	 IKKβ	 by	 interacting	 with	 its	 kinase	 domain	while	 in	 the	 cytoplasm,	thereby	inhibiting	downstream	signalling	(Wang,	Zhang	et	al.	2014).	 	Bioinformatic	analysis	of	transcription	factor	binding	sites	indicated	that	NFκB	activation	can	directly	compete	with	and	 inhibit	 IRF3	mediated	 transcription.	 	IRF3	activation	similarly	 inhibited	NFκB	 function,	but	 indirectly,	 possibly	 through	 cooperation	with	 other	 transcription	 factors	 such	 as	 AP-1	(Iwanaszko	and	Kimmel	2015).	 	TBK1	and	IKKε	can	phosphorylate	the	catalytic	domains	of	IKKα	and	β,	resulting	in	less	IKK	complex	activity	and	lower	expression	of	NFκB	dependent	gene	 expression.	 	IKKε	 and	 TBK1	 phosphorylation	 of	 TANK	 may	 also	 be	 involved	 in	 this	regulation	of	canonical	IKK	activity	(Oeckinghaus,	Hayden	et	al.	2011).		
1.4.2.6	Syk	Spleen	 tyrosine	 kinase	 (Syk)	 is	 an	 important	 signalling	 molecule	 that	 is	 activated	 by	 a	number	of	receptors	including	TCR,	BCR,	lectins,	and	Fc	receptors.		Several	lectins	including	dectin-1,	dectin-2,	and	Mincle	signal	via	Syk.		Lectin	meditated	Syk	signalling	usually	requires	ITAM	 containing	 adaptor	 proteins,	 though	 a	 few	 signal	 directly	 through	 hemITAM	intracellular	domains	(Osorio	and	Reis	e	Sousa	2011).		Downstream	of	Syk	phosphorylation,	the	 adaptor	protein	CARD9	 is	 recruited,	which	 recruits	Mucosa-associated	 lymphoid	 tissue	lymphoma	 translocation	 protein	 1	 (MALT-1)	 and	 B	 cell	 leukaemia/lymphoma	 10	 (Bcl-10),	which	activates	the	IKK	complex.		CARD9	is	recruited	to	phagosomes,	but	also	appears	to	act	at	the	cell	membrane.		c-Rel	is	preferentially	activated	by	MALT-1,	and	is	the	only	subunit	of	
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NFκB	that	 is	activated	by	dectin-2,	whereas	dectin-1	activates	all	subunits	(Drummond	and	Brown	2013).		Syk	also	activates	the	inflammasome	via	ROS	and	thus	leads	to	IL1β	activation	and	 in	 addition	 stimulates	 calcium	 flux	 that	 drives	 NFAT	 activation	 (Geijtenbeek	 and	Gringhuis	2009).	
1.4.2.7	c-RAF	DC-SIGN	 is	 known	 to	 have	 a	 pro-inflammatory	 role	 in	 other	 infections.	 	 Once	 mannose	 is	bound	 on	 the	 cell	 surface,	 Syk-independent	 pathways	 cause	 cellular	 Rapidly	 Accelerated	Fibrosarcoma	(cRAF)	(a	serine/threonine	protein	kinase)	to	phosphorylate	RelA.		cRAF,	best	known	as	a	primary	member	of	MAPK	signalling,	does	not	 signal	via	ERK	 for	 this	 function.		RelA	 phosphorylation	 allows	 histone	 acetyltransferases	 such	 as	 CREB-binding	 protein	 or	p300	 to	 acetylate	 RelA,	when	 it	 is	 already	 in	 the	 nucleus.	 	 This	 increases	 its	 DNA	 binding	affinity	thus	prolonging	pro-inflammatory	cytokine	transcription	(Gringhuis,	den	Dunnen	et	al.	2007).		Acetylation	of	RelA	also	results	in	the	formation	of	RelA-RelB	dimers,	which	cannot	bind	DNA.		This	can	limit	the	function	of	RelB-p52	dimers,	which	usually	inhibit	inflammatory	cytokine	transcription	(Geijtenbeek	and	Gringhuis	2009).	
1.4.3	Phagocytosis	Phagocytosis	is	the	receptor-mediated	uptake	of	particles	≥0.5	μm	into	cells.		These	receptors	include	 non-opsonic	 PRRs	 such	 as	 MR,	 MARCO,	 CD14,	 and	 opsonic	 receptors	 such	 as	 Fcγ,	complement	 receptors,	 and	apoptosis	 receptors	 such	as	αVβ5	 integrin.	 	 The	effectiveness	of	these	 receptors	 depends	 on	 the	 density	 of	 receptor	 expression,	 and	 their	 affinity	 to	 their	ligand.	 	Usually	receptors	cluster	on	the	cell	membrane	to	tether	the	pathogen	to	overcome	low	affinity	and	active	movement	of	the	microbe.	
The	best	understood	phagocytosis	receptor	is	the	Fc	family,	which	binds	antibody.		Antibody	coated	particles	bind	to	the	Fcγ	receptor,	leading	to	clustering	of	Fcγ	receptors	that	leads	to	actin-driven	 extension	 of	 pseudopodia,	 and	 further	 receptor	 binding.	 	 Once	 the	 target	engages	 with	 the	 receptors	 on	 all	 sides	 engulfment	 begins.	 	 Multivalent	 ligand	 binding	 is	
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required	 to	 trigger	 intracellular	 signalling,	 which	 requires	 lateral	 clustering	 such	 that	 the	cytosolic	domains	(containing	ITAM	regions)	are	brought	together	to	be	phosphorylated	by	intracellular	kinases,	then	leading	to	actin	polymerisation	by	recruitment	of	adaptor	proteins.		Rho	 family	 GTPases,	 located	 on	 the	 inner	 layer	 of	 the	 cell	 membrane	 regulate	 actin	polymerisation.	 	 Dectin	 1	 recognition	 of	 fungal	 wall	 ligands	 also	 signals	 via	 Syk	 to	 have	 a	similar	 effect.	 CR3	 signals	 via	 different	 pathways	dependent	 on	RhoA,	which	 activates	Rho	kinase	 and	 subsequently	myosin.	 	Unlike	 other	members	 of	 its	 family,	 FcγRIIB	 contains	 an	immunoreceptor	 tyrosine-based	 inhibition	motif	 (ITIM),	which	 recruits	kinases	 that	 inhibit	phagocytosis	(Moretti	and	Blander	2014).			
Once	 engulfment	 is	 complete,	 a	 phagosome	 matures.	 	 Vesicle	 traffic	 to	 the	 phagosome	 is	mediated	 by	 Rab	 GTPases.	 	 As	 proton	 pumps	 are	 acquired,	 the	 interior	 of	 the	 phagosome	becomes	 acidic.	 	 Lysosomal	 associated	membrane	proteins	 (LAMP)	 are	 integral	membrane	proteins	 associated	 with	 lysosomes	 and	 mature	 phagosomes	 that	 are	 essential	 for	recruitment	 of	 Rab7,	 a	 small	 GTPase	 essential	 for	 full	 maturation	 of	 the	 phagosome.		Lysosomes	fuse	with	the	phagosome	to	make	a	phagolysosome,	and	by	this	stage	the	vacuole	contents	are	very	acidic.			
NOX2,	an	NADPH	oxidase,	 forms	at	 the	membrane	 in	response	to	 inflammatory	stimuli	and	shuttles	 electrons	 across	 the	 phagolysosomal	 membrane,	 allowing	 the	 production	 of	 ROS.		The	formation	of	reactive	nitrogen	species	(RNS)	is	then	catalysed	by	iNOS.		Nitric	oxide	(NO)	is	 synthesised	 on	 the	 cytosolic	 face	 of	 the	membrane	 and	 diffuses	 into	 the	 phagolysosome	and	 react	 with	 ROS	 to	 form	 reactive	 nitrogen	 intermediates	 (RNI).	 	 Cytoplasmic	 granules	containing	 antibacterial	 peptides	 then	 fuse	 with	 the	 phagolysosome.	 	 Specific	 cathepsins	work	 at	 differing	 pH	 ranges	 and	 need	 to	 be	 delivered	 to	 the	 phagosome	 at	 the	 right	maturation	phase	to	allow	effective	function.						
TLR	stimulation	and	consequent	p38	MAPK	activation	results	in	increased	macropinocytosis.		TLR	 stimulation	 may	 also	 increase	 phagosomal	 assembly	 and	 increase	 NADPH	 mediated	
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microbicidal	 function.	 	 Activation	 of	 inflammasomes	 allows	 the	 accumulation	 of	 caspase	 1	around	phagosomes,	which	hydrolyses	components	of	NOX2	and	encourages	acidification	of	the	 phagolysosome	 (Moretti	 and	 Blander	 2014).	 	 The	 circumstances	 under	 which	 a	phagosome	 forms	 affect	 the	 receptors	 present	 on	 the	 phagosome	 membrane,	 and	 thus	subsequent	signalling	events.		Blocking	actin	polymerisation	and	thus	phagocytosis	increased	cytokine	production	by	macrophages,	as	did	frustrated	phagocytosis	of	fungal	wall	particles	too	 large	to	 internalise	(Rosas,	Liddiard	et	al.	2008),	possibly	due	to	 increased	engagement	with	cell	surface	PRR.	
1.4.4	Apoptosis	Apoptosis	of	alveolar	macrophages	is	found	after	S.	pneumoniae	 infection.		 	Bacterial	uptake	of	S.	 pneumoniae	 and	 subsequent	 apoptosis	 contributes	 to	bacterial	 clearance.	Macrophage	apoptosis	 results	 in	 intracellular	 bacterial	 death	while	minimising	 inflammatory	 signalling,	with	downregulation	of	pro-inflammatory	cytokine	secretion	compared	to	necrotic	cell	death	(Haslett	1999,	Marriott,	Hellewell	 et	 al.	2006).	 	Once	phagolysosomal	 capacity	 for	bacterial	killing	 is	 exceeded,	 lysosomal	 permeabilisation	 and	 cathepsin	 D	 activation	 results	 in	macrophage	 apoptosis.	 	 Cathepsins	 cleave	 members	 of	 the	 Bcl-2	 family	 and	 increase	degradation	of	the	anti-apoptotic	protein	Mcl-1,	to	trigger	either	the	mitochondrial	pathway	of	 apoptosis	 or	 directly	 activate	 caspases	 (Bewley,	 Marriott	 et	 al.	 2011).	 	 Inhibition	 of	cathepsins	 decreases	 late	 phase	 macrophage-mediated	 killing	 of	 S.	 pneumoniae	 (Dockrell,	Marriott	et	al.	2003).	
Apoptotic	 cell	 death	 results	 in	 phosphatidylserine	 accumulation	 at	 the	 cell	 surface,	 which	increases	 scavenger	 receptor	mediated	 recognition	 by	 other	macrophages.	 	 The	 uptake	 of	apoptotic	bodies,	 i.e.	 efferocytosis,	 is	 into	 efferosomes	where	 the	dead	 cell	 is	 broken	down	(Martin,	 Peters	 et	 al	 2014).	 	 	 This	 results	 in	 anti-inflammatory	 cytokine	 secretion	 such	 as	TGFβ	and	IL10	in	addition	to	limiting	pro-inflammatory	cytokine	secretion.		Though	this	also	
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results	 in	 reduced	 phagocytic	 and	 microbicidal	 ability	 of	 the	 remaining	 macrophages	(Medeiros,	Serazani	et	al.	2009)	 	
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1.5	S.	pneumoniae	virulence	factors	and	macrophages	
S.	pneumoniae	has	a	number	of	genetically	conserved	factors	that	contribute	to	its	virulence.		Two	of	the	best-described	virulence	factors	are	the	extracellular	polysaccharide	capsule	and	toxin	 Ply	 and	 are	 described	 in	 detail.	 For	 context	 some	 of	 the	 other	 important	 virulence	factors	are	described	in	brief	below	and	summarised	in	table	1.8.	
Table	 1.8:	Major	 S.	 pneumoniae	 virulence	 factors	 (modified	 from	 Ferreira	 and	 Gordon,	2015)	 Virulence	factor	 Function	
Autolysin	A	 Autolysis	 by	 PG	 breakdown,	 releasing	inflammatory	bacterial	components	Capsule	 See	1.5.1	
Hyaluronate	 Breaks	 down	 hyaluronan	 in	extracellular	 matrix	 allowing	 tissue	invasion	IgA1	protease	 Cleaves	human	IgA	
Neuraminidase	A	 Cleaves	 sugars	 from	 host	 cell	 surfaces,	revealing	adhesion	sites	Phosphorylcholine	 Binds	 to	 PAFr	 on	 epithelial	 cells,	increasing	adhesion	Pneumolysin	 See	1.5.2	
Pneumococcal	 adherence	 and	virulence	factor	A	 Binds	to	fibronectin,	allowing	adhesion	Pneumococcal	surface	antigen	A	 Resistance	 to	 oxidative	 stress	 by	mediating	metal	ion	uptake	Pneumococcal	surface	protein	A	 Inhibits	complement	binding	by	blocking	alternate	pathway	C3	convertase	Pneumococcal	surface	protein	C	 Binds	factor	H	to	limit	complement	deposition,	and	binds	pIgR	to	increase	invasion		
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Choline	 binding	 proteins	 (CBP)	 are	 a	 family	 of	 15	 S.	 pneumoniae	 proteins	 that	 are	 non-covalently	anchored	to	the	cell	surface	via	choline	present	in	the	cell	wall.		Autolysin	A	(LytA)	is	the	major	S.	pneumoniae	autolysin,	and	is	required	for	virulence	(Martner,	Skovbjerg	et	al.	2009).	 	 LytB	 and	 CbpE	 are	 involved	 in	 nasopharyngeal	 colonisation	 (Mitchell	 and	Mitchell	2010).	 	PspA	interferes	with	complement	binding	to	S.	pneumoniae	and	binds	to	lactoferrin,	thus	 inhibiting	 host-mediated	 killing	 of	 the	 bacteria	 (Ricci,	 Gerlini	 et	 al.	 2013).	 	 PspA	 also	inhibits	complement	deposition	(Tu,	Fulgham	et	al.	1999).	 	PspC	(also	known	as	CbpA)	acts	as	 an	 adhesin	 to	 PAFr	 as	 well	 as	 binding	 to	 factor	 H,	 thus	 inhibiting	 the	 alternative	complement	pathway	(Dave,	Carmicle	et	al.	2004).	 	During	colonisation	PspC	interacts	with	epithelial	cells	by	the	polymeric	Ig	receptor,	facilitating	invasion.			
S.	pneumoniae	expresses	around	50	lipoproteins	that	possess	an	acyl	group,	allowing	them	to	be	anchored	to	cell	membrane	phospholipids.	Lipoproteins	have	multiple	functions	including	adhesion,	 transport,	 nutrient	 uptake,	 and	 signal	 transduction.	 	 Lipoproteins	 are	 translated	with	 a	 characteristic	 signal	 sequence	 and	 exported	 to	 the	 cell	 membrane,	 where	 post-translational	conformational	changes	occur.		Action	by	the	enzyme	lipoprotein	diacylglyceryl	transferase	 (Lgt)	 adds	an	acyl	 group,	 this	prolipoprotein	 is	 further	modified	by	 lipoprotein	signal	 peptidase	 (Lsp),	 to	 leave	 mature	 lipoprotein	 in	 Gram-positive	 organisms.	 	 The	 acyl	moiety	of	 lipoproteins	 interacts	directly	with	TLR2	(Kovacs-Simon,	Titball	et	al.	2011).	 	Lgt	deficient	S.	pneumoniae	have	been	used	to	confirm	that	lipoproteins	are	the	dominant	PAMP	inducing	 TLR2	 stimulation	 and	 thus	 inflammatory	 response	 in	 S.	 pneumoniae	 infection	(Khandavilli,	Homer	et	al.	2008,	Basavanna,	Khandavilli	et	al.	2009,	Chimalapati,	Cohen	et	al.	2012,	Tomlinson,	Chimalapati	et	al.	2014).	 	Lgt	deficient	mutants	are	also	cleared	 less	well	than	 wild-type	 from	 the	 nasopharynx	 (Moffitt,	 Skoberne	 et	 al.	 2014).	 	 The	 majority	 of	 S.	
pneumoniae	 lipoproteins	 are	 components	 of	 ABC	 transporters	 required	 for	 import	 of	micronutrients	 into	 the	 bacteria.	 For	 example	 pneumococcal	 surface	 antigen	 (Psa)	 A	 is	 a	manganese	binding	 lipoprotein	 that	 is	part	of	an	ABC	 transporter	 that	 imports	manganese,	and	is	important	for	resistance	to	oxidative	stress	(Kadioglu,	Weiser	et	al.	2008).		
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S.	pneumoniae	has	several	surface	proteins	that	are	covalently	attached	to	PG	in	the	cell	wall	via	 sortase	 peptidases	 that	 recognise	 the	 amino	 acid	 sequence	 LPXTG,	 including	hyaluronidase,	 neuraminidases,	 and	 pili.	 	 Hyaluronidase	 (Hyal)	 breaks	 down	 mammalian	connective	 tissue	 and	 extracellular	 matrix,	 possibly	 aiding	 bacterial	 spread	 once	 the	organism	has	reached	the	basement	membrane.	 	Neuraminidase	(NanA)	cleaves	glycolipids,	lipoproteins,	 and	 oligosaccharides	 by	 removing	 sialic	 acid	 from	 soluble	 proteins,	 causing	direct	damage	to	the	host	or	possibly	exposing	binding	sites	to	aid	adherence.		Some	strains	of	S.	pneumoniae	express	a	pilus-like	structure	encoded	by	the	pathogenicity	island	rlrA.		Pili	bind	to	components	of	host	extracellular	matrix,	and	ΔrlrA	mutants	have	reduced	adherence	to	epithelial	 cells	 and	cause	 lower	mortality	 in	a	 lung	 infection	model	 (Barocchi,	Ries	et	 al.	2006).		
As	 discussed	 in	 the	 adaptive	 immunity	 section,	 S.	 pneumoniae	 possesses	 an	 IgA1	 protease	that	 cleaves	 the	 mucosally	 abundant	 IgA,	 the	 main	 function	 of	 which	 is	 to	 neutralise	 and	agglutinate	 pathogens.	 	 Pneumococcal	 adherence	 and	 virulence	 factor	 A	 (PavA)	 binds	 to	fibronectin,	 thus	 mediating	 attachment	 to	 endothelium	 and	 facilitates	 transmigration	through	 the	basement	membrane	 (Mitchell	 and	Mitchell	 2010).	 	 PavB	 is	 a	 surface	 exposed	multi-domain	 protein	 that	 similarly	 binds	 to	 components	 of	 extracellular	 matrix	 (Jensch,	Gamez	et	al.	2010)	
1.5.1	Capsule	Biology	
S.	 pneumoniae	 is	 surrounded	 by	 a	 capsule	 that	 is	 vital	 for	 full	 virulence.	 	 The	 capsule	 is	usually	a	polyanionic	highly	hydrated	shell	consisting	of	chains	of	polysaccharide.	 	Electron	microscopy	demonstrates	that	 the	capsule	size	varies	between	strains	but	 is	usually	200	to	400nm	in	thickness	(Skov	Sorensen,	Blom	et	al.	1988).	 	Capsular	polysaccharide	consists	of	mono-	or	oligo-	saccharide	repeats	and	is	usually	covalently	bonded	to	the	cell	wall	(except	for	serotype	3),	which	nuclear	magnetic	resonance	data	suggests	forms	an	extended	flexible	
	 97	
ribbon-like	 structure	with	 no	 stabilisation	 of	 secondary	 structure	 (Rutherford,	 Jones	 et	 al.	1994).		
S.	 pneumoniae	 undergo	 spontaneous	 phase	 switching	 between	 transparent	 (low	 capsule	expression,	 and	 increased	 cell	wall	TA)	 and	opaque	 (high	 capsule	 expression,	 and	 less	TA)	phenotypes.	 	 These	 differences	 are	 visible	 in	 oblique	 light	 on	 an	 agar	 plate.	 	 The	 ability	 to	switch	phenotypes	allows	expansion	of	S.	pneumoniae	expressing	a	phenotype	that	is	better	able	to	cope	with	the	present	bacterial	environment.	 	For	example,	transparent	variants	are	more	efficient	at	colonisation	and	adhere	more	strongly	to	epithelial	cells	and	predominate	during	 colonisation,	whereas	opaque	variants	have	 greater	 virulence	 and	 survive	 longer	 in	blood	 and	 are	 the	 dominant	 phenotype	 amongst	 bacteria	 recovered	 from	 blood	 in	 mouse	models	of	 infection	(Kim	and	Weiser	1998).	 	The	ability	 to	dynamically	vary	 the	amount	of	capsule	 expressed	 is	 important	 in	 causing	 disease	 in	 a	 mouse	 model;	 mutants	 that	constitutively	 overexpress	 or	 underexpress	 the	 capsule	 are	 attenuated	 in	 mouse	 models	compared	 to	 wild-type	 bacteria	 (Shainheit,	 Mule	 et	 al.	 2014).	 	 Table	 1.9	 summarises	 the	recognised	functions	of	the	capsule	on	the	host	immune	system.		
1.5.1.1	Structure	The	carbohydrate	chain	structure	is	defined	by;	i)	the	nature	and	number	of	mono-	or	oligo-	saccharide	 units,	 ii)	 the	 sequence	 and	 ring	 size	 of	 the	 monosaccharides,	 iii)	 the	 type	 and	configuration	of	glycosidic	linkages,	and	iv)	non-sugar	substituents	(Yother	2011).		The	outer	surface	of	S.	pneumoniae	exhibits	various	degrees	of	negative	charge,	primarily	due	to	acidic	sugars,	 pyruvate	 or	 phosphate	 in	 the	 capsular	 polysaccharide.	 	 This	 may	 play	 a	 role	 in	repulsion	from	anionic	mucus	and	phagocytes.		There	is	a	correlation	between	increased	net	negative	 charge,	 resistance	 to	 neutrophil	 mediated	 killing,	 and	 increased	 nasopharyngeal	carriage	(Li,	Weinberger	et	al.	2013).																																																																																																				
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Table	1.9:	Effects	of	S.	pneumoniae	capsule	(Jonsson,	Musher	et	al.	1985,	Musher	1992,	
Nelson,	Roche	et	al.	2007,	Wartha,	Beiter	et	al.	2007,	Hyams,	Camberlein	et	al.	2010)	
	
Effects	of	S.	pneumoniae	capsule	on	host	immune	response	Inhibition	of	complement	mediated	phagocytosis	Inhibition	of	antibody	binding	to	cell	surface	proteins	Inhibition	of	phagocyte	engagement	with	opsonins	on	cell	surface	Inhibition	of	opsonin-independent	phagocytosis		Inhibition	of	mucus	entrapment	Inhibition	of	neutrophil	extracellular	traps		
1.5.1.2	Capsule	synthesis	Capsular	 biosynthesis	 requires	 the	 synthesis	 of	 a	 monosaccharide,	 attachment	 of	 each	monosaccharide	to	a	nucleotide	precursor,	coordinated	transfer	of	each	sugar	to	the	capsule	chain,	export	and	attachment	to	the	cell	surface	of	the	finished	product	in	succession.		There	are	 two	main	mechanisms	of	 capsule	 synthesis,	with	most	 serotypes	using	Wzy-dependent	pathway,	and	serotype	3	and	37	having	a	synthase	dependent	pathway.	
Capsule	 production	 is	 controlled	 by	 the	 cps	 portion	 of	 the	 bacterial	 genome	 and	 is	 highly	conserved	 amongst	 most	 serotypes.	 	 These	 genes	 lie	 between	 the	 homologous	 sequences	
dexB	and	aliA.		Conserved	genes	are	cps	A	–	D	which	encode	assembly	and	export	proteins,	a	gene	coding	for	a	flippase	that	transports	the	repeat	unit	from	inside	the	cell	to	the	external	surface	of	the	cell	membrane,	and	the	gene	encoding	a	polymerase	that	links	the	repeat	units	together.	 	 Non-conserved	 genes	 are	 those	 genes	 coding	 for	 specific	 glycosyl	 transferases	(Lopez	and	Garcia	2004,	Kadioglu,	Weiser	et	al.	2008).	 	CpsA	appears	 to	be	responsible	 for	the	covalent	bonding	of	the	polysaccharide	to	cell	wall.		However,	if	cpsA	is	inactivated,	LytR	(another	 enzyme	 involved	 in	 cell	 wall	 assembly,	 particularly	 TA	 to	 PG)	 takes	 over	responsibility	of	retaining	the	capsule	at	the	cell	wall	(Eberhardt,	Hoyland	et	al.	2012).		Two	
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proteins	 involved	 in	 sugar	 metabolism	 are	 also	 critical	 for	 capsule	 formation.		Phosphoglucomutase	 (Pgm)	 catalyses	 the	 conversion	 of	 G-6-P	 to	 G-1-P,	 and	 G-1-P	uridyltransferase	 (GalU)	 catalyses	 the	 formation	 of	 UDP-Glc	 from	 G-1-P.	 	 Mutations	 in	 the	genes	encoding	either	protein	result	in	almost	no	capsule	and	limited	growth.			
Amongst	 synthase-dependent	 serotypes	 a	 single	 enzyme	 initiates,	 polymerises,	 and	transports	the	sugars.	 	 In	serotype	3,	 the	 locus	for	the	synthase	genes	 is	also	between	dexB	and	 aliA,	 however	 the	 common	 region	 is	 not	 transcribed.	 	 The	 3’	 end	 of	 the	 locus	 is	 also	truncated	with	only	2	genes	required	for	capsule	synthesis:	Cps3D	encodes	UDP-glucuronyl	dehydrogenase	and	cps3S	encodes	the	synthase	(Yother	2011).		Type	3	capsule	is	synthesised	by	the	addition	of	alternating	glucose	and	glucuronic	acid	after	initiation	onto	a	lipid	primer.		The	chain	 is	 terminated	when	either	constituent	drops	below	the	necessary	concentrations	(Lopez	 and	 Garcia	 2004).	 	 Serotypes	with	 less	metabolically	 demanding	 capsules	 generate	thicker	 capsules	 in	 metabolically	 restricted	 environments,	 giving	 them	 an	 advantage	 in	nasopharyngeal	colonisation	(Hathaway,	Brugger	et	al.	2012).	
1.5.1.3	Effect	on	colonisation	Nasopharyngeal	colonisation	of	mice	with	isogenic	unencapsulated	strains	of	S.	pneumoniae	occurs	at	much	lower	density	and	is	cleared	more	quickly	than	encapsulated	strains	(Magee	and	 Yother	 2001).	 		 Apart	 from	 serotype	 1,	 7A,	 7F,	 15,	 33F,	 and	 37,	 which	 have	 a	 neutral	overall	charge,	all	other	serotypes	of	S.	pneumoniae	are	negatively	charged	by	virtue	of	their	capsule	make	up.	 	The	capsular	serotype	is	thus	the	strongest	factor	in	determining	surface	charge,	which	allows	movement	through	mucus	and	correlates	with	carriage	(Nelson,	Roche	et	 al.	 2007,	 Li,	Weinberger	 et	 al.	 2013).	 Strongly	negatively	 charged	 serotypes	 (4,	 6A,	23F)	and	 opaque	 phenotype	 variants	 are	 bound	 less	 by	 mucus	 than	 less	 strongly	 charged	serotypes	 (7F,	14)	 and	 transparent	mutants	 (Nelson,	Roche	et	 al.	 2007).	 	The	difference	 in	bacterial	 clearance	 between	 wild-type	 and	 unencapsulated	 strains	 is	 preserved	 in	 the	absence	of	AM,	further	evidence	that	capsule	has	an	effect	on	physical	defences	(Camberlein,	Cohen	et	al.	2015).	
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Capsule	 expression	 is	 reduced,	 albeit	 temporarily,	 during	 tissue	 invasion.	 	 Unencapsulated	mutants	 adhere	 more	 strongly	 to	 epithelial	 cells	 than	 wild-type	 S.	 pneumoniae	 (Morona,	Morona	et	al.	2006).		Electron	microscopy	confirms	reduced	capsular	material	upon	adhesion	to	 epithelium,	 and	 subculture	 of	 the	 internalised	 bacteria	 shows	 increased	 ability	 to	 both	adhere	to	and	invade	epithelial	cells	(Hammerschmidt,	Wolff	et	al.	2005).		While	transparent	
S.	pneumoniae	adhere	better	than	opaque	variants	to	resting	buccal	cells	by	GlcNAcb1-3Gal,	lung	epithelial	and	endovascular	cells	needed	to	be	stimulated	by	IL1β	and	TNF	respectively	to	increase	adherence	by	upregulation	of	PAFr	and	GlcNAc	(Cundell,	Weiser	et	al.	1995).		This	again	 had	 a	 more	 pronounced	 effect	 in	 transparent	 phenotypes	 than	 opaque	 variants.		Similarly,	opaque	S.	pneumoniae	are	taken	up	less	by	endothelium	and	are	more	likely	to	be	degraded	in	the	internalised	vacuole	(Ring,	Weiser	et	al.	1998).		
1.5.1.4	Effect	on	phagocytosis	The	 capsule	 of	 S.	 pneumoniae	 inhibits	 opsonophagocytosis,	 by	 inhibiting	 deposition	 of	complement,	 IgG	 and	 CRP,	 and	 inhibits	 neutrophil	 phagocytosis	 mediated	 by	 Fcγ,	complement	receptors,	and	non-opsonic	receptors	(Hyams,	Camberlein	et	al.	2010).		In	vivo,	mouse	AM	 internalised	unencapsulated	S.	 pneumoniae	more	 than	wild-type,	 particularly	 at	high	 inocula.	 	 The	 use	 of	 capsule	 switch	 mutants	 confirms	 that	 capsule	 makeup	 affects	resistance	 to	 neutrophil	 killing.	 	 This	 correlates	 with	 degree	 of	 encapsulation.	 	 However,	generating	thick	capsule	has	a	metabolic	cost	(Weinberger,	Trzcinski	et	al.	2009).		In	specific	circumstances	 capsule	 increases	 bacterial	 uptake;	 SIGN-R1	 positive	 macrophages	 allow	recognition	 of	 capsular	 polysaccharide	 from	 a	 variety	 of	 serotypes	 to	 be	 phagocytosed	 in	mice	 (Koppel,	Wieland	 et	 al.	 2005),	 and	 the	 human	 homologue	DC-SIGN	 similarly	 binds	 to	capsular	 polysaccharide,	 though	 it	 also	 binds	 some	 heat	 killed	 strains	 suggesting	 non	capsular	polysaccharides	may	also	be	recognised	by	DC-SIGN	(Koppel,	Saeland	et	al.	2005).		Similarly	 neutrophil	 binding	 to	 SP-D	 varies	 by	 capsular	 serotype	 (Jounblat,	 Kadioglu	 et	 al.	2004),	 meaning	 that	 capsule	 may	 affect	 binding	 to	 the	 bacterial	 ligand	 or	 that	 capsular	polysaccharide	may	be	a	 ligand	 itself	depending	on	 the	oligosaccharide	makeup.	 	However,	
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neutrophil	 killing	 of	 internalised	 S.	 pneumoniae	 by	 α	 defensins	 is	 decreased	 in	unencapsulated	S.	pneumoniae,	due	to	alteration	in	surface	charge,	as	surface	exposed	LTA	is	positively	charged	(Beiter,	Wartha	et	al.	2008).	
1.5.1.5	Effect	on	complement	Capsule	also	plays	a	 role	 in	binding	of	 complement	 to	S.	 pneumoniae.	 	 The	 capsule	 inhibits	deposition	 of	 C3b/iC3b	 as	well	 as	 inhibiting	 the	 conversion	 of	 bound	C3b	 to	 iC3b	 (Hyams,	Camberlein	 et	 al.	 2010).	 	 Cleavage	 of	 bound	 IgG	 still	 results	 in	 increased	 C3b	 binding,	suggesting	 the	 alternative	 pathway	 is	 inhibited	 in	 addition	 to	 the	 classical	 pathway.	 	 C3	deposition	on	S.	pneumoniae	varies	by	capsular	serotype,	 this	difference	persists	 in	capsule	switch	 strains,	 even	 in	 IgG	 depleted	 systems.	 	 The	 strains	 with	 increased	 complement	deposition	were	phagocytosed	more	readily	by	neutrophils	and	had	reduced	virulence	 in	a	mouse	sepsis	model	(Hyams,	Yuste	et	al.	2010).	 	However,	variation	in	C3b	deposition	on	S.	
pneumoniae	did	not	correlate	with	capsular	thickness,	and	varies	between	different	isolates	of	the	same	serotype.		Binding	of	C3b	correlates	with	C1q,	and	less	so	with	IgG	binding.		This	suggests	 that	 capsule	 independent	 variation	 between	 strains	 is	 important	 in	 complement	recognition	(Hyams,	Opel	et	al.	2011).		Similarly	factor	H	binding	(mainly	to	PspC)	varies	by	capsular	 serotype;	 this	 is	 inversely	 correlated	 with	 factor	 B	 binding,	 C3	 deposition,	 and	neutrophil	association	(Hyams,	Trzcinski	et	al.	2013).		These	differences	are	abrogated	when	PspC	mutant	strains	are	used,	suggesting	that	variations	in	complement	resistance	are	driven	by	 the	 degree	 of	 factor	H	 binding	 due	 to	 variations	 in	 capsular	makeup	 but	 not	 thickness,	probably	by	affecting	PspC	access	to	circulating	factor	H	(Hyams,	Trzcinski	et	al.	2013).			
1.5.1.6	Effect	on	inflammation	There	is	some	evidence	that	capsular	serotype	affects	inflammation.		A	13-year	single	centre	Spanish	 study	 looked	 at	 cases	 of	 CAP	 caused	 by	 S.	 pneumoniae.	 	 Serotype	 3	 was	overrepresented,	 and	 serotype	 1	 was	 underrepresented	 in	 cases	 presenting	 with	 shock	compared	 to	 those	without	 shock	 (Garcia-Vidal,	 Ardanuy	 et	 al.	 2010),	with	 a	OR	 of	 2.2	 for	serotype	3	causing	shock	on	multivariate	analysis.	 	However,	only	10	serotypes	were	found	
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in	650	patients,	with	serotype	3	being	 far	 the	commonest,	and	only	a	handful	of	cases	with	shock	due	to	other	serotypes,	possibly	underestimating	their	predisposition	to	cause	shock.		Additionally	an	analysis	of	the	patients	with	bacteraemia,	i.e.	true	septic	shock,	only	showed	a	correlation	with	steroid	treatment.		Immunosuppressed	patients	were	also	largely	excluded,	which	 may	 have	 skewed	 the	 data.	 	 Given	 the	 variation	 in	 serotype	 prevalence	 by	 region,	ideally	similar	data	from	other	countries	and	from	multiple	centres	would	be	considered	to	confirm	the	serotype	association	with	shock.	
A	3-year,	country	wide	study	of	bacterial	meningitis	in	adults	from	the	Netherlands	gathered	211	CSF	samples	from	patients	 infected	with	S.	pneumoniae.	 	The	authors	suggest	that	IL1β	and	IL18	levels	in	CSF	of	patients	with	meningitis	vary	by	the	serotype	causing	the	infection	(Geldhoff,	 Mook-Kanamori	 et	 al.	 2013),	 however	 there	 are	 16	 serotypes	 identified,	 and	 a	further	50	cases	not	 categorised	by	serotype.	 	For	 several	of	 the	 serotypes,	 they	were	only	identified	in	a	handful	of	cases.		In	addition	the	cytokine	data	shows	a	lot	of	variation	within	serotype,	 and	 although	 Kruskal-Wallis	 analysis	 suggests	 variation	 between	 strains,	 no	multiple	 comparison	 tests	were	 undertaken	 that	 suggest	 specific	 serotypes	 cause	more	 or	less	inflammation	than	others.	
In	 a	mouse	model	 of	 sepsis	 serotypes	 1	 and	 7F	 induced	 less	 serum	TNF	 than	 6B	 and	 19F	(Sandgren,	Albiger	et	al.	2005).		In	a	rabbit	model	of	meningitis	serotypes	5	and	7F	developed	a	 milder	 phenotype	 than	 serotypes	 6B,	 14,	 and	 23F	 as	 measured	 by	 leucocytes,	 protein	concentration,	lactate	levels,	and	cytokine	response	in	CSF	(Engelhard,	Pomeranz	et	al.	1997).		In	 a	mouse	 pneumonia	model	 serotype3	 induced	 greater	 lung	 inflammation	 and	mortality	than	serotype8	(Seyoum,	Yano	et	al.	2011).	
Despite	 the	 evidence	 for	 the	 capsule	 serotype	 affecting	 inflammatory	 responses,	 capsular	polysaccharide	 itself	 does	 not	 appear	 to	 provoke	 a	 profound	 inflammatory	 response.		Purified	polysaccharide	only	causes	pro-inflammatory	cytokine	release	from	whole	blood	at	much	 higher	 concentrations	 than	 heat	 killed	 bacteria	 (Jagger,	 Huo	 et	 al.	 2002),	 and	 RAW	
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macrophages	 require	 longer	 to	 release	 TNF	 after	 stimulation	 with	 purified	 capsular	polysaccharide	compared	to	heat	killed	S.	pneumoniae	(Simpson,	Singh	et	al.	1994).		Similarly,	injection	of	purified	capsular	polysaccharide	does	not	generate	an	inflammatory	response	in	a	 rabbit	 meningitis	 model	 when	 compared	 to	 purified	 cell	 wall	 or	 equivalent	 numbers	 of	heat-killed	bacteria	(Tuomanen,	Tomasz	et	al.	1985).	 	CXCL8	release	 from	human	epithelial	and	monocyte	cell	lines	is	lower	with	wild-type	bacteria	than	isogenic	unencapsulated	strains	(Marriott,	 Gascoyne	 et	 al.	 2012).	 	 There	 are	 however	 data	 suggesting	 that	 the	 presence	 of	capsule	increases	inflammatory	responses.		In	a	mouse	model	of	meningitis,	unencapsulated	mutants	 induced	 less	 inflammation	 than	wild-type	(Ricci,	Gerlini	et	al.	2013).	 	Additionally,	mice	 infected	 intranasally	 with	 wild-type	 S.	 pneumoniae	 had	 greater	 lung	 TNF,	 IL6,	 and	CXCL8	than	unencapsulated	mutants,	though	levels	of	IL1β	were	similar.		However,	in	MyD88	deficient	mice,	the	difference	was	markedly	reduced	(De	Vos,	Dessing	et	al.	2015).		However	data	 from	mouse	models	 are	 likely	 to	 be	 confounded	by	 differences	 in	 bacterial	 counts,	 as	unencapsulated	bacteria	are	cleared	more	rapidly.	
1.5.2	Pneumolysin	Biology	Ply	is	a	53kDa	cytosolic	protein	expressed	by	most	strains	of	S.	pneumoniae,	with	upregulated	expression	in	clinical	strains,	(Hu,	Liu	et	al.	2015).		Ply	is	released	on	bacterial	lysis,	although	it	also	localises	to	the	bacterial	cell	wall	(Price,	Greene	et	al.	2012)	independently	of	autolysis.		The	bacterial	cell	wall	inhibits	Ply	activity	as	the	branched	peptides	of	mature	PG	inhibit	Ply	release	 extracellularly	 from	 the	 cell	 wall,	 and	 this	 is	 dependent	 on	 remodelling	 of	 PG	 by	choline	binding	proteins	(Greene,	Narciso	et	al.	2015).			
Ply	has	multiple	 functional	 effects	 (table	1.10).	 	Ply	 is	 a	 cholesterol-binding	 toxin,	 and	best	known	 for	 inducing	 pore	 formation	 in	 host	 cell	 membranes	 and	 therefore	 host	 cell	 lysis.		Multiple	 monomers	 of	 Ply	 bind	 to	 cell	 membranes	 and	 oligomerise	 into	 a	 circular	 barrel	structure	 of	 30-50	 monomers,	 which	 unfolds	 and	 penetrates	 the	 membrane	 to	 create	 the	pore.		This	appears	to	be	related	to	interactions	with	actin	within	the	cell	(Hupp,	Fortsch	et	al.	
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2013).	 	 Neuroblastoma	 cells	 incubated	with	 purified	 Ply	 exhibit	membrane	 depolarisation	within	 60	 seconds	 of	 exposure,	 and	 cell	 morphological	 changes	 within	 8	 minutes.	 	The	morphological	changes	were	dependent	on	voltage	gated	calcium	channel	mediated	calcium	influx	 and	 consequent	 Rho	 GTPase	 activation	 (Iliev,	 Djannatian	 et	 al.	 2007).	 	 This	 was	dependent	on	Ply	binding	cholesterol,	and	occurred	even	at	sub-lytic	concentrations.		
1.5.2.1	Effects	in	vivo	Mice	infected	intranasally,	intraperitoneally	or	intravenously	with	S.	pneumoniae	lacking	Ply	(Δply)	had	longer	median	survival	than	if	 infected	with	wild-type	bacteria	(Berry,	Yother	et	al.	1989).		Similarly	wild-type	bacteria	induced	more	protein	leak	in	a	pneumonia	model,	and	invaded	 the	blood	much	more	 rapidly	 than	a	Δply	 strain	 (Rubins,	 Charboneau	et	 al.	 1995).		The	co-administration	of	purified	Ply	with	the	Δply	strain	replicated	the	wild-type	phenotype.		Purified	 Ply	 induced	 vascular	 leakage	 and	 lung	 oedema	 in	 mice	 when	 administered	intratracheally.		This	was	associated	with	neutrophil	recruitment	and	early	depletion	of	AM.		Pre-depleting	 AM	 had	 no	 effect	 on	 this	 phenomenon,	 suggesting	 other	 cell	 types,	 such	 as	epithelium	 are	 involved	 in	 this	 response	 (Maus,	 Srivastava	 et	 al.	 2004).	 	 Ply	 also	 causes	elevation	of	pro-inflammatory	cytokines	in	BALF	and	leukocyte	trafficking	that	was	mediated	by	CXCL2	(Rijneveld,	van	den	Dobbelsteen	et	al.	2002).		Purified	Ply	caused	alveolar	epithelial	damage	when	instilled	intranasally	(Kadioglu,	Taylor	et	al.	2002).		Sublytic	doses	of	Ply	also	elicited	significant	epithelial	barrier	damage	(Los,	Randis	et	al.	2013).		Ply	is	also	implicated	in	breaching	the	endothelial	barrier	prior	to	causing	meningitis.		Intravenous	administration	of	 wild-type	 S.	 pneumoniae	 into	 mice	 induced	 more	 systemic	 IL6	 than	 intravenous	administration	 of	 the	 Δply	 strain,	 with	 Δply	 leading	 to	 a	 chronic	 bacteraemic	 phenotype	rather	 than	an	acute	sepsis	phenotype	(Benton	KA,	VanCott	 JL	et	al.	1998).	 	 In	 this	context,	the	role	of	Ply	occurs	early	in	infection,	with	early	host	resistance	to	Δply	being	dependent	on	TNF.	 	 Large	amounts	of	Ply	 are	 released	by	S.	 pneumoniae	 on	exposure	 to	 antibiotics,	with	perhaps	potentially	negative	consequences	for	the	host.	
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Table	1.10:	Effects	of	Pneumolysin	(Bewley,	Naughton	et	al.	2014,	Davis,	Nakamura	et	al.	2011,	Ferrante,	Rowan-Kelly	et	al.	1984,	Los,	Randis	et	al.	2013,	Malley,	Henneke	et	al.	2003,	McNeela,	Burke	et	al.	2010,	Paton,	Rowan-Kelly	et	al.	1984)	
	
Effects	of	pneumolysin	on	host	immune	response	Activates	TLR4	Activates	inflammasome	&	NOD	Reduces	neutrophil	killing	of	S.	pneumoniae	Breaks	down	epithelial	tight	junctions	Induces	apoptosis	Activate	and	deplete	host	complement	Activate	memory	T	cell	responses	Inhibit	T	cell	inflammatory	responses	
	
1.5.2.2	Non	haemolytic	pneumolysin	Although	 virtually	 all	 clinical	 isolates	 of	 S.	 pneumoniae	 produce	 Ply,	 some	 invasive	 strains	express	allelic	variants	of	the	ply	gene	that	encode	non-haemolytic	Ply.		For	example,	50%	of	serotype	 1	 clinical	 isolates	 in	 Scotland	 have	 a	 mutation	 in	 the	 pore-forming	 region	 of	 the	pneumolysin	gene,	rendering	it	non-haemolytic	(Kirkham,	Jefferies	et	al.	2006).	 	These	non-haemolytic	 strains	 are	 of	 MLST	 sequence	 type	 306,	 whereas	 the	 normal	 Ply	 expressing	strains	were	sequence	 type	227.	 	Ply	 from	serotypes	7	&	8	 strains	can	have	a	 threonine	 to	isoleucine	substitution	at	position	172	that	reduces	haemolytic	activity	(Kirkham,	Jefferies	et	al.	 2006).	 	 Non-haemolytic	 alleles	 are	 also	 found	 in	 some	 serotype	 8	 (sequence	 type	 53)	strains,	 and	may	 be	 overrepresented	 in	 outbreak	 causing	 strains	 (Jefferies,	 Johnston	 et	 al.	2007).	 	 Relatively	 little	 epidemiological	 data	 about	 non-haemolytic	 Ply	 exists	 elsewhere,	though	isolates	have	been	found	in	Australia	(Lock,	Zhang	et	al.	1996)	and	France	(Garnier,	Janapatla	et	al.	2006).		In	mouse	infection	models	the	non	cytotoxic	strain	induced	less	lung	oedema	and	leukocyte	trafficking,	and	caused	less	mortality	but	had	better	survival	in	blood	
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than	 both	 wild-type	 and	 Δply	 strains	 (Harvey,	 Hughes	 et	 al.	 2014,	 Harvey,	 Ogunniyi	 et	 al.	2011,	Maus,	Srivastava	et	al.	2004,	Rijneveld,	van	den	Dobbelsteen	et	al.	2002).		This	suggests	that	the	non-cytolytic	functions	of	Ply	enhance	survival	of	the	bacterium	in	blood.		
1.5.2.3	Effect	on	inflammation	Multiple	mechanisms	have	been	described	by	which	Ply	affects	inflammation,	most	of	which	lead	to	enhanced	inflammatory	responses	(figure	1.8).		Purified	Ply	induces	secretion	of	TNF	and	IL1β	 in	human	monocytes,	as	well	as	 inhibiting	H2O2	release,	suggesting	that	 it	 inhibits	the	respiratory	burst	(Houldsworth,	Andrew	et	al.	1994).	
TLR4	Purified	 Ply	 induces	 TNF	 and	 IL6	 secretion	 from	mouse	macrophages	 that	 is	 abrogated	 in	macrophages	 from	MyD88	 deficient	 mice	 (Malley,	 Henneke	 et	 al.	 2003).	 	 Ethanol-killed	 S.	
pneumoniae	 induced	CXCL8	secretion	in	HEK	cells	transfected	with	TLR4	and	NFκB	nuclear	translocation	 in	mouse	macrophages	 incubated	with	 purified	Ply	was	TLR4	dependent.	 	 In	
vivo,	 mice	 infected	 with	 S.	 pneumoniae	 had	 improved	 survival	 when	 infected	 with	 Δply	compared	to	wild-type	bacteria,	however	the	virulence	of	wild-type	was	reduced	in	mice	that	did	not	express	TLR4.		In	addition,	purified	Ply	coated	onto	ELISA	plates	bound	to	TLR4	but	not	TLR2	(Srivastava,	Henneke	et	al.	2005).	 	These	data	all	 support	 the	hypothesis	 that	Ply	stimulates	TLR4	dependent	inflammatory	responses.		However,	other	data	suggest	Ply	is	not	recognized	directly	by	TLR4	 in	vitro	 (McNeela	Burke	et	al.	2010)	and	 low	dose	purified	Ply	induced	mild	leukocytosis	in	BALF	as	well	as	raised	levels	of	TNF,	CXCL2	and	KC	when	given	to	mice	intranasally.		These	effects	were	also	seen	in	in	TLR2	deficient	mice,	and,	apart	from	reduced	KC,	in	TLR4	deficient	mice	(Dessing,	Hirst	et	al.	2009),	suggesting	that	inflammation	may	 be	 TLR4	 independent.	 	 As	 such,	 the	 concept	 of	 TLR4	 recognition	 of	 Ply	 remains	contentious.		Indirect	effects	of	Ply	on	TLR4	could	possibly	explain	these	discrepancies.	
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Figure	1.9	Effects	of	pneumolysin	on	inflammation	Ply	 is	 thought	 to	 activate	 TLR4	 and	 so	 induce	 NFκB	 mediated	 transcription	 of	 pro-inflammatory	cytokines.		In	addition	due	to	its	pore-forming	effects,	it	allows	the	penetration	of	 PG	 and	 bacterial	 DNA	 into	 the	 cytosol.	 	 Here	 PG	 activates	 NOD2	 and	 hence	 pro-inflammatory	 cytokines.	 	 Bacterial	DNA	entering	 the	 cytosol	 by	means	 of	 Ply	 induces	 IRF7	and	type	1	IFN	transcription.		Additionally	the	pore	forming	effects	of	Ply	are	thought	to	lead	to	ion	shifts	that	result	 in	the	activation	of	NLRP3,	a	component	of	the	inflammasome,	such	that	post-translational	activation	of	IL1β	occurs.		
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NOD2	The	 ability	 of	 S.	 pneumoniae	 to	 induce	 NOD2	 activation	 is	 dependent	 on	 the	 pore-forming	effect	of	pneumolysin,	allowing	delivery	of	PG	fragments	in	the	phagosome	into	the	cytosol,	resulting	in	chemokine	release	and	leucocyte	recruitment	(Davis,	Nakamura	et	al.	2011)	
Inflammasome	Ply	activates	the	inflammasome	independently	of	TLR4.	 	While	purified	Ply	at	up	to	1μg/ml	did	 not	 induce	 cytokine	 production	 from	 murine	 DC	 or	 BMDM,	 and	 caused	 cell	 death	 at	greater	concentrations,	the	addition	of	purified	Ply	to	heat	killed	S.	pneumoniae	increased	the	secretion	of	IL1β,	IL12,	IL23,	TNF,	and	IL6	from	DCs,	and	IL6	and	TNF	from	BMDM	(McNeela,	Burke	 et	 al.	 2010),	with	 an	 initial	 signal	 required	 to	 upregulate	 inflammasome	 expression	before	 a	 second	 signal	 causing	 its	 activation.	 	 Caspase	 1	 inhibition	 reduced	 the	 amount	 of	IL1β	released	due	to	Ply	 in	combination	with	a	TLR2	agonist,	while	DC	from	caspase	1	and	NLRP3	 deficient	 mice	 also	 exhibited	 reduced	 IL1β	 secretion	 in	 response	 to	 purified	 Ply.		However	non-haemolytic	Ply	 induced	 less	 IL1β	secretion	 that	wild	 type	Ply	suggesting	 that	the	 pore-forming	 component	 is	 critical.	 	 Inhibition	 of	 potassium	 efflux	 and	 phagosome	rupture	also	inhibited	IL1β	secretion	from	DC.		In	mouse	pneumonia,	while	infection	with	the	Δply	 strain	 resulted	 in	 reduced	 bacterial	 lung	 counts	 compared	 to	wild-type,	 this	was	 less	evident	in	NLRP3	deficient	mice	(McNeela,	Burke	et	al.	2010,	Witzenrath,	Pache	et	al.	2011).		NLRP3	deficient	BMDM	had	a	reduced	capacity	 to	secrete	 IL1β,	and	ASC	deficient	cells	had	complete	 abrogation	 of	 IL1β	 and	 18	 release	 in	 response	 to	 S.	 pneumoniae.	 	 This	 was	recapitulated	with	 AIM2	 deficient	macrophages,	 but	 not	 Δply	 mutants,	 suggesting	 that	 Ply	plays	 a	 role	 in	 delivering	 bacterial	 DNA	 to	AIM2	 (Fang,	 Tsuchiya	 et	 al.	 2011).	 Additionally	fibroblast	and	epithelial	cell	secretion	of	TGFβ	in	response	to	S.	pneumoniae	is	dependent	on	Ply-dependent	ion	fluxes	and	likely	NLRP3	(Neill,	Coward	et	al.	2014).	
MAPK	Low	 doses	 of	 purified	 Ply	 induced	 rapid	 phosphorylation	 of	 p38	MAPK	 in	 A549	 cells,	 and	induced	CXCL8	release,	as	well	as	TNF	and	IL1β	transcription	(Lu,	Sun	et	al.	2014).		This	was	
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recapitulated	 with	 live	 wild-type	 S.	 pneumoniae,	 but	 not	 Δply	 strains.	 	 This	 effect	 was	dependent	 on	 the	pore	 forming	 ability	 of	 Ply,	 and	not	mediated	by	TLR2	or	 4.	 	 P38	MAPK	activation	 is	 inhibited	 by	 dextran,	 indicating	 that	 pores	 induce	 osmolar	 changes	 that	 are	responsible	for	this	effect	(Ratner,	Hippe	et	al.	2006).			
The	deubiquitinating	enzyme	CYLD	acts	as	a	negative	regulator	of	the	MAPK	pathway	(Lim,	Stirling	et	al.	2007),	and	was	upregulated	in	mouse	lungs	after	administration	of	intranasal	S.	
pneumoniae	or	purified	Ply	but	not	after	infection	with	the	Δply	strain.	 	CYLD	deficient	mice	had	reduced	mortality	and	protein	leak,	as	well	as	less	bacteraemia	than	wild-type.		NFAT	is	a	rapidly	 inducible	 transcription	 factor	 that	 requires	dephosphorylation	 to	 translocate	 to	 the	nucleus,	 which	 then	 binds	 to	 the	 IL2	 promoter	 as	 well	 as	 inflammatory	 cytokines.	 	 NFAT	phosphorylation,	mediated	by	p38	MAPK	and	calcineurin,	was	stimulated	by	S.	pneumoniae	lysate	 but	 not	 a	 lysate	 made	 with	 the	 Δply	 strain	 (Koga,	 Lim	 et	 al.	 2008).	 	 The	 NFAT	dependent	genes	COX-2	and	IL6	were	also	upregulated	in	A549	by	S.	pneumoniae	lysate,	and	this	was	also	seen	in	mouse	lungs	after	intranasal	instillation.	Calcium	chelation,	calcineurin,	and	 p38	 MAPK	 inhibition	 all	 reduced	 NFAT	 induction	 in	 response	 to	 bacterial	 lysate.		Conversely	 NFAT	 activation	 was	 increased	 in	 CYLD	 deficient	 cells,	 dependent	 on	 its	deubiquitinating	function.			
CCL2	 was	 upregulated	 at	 mRNA	 and	 protein	 level	 in	 respiratory	 epithelial	 cell	 lines	 and	mouse	 lungs	 after	 exposure	 to	 S.	 pneumoniae	 lysate.	 	 Δply	 mutants	 did	 not	 induce	 CCL2,	whereas	purified	Ply	did	(Shin,	Yoo	et	al.	2010).		This	was	inhibited	by	a	p38	MAPK	inhibitor;	conversely	DUSP-1	 inhibition	 increased	Ply	mediated	p38	phosphorylation,	 suggesting	 that	Ply	 also	 induces	DUSP-1,	which	 acts	 as	 a	 negative	 regulator	 of	 CCL2	 release.	 	Wild-type	 S.	
pneumoniae	 culture	 supernatant	 induced	more	CXCL8	 from	nasopharyngeal	 cells	 than	Δply	(Dogan,	 Zhang	 et	 al.	 2011).	 	 Intracellular	 Ca2+	 chelation	 reduced	 CXCL8	 release,	 as	 did	inhibition	of	MEK,	p38	MAPK,	and	JNK.	
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These	 data	 suggest	 that	 Ply	 can	 both	 promote	 and	 inhibit	 MAPK	 signalling.	 	 	 While	 Ply	induces	NFAT-dependent	pro-inflammatory	cytokine	production,	it	also	upregulates	CYLD,	so	inhibiting	 MAPK	 pathways.	 	 Similarly	 Ply	 stimulates	 MAPK-dependent	 chemokine	 release	whilst	also	inducing	DUSP-1.	
Interferons	Mouse	macrophages	pre-incubated	with	IFNγ	then	with	S.	pneumoniae	produced	significantly	more	NO	in	response	to	the	wild-type	compared	to	the	Δply	strain	(Braun,	Novak	et	al.	1999).		Purified	Ply	also	induced	NO	from	wild-type	macrophages,	but	not	in	macrophages	from	mice	deficient	 in	 IFNγ	 or	 IRF1.	 	 Type	 I	 IFN	 is	 released	 by	macrophages	 after	 phagocytosis	 of	 S.	
pneumoniae	and	Ply	dependent	release	of	bacterial	DNA	or	PG	from	the	phagosome	into	the	cytosol	for	recognition	in	a	STING	or	NOD	dependent	manner	respectively	(Kafka,	Ling	et	al.	2008).		Mouse	lungs	produce	more	IFNβ,	less	IL6	and	have	a	reduced	neutrophil	infiltrate	in	response	 to	 intranasal	 infection	with	wild-type	S.	 pneumoniae	compared	 to	 the	Δply	 strain.		Mouse	 nasopharyngeal	 epithelial	 cells	 also	 upregulate	 IFNβ	 after	 incubation	 with	 S.	
pneumoniae,	 mediated	 by	 LytA	 and	 the	 pore	 forming	 function	 of	 Ply.	 	 In	 addition,	 DNAse	treatment,	inhibition	of	phagocytosis,	inhibition	of	phagolysosome	acidification	or	inhibition	of	 STING,	 TBK1,	 and	 IRF3	 all	 inhibit	 IFNβ,	 suggesting	 that	 Ply	 allows	 delivery	 of	 bacterial	DNA	into	the	cytosol	to	induce	IFNβ	(Parker,	Martin	et	al.	2011).		In	vivo	IFNAR	deficient	mice	produced	 less	 CCL5	 in	 BAL	 in	 response	 to	 wild-type	 but	 not	 Δply	 suggesting	 that	 this	chemokine	is	dependent	on	IFN	release	(Koppe,	Hogner	et	al.	2012).	
Anti-inflammatory	effects	The	above	data	largely	show	Ply	induces	an	enhanced	inflammatory	response	either	directly	(e.g.	via	TLR4	stimulation	or	activation	of	the	inflammasome)	or	indirectly	(e.g.	by	releasing	DNA	and	PG	 from	phagolysosomes	 into	 the	cytosol	 to	activate	NODs	and	RIGs).	 	 In	vitro,	 S.	
pneumoniae	 induces	 TNF	 and	 IL1β	 transcription	 relatively	 late,	 and	 there	 are	 limited	 data	suggesting	 Ply	 has	 an	 anti-inflammatory	 effect	 instead.	 	 Ply	 acts	 via	 DUSP1	 to	 act	 as	 a	negative	 regulator	of	p38	MAPK	and	 thus	 reduces	 early	TNF	 transcription	 (Shin,	Yoo	et	 al.	
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2010).	 	Human	DC	produced	 less	 IL12	and	CXCL8	 in	 the	presence	of	Ply	expressing	strains	than	those	without.		Ply	is	also	required	for	activation	of	caspase	1,	3,	and	8,	and	subsequent	apoptosis	and	cell	death,	with	slightly	less	apoptosis	in	strains	producing	non-haemolytic	Ply	(Littmann,	Albiger	et	al.	2009).		Interestingly	the	Δply	strain	also	induced	more	IL1β	at	both	transcriptional	and	secreted	protein	levels	in	this	model	of	primary	human	DCs.		It	is	unclear	whether	this	discrepancy	is	explained	by	type	of	cell,	or	the	species	origin,	and	whether	this	could	be	replicated	in	vivo.	
1.5.2.4	Effect	on	Apoptosis	There	 is	 considerable	 evidence	 that	 Ply	 promotes	 host	 cell	 apoptosis.	 	 Purified	 Ply	 caused	dose-dependent	 increase	 in	 apoptosis	 of	 RAW	 macrophages	 at	 18	 hours	 and	 this	 was	inhibited	 by	 a	 TLR4	 inhibitor.	 	 Similarly	 HEK	 TLR4	 cells	 underwent	 more	 apoptosis	 in	response	 to	 Ply	 than	 HEK	 TLR2	 cells.	 	 This	 effect	 was	 partially	 inhibited	 by	 ZVAD-FMK	indicating	 that	 Ply	 induction	 of	 apoptosis	 is	 at	 least	 partially	 caspase	 dependent.	 	 In	mice	infected	 intranasally,	 there	 was	 greater	 nasopharyngeal	 apoptosis	 with	 wild-type	 S.	
pneumoniae	than	the	Δply	strain,	and	again	this	difference	was	abrogated	in	TLR4	knockout	mice.	 	 Wild-type	 mice	 pretreated	 with	 ZVAD	 had	 increased	 mortality,	 indicating	 that	 the	apoptotic	 response	 is	 important	 in	 protection	 from	 infection	 (Srivastava,	 Henneke	 et	 al.	2005).	 	Human	MDM	incubated	with	S.	pneumoniae	had	 increased	 iNOS	expression	and	NO	production,	which	resulted	in	mitochondrial	membrane	permeabilisation	(Marriott,	Ali	et	al.	2004).	 	This	 NO	 is	 expressed	 adjacent	 to	 internalised	 bacteria,	 not	 in	 mitochondria.	 	iNOS	inhibition	 reduced	 killing	 of	 internalised	 bacteria,	 reduced	 MDM	 apoptosis,	 and	 increased	necroptosis.	 	Δply	 induced	 less	 mitochondrial	 membrane	 permeabilisation	 and	 apoptosis	than	wild-type	suggesting	that	Ply	is	involved	in	apoptosis	induction.		Ply	did	not	contribute	to	apoptosis	if	added	exogenously,	and	S.	pneumoniae	expressing	Ply	must	be	phagocytosed	in	 conjunction	 with	 TLR	 stimulation	 to	 induce	 programmed	 cell	 death;	 this	 occurred	independently	of	 its	 cytolytic	and	 inflammasome	activating	 functions	 (Bewley,	Naughton	et	al.	2014).		
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1.5.2.5	Effects	on	antimicrobial	peptides	Incubation	of	S.	pneumoniae,	but	not	the	Δply	strain,	with	A549	cells	induced	upregulation	of	HBD2	mRNA.		This	was	dependent	on	p38	MAPK	signalling,	but	Ply	also	induced	DUSP1	that	then	rapidly	inhibited	HBD2	expression	(Kim,	Shin	et	al.	2013).	 	The	host	immunity	peptide	BPI	increased	TNF	release	caused	by	S.	pneumoniae	from	mouse	macrophages,	which	caused	apoptosis;	 this	 effect	 on	 TNF	 response	 to	 BPI	 was	 Ply	 dependent	 but	 TLR4	 independent	(Srivastava,	 Casey	 et	 al.	 2007).	 	 	 These	 data	 suggest	 that	 Ply	 is	 important	 in	 inducing	epithelial-derived	antimicrobial	peptides,	which	may	have	an	impact	on	inflammation	as	well	as	their	recognised	role	in	bacterial	killing.		 	
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1.6	Summary	In	summary,	generation	of	an	 inflammatory	response	 is	key	 in	 the	human	host	response	to	clear	S.	pneumoniae.		Alveolar	macrophages	are	the	sentinels	of	the	lung	and	are	crucial	to	the	initial	phagocytosis	of	S.	pneumoniae	and	orchestration	of	the	inflammatory	response	to	help	augment	 bacterial	 clearance.	 	 The	 capsule	 and	 Ply	 are	 central	 to	 the	 virulence	 of	 S.	
pneumoniae,	though	their	effects	on	inflammation	have	not	been	fully	explored.	
Most	data	 regarding	 the	effect	of	 capsule	on	 the	 inflammatory	 response	 suggest	 that	 it	has	little	role,	particularly	in	comparison	to	cell	wall	lipoproteins.		Ply	on	the	other	had	appears	to	have	pleiotropic	pro-inflammatory	effects.		However,	there	are	some	data	that	suggests	it	may	play	a	more	complex	role,	including	some	anti-inflammatory	effects.	 	In	both	cases,	the	roles	 of	 the	 purified	 components	 have	 been	 explored	 fully	 in	 the	 past,	 but	 less	 so	 in	 the	context	of	 live	bacteria	and	particularly	 in	early	 infection.	 	Further	exploration	of	the	initial	host-pathogen	 interactions	and	how	specific	bacterial	components	affect	 inflammation	may	improve	understanding	 of	 pathogenesis	 and	possibly	 identify	 factors	 that	 could	be	used	 in	adjunctive	treatment	of	S.	pneumoniae	infection.		 	
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1.7	Aims	
S.	pneumoniae	expresses	several	factors	that	are	important	in	promoting	virulence,	foremost	of	 which	 are	 the	 polysaccharide	 capsule	 and	 toxin	 pneumolysin.	 The	 capsule	 is	 best	recognised	as	a	mechanism	for	evading	opsonophagocytosis,	with	 little	and	conflicting	data	on	its	effects	on	inflammation.		As	it	inhibits	host	recognition	of	bacterial	surface	molecules	it	would	be	predicted	 to	 reduce	 inflammatory	 responses	 to	S.	 pneumoniae.	 	 Pneumolysin	has	pleiotropic	 effects	 on	 the	 host	 immune	 response,	 which	 previous	 data	 suggest	 are	 largely	pro-inflammatory,	 but	 there	 are	 some	 conflicting	 data	 and	 the	 effects	 of	 pneumolysin	 on	early	macrophage	responses	have	on	the	whole	not	been	investigated.	
The	aim	of	this	thesis	is	to	address	the	hypothesis:	
‘The	 polysaccharide	 capsule	 inhibits	 and	 pneumolysin	 stimulates	 the	 macrophage	inflammatory	response	to	live	S.	pneumoniae.’	
The	specific	aims	are:	
1.	 To	 compare	 the	 effects	 of	 encapsulated	 and	 unencapsulated	 S.	 pneumoniae	 on	 the	inflammatory	response	of	macrophages	and	epithelial	cells,	and	in	murine	infection	models.	
2.	 To	 characterise	 the	 effects	 of	 pneumolysin	 on	 the	 inflammatory	 response	 to	 live	 S.	
pneumoniae	of	macrophages	and	epithelial	cells	in	culture	and	in	murine	infection	models.	
3.	To	identify	the	mechanisms	causing	any	capsule	or	pneumolysin	dependent	effects	on	the	macrophage	inflammatory	response.		
4.	To	assess	the	functional	consequences	of	any	capsule	or	pneumolysin	dependent	effects	on	the	 macrophage	 inflammatory	 response	 for	 disease	 development	 using	 rodent	 infection	models.		 	
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2	Materials	and	Methods	Many	thanks	should	go	to	others	in	UCL	who	helped	with	generating	some	of	the	data	in	this	thesis.	 	 Emilie	 Camberlein	 performed	 some	 of	 the	 initial	 mouse	 experiments,	 Alex	 Dyson	performed	 the	 instrumentation	 for	 the	 rat	 sepsis	 experiments,	 and	 Gillian	 Tomlinson	performed	some	of	the	MDM	transcription	experiments.		The	relevant	experiments	are	noted	in	 the	 results	 when	 presented.	 	 All	 data	 was	 analysed	 by	 myself.	 	 General	 reagents	 were	largely	supplied	by	Sigma	Aldrich	(Gillingham).	
2.1	Bacterial	Culture	and	Strains	
2.11Growth	conditions	and	media	
Streptococcus	pneumoniae	was	grown	in	autoclaved	THY	medium;	Todd	Hewitt	broth	(Oxoid,	Basingstoke)	 supplemented	with	0.5%	yeast	 extract	 (Sigma	Aldrich,	Gillingham)	at	 37°C	 in	5%	CO2	till	mid	log	phase.		This	was	considered	to	be	when	optical	density	(OD)	measured	at	580nm	 by	 spectrophotometer	 (Amersham	 Pharmacia,	 Amersham)	 reached	 0.4-0.5.	 	 Stocks	were	archived	 in	10%	glycerol	at	 -80°C.	 	S.	pneumoniae	 strains	were	cultured	on	5%	blood	Columbia	agar	(Sigma	Aldrich,	Gillingham)	plates	made	with	defibrinated	horse	blood	(E&O	Laboratories,	 Bonnybridge,	 UK).	 	 Mutant	 strains	 were	 streaked	 and	 grown	 in	 antibiotic	supplemented	 media	 (table	 2.1	 –	 list	 of	 all	 strains	 used	 in	 thesis).	 	 For	 a	 number	 of	experiments	 (involving	Δpab	strains)	bacteria	were	grown	 to	an	OD	of	0.8	 in	50ml	of	THY,	pelleted	 and	 resuspended	 in	 smaller	 volumes	 of	 sterile	 phosphate	 buffered	 saline	 (PBS)	(Gibco,	Loughborough)	with	10%	glycerol	to	create	concentrated	stocks.			
Stock	 concentrations	 were	 confirmed	 by	 defrosting	 glycerol	 stocks,	 centrifuging	 for	 10	minutes	at	13,000	g,	and	resuspending	the	pellet	in	PBS.		This	suspension	was	serially	diluted	and	plated	on	blood	agar	and	incubated	overnight	at	37°C	in	5%	CO2.	
The	 strains	 used	 in	 animal	 experiments	 (excepting	 the	 ΔpabB)	 were	 grown	 from	 animal	passaged	 isolates	 obtained	 from	 mouse	 spleen	 homogenates	 after	 infection	 to	 ensure	
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virulence.		All	strains	used	in	this	thesis	were	additionally	sent	for	whole	genome	sequencing	at	 the	 Sanger	 Centre,	 with	 no	 significant	 mutations	 noted.	 	 Phenotype	 was	 not,	 however	checked	 for	each	experiment.	 	Though	 the	encapsulated	 strains	were	visually	distinct	 from	unencapsulated	strains	and	haemolytic	 function	of	Δply	 strains	were	checked	several	 times	during	the	course	of	my	PhD.	
Table	2.1	Strains	used	in	this	thesis	
Strain	 Serotype	 Phenotype	 Resista
nce	
Source	TIGR4	D39	OXC-1417-23F		6A	14	
4	2	23F	3	6A	14	
Wild-type	Wild-type	Wild-type	Wild-type	Wild-type	Wild-type	
Nil	Nil	Nil	Nil	Nil	Nil	
	
TIGR4Δcps	D39Δcps	3Δcps	23FΔcps	
S.	mitis	
S.	mitis	Δcps	
S.	mitis	+	TIGR4cps		
4	2	23F	3	NCTC	12261	
Unencapsulated	Unencapsulated	Unencapsulated	Unencapsulated		Unencapsulated	Express	TIGR4	capsule		
Kan	Kan	Kan	Kan	Nil	Kan	KanEry	
				F	Peterson	F	Peterson	F	Peterson	TIGR4	+	6A		TIGR4	+	7F	TIGR4	+	14	TIGR4	+	23F		
4	4	4	4		
Express	6A	capsule	Express	7F	capsule	Express	14	capsule	Express	23F	capsule		
Strep	Strep	Strep	Strep		
J	Weiser	J	Weiser	J	Weiser	J	Weiser		TIGR4Δply	TIGR4ΔcpsΔply	D39Δply	D39	D39	complemented	3Δply	23FΔply	
4	4	2	2	2	3	23F	
Lack	pneumolysin	Lack	pneumolysin	and	capsule	Lack	pneumolysin	Wildtype	Pneumolysin	complemented	Lack	pneumolysin	Lack	pneumolysin	
Ery	EryKan	Ery		Strep	Ery	Ery	
T	Mitchell		J	Weiser		J	Weiser		INV104B	03.3038		NCTC7465	
1	1		1	
Wild-type	Wild-type	–	non-lytic	pneumolysin	Wild-type	–	lacks	pneumolysin	
	 	
TIGR4ΔpabB	TIGR4ΔpabBΔcps	 4	4	 Non-replicating	in	vivo	Unencapsulated	and	non	replicating	in	vivo	 Kan	KanEry	 		
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2.12	FAM-SE	labelling	
S.	pneumoniae	was	labelled	fluorescently	for	uptake	experiments	using	6-carboxyfluorescein	succinimidyl	 ester	 (FAM-SE,	 Molecular	 Probes,	 Eugene,	 USA)	 (Yuste,	 Sen	 et	 al.	 2008).		Bacteria	 were	 grown	 in	 THY	 till	 an	 OD	 of	 0.6-0.7.	 	 The	 bacteria	 were	 pelleted	 by	centrifugation,	then	washed	and	resuspended	in	sterile	filtered	0.1M	NaHCO3.		50μl	of	FAM-SE	solution	(10mg/ml	in	dimethyl	sulphoxide	-	DMSO)	was	added	and	the	resulting	solution	was	 incubated	at	37°C	 in	5%	CO2	 for	1	hour.	 	This	was	 then	washed	by	 centrifugation	and	resuspension	 in	 PBS	 till	 the	 supernatant	 was	 free	 of	 dye.	 	 The	 FAM-SE	 stocks	 were	 then	resuspended	in	PBS	with	10%	glycerol	and	stored	as	above.	
2.13	Opsonisation	&	IgG	Binding	
S.	pneumoniae	was	opsonised	in	human	serum	or	intravenous	immunoglobulin	by	defrosting	an	aliquot,	centrifugation,	and	then	resuspension	in	diluted	human	serum	for	30	minutes	at	37°C	in	5%	CO2,	then	centrifuging	and	resuspended	in	required	media	for	experiment.	
IgG	 binding	 to	 bacteria	was	 assessed	 (Yuste,	 Sen	 et	 al.	 2008)	 by	 pelleting	 5×106	 CFU	 of	 S.	
pneumoniae,	 resuspending	 in	 25μl	 of	 anti-human	 IgG	 conjugated	 to	 PE	 (Sigma	 Aldrich,	Gillingham)	at	1:100	dilution	for	20	minutes	at	4°C.		The	bacteria	were	then	washed	twice	by	centrifugation	 and	 resuspension	 in	 PBS,	 then	 resuspending	 in	 4%	paraformaldehyde	 (PFA,	Sigma	Aldrich,	Gillingham),	and	transferred	to	FACS	tubes.		Binding	was	assessed	on	the	FACS	Verse	(Becton	Dickinson,	Oxford)	by	relative	fluorescence	and	analysed	on	Flojo.	
2.14	Bacterial	DNA	extraction	(Wizard	Promega	kit)		A	 loop	 of	 bacterial	 stock	 was	 plated	 and	 incubated	 overnight	 at	 37°C,	 5%	 CO2.	 	 This	 was	inoculated	 into	THY	broth	and	grown	 till	OD580	was	0.4-0.6.	 	This	was	 split	 into	 eppendorf	tubes	and	centrifuged	for	10	mins	at	13000g.		The	supernatant	was	aspirated	and	the	pellet	resuspended	 in	 200µl	 of	 50mM	 EDTA+0.1%	 DOC	 (deoxycholic	 acid)	 (Sigma	 Aldrich,	Gillingham).		This	was	incubated	for	10	minutes	at	37°C,	then	200µl	of	50mM	EDTA	+	300µl	of	nuclei	lysis	buffer	was	added	and	incubated	for	a	further	10	minutes	at	80°C,	then	allowed	
	 118	
to	cool	to	room	temperature.	 	1.5µl	of	RNAse	was	added	and	incubated	at	37°C	for	40mins.		Then	100µl	of	protein	precipitation	solution	was	added	and	vortex	vigorously	for	20s.	 	This	was	 then	 incubated	on	 ice	 for	5	minutes	and	 centrifuged	at	13000g.	 	 The	 supernatant	was	then	 aspirated,	 added	 to	 600µl	 of	 isopropanol	 in	 a	 new	 eppendorf,	 then	 gently	 mixed	 by	inverting	the	tube,	till	thread-like	DNA	formed	a	solid	mass.		This	was	centrifuged	at	13000g	for	10	minutes.	 	The	supernatant	was	discarded	and	750µl	of	70%	ethanol	was	added.	This	solution	was	then	centrifuged	at	13000g	for	10	minutes	and	the	supernatant	discarded.		The	DNA	was	left	open	overnight	at	room	temperature.		Hours	later,	25µl	of	rehydration	solution	was	added	and	incubated	at	1	hour	for	65°C,	while	periodically	mixing	the	solution	by	gently	tapping	the	tube.		The	DNA	was	then	stored	at	-20°C.			
2.15	Bacterial	Transformation	to	Create	TIGR4	Δcps	Δply	TIGR4	Δply	was	grown	 from	a	 fresh	colony	 till	OD580	0.015	 in	20ml	THY	pH	6.8	 (the	acidic	nature	delays	entry	of	S.	pneumoniae	 into	 its	natural	competence	state).	 	The	bacteria	were	transferred	 into	 eppendorfs	 and	 centrifuged	 at	 13000g	 at	 4°C	 for	 10	 minutes.	 	 The	supernatant	was	 then	discarded	 and	 the	pellets	 resuspended	 and	 combined	 in	 1ml	 of	 pre-warmed	 (to	 37°C)	 filtered	 THY	 pH	 8.0	 supplemented	 with	 1mM	 CaCl,	 0.2%	 BSA.	 	 The	bacterial	 suspension	was	 split	 into	 ‘positive’	 and	 ‘negative’	marked	 conical	 tubes	 and	 20µl	CSP	2	added,	allowed	 to	 sit	 for	5	minutes	at	 room	 temperature,	 then	5-10µl	of	TIGR4	Δcps	DNA	 was	 added	 to	 the	 positive	 tube	 (Havarstein,	 Coomaraswamy	 et	 al.	 1995).	 	 This	 was	incubated	 for	 2	 hours	 at	 37°C	 in	 5%CO2.	 	 All	 of	 transformant	 was	 plated	 onto	 double	antibiotic	(Kanamycin	and	erythromycin)	selection	plates	(and	200µl	of	control)	overnight	at	37°C	 5%	 CO2.	 	 The	 colonies	 were	 then	 grown	 in	 double	 antibiotic	 containing	 THY	 and	archived	 as	 normal.	 	 Transformation	was	 confirmed	 by	 picking	 colonies	 across	 single	 and	double	 antibiotic	 impregnated	 agar	 plates.	 	 Additionally	 DNA	was	 isolated	 and	 sent	 to	 the	Sanger	Institute	in	Cambridge	for	DNA	sequencing.	
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2.16	Haemolysis	assay	100	µl	of	2%	horse	blood	was	added	 to	U-bottomed	96	well	plates,	 then	serial	dilutions	of	bacteria,	 purified	 pneumolysin,	 or	 0.5%	 saponin	 (positive	 control)	 in	 PBS	 were	 added	 at	100µl	volumes.		The	plate	was	incubated	at	37°C	5%	CO2	for	30	minutes	then	centrifuged	at	1000g	 for	1	minute.	 	The	supernatant	was	aspirated	and	placed	 in	a	 flat-bottomed	96	well	plate	(Brand,	Wertheim,	Germany)	and	absorbance	at	540nm	was	measured	on	a	microplate	reader.		Absorbance	reflected	free	haemoglobin	liberated	from	lysed	cells,	with	0.5%	saponin	considered	to	be	100%	haemolysis	(Kirkham,	Kerr	et	al.	2006).			 	
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2.2	Cell	culture	
2.21	Monocyte	Derived	Macrophages	MDM	were	used	to	simulate	AM	as	obtaining	sufficient	numbers	of	human	AM	from	healthy	volunteers	 would	 pose	 both	 ethical	 and	 practical	 difficulties.	 	 Given	 the	 plasticity	 of	macrophages,	it	was	hoped	that	similar	effects	would	be	seen	with	MDM	in	terms	of	bacterial	phagocytosis,	transcription,	and	inflammatory	cytokine	secretion.		50	ml	of	healthy	volunteer	blood	was	obtained	with	 consent	 into	heparinised	 syringes	 along	with	10	ml	of	 blood	 into	separation	tubes.		The	heparinised	blood	was	diluted	1:2	with	sterile	PBS,	then	layered	onto	Ficoll-Paque	Plus	(GE	Healthcare	Life	Sciences,	Hatfield)	(20ml	blood	onto	15ml	of	Ficoll)	in	50ml	conical	 tubes.	 	This	was	centrifuged	at	800g	 for	20	minutes	with	minimal	brake.	 	The	resulting	 Buffy	 coats,	 made	 up	 of	 peripheral	 blood	 mononuclear	 cells	 (PBMCs)	 were	aspirated	with	a	Pasteur	pipette,	pooled	and	topped	up	with	PBS.	 	The	resulting	suspension	was	 centrifuged	 at	 800g	 for	 10	 minutes	 with	 maximum	 brake.	 	 The	 resulting	 pellet	 was	washed	 3	 times	 in	 PBS	 by	 resuspension	 then	 centrifuging	 at	 400g	 for	 5	 minutes.	 	 The	resulting	 pellet	 was	 resuspended	 in	 Roswell	 Park	 Memorial	 Institute	 (RPMI)	 media	supplemented	with	5%	AB	serum	and	2mM	L-glutamine	at	1×107	cells/ml.	 	This	single	cell	suspension	was	added	 to	 tissue	culture	plates	 (Nunc,	Roskilde,	Denmark)	and	 incubated	at	37°C	 5%	 CO2	 for	 1	 hour.	 	 Meanwhile,	 the	 coagulated	 blood	 in	 separation	 tubes	 was	centrifuged	at	3000g	for	20	minutes	to	obtain	autologous	serum,	which	was	heat	inactivated	by	 incubation	at	56°C	 for	30	minutes.	 	Non-adherent	cells	were	aspirated	at	 this	 time,	 then	adherent	 cells	 were	 washed	 gently	 in	 PBS	 3	 times,	 then	 RPMI	 supplemented	 with	 10%	autologous	 serum,	 2mM	 L-glutamine	 and	 20ng/ml	 human	macrophage	 colony	 stimulating	factor	(M-CSF).		After	3	days	the	medium	was	removed,	the	cells	washed	again	3	times	in	PBS,	and	 RPMI	 supplemented	 with	 10%	 autologous	 serum	 and	 2mM	 L-glutamine	 was	 added.		After	 a	 further	 3	 days	 the	 resulting	 monocyte	 derived	 macrophages	 were	 ready	 for	experiments.	
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This	 method	 has	 been	 long	 established	 in	 the	 Noursadeghi	 lab.	 	 Previous	 members	 have	confirmed	 cell	 surface	 expression	 of	 CD14	 and	 CD68,	 and	 lab	 experience	 is	 that	morphological	 change	 from	rounded	cells	 to	 flattened	enlarged	adherent	 cells	 is	 consistent	with	a	macrophage	phenotype	 (Tsang,	Chain	et	 al.	 2009).	 	 Further	 confidence	was	built	by	evidence	 of	 transcriptional	 signature	 of	 characteristically	 expressed	 molecules	 such	 as	CXCL5.	
MDM	viability	was	assessed	during	culture	and	at	end	of	experiments	by	visual	 inspection.		Confirmatory	 data	 on	 cell	 death	 during	 incubation	 with	 bacteria	 was	 obtained	 using	 LDH	assays	(Cayman	Chemical,	Michigan).		This	showed	significant	cell	death	at	24	hours	with	Ply	containing	 strains	 (figure	 2.1).	 	 This	 cytokine	 suggested	 that	 data	 at	 24	 hours	 would	 not	necessarily	 be	 reliable	 as	 cell	 death	 could	 be	 a	 confounder.	 	 Ideally	 this	 would	 have	 been	confirmed	across	a	range	of	bacterial	concentrations,	but	holds	true	for	the	majority	of	MDM	data	contained	within	this	thesis.	Experiments	using	MDM	were	approved	by	the	joint	University	College	London/University	College	Hospitals	National	Health	Service	Trust	Human	Research	Ethics	Committee	(Ref:	3076/001),	and	written	informed	consent	was	obtained	from	all	participants. 
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Figure	2.1	LDH	assay	of	MDM	during	incubation	with	bacteria	Supernatants	of	MDM	incubated	with	control	media,	positive	control,	or	bacteria	at	MOI	10	taken	at	various	timepoints	were	analysed	for	LDH	content	by	a	commercial	ELISA	kit.		Data	presented	are	mean	+/-	SEM	of	4	experiments	and	analysed	by	2	way	ANOVA	with	Tukey’s	multiple	comparison	test.		 	
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2.22	RAW	Macrophages		RAW	 264.7	 cells,	 a	 murine	 Abelson	 murine	 leukaemia	 virus	 transformed	 cell	 line	 with	macrophage-like	 phenotype,	 were	 cultured	 in	 RPMI	 media	 (Gibco,	 Loughborough)	supplemented	with	 10%	 foetal	 bovine	 serum	 (Lonza,	 Blackley,	 UK)	 and	 2mM	L-glutamine.		They	were	passaged	at	70-80%	confluence	by	rinsing	in	sterile	PBS	then	gentle	scraping	into	PBS.	 	 The	 cell	 suspension	 was	 centrifuged	 at	 400g	 for	 5	 minutes,	 then	 resuspended	 in	supplemented	RPMI	 and	 seeded	 into	T175	 tissue	 culture	 flasks	 (Nunc,	Roskilde,	Denmark)	and	incubated	at	37°C	at	5%	CO2.		Cells	were	archived	in	RPMI	with	20%	foetal	bovine	serum	(FBS)	and	10%	DMSO	in	cryovials	in	liquid	nitrogen.			
2.23	A549	Alveolar	Epithelial	Cells	A549	cells,	a	human	adencarcinomic	human	alveolar	basal	epithelial	cell	line,	were	cultured	in	 F12	media	 (Gibco,	 Loughborough)	 supplemented	with	 10%	 FBS	 and	 2mM	 L-glutamine.		They	 were	 passaged	 at	 70-80%	 confluence	 by	 rinsing	 in	 sterile	 PBS	 then	 detaching	 with	0.05%	 Trypsin/EDTA	 (Gibco,	 Loughborough)	 and	 incubation	 at	 37°C.	 	 Once	 cells	 were	observed	to	be	detached	under	an	inverted	light	microscope,	the	suspension	was	centrifuged	at	300g	for	5	minutes,	then	resuspended	in	supplemented	F12	and	seeded	into	T175	tissue	culture	 flasks	 (Nunc,	 Roskilde,	 Denmark)	 and	 incubated	 at	 37°C	 at	 5%	 CO2.	 	 Cells	 were	archived	in	F12	with	20%	FBS	and	10%	DMSO	in	cryovials	in	liquid	nitrogen.			
2.24	HEK	TLR2	Reporter	Cells	HEK	293	cells,	a	human	embryonic	kidney	cell	 line,	stably	transfected	with	TLR2	and	CD14	(Invivogen,	San	Diego)	were	cultured	in	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	(Gibco,	Loughborough)	supplemented	with	10%	FBS	and	2mM	L-glutamine.		They	were	passaged	at	70-80%	 confluence	 by	 rinsing	 in	 sterile	 PBS	 then	 gentle	 scraping	 into	 PBS.	 	 The	 cell	suspension	was	centrifuged	at	300g	for	5	minutes,	then	resuspended	in	supplemented	DMEM	and	seeded	into	T175	tissue	culture	flasks	(Nunc,	Roskilde,	Denmark)	and	incubated	at	37°C	
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at	5%	CO2.		Cells	were	archived	in	DMEM	with	20%	FBS	and	10%	DMSO	in	cryovials	in	liquid	nitrogen.			
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2.3	Tissue	Culture	Assays	
2.31	Antibiotic	Protection	Assay	MDM	or	RAW	cells	were	incubated	with	specified	bacterial	concentrations	for	1	hour	at	37°C	5%	CO2,	 then	 supernatant	was	 removed,	plated	 for	 external	CFU	and	 replaced	with	PBS	or	PBS	 containing	 gentamicin	 200μg/ml.	 	 After	 1	 hour	 the	 supernatant	 was	 removed	 and	washed	 twice	 in	 PBS.	 	 The	 cells	 were	 lysed	 with	 sterile	 water	 and	 lysate	 plated	 for	internalised	bacteria	(Ring,	Weiser	et	al.	1998).			
2.32	Adhesion	Assay	A549	 cells	were	 incubated	with	 specified	 bacterial	 concentrations	 for	 2	 hours	 at	 37°C	 5%	CO2,	 then	 washed	 twice	 in	 PBS.	 	 Cells	 were	 then	 lysed	 with	 sterile	 water	 and	 plated	 to	establish	numbers	of	adherent	bacteria	(Suri,	Periselneris	et	al.	2016).	
2.33	Phagocytosis	of	Fluorescent	Bacteria	By	MDM	MDM	were	seeded	into	a	96	well	optical	cell	carrier	plate	(Perkin	Elmer,	Wokingham)	at	5	×	104	per	well.	 	 FAM-SE	 labelled	bacteria	were	defrosted,	 and	 resuspended	 in	pooled	human	serum	 for	 30	 minutes	 at	 37°C	 in	 the	 dark.	 	 They	 were	 then	 centrifuged	 again	 and	resuspended	in	media	at	the	required	concentration.		Medium	was	aspirated	from	the	MDM	and	replaced	with	opsonised	bacteria.	 	At	specified	timepoints	medium	was	aspirated,	cells	were	washed	once	in	PBS,	then	fixed	in	4%	PFA	for	15	minutes	at	room	temperature	in	the	dark.	 	The	MDM	were	then	washed	3	times	in	PBS.	 	Then	the	wells	were	blocked	with	10%	goat	 serum	 in	PBS	 for	30	minutes	at	 room	temperature	 in	 the	dark.	 	The	blocking	solution	was	then	replaced	with	PE	labelled	goat	anti	human	IgG	(Sigma	Aldrich,	Gillingham)	in	PBS	with	10%	goat	serum.	 	This	was	incubated	in	the	dark	for	1	hour	at	room	temperature;	the	cells	were	then	washed	3	times	in	PBS.		DAPI	at	2	μg/ml	in	PBS	was	added	to	the	wells	for	5	minutes;	 the	cells	were	 then	washed	again	 in	PBS	 three	 times	and	stored	 in	0.01%	sodium	azide	(Sigma	Aldrich,	Gillingham)	in	PBS	at	4°C	in	foil	until	imaging	on	HERMES	microscope	(Biotech-Europe,	 Prague,	 Czech	Republic).	 	 Plates	were	 imaged	with	 ×20	 objective	 using	 3	
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LED	sources	at	DAPI,	GFP,	and	RFP	settings;	with	nuclei	in	blue,	fluorescent	bacteria	in	green,	and	external	bacteria	in	red	(bound	with	serum	IgG).		Images	were	analysed	on	Metamorph	(Metamorph	Inc)	software.			
2.34	Phagocytosis	of	Fluorescent	Bacteria	By	RAW	Cells	RAW	macrophages	were	incubated	with	FAM-SE	labelled	bacteria	at	specified	concentrations	for	1	hour	at	37°C	5%	CO2.		Supernatant	was	aspirated	and	replaced	by	PBS	or	0.5%	Trypan	blue	 (Thermo	 Fisher	 Scientific,	 Loughborough)	 for	 15	minutes	 at	 room	 temperature.	 	 The	cells	were	then	washed	twice	with	PBS	then	300μl	0.25%	Trypsin-EDTA	was	added	to	each	well,	pipetted	vigorously,	and	 incubated	at	37	°C	 till	 cells	were	detached	 	 (visualised	under	inverted	 microscope).	 	 The	 cell	 suspension	 was	 transferred	 to	 FACS	 tubes,	 centrifuged	 at	400g	 for	 5	 minutes,	 then	 supernatant	 was	 removed	 and	 replaced	 with	 200μl	 4%	 PFA,	vortexed	and	stored	under	foil	at	4°C	till	analysis	(Hyams,	Camberlein	et	al.	2010).	
2.35	TLR2	reporter	assay	HEK	TLR2	transfected	cells	had	a	SEAP	reporter	gene	placed	under	control	of	IFN-β	minimal	promoter	 fused	 to	NFκB	and	AP-1	binding	 sites,	 such	 that	with	 the	 addition	of	 substrate	 a	colorimetric	change	was	induced	to	reflect	TLR2	activation,	as	per	manufacturer	instructions.			
HEK	TLR2	cells	were	resuspended	in	HEK-Blue	detection	media	(Invivogen,	San	Diego)	at	5	×	105	cells/ml	and	added	to	96	well	tissue	culture	plates	(Nunc,	Roskilde,	Denmark);	100µl	per	well.		Then	100µl	of	stimulant,	e.g.	bacterial	suspension	or	PAM2CSK4	(Invivogen,	San	Diego),	as	a	positive	control,	was	added.		The	cells	were	incubated	at	37°C	at	5%	CO2	for	16-24	hours	and	optical	density	was	measured	on	a	microplate	reader	(Versamax,	Sunnyvale,	USA).			
2.36	Nuclear	density	Analysis	by	High	Throughput	Microscopy	MDM	were	cultured	on	Cell	Carrier	optical	plates,	then	incubated	with	bacteria	for	specified	timepoints,	 the	 supernatant	 was	 removed,	 then	 the	 cells	 were	 fixed	 in	 4%	 PFA	 for	 15	minutes.		The	cells	were	washed	3	times	in	PBS,	then	DAPI	(2μg/ml	in	PBS)	was	added.		The	cells	were	then	washed	in	PBS	3	times	and	stored	in	PBS	0.01%	sodium	azide	at	4°C	in	foil	till	
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imaging.		The	cells	were	imaged	on	the	HERMES	microscope	with	the	×10	objective.		Nuclear	counts,	size,	and	density	were	measured	with	Metamorph	software.	
2.37	 Transcription	 Factor	 Translocation	 Analysis	 by	 High	 Throughput	
Microscopy	MDM	cultured	in	96	well	Cell	carrier	plates	were	incubated	with	bacteria	or	controls	for	the	specified	 times.	 	 The	media	was	 aspirated,	 then	 the	 cells	were	 fixed	 for	 15	minutes	 in	 4%	PFA.		The	cells	were	then	washed	3	times	in	PBS,	then	stored	at	4°C	in	PBS	+	0.01%	sodium	azide	 in	 foil	 till	 staining.	 	 The	 cells	 were	 permeabilised	 with	 0.2%	 Triton-X100	 (Sigma	Aldrich,	Gillingham)	for	10	minutes	at	room	temperature,	then	washed	3	times	with	PBS.		The	cells	were	blocked	with	10%	goat	 serum	 in	PBS	 for	30	minutes	at	 room	 temperature,	 then	primary	antibody	diluted	1	in	100	in	10%	goat	serum	was	added	to	each	well	and	incubated	overnight	at	4°C.		The	cells	were	then	washed	3	times	in	PBS,	then	incubated	with	secondary	antibody;	 goat	 anti-rabbit	 conjugated	 to	AF488	 (Invitrogen,	Loughborough)	 for	1h	at	 room	temperature.	 	 The	 cells	 were	 then	 washed	 3	 times	 in	 PBS,	 and	 then	 incubated	 with	 DAPI	(2μg/ml	in	PBS)	for	5	minutes.	 	The	cells	were	washed	3	more	times	in	PBS,	then	stored	at	4°C	in	the	dark	in	PBS	+	0.01%	sodium	azide	in	foil	till	imaging.		The	cells	were	imaged	on	the	HERMES	microscope	×20	objective	with	3	 lasers	 (Noursadeghi,	Tsang	et	al.	2008).	 	 Images	were	analysed	with	Metamorph	nuclear	translocation	software.	
ImageJ	was	used	to	collate	and	overlay	images.			
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2.4	Enzyme-Linked	Immunosorbent	Assay	(ELISA)	for	cytokines	Cytokines	 levels	 in	 cell	 culture	 supernatant,	 mouse	 bronchoalveolar	 lavage	 fluid,	 and	 lung	homogenate	 supernatant	 were	 measured	 using	 ELISA	 as	 per	 manufacturer	 instructions.		Coating	 antibody	diluted	 in	 PBS	was	 added	 to	 96	well	 plates	 (Brand,	Wertheim,	Germany)	and	 incubated	 at	 room	 temperature	 overnight.	 	 The	 next	 morning	 plates	 were	 washed	 3	times	using	wash	buffer:	PBS	with	0.05%	Tween	20	(Fisher	Scientific,	Loughborough).	 	The	wells	were	then	blocked	with	1%	BSA	in	PBS	for	1	hour.		Samples	were	added	diluted	in	1%	BSA	in	PBS	(reagent	diluent)	 if	necessary,	 then	added	to	the	wells	 in	duplicate.	 	A	standard	curve	was	 also	 added	using	 serial	 two	 fold	dilutions,	with	 reagent	 diluent	 as	 a	 blank.	 	 The	plates	were	 allowed	 to	 incubate	 at	 room	 temperature	 for	 2	 hours	 then	washed	 3	 times	 in	wash	buffer.	 	Then	detection	antibody	diluted	 in	 reagent	diluent	and	added,	 and	 incubated	for	a	further	2	hours	at	room	temperature.		Plates	were	washed	3	times	in	wash	buffer,	then	streptavidin-horseradish	peroxidase	(HRP)	diluted	in	reagent	buffer	was	added	to	the	wells,	and	 incubated	 for	 30	minutes	 at	 room	 temperature.	 	 Plates	were	washed	 again	 3	 times	 in	wash	buffer	then	substrate,	tetramethylbenzidine	(TMB)	(Life	Technologies,	Loughborough),	was	added.	 	This	was	 incubated	 in	 the	dark	 till	 sufficient	 colour	 change	occurred,	 at	which	point	2N	H2SO4	was	added	 to	stop	 the	reaction.	 	Absorbance	was	measured	at	450	nm	and	540	nm	using	a	microplate	reader	(Versamax,	Sunnyvale,	USA).	 	Samples	were	compared	to	standard	curve	(formulated	by	2	fold	serial	dilution	in	reagent	diluent	of	a	supplied	standard)	to	obtain	cytokine	concentrations.		
ELISAs	were	carried	out	using	R&D	Systems	kits	 (Abingdon)	 to	measure	human	TNF,	 IL1β,	IL6,	CXCL8,	and	murine	TNF,	IL1β,	and	IL6.		Lower	limits	of	detection	were:	hTNF	100pg/ml,	hIL1β	10pg/ml,	hIL6	50pg/ml,	hCXCL8	200pg/ml,	mTNF	100pg/ml,	mIL1β	100pg/ml,	mIL6	50pg/ml.	 These	 were	 carried	 out	 as	 above	 except	 as	 follows.	 	 In	 the	 human	 CXCL8	 kit,	blocking	was	 carried	 out	with	 1%	BSA	 in	 PBS	with	 0.05%	NaN3,	 and	 reagent	 diluent	was	made	 up	 as	 0.1%	 BSA	 in	 0.05%	 Tween	 20	 in	 Tris	 buffered	 saline	 (TBS)	 (Sigma	 Aldrich,	
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Gillingham).		In	the	murine	IL1β	kit	reagent	diluent	was	also	made	up	as	0.1%	BSA	in	0.05%	Tween	20	in	TBS.			
Rat	TNF,	IL1β,	and	IL6	were	measured	using	Peprotech	kits	(lowers	limits	of	detection	were		100pg/ml).		These	were	carried	out	as	above,	except	reagent	diluent	was	made	up	as	0.05%	Tween	20,	0.01%	BSA	in	PBS.		Human	CXCL10	was	measured	with	an	Insight	Biotechnology	kit,	(lower	limit	of	detection	was	10pg/ml).		ELISAs	were	carried	out	as	above,	except	reagent	diluent	was	made	up	as	0.05%	Tween	20,	0.01%	BSA	in	PBS.	 	Mouse	 lavage	albumin	 levels	(lower	 limit	 of	 detection	 500pg/ml)	 were	 measured	 with	 a	 Bethyl	 Laboratories	 kit	 and	differed	from	the	other	ELISA	protocols	as	follows.	 	Coating	antibody	was	diluted	in	 	0.05M	Carbonate-bicarbonate,	 pH	 9.6,	 and	 once	 added	 to	 the	 plate,	 was	 incubated	 for	 1	 hour	 at	room	 temperature.	 	Washes	were	 performed	 as	 other	 ELISAs.	 	 Blocking	was	 performed	 as	other	 ELISAs	 for	 an	 hour,	 then	 the	 plate	 was	 washed.	 	 Sample	 and	 standard	 was	 added,	diluted	 in	 diluent	 buffer	 (1%	 BSA	 0.05%	 Tween	 20	 in	 PBS),	 and	 incubated	 at	 room	temperature	for	1	hour.		Plates	were	washed	then	detection	antibody	(directly	conjugated	to	HRP)	diluted	 in	diluent	 buffer	was	 added	 to	 the	plates.	 	 The	plate	was	washed	 again,	 then	TMB	was	used	as	a	substrate.		The	reaction	was	stopped	and	measured	as	other	ELISA	kits.	
IFNβ	was	measured	with	a	Verikine	kit	(PBL	Assay	Science,	Piscataway	Township,	USA)	using	pre-coated	wells	in	strips,	lower	limit	of	detection	was	50pg/ml.		Wash	buffer	was	diluted	1	in	 10	 in	 distilled	 water.	 	 A	 standard	 curve	 was	 constructed	 by	 dilution	 to	 4000pg/ml	 in	sample	diluent.	 	 Samples	of	 standard	were	applied	 to	pre-coated	wells	and	 incubated	 for	1	hour	 at	 room	 temperature.	 	 Wells	 were	 then	 washed	 3	 times	 in	 wash	 buffer.	 	 Detection	antibody	was	 defrosted	15	minutes	 before	 use,	 and	dilute	 in	 dilution	 buffer	 then	 added	 to	each	 well.	 	 Wells	 were	 then	 washed	 3	 times	 in	 wash	 buffer.	 	 HRP	 conjugated	 detection	antibody	was	diluted	in	dilution	buffer	15	minutes	prior	to	use,	and	added	to	each	well,	and	incubated	for	1	hour.	 	Wells	were	washed	3	times	in	wash	buffer.	 	Then	TMB	was	added	to	each	well	and	incubated	in	the	dark	at	room	temperature	for	15	minutes.		Stop	solution	was	added,	and	the	plate	read	at	450nm	on	a	microplate	reader.	
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2.5	Quantitative	polymerase	chain	reaction	(qPCR)	RNA	 extraction	 of	 MDM	 was	 performed	 with	 Quiagen	 RNeasy	 Mini	 kit	 (Quiagen,	 Hilden,	Germany)	as	per	manufacturer	instructions.		MDM	were	cultured	at	4	×105	cells	per	well	in	a	12	well	plate	and	incubated	with	bacteria	or	media.		At	specified	timepoint	supernatant	was	aspirated,	and	cells	washed	twice	with	ice-cold	PBS.		350μl	of	RLT	buffer	(supplemented	with	1%	14.3	M	β	mercaptoethanol)	was	added	to	each	well	in	an	ice	bucket.		MDM	were	scraped,	pipette	mixed,	and	lysate	was	aspirated	and	stored	at	-80°C.	
Lysate	was	defrosted	on	 ice	and	vortex	mixed,	 then	350μl	of	70%	ethanol	was	added.	 	The	sample	was	then	transferred	to	a	spin	column	in	a	collecting	tube	and	centrifuged	at	8000g	for	30s	at	4°C.		The	flow	through	was	discarded	and	700μl	of	RW1	buffer	and	centrifuged	at	8000g	 for	 30s	 at	 4°C.	 	 500	 ml	 RPE	 buffer	 (with	 ethanol)	 was	 added	 to	 the	 column,	 and	centrifuged	at	8000g	for	30s	at	4°C.	 	This	was	repeated	once	but	centrifuged	for	2	minutes.		The	spin	column	was	placed	in	a	new	collection	tube	and	30μl	of	RNAse	free	water	added	to	the	column	and	centrifuged	at	8000g	for	1	minute.		The	resulting	RNA	was	stored	at	-80°C.			
Contaminating	DNA	was	eliminated	with	Precision	DNase	(Primer	Design,	Southampton)	by	adding	1.5μl	buffer	 to	0.5μl	nuclease	 free	water,	and	0.5μl	DNAse	 to	12.5μl	RNA.	 	This	was	placed	 in	a	PCR	machine	at	30°C	 for	10	minutes	 then	55°C	 for	5	minutes.	 	Nanodrop	3000	was	used	to	measure	RNA	concentration	and	quality	established	using	ratio	of	absorbance	at	260:280	(aiming	for	2.0).			
cDNA	was	synthesised	in	clear	PCR	plates	(Thermoscientific,	Loughborough)	on	ice.		4µl	of	5×	qScript	cDNA	SuperMix	(QuantaBiosciences,	Beverley,	USA)	was	added	to	1µg	RNA	and	made	up	to	20µl	with	nuclease	free	water.		A	sealplate	(Thermo	Scientific,	Loughborough)	was	used	to	seal	the	plate,	which	was	then	vortexed	for	1	minute	at	1000rpm,	then	centrifuged	1000g	for	1	minute.		This	was	placed	in	a	PCR	machine	(Tetrad,	Ramsey,	USA)	for	5	minutes	at	25°C,	then	30	minutes	at	42°C,	 then	5	minutes	at	85°C.	 	The	product	was	diluted	by	adding	40µl	nuclease	free	water	then	stored	at	4°C	till	qPCR.			
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TaqMan	 gene	 expression	 assays	 were	 thawed	 on	 ice,	 vortexed	 and	 pulse	 centrifuge.	 	 The	Universal	 master	 mix	 II	 (Life	 Technologies,	 Loughborough)	 was	 warmed	 to	 room	temperature.		A	master	mix	was	made	with	enough	volume	for	required	samples	in	duplicate:	5.0µl	of	2×	TaqMan	Universal	Master	Mix	II,	0.5	µl	of	specified	20×	Taqman	Gene	Expression	Assay	and	2.5µl	of	nuclease	free	water.		8µl	of	mastermix	and	2µl	of	cDNA	was	then	added	per	well	 in	 white	 PCR	 plates	 (Thermoscientific,	 Loughborough),	 then	 sealed	 with	 optical	 film,	vortexed	at	1000rpm	for	1	min,	then	centrifuged	at	1000g	for	1	minute.	 	The	qPCR	was	run	on	a	Realplex	Mastercycler	(Eppendorf,	Stevenage)	and	run	for	2	minutes	at	50°C,	then	for	10	min	 at	 95°C,	 followed	 by	 40	 cycles	 of	 15	 seconds	 at	 95°C,	 then	 1	 minute	 at	 60°C.	 	 Cycle	threshold	(CT)	was	determined	for	all	samples	and	analysed	by	ΔΔCT	for	relative	expression	values,	with	GAPDH	as	a	housekeeping	gene	(Tomlinson,	Cashmore	et	al.	2010).	
2.6	Western	Blotting	
2.61	DC	Assay	(Biorad)	This	 assay	 was	 used	 to	 determine	 protein	 concentrations	 in	 lysates	 as	 per	 manufacturer	instructions.	 	 If	detergent	was	 in	 the	 lysate	(e.g.	after	nuclear	extraction),	20μl	of	reagent	S	was	 added	 to	 1	 ml	 of	 reagent	 A.	 	 A	 standard	 curve	 was	 made	 by	 making	 twofold	 serial	dilutions	 of	 bovine	 serum	 albumin	 (Alpha	 diagnostics)	 in	 PBS,	with	 a	 top	 concentration	 of	2μg/ml.	 	5μl	of	 lysate	or	standard	curve	was	added	in	duplicate	to	a	microtitre	plate.	 	Then	25μl	of	reagent	A	solution	(i.e.	with	or	without	reagent	S)	was	added	to	each	well,	followed	by	200μl	 of	 reagent	B.	 	 This	was	mixed	 for	 5	 seconds	 then	 incubated	 for	 15	minutes	 at	 room	temperature.		OD	was	measure	on	a	microplate	reader.			
2.62	Western	Blot	MDM	at	4×106	cells	per	well	in	12	well	plates	were	incubated	with	bacteria	for	the	required	time	 then	washed	 twice	 in	 ice	 cold	 PBS	 in	 an	 ice	 bucket	 and	 lysed	 in	 RIPA	 buffer	 (Sigma	Aldrich,	Gillingham)	supplemented	with	100×	phosphatase	inhibitor	(Thermo	Scientific)	and	
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100×	phosphatase	 inhibitor	 (Thermo	Scientific,	Loughborough).	 	The	 lysate	was	stored	at	 -80°C	till	required.		
Lysate	concentration	was	equalised	in	RIPA	buffer.		Then	2.5μl	of	4×	sample	buffer	(Thermo	Scientific,	Loughborough)	and	1μl	of	10×	reducing	buffer	(Thermo	Scientific,	Loughborough)	was	 added	 to	 the	 lysates.	 	 Deionised	 water	 was	 added	 to	 make	 the	 final	 volume	 20μl.		Samples	were	then	heated	to	70	°C	for	10	minutes.		50ml	of	NuPage	20×	MES	buffer	(Thermo	Scientific,	Loughborough)	was	added	to	950ml	deionised	water	to	make	running	buffer.		The	combs	were	removed	from	a	NuPage	BisTris	mini	gel	(Thermo	Scientific,	Loughborough)	and	the	wells	were	rinsed	with	running	buffer.		The	gel	was	placed	in	the	tank,	clamped	in	place,	then	 running	 buffer	 was	 added.	 	 PageRuler	 Plus	 Protein	 ladder	 (Thermo	 Scientific,	Loughborough)	and	samples	were	loaded	into	the	wells.	Electrophoresis	of	the	gel	was	run	at	200V	for	30-60	minutes.		Once	the	gel	had	run,	the	gel	was	extracted	from	its	cassette	then	an	iBlot	gel	 transfer	device	 (Thermo	Scientific,	Loughborough)	was	used	 to	 transfer	separated	proteins	to	a	membrane.			
Membranes	 were	 blocked	 in	 5%	 BSA	 in	 0.1%	 Tween20	 in	 TBS	 for	 one	 hour	 at	 room	temperature	on	a	 rocker.	 	Then	primary	antibody	was	added	 in	5%	TBST	 in	a	conical	 tube	and	placed	on	a	roller	at	4°C	overnight.		The	membrane	was	then	washed	3	times	in	TBST	for	10	minutes	on	a	rocker.		Then	secondary	antibody	(conjugated	to	HRP)	was	added	to	5%	BSA	in	TBST	 in	a	new	conical	 tube	and	placed	on	a	roller	at	room	temperature	 for	1	hour.	 	The	membrane	was	 then	washed	3	 times	again	 in	TBST.	 	 1	ml	of	Luminata	Crescendo	Western	HRP	 substrate	 (Merck,	 Readington,	 USA)	 was	 added	 to	 the	membrane,	 incubated	 at	 room	temperature	for	a	minute,	 then	excess	substrate	was	drained	off.	 	The	blot	was	 imaged	and	analysed	 on	 an	 Imagequant	 (GE	 Healthcare,	 Hatfield).	 	 All	 steps	 performed	 as	 per	manufacturer	instructions.	
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2.63	Phosphoarray	(R&D	Systems,	Abingdon)	MDM	were	cultured	in	6	well	plates	at	1×106	cells	per	well.		Bacteria	were	added	at	specified	concentrations,	and	incubated	at	37°C	in	5%	CO2.		After	half	an	hour	the	cells	were	placed	on	ice,	 rinsed	with	PBS,	 then	Lysis	Buffer	6	was	added.	 	This	was	 incubated	at	4	degrees	on	a	rocking	 platform	 for	 30	 minutes.	 	The	 samples	 were	 then	 placed	 in	 eppendorfs	 and	centrifuged	at	14000g	for	5	minutes,	and	the	supernatants	stored	at	-80	till	required.	
Array	buffer	5	was	placed	 in	a	4	well	multi	dish,	and	one	nitrocellulose	membrane	printed	with	 capture	 antibodies	 placed	 in	 each	 well.	 	This	 was	 incubated	 for	 an	 hour	 at	 room	temperature	on	a	rocking	platform.		Meanwhile	samples	were	diluted	in	array	buffer	1	so	that	all	 samples	 were	 at	 equivalent	 concentrations.	 	Detection	 antibody	 cocktail	 was	 added	 to	each	 sample	 and	 incubated	 at	 room	 temperature	 for	 1	 hour.	 	The	 array	 buffer	 was	 then	removed	 from	 the	membranes	 and	 replaced	 with	 the	 sample	 antibody	mixture.	 	This	 was	incubated	 overnight	 at	 4°C	 on	 a	 rocking	 platform.	 	The	membranes	were	 then	 removed	 to	individual	 containers	 and	 washed	 3	 times	 in	 washing	 buffer,	 10	 minutes	 at	 a	time.		Streptavidin-HRP	was	diluted	in	array	buffer	5	and	placed	in	the	4	well	multidish.		The	membranes	 were	 placed	 back	 in	 the	 wells	 and	 incubated	 on	 a	 rocking	 platform	 for	 3	minutes.		The	membranes	were	then	washed	again	3	times	in	wash	buffer.		After	excess	wash	buffer	was	removed	from	the	membranes,	chemi-reagent	mix	was	added	to	each	membrane,	then	 the	membranes	were	placed	 in	 an	 autoradiography	 cassette	 till	 imaging	on	hyperfilm	(GE	Healthcare,	Hatfield)	by	exposure	to	an	autoradiography	film	developer	(Kodak,	UK).		All	steps	carried	out	as	per	manufacturer	instructions.	
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2.7	Transcription	Factor	Array	The	 Protein/DNA	 array	 (Panomics,	 Fremont,	 USA)	 allows	 examination	 of	 multiple	transcription	factors’	function.		Biotin	labelled	DNA	binding	oligonucleotides	were	incubated	with	nuclear	extract,	to	bind	to	transcription	factors	bound	to	DNA.		The	bound	probes	were	separated	by	columns,	then	eluted	and	incubated	with	an	oligonucleotide	spotted	membrane.		Chemiluminescence	was	used	to	identify	bound	transcription	factors.		
2.71	Nuclear	Extraction	Nuclear	 extraction	 of	 MDM	 was	 performed	 with	 a	 Panomics	 kit	 as	 per	 manufacturer	instructions.	 	MDM	in	a	6	well	plate	had	media	aspirated,	and	were	washed	twice	with	 ice-cold	PBS.		250μl	Reagent	A	(750μl	buffer	A,	7.5μl	phosphatase	inhibitor	I,	7.5μl	phosphatase	inhibitor	II,	7.5μl	protease	inhibitor,	and	7.5μl	DTT)	added	per	well.		The	plate	was	placed	on	an	 ice	 bucket	 and	 transferred	 to	 a	 rocker	 at	 200rpm.	 	 Cells	 were	 scraped	 and	 lysate	transferred	 to	 eppendorfs	 and	 centrifuged	 at	 14,000g	 for	 5	 minutes	 at	 4°C.	 	 The	superntatants	were	discarded	and	50μl	of	reagent	B	was	added	to	each	pellet,	while	on	ice.		This	was	vortexed	and	incubated	on	ice	for	1	hour,	with	intermittent	agitation	by	hand.		The	nuclear	 extract	 was	 centrifuged	 again	 at	 14,000g	 for	 5	 minutes	 at	 4°C.	 	 The	 pellets	 were	stored	at	-80°C	till	required.			
2.72	Protein/DNA	Array	Nuclear	 extracts	 and	 DNA	 binding	 oligonucleotides	 (probe	 mix)	 were	 thawed	 on	 ice.		Meanwhile	 array	 membranes	 were	 incubated	 in	 pre-treatment	 buffers	 at	 45°C	 then	hybridisation	buffer	at	42°C	in	hybridisation	bottles.	 	10μl	of	nuclear	extract	(concentration	of	 different	 donors	 and	 conditions	 equalised	 in	 distilled	 water)	 was	 added	 to	 10μl	 of	TransSignal	probe	mix	and	incubated	at	15°C	for	30	minutes.		The	spin	columns	were	washed	in	 incubation	buffer,	 then	the	transcription	 factor	probe	mix	was	added	to	 the	spin	column	and	incubated	on	ice	for	30	minutes.		The	spin	column	was	then	centrifuged	at	6000g	for	30	seconds	at	4°C,	the	flow	through	discarded	and	the	column	was	then	washed	through	3	times	
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with	column	wash	buffer.	 	Then	60μl	of	 column	elution	buffer	was	added	and	 incubated	at	room	 temperature	 for	 5	 minutes.	 	 The	 spin	 column	 was	 then	 centrifuged	 at	 8500g	 for	 1	minute	at	room	temperature,	and	the	eluate	was	collected	on	ice.		The	eluate	was	then	heated	to	95°C	 for	3	minutes	 then	chilled	on	 ice	 for	2	minutes.	 	The	eluate	was	 then	added	 to	 the	hybridisation	 bottles	 and	 incubated	 overnight	 in	 a	 rotating	 hybridisation	 oven	 at	 42°C	overnight.	 	The	membranes	were	then	washed	in	hybridisation	wash	I	and	II,	then	removed	to	 a	 container	 holding	 blocking	 buffer	 for	 15	 minutes	 with	 gentle	 agitation.	 	 Then	Strepavidin-HRP	was	added	 to	 the	 container	and	 incubated	under	gentle	 agitation	at	 room	temperature	for	15	minutes.		The	membranes	were	then	washed	in	wash	buffer	3	times	and	then	 20ml	 of	 detection	 buffer	 was	 added	 and	 allowed	 to	 incubate	 for	 5	 minutes	 at	 room	temperature.		The	substrate	solution	was	then	added	to	the	membrane	for	5	minutes,	excess	solution	 removed,	 then	 the	 membrane	 was	 imaged	 on	 an	 Imagequant	 (GE	 Healthcare,	Hatfield).		All	steps	were	carried	out	as	per	manufacturer	instructions.	
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2.8	Microarray	genome	wide	transcriptional	assessment	Microarray	 (Agilent,	 Santa	 Clara,	 USA)	 analysis	 was	 used	 to	 perform	 whole	 genome	transcriptional	analysis	of	MDM	incubated	with	bacteria	 for	specified	 timepoints	at	1	×	106	cells	per	well	in	6	well	plates.	 	RNA	was	extracted	as	above	and	purity	was	established	on	a	bioanalyser	with	an	Agilent	RNA	6000	kit.	
2.81	Bioanalyser	(Agilent	2100)	Nano	dye	concentrate	was	allowed	to	equilibrate	to	room	temperature	and	1μl	was	added	to	65μl	 filtered	 gel	matrix,	 vortexed,	 then	 centrifuged	 at	 13,000g	 for	 10	minutes.	 	 Nanochips	were	placed	in	a	chip	priming	station	and	9	μl	gel/dye	mix	added	to	specified	wells,	then	the	chip	is	primed	with	a	plunger.		9μl	gel/dye	mix	was	added	to	the	remaining	control	wells.		5	μl	 of	marker	was	added	 to	 each	well,	 1μl	of	 sample	was	added	 to	 sample	wells,	 and	1μl	of	ladder	 to	 the	 ladder	well.	 	 The	 chip	was	 then	 vortexed	 in	 an	 IKA	 vortexer	 for	 1	minute	 at	2400rpm.	 	The	bioanalyser	was	cleaned	with	RNAzap	 then	RNAse	 free	water,	and	 then	 the	chip	was	run	and	analysed	with	2100	Expert	software.	
2.82	Microarray	Labelling	&	Scanning	Low	input	quick	amp	labelling	kit	was	used	for	two	colour	microarray	based	gene	analysis.		Spike	A	(Cy3)	and	spike	B	(Cy5)	mix	was	diluted	in	dilution	buffer	for	the	appropriate	RNA	mass.		RNA	was	diluted	to	the	required	concentration	with	RNA	free	water.		2μl	spike	A	mix	was	added	 to	half	 the	 samples	 and	2μl	 spike	B	mix	 to	 the	other	half.	 	 T7	promoter	primer	master	mix	was	 diluted	 in	 nuclease	 free	water	 and	 1.8μl	 added	 to	 each	 sample.	 	 This	was	placed	in	a	PCR	machine	and	heated	at	65°C	for	10	minutes,	then	cooled	to	4°C	for	5	minutes.		Meanwhile	 strand	buffer	was	warmed	 to	 80°C	 for	 a	 few	minutes	 to	 adequately	 resuspend,	and	make	cDNA	mastermix	(2μl	5×	strand	buffer,	1μl	0.1M	DTT,	0.5μl	dNTP,	and	1μl	Affinity	script	RNAseblock	mix).		4.7μl	of	the	cDNA	mastermix	was	added	to	each	sample	and	then	it	was	 placed	 in	 a	 PCR	 machine,	 then	 it	 was	 heated	 to	 40°C	 for	 2hours,	 then	 70	 °C	 for	 15	minutes,	then	cooled	to	4°C	for	5	minutes,	then	stored	at	-80°C.			
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A	transcription	master	mix	was	prepared	(0.75μl	nuclease	free	water,	3.2μl	5×	transcription	buffer,	0.6μl	0.1M	DTT,	1μl	NTP	mix,	0.21μl	T7	RNA	polymerase	blend,	and	0.24μl	Cyanine	3-CTP	 or	 0.24μl	 Cyanine	 5-CTP	 for	 ‘A	 ‘	 or	 ‘B’	 samples	 respectively).	 	 6μl	 of	 transcription	mastermix	was	 added	 to	 each	 sample	 and	 pipette	mixed.	 	 This	was	 heated	 to	 40	 °C	 for	 2	hours	in	a	PCR	machine,	then	cooled	to	4°C	(or	stored	at	-80°C).				
The	RNA	was	then	purified	with	a	Quiagen	kit	(Hilden,	Germany).	 	84μl	nuclease-free	water	was	 added	 to	 each	 sample	 and	 pipette	 mixed	 with	 350μl	 RLT	 buffer.	 	 Then	 250μl	 100%	ethanol	 was	 added	 with	 further	 pipette	 mixing.	 	 This	 was	 transferred	 to	 an	 RNeasy	 spin	column,	centrifuged	at	10,000g	for	30	seconds	at	4°C.		The	flow	through	was	discarded	then	500μl	RPE	(with	ethanol)	added,	then	centrifuged	again,	and	repeated.		The	spin	column	was	placed	 in	 a	 new	 tube	 and	 30μl	 RNAse	 free	 water	 was	 added.	 	 After	 30	 seconds	 the	 spin	column	 was	 then	 centrifuged	 at	 10,000g	 for	 30	 seconds	 at	 4°C.	 	 The	 eluate	 RNA	 was	measured	on	a	nanodrop;	RNA	concentration	and	Cy3	or	Cy5	concentration	was	determined.			
Next	300ng	Cy3	labelled	RNA	was	added	to	300ng	Cy5	labelled	(paired	sample)	RNA,	5μl	10×	blocking	 agent,	 1μl	25×	 fragmentation	mix,	 and	made	up	 to	25μl	with	nuclease	 free	water.		This	was	vortexed	gently	then	heated	to	60	°C	for	30	minutes,	then	cooled	immediately	in	ice	for	 1	minute.	 	 25μl	 of	 2×	 GE	 hybridisation	 buffer	 HI-RPM	was	 added	 to	 each	 sample	 then	pipette	mixed	gently,	then	centrifuged	at	10,000g	for	1	minute	and	placed	on	ice.			
A	gasket	slide	was	loaded	onto	an	Agilent	SureHyb	chamber	base	and	40μl	of	hybridisation	sample	was	dispensed	and	gently	dragged	down	 the	 slide.	 	An	array	 slide	was	 then	placed	face	down,	and	then	a	chamber	cover	was	clamped	to	the	sandwiched	slide.	 	This	was	then	placed	in	a	rotisserie	hybridisation	oven	for	17	hours	at	65	°C	10rpm.		The	gasket	slide	was	placed	in	a	slide	rack	and	washed	in	Gene	expression	wash	buffer	I,	then	the	array	separated	from	 the	 gasket	 slide	 while	 submerged.	 	 The	 array	 slide	 was	 then	 placed	 in	 fresh	 Gene	expression	wash	 buffer	 I	 and	washed,	 then	 placed	 in	 a	 third	 staining	 dish	 containing	 pre-warmed	Gene	expression	wash	buffer	II.		This	was	washed	again	then	transferred	in	a	holder	
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to	 an	 Agilent	 Microarray	 Scanner.	 	 All	 steps	 were	 carried	 out	 as	 per	 manufacturer	instructions.	
2.83	Multi	Experiment	Viewer	Data	 from	 the	microarray	 was	 normalised	 (Chain,	 Bowen	 et	 al.	 2009)	 and	 analysed	 using	multi	experiment	viewer	(Sourceforge)	and	Bioagilent	insert	for	R	(R-project).			Bioinformatic	analysis	was	using	the	online	analysis	tools	 Innate	DB	(Breuer,	Foroushani	et	al.	2013)	and	OPOSSUM	(Kwon,	Arenillas	et	al.	2009).		
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2.9	In	vivo	models	Murine	 work	 was	 carried	 out	 within	 Home	 Office	 guidelines	 under	 project	 license	PPL70/7361.		The	rat	sepsis	model	was	carried	out	under	project	license	PPL70/7028.		
2.91	Mouse	pneumonia	
S.	 pneumoniae	 stocks	 were	 defrosted,	 centrifuged,	 and	 resuspended	 in	 sterile	 PBS.		Concentration	was	adjusted	 (1×107	or	1×108	CFU/ml).	 	 Female	CD1	5	week	old	mice	were	anaesthetised	 with	 inhaled	 isoflurane,	 and	 then	 50μl	 of	 bacterial	 suspension	 was	administered	via	one	nostril.		Bacterial	inoculum	was	then	plated	to	ensure	consistency.			In	specific	 experiments,	 antibodies	 or	 inhibitors	 were	 administered	 intranasally	 under	isoflurane	 anaesthesia	 or	 intraperitoneally.	 	 At	 specified	 timepoints	 the	 mice	 were	euthanised	 with	 intraperitoneal	 pentobarbital,	 and	 death	 was	 confirmed	 by	 severing	 the	inferior	 vena	 cave.	 	 Blood	 was	 obtained	 for	 bacterial	 counts	 at	 this	 time	 into	 heparinised	tubes.	 	Cannulation	of	 the	 trachea	was	 then	performed,	and	 the	bronchial	 tree	was	 flushed	with	 3	 times	with	 1ml	 of	 PBS	 to	 obtain	 bronchoalveolar	 lavage	 fluid	 (BALF).	 	 Lastly	 lungs	were	 dissected	 out	 carefully.	 	 The	 lungs	 were	 homogenised	 using	 cell	 strainers	 (Falcon,	Corning,	 USA)	 and	 the	 homogenate	 was	 diluted	 in	 3ml	 PBS.	 	 Blood,	 BALF	 and	 lung	homogenate	was	plated	 at	 serial	 dilution	 to	 obtain	 bacterial	 counts	 if	 required.	 	 BALF	was	centrifuged	 at	 300g,	 the	 supernatant	 was	 stored	 for	 further	 analysis,	 and	 the	 cell	 pellet	resuspended	 in	 PBS.	 	 The	 cell	 suspension	was	 counted	 using	 a	 haemocytometer	 to	 obtain	BALF	 cell	 counts,	 and	 200μl	 was	 centrifuged	 onto	 slides	 using	 a	 cytospin	 (700rpm	 for	 7	minutes),	then	stained	with	Romanowsky’s	solutions	to	examine	under	a	light	microscope	for	cell	 morphology.	 	 Lung	 homogenate	 was	 centrifuged	 at	 600g,	 supernatant	 was	 stored	 for	analysis	 and	bacterial	 counts.	 	Blood	was	allowed	 to	 clot,	 then	centrifuged	at	2000g	 for	20	mins;	the	resulting	serum	supernatant	was	stored	for	downstream	analysis.		As	seen	in	figure	6.20	to	6.22,	intranasal	PBS	does	not	induce	an	inflammatory	response	in	mice.	
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2.92	Alveolar	Macrophage	Association	with	Fluorescent	Bacteria	CD1	mice	were	infected	intranasally	with	5*106	CFU	FAM-SE	labelled	bacteria	and	culled	at	4	hours,	 then	 bronchoalveolar	 lavage	 fluid	 was	 recovered	 (in	 PBS)	 and	 placed	 on	 ice.	 	 The	lavage	 fluid	was	centrifuged	at	700g	 for	5	minutes	and	resuspended	 in	100μl	of	1%	FBS	 in	PBS	 with	 1	 in	 10	 rat	 anti	 F4/80	 conjugated	 to	 APC	 (Biolegend,	 San	 Diego).	 	 They	 were	incubated	in	the	dark	in	FACS	tubes	for	30	minutes	at	room	temperature,	then	washed	twice	in	 1%	FBS	 in	 PBS	 (by	 centrifuging	 at	 700g	 for	 5	minutes,	 decanting	 the	 supernatant,	 then	resuspending	 in	1%	FBS).	 	They	were	 then	 fixed	 in	200μl	4%	PFA	 for	15	minutes	 at	 room	temperature	(in	 the	dark).	 	The	cells	were	 then	washed	twice	 in	1%	FBS	 in	PBS	and	 left	 in	200μl	1%	FBS	in	the	fridge	till	FACS	analysis.	
2.93	Rat	sepsis	Male	Wistar	rats	had	PVC	tubes	inserted	into	the	right	jugular	vein	and	left	carotid	artery	and	tunnelled	subcutaneously	to	emerge	at	the	nape	of	the	neck	under	2%	isoflurane	anaesthesia.		These	were	mounted	on	a	swivel-tether	system	so	that	the	rats	had	unimpeded	movement.		After	24	hours,	1×109	CFU	non-replicating	TIGR4Δpab	were	 injected	via	 the	tunnelled	 lines	over	10	minutes.		Fluid	resuscitation	was	carried	out	with	1:1	0.9%	NaCl	and	6%	glucose	at	10	ml/kg/hr.	 	 Blood	pressure	 and	heart	 rate	were	 continually	measured	using	 the	 arterial	line	(Brealey,	Karyampudi	et	al.	2003).			
Blood	was	withdrawn	into	capillary	tubes	from	the	tunnelled	lines	at	baseline,	1	and	4	hours,	where	 the	 lines	 remained	patent.	 	When	 lines	were	not	patent	4	hour	blood	was	 taken	via	terminal	cardiac	puncture.	 	Blood	gas	measurements	were	obtained	using	an	ABL800	FLEX	(Radiometer,	 Crawley).	 	 Blood	was	 also	 plated	 for	 CFU,	 allowed	 to	 clot	 and	 centrifuged	 at	4000g	for	20	minutes	to	obtain	serum.		Serum	was	frozen	at	-20°C	until	cytokine	analysis.	
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2.10	Statistics	Statistical	analyses	of	data	were	performed	with	Graphpad	Prism	V	7	(La	Jolla,	USA).		Data	in	this	thesis	are	largely	presented	as	means	+/-	SEM	(e.g.	cytokines,	qPCR,	cell	counts).		When	two	 groups	 were	 compared	 an	 unpaired	 t-test	 was	 used.	 	 When	 several	 groups	 were	compared,	 a	 one	way	 analysis	 of	 variance	 (ANOVA)	with	Tukey’s	multiple	 comparison	 test	was	 used.	 	 When	 several	 pairs	 of	 grouped	 data	 were	 compared,	 a	 two	 way	 ANOVA	 with	Tukey’s	multiple	comparison	test	was	used.			
Non-parametric	 data	 (e.g.	 CFU	 data)	 are	 presented	 as	 individual	 data	 points	 and	 median	values.	 	 Two	 groups	 were	 compared	 with	 a	 Mann	Whitney	 U	 test.	 	 Multiple	 groups	 were	analysed	with	a	Kruskal-Wallis	test,	with	Dunn’s	multiple	comparison	test.			
Significance	is	denoted	as	follows:	*=p<0.05	**=p<0.01	***=p<0.001	****=p<0.0001	 	
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3	 Effect	 of	 capsule	 on	 the	 inflammatory	 response	 to	 S.	
pneumoniae	
S.	pneumoniae	capsule	has	an	important	role	in	reducing	antibody	and	complement	binding	and	 so	 inhibits	 phagocytosis	 (Hyams,	 Camberlein	 et	 al.	 2010).	 	 As	 the	 capsule	 inhibits	engagement	with	the	host,	 it	should	also	inhibit	 interaction	with	PRR.	 	Hence I	 investigated 
the hypothesis that the capsule would	reduce	the	inflammatory	response	of	the	host	to	S.	
pneumoniae.	
To	 explore	 this,	 wild-type	 and	 isogenic	 unencapsulated	 mutants	 were	 used,	 allowing	investigation	of	the	effect	of	capsule	with	live	bacteria.		A	serotype	4	strain,	TIGR4	was	used	in	the	majority	of	experiments,	along	with	an	unencapsulated	strain,	Δcps,	with	an	antibiotic	resistance	cassette	inserted	in	place	of	the	capsule	locus.		Macrophages	are	the	sentinel	cells	of	 the	 immune	 system	 so	 in	prime	position	 to	 initiate	 inflammatory	 responses,	 so	primary	human	monocyte	derived	macrophages	 (MDM)	 from	volunteers	were	 the	primary	cell	 type	used	to	investigate	the	inflammatory	response	to	S.	pneumoniae.	
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3.1	Effects	of	capsule	on	inflammatory	response	of	macrophages		To	assess	the	 inflammatory	response,	supernatant	 levels	of	the	pro-inflammatory	cytokines	TNF,	 IL1β,	 and	 IL6	were	measured	 in	 primary	 human	MDM	 cultures	 after	 incubation	with	TIGR4	 or	 TIGR4Δcps	 at	 different	 timepoints	 (figure	 3.1)	 and	 varying	 concentrations	 of	bacteria	 (figure	 3.2).	 	 Unstimulated	 MDM	 levels	 of	 TNF,	 IL1β,	 and	 IL6	 were	 undetectable.		There	 was	 a	 trend	 towards	 increased	 pro-inflammatory	 cytokine	 release	 during	 the	timecourse,	 most	 evident	 across	 the	 analysed	 cytokines	 at	 6	 and	 12	 hours.	 	 Others	 have	shown	that	there	is	large	scale	MDM	cell	death	after	16	hours	(Dockrell,	Marriott	et	al.	2003),	and	indeed	LDH	data	(figure	2.1)	suggested	significant	cell	death	at	24	hours	in	my	datasets,	so	earlier	timepoints	were	used	to	reflect	the	initial	inflammatory	response	to	S.	pneumoniae.		At	 6	 hours	 wild-type	 bacteria	 induced	 higher	 inflammatory	 cytokine	 levels	 than	unencapsulated	 at	 all	multiples	 of	 infection	 (MOI)	 for	TNF,	 and	 at	 low	MOIs	 for	 IL6.	There	was	 little	 difference	 in	 IL1β	 levels,	 though	 these	 were	 possibly	 too	 low	 to	 interpret	effectively.	 	 Interestingly	 IL1β	 and	 IL6	 release	 gradually	 decreased	 with	 more	 bacteria,	possibly	reflecting	cell	death	with	higher	concentrations	of	bacteria.		qPCR	results	at	4	hours	replicated	this	pattern	(figure	3.3),	 indicating	that	 the	differences	between	bacterial	strains	in	inflammatory	response	are	likely	to	be	transcriptionally	regulated.				 	
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Figure	 3.1	 Timecourse	 of	 cytokine	 response	 of	 MDM	 to	 TIGR4	 and	 unencapsulated	
mutant	MDM	were	incubated	with	TIGR4	or	TIGR4Δcps	in	tissue	culture	plates,	with	10	bacteria	per	cell	 (multiples	 of	 infection	 -	 MOI	 10).	 	 Supernatant	 was	 aspirated	 at	 6	 hours	 and	 later	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6.		The	data	from	3	different	donors	are	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test,	with	no	significant	differences	seen.	
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Figure	3.2	MDM	cytokine	responses	to	varying	numbers	of	bacteria	MDM	were	incubated	with	TIGR4	or	Δcps	at	varying	concentrations;	from	MOI	1	to	100.		After	6	hours,	supernatant	was	removed,	and	later	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6.	 	The	data	 obtained	 are	 from	 3	 different	 donors,	 and	 analysed	 by	 2	 way	 ANOVA	 and	 Tukey’s	multiple	comparison	test.	
MOI	1 MOI	10 MOI	1000
20004000
60008000
TNF	(p
g/ml)
TIGR4Δcps ***
MOI	1 MOI	10 MOI	1000
200400
600800
IL6	(pg
/mL)
TIGR4Δcps**
MOI	1 MOI	10 MOI	1000
1020
3040
IL1β	(p
g/mL)
TIGR4Δcps
A
B
C
	 146	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.3		MDM	qPCR	response	to	TIGR4	and	unencapsulated	mutant	Pro-inflammatory	 cytokine	 (A)	 TNF,	 B)	 IL1β,	 and	 C)	 IL6	 transcriptional	 response	 of	 MDM	after	4	hours	incubation	with	TIGR4	or	Δcps	at	MOI	10	as	measured	by	Taqman	qPCR	of	cell	lysate.	 	 Results	 from	 3	 donors	 presented	 as	 change	 in	 cycle	 threshold	 with	 GAPDH	 as	 a	housekeeping	gene,	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.	
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3.2	Effects	of	capsule	on	inflammatory	response	of	epithelial	cells	Alveolar	epithelial	cells	are	another	 important	cell	 type	that	might	recognise	S.	pneumoniae	and	induce	an	inflammatory	response	in	the	context	of	pneumonia.		Owing	to	the	difficulty	of	obtaining	 primary	 alveolar	 epithelial	 cells,	 a	 transformed	 cell	 line	was	 used	 (A549s).	 	 The	capsule	inhibited	adhesion	of	S.	pneumoniae	to	an	epithelial	cell	layer	(figure	3.4),	which	is	a	potential	confounder	of	epithelial	inflammatory	responses.	 	No	internalisation	was	detected	by	 antibiotic	 protection	 assay	 (data	 not	 shown).	 	 A	 1	 hour	 timepoint	 was	 used	 as	 per	previously	established	assay	in	the	Brown	lab	(Suri,	Periselneris	et	al.	2015).	
Direct	 incubation	of	bacteria	with	A549s	 for	up	to	24	hours	 induced	minimal	 inflammatory	responses	compared	 to	unstimulated	cells	 (figure	3.5).	 	Again,	by	24	hours,	 there	may	well	have	been	some	significant	cell	death,	that	could	have	confounded	the	data.		At	higher	MOIs,	there	was	 a	 suggestion	 of	 some	 cytokine	 response	 to	 bacteria,	 but	much	 less	 than	 that	 of	MDM	 (figure	 3.6).	 	 However,	 MDM	 conditioned	 media	 induced	 significant	 IL6	 and	 CXCL8	release,	 and	 detectable	 TNF	 (figure	 3.7),	 with	 no	 detectable	 IL1β	 (data	 not	 shown).	 	 The	cytokine	response	here	reflected	that	of	MDM,	i.e.	more	TNF	and	IL6		(and	trend	toward	more	CXCL8)	 with	 TIGR4	 compared	 to	 Δcps.	 	 Although	 this	 may	 reflect	 the	 cytokines	 initially	produced	by	the	MDM,	the	levels	of	TNF	for	example	are	significantly	less	than	that	produced	by	MDM	(possibly	due	to	either	uptake	of	TNF	by	TNF	receptors	or	TNF	decay	in	media)	with	less	of	a	difference	in	IL6,	suggesting	downstream	effects	of	the	secreted	products	of	MDM.		
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Figure	3.4	Adhesion	of	bacteria	to	A549	cells	The	 number	 of	 TIGR4	 and	 Δcps	 adhering	 to	 an	 A549	 cell	 layer	 after	 1	 hour	 is	 shown.	 	 A	representative	 experiment	 of	 3	 is	 shown,	 presented	 as	median	 +/-	 range,	 and	 analysed	 by	Mann-Whitney	U	test.	
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Figure	3.5	Timecourse	of	cytokine	release	by	A549	alveolar	epithelial	cells	incubated	
with	bacteria	Mean	+/-	SEM	of	3	experiments	at	MOI	1,	at	various	timepoints	supernatant	was	analysed	for	cytokine	 secretion.	 	 Panel	 A	 shows	 TNF,	 B	 shows	 IL6,	 and	 C	 shows	 CXCL8	 (IL1β	 was	undetectable).	 	Data	were	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test,	with	no	significant	differences	seen.	
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Figure	3.6	Cytokine	release	by	A549	cells	in	response	to	different	numbers	of	bacteria	A549	cells	were	incubated	with	positive	controls	and	varying	multiple	infections	of	TIGR4	or	Δcps.	Supernatant	was	analysed	for	cytokines	after	6	hours.		Mean	+/-	SEM	of	3	experiments	shown.		Panel	A	shows	TNF,	B	shows	IL6,	and	C	shows	CXCL8.		Data	were	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test,	with	no	significant	differences	seen.	
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Figure	3.7	Cytokine	release	by	A549	cells	in	response	to	conditioned	media	from	MDM	A549	 cells	were	 incubated	with	 pooled	 conditioned	media	 from	MDM	 incubated	 TIGR4	 or	Δcps	(4	separate	experiments	were	pooled)	at	MOI	10.		The	conditioned	media	was	diluted	1	in	 5	 in	media	 before	 adding	 to	 A549	 cells.	Supernatant	was	 analysed	 for	 cytokines	 after	 6	hours.	 	Mean	+/-	SEM	of	3	experiments	shown.		Panel	A	shows	TNF,	B	shows	IL1β,	C	shows	IL6,	 and	 D	 shows	 CXCL8.	 	 Data	 were	 analysed	 by	 1	 way	 ANOVA	 and	 Tukey’s	 multiple	comparison	analysis.		 	
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3.3	 Effect	 of	 capsule	 on	 macrophage	 internalisation	 of	 S.	
pneumoniae	The	capsule	has	been	shown	to	inhibit	phagocytosis	of	S.	pneumoniae	 in	human	neutrophils	
in	vitro	(Hyams,	Camberlein	et	al.	2010)	and	mouse	AM	recovered	after	intranasal	infection	(Camberlein,	 Cohen	 et	 al.	 2015).	 	 Primary	 human	 MDM	 also	 phagocytose	 unencapsulated	bacteria	 more	 readily	 as	 shown	 below	 in	 a	 high	 throughput	 microscopy	 experiment	 with	fluorescently	 labelled	bacteria.	 	 FAM-SE	 labelled	bacteria	were	opsonised	 in	pooled	human	serum,	and	added	to	MDM.	After	fixation,	PE	labelled	anti	human	IgG	was	added.		Internalised	bacteria	fluoresce	green,	whereas	external	bacteria	are	yellow	due	to	colocalised	FAM-SE	and	PE.		The	results	showed	that	double	the	number	of	unencapsulated	mutant	were	internalised	after	 2	 hours	 compared	 to	 encapsulated	 S.	 pneumoniae	 (figure	 3.8,	 A	 &	 B).	 	 This	was	 also	confirmed	 using	 the	 mouse	 RAW	 macrophage	 cell	 line	 and	 a	 flow	 cytometry	 assay	 of	association	of	 cells	with	 fluorescent	bacteria,	 though	 this	 assay	measures	both	 internalised	and	adherent	bacteria.	 	Again	greater	numbers	of	unencapsulated	bacteria	were	associated	with	RAW	macrophages	than	wild-type	(figure	3.8	C	&	D).		
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Figure	3.8	Macrophage	uptake	of	FAM-SE	labelled	bacteria	MDM	were	incubated	with	FAM-SE	labelled	bacteria	for	2	hours	before	fixing	in	PFA.		Nuclei	stained	with	DAPI	 are	 in	blue,	 internalised	bacteria	 are	 in	 green,	 and	 external	 bacteria	 are	labelled	 in	 yellow.	 	 Panel	 A	 shows	 TIGR4,	 panel	 B	 Δcps,	 and	 C	 shows	 the	 percentage	 of	bacteria	internalised,	analysed	on	metamorph	software.		The	displayed	results	are	the	means	+/-	SEM	of	3	donors.		Panel	D	is	flow	cytometry	analysis	of	RAW	macrophages	incubated	with	FAM-SE	 labelled	 bacteria	 for	 2	 hours	 presented	 as	 mean	 fluorescence	 index	 (product	 of	number	of	FITC	positive	cells	and	the	geometric	mean	of	their	fluorescence).		The	displayed	data	is	the	mean	+/-	SEM	of	4	experiments.		Data	were	analysed	by	t	test.	
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3.4	Effects	of	capsule	on	bacterial	counts	As	 the	 capsule	 is	 known	 to	 affect	 opsonophagocytosis	 and	 therefore	 there	 is	 likely	 to	 be	increased	 clearance	 of	 unencapsulated	 bacteria,	 one	 possible	 explanation	 for	 difference	 in	inflammatory	response	is	that	encapsulated	bacteria	are	cleared	less	well	and	therefore	there	are	 present	 in	 greater	 numbers	 to	 elicit	 a	 greater	 inflammatory	 response	 than	unencapsulated	bacteria.	
Bacterial	 counts	 in	 MDM	 supernatant	 show	 that	 wild-type	 bacteria	 are	 present	 in	significantly	 greater	 numbers	 than	 unencapsulated	 by	 6	 hours	 (figure	 3.9).	 	 To	 see	 if	 the	bacterial	 numbers	 accounted	 for	 the	 variation	 in	 inflammatory	 response,	 penicillin	 was	added	 to	 the	 supernatant	 to	 kill	 the	 bacteria.	 	 Plating	 supernatant	 within	 1	 hour	 of	 the	addition	of	penicillin	confirmed	no	surviving	bacteria	(data	not	shown).	 	 If	antibiotics	were	added	 30	 minutes	 after	 the	 addition	 of	 bacteria	 the	 inflammatory	 response	 was	 largely	abrogated	when	 incubated	with	both	 strains	 (figure	3.10).	 	Antibiotics	added	after	4	hours	allowed	the	bacteria	sufficient	time	to	elicit	an	inflammatory	response,	though	much	reduced	compared	to	live	replicating	bacteria,	the	difference	between	wild-type	and	unencapsulated	organisms	was	preserved	(figure	3.11).		This	suggests	that	bacterial	count	differences	are	not	sufficient	 to	explain	all	 the	difference	between	 the	 strains.	 	Of	note,	penicillin	 is	 thought	 to	cause	cell	lysis	and	may	have	been	expected	to	cause	inflammation	from	disgorgement	of	cell	contents,	 though	 this	 was	 not	 seen	 in	 this	 series	 of	 experiments.	 	 This	 may	 suggest	 that	ongoing	 bacterial	 replication	 is	 the	 most	 important	 factor	 in	 causing	 an	 inflammatory	response.		 	
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Figure	3.9	Bacterial	counts	in	supernatant	of	MDM	Bacteria	were	added	to	MDM	at	MOI	10,	then	supernatant	was	plated	at	specified	timepoints.		The	data	shown	is	from	6	different	experiments,	individual	values	and	means	are	presented.		Data	are	analysed	by	Kruskal-Wallis	and	Dunn’s		multiple	comparison	test.			 	
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Figure	3.10	MDM	response	to	bacteria	with	the	addition	of	antibiotics	after	30	minutes	MDM	 were	 incubated	 with	 TIGR4	 or	 Δcps	 at	 MOI	 10,	 some	 wells	 had	 penicillin	 (Sigma	Aldrich,	Gillingham)	added	after	30	minutes	.	 	After	4	hours,	supernatant	was	removed,	and	later	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6.		The	data	obtained	are	from	3	different	donors,	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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Figure	3.11	MDM	response	to	bacteria	with	antibiotics	added	after	4	hours	MDM	 were	 incubated	 with	 TIGR4	 or	 Δcps	 at	 MOI	 10,	 some	 wells	 had	 penicillin	 (Sigma	Aldrich,	Gillingham)	added	after	4	hours.	 	At	various	timepoints,	supernatant	was	removed,	and	 later	analysed	 for	A)	TNF,	B)	 IL1β,	and	C)	 IL6.	 	The	data	obtained	are	 from	3	different	donors,	 presented	 as	mean	 +/-	 SEM,	 and	 analysed	 by	 2	way	 ANOVA	 and	 Tukey’s	multiple	comparison	test.		
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3.5	Purified	Capsule	To	 establish	 whether	 capsular	 polysaccharide	 induced	 inflammatory	 cytokine	 directly,	purified	 polysaccharide	 was	 incubated	 with	 MDM.	 	 Purified	 serotype	 4	 capsular	polysaccharide	 (ATCC)	 induced	 a	 dose	 dependent	 release	 of	 inflammatory	 cytokines	 from	MDM	 (figure	 3.12).	 	 It	 has	 been	 estimated	 that	 105	 bacteria	 equates	 to	 0.2μg	 of	 capsular	material	 (Tuomanen,	 Tomasz	 et	 al.	 1995),	 so	 MOI	 10	 infection	 is	 roughly	 equivalent	 to	5μg/ml.		Importantly	the	secretion	of	pro-inflammatory	cytokines	was	abrogated	by	the	use	of	polymyxin	B	(figure	3.13),	suggesting	that	the	pro-inflammatory	effect	of	purified	capsular	polysaccharide	was	likely	due	to	LPS	contamination.		Polymyxin	B	is	a	cationic	basic	peptide	that	binds	 to	 the	negatively	charged	 lipid	A	portion	of	LPS,	and	 thus	has	a	dose-dependent	inhibitory	effect.	 	 	These	data	suggest	that	capsular	polysaccharide	does	not	directly	 induce	an	inflammatory	response,	but	that	capsule	modifies	how	other	factors	within	the	bacterium	interact	with	host	cells	to	induce	cytokine	release.	
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Figure	3.12	Inflammatory	response	to	purified	polysaccharide	Purified	 polysaccharide	 (PPS)	 was	 incubated	 with	 MDM	 at	 various	 concentrations	 and	supernatant	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6	after	6	hours.		Data	from	3	donors	are	presented	as	mean	+/-	SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test,	with	no	significant	differences	seen.		
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Figure	3.13	Effect	of	polymyxin	B	on	purified	capsular	polysaccharide	In	panels	A,	B,	and	C	MDM	were	incubated	with	PPS	with	or	without	30	μg/ml	polymyxin	B	(PMxB),	 and	 TNF,	 IL1β,	 and	 IL6	 measured	 respectively.	 	 LPS	 at	 100ng/ml	 was	 used	 as	 a	positive	 control,	 and	 both	 sets	 of	 experiments	 are	 represented	 as	 means	 +/-	 SEM	 of	 3	experiments.		Analysis	was	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test.	
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3.6	Effects	of	capsule	on	pneumonia	in	mice	A	well-established	model	of	mouse	pneumonia	was	used	to	assess	whether	the	differences	in	inflammatory	 response	 between	 wild-type	 and	 unencapsulated	 bacteria	 seen	 in	 a	 tissue	culture	model	translated	into	physiological	effects.		This	model	results	in	bacterial	replication	in	the	alveolar	space,	 invasion	into	the	lungs	and	into	the	blood	stream.	 	The	host	response	includes	 local	 inflammation	 and	 a	 neutrophil	 influx.	 	 Early	 timepoints	 were	 examined	 to	correlate	with	initiation	of	the	inflammatory	response.	
The	 animal	 work	 for	 this	 experiment	 was	 carried	 out	 by	 Dr	 Emilie	 Camberlein,	 from	 the	Brown	laboratory.		Even	by	30	minutes,	recovery	of	wild-type	bacteria	from	BALF	was	a	log10	fold	 greater	 than	 unencapsulated	 bacteria	 (figure	 3.14).	 	 Inflammatory	 cytokine	 levels	 in	BALF	 showed	 different	 temporal	 patterns,	 with	 TNF	 levels	 rising	 very	 early,	 then	 dipping	again,	with	later	modest	increases	in	IL1β,	and	later	increases	in	IL6	(figure	3.15).		At	2	hours	there	was	significantly	more	TNF	with	the	encapsulated	bacteria,	and	a	similar	pattern	seen	at	 4	 hours	 with	 IL1β	 and	 IL6.	 	 This	 reflects	 the	 in	 vitro	 data,	 but	 may	 be	 confounded	 by	bacterial	numbers.	
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Figure	3.14		Bacterial	counts	in	BALF	after	intranasal	infection	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia.		The	mice	were	culled	at	specified	timepoints,	bronchoalveolar	lavage	was	 performed	 and	 plated	 to	 ascertain	 bacterial	 numbers.	 	 There	were	 5	mice	 per	 group,	analysis	by	Kruskal-Wallis	and	Dunn’s	multiple	comparison	test.				 	
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Figure	3.15	Cytokine	levels	in	BALF	after	intranasal	infection	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	 The	 lavage	 fluid	 of	mice	was	 stored	 and	 the	 cytokines	 levels	were	measured	by	ELISA.	 	Three	were	5	mice	per	group,	 and	 results	 are	presented	as	mean	+/-	SEM	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test.		 	
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3.7	Effects	of	alveolar	macrophages	depletion	on	capsule	effects	on	
mouse	pneumonia	The	in	vitro	data	suggested	that	macrophages	were	critical	in	initial	inflammatory	responses	to	S.	 pneumoniae,	 as	well	 as	being	 important	 in	 initial	 clearance	of	 bacteria.	 	 So	 the	mouse	experiments	 were	 repeated	 with	 liposomal	 clodronate,	 which	 induces	 apoptosis	 of	phagocytes.		Groups	of	mice	had	AM	depleted	by	the	administration	of	intranasal	clodronate	72	hours	prior	to	infection.		The	mouse	work	was,	again	carried	out	by	Dr	Emilie	Camberlein.		Depletion	 of	 macrophages	 with	 lysosomal	 clodronate	 (from	 the	 van	 Rooijen	 lab)	 reduced	clearance	 of	 bacteria	 by	 4	 hours	 in	 both	 groups	 (figure	 3.16).	 	 The	 efficacy	 of	 intranasal	clodronate	 was	 confirmed	 by	 examining	 AM	 counts	 in	 PBS	 sham-infected	 animals.	 	 This	confirmed	 approximately	 80%	 reduction	 of	 AM	numbers	 (performed	 by	 Emily	 Camberlein	and	data	not	shown).	
At	 4	 hours	 TNF	 levels	 were	 decreased	 in	 response	 to	 both	 strains	 by	 depletion	 of	macrophages,	 though	 the	difference	between	 the	strains	was	preserved	(figure	3.17	A).	 	At	the	same	timepoint	IL1β	levels	(figure	3.17	B)	were	decreased	in	response	to	the	wild-type	strain,	but	there	was	little	difference	with	the	unencapsulated	strain,	albeit	from	an	already	low	starting	point.	 	 In	this	experiment	there	was	non-significant	differences	 in	IL6	between	the	strains	(figure	3.17	C),	though	removal	of	macrophages	markedly	reduces	IL6	release.	
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Figure	3.16	Bacterial	counts	in	lavage	fluid	at	4	hours	after	intranasal	infection	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	 Mice	 were	 culled	 after	 4	 hours,	 bronchoalveolar	 lavage	 was	performed	and	plated	to	ascertain	bacterial	numbers.		There	were	5	mice	per	group,	and	data	is	presented	as	mean	+/-	SEM.		Analysed	by	Kruskal-Wallis	and	Dunn’s	multiple	comparison	test.		
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Figure	3.17	Cytokine	levels	in	BALF	at	4	hours	after	intranasal	infection		5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	 The	 lavage	 fluid	 of	mice	was	 stored	 and	 the	 cytokines	 levels	were	measured	by	ELISA.	 	Three	were	5	mice	per	group,	 and	 results	 are	presented	as	mean	+/-	SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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3.8	Effects	of	capsule	and	macrophage	in	low	inoculum	respiratory	
infection	The	effect	of	macrophages	appears	to	be	most	pronounced	with	low	numbers	of	bacteria,	so	the	inflammatory	response	was	assessed	in	a	low	inoculum	mouse	pneumonia	model	where	
S.	pneumoniae	is	usually	cleared	24	hours	after	intranasal	infection,	with	mice	that	had	been	treated	with	liposomal	clodronate	or	a	liposome	only	control.	
At	2	hours	there	was	rapid	clearance	of	unencapsulated	bacteria	in	comparison	to	wild-type	from	 the	 alveolar	 compartment	 (figure	 3.18,	 A),	with	 a	 log	 fold	 increase	 in	 both	 groups	 in	macrophage-depleted	 mice.	 	 By	 4	 hours	 there	 was	 less	 difference	 between	 wild-type	 and	unencapsulated	 bacteria,	 but	 in	macrophage-depleted	mice	 there	was	 a	 2	 log10	 increase	 in	wild-type	 bacteria	 compared	 to	 unencapsulated,	 indicating	 that	 AM	 are	 important	 in	clearance	 of	 encapsulated	 bacteria	 at	 low	 numbers,	 but	 non-phagocyte	 defences	 are	more	important	 in	dealing	with	unencapsulated	bacteria.	 	Bacterial	numbers	 in	 lung	homogenate	are	much	 lower	 than	 in	 the	 alveolar	 compartment,	with	no	 significant	differences	between	groups	(figure	3.18,	B).	
Cytokine	 levels	 were	 generally	 much	 lower	 in	 BALF	 than	 with	 the	 higher	 inoculum	experiments,	probably	due	to	better	control	of	replicating	bacteria.		Here	TNF	levels	in	BALF	were	higher	in	wild-type	bacteria	at	2	and	4	hours	(figure	3.19),	and	the	depletion	of	alveolar	macrophages	 reduced	 TNF	 secretion	 in	 response	 to	 wild-type	 but	 not	 unencapsulated	bacteria	at	2	hours,	though	by	4	hours	there	was	little	difference.	Wild-type	bacteria	induced	more	 IL1β	 secretion	 than	 unencapsulated	 at	 2	 hours,	 though	 IL1β	 levels	 were	 very	 low.		There	was	very	little	difference	between	groups	in	IL6	secretion.	
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Figure	 3.18	 Bacterial	 counts	 at	 specified	 timepoints	 after	 low	 inoculum	 intranasal	
infection		5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×105	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	 The	 lavage	 fluid	 of	mice	was	 stored	 and	 the	 cytokines	 levels	were	measured	by	ELISA.	 	There	were	6	mice	per	group,	and	results	are	presented	as	 individual	mouse	results	with	medians	in	BALF	(panel	A)	and	lung	homogenate	(panel	B)	and	analysed	by	Kruskal-Wallis	and	Dunn’s	multiple	comparison	test,	with	no	significantly	different	results	in	lung	homogenate.		
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Figure	3.19	Cytokines	in	BALF	after	low	inoculum	intranasal	infection		5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×105	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	 The	 cytokine	 levels	 in	 lavage	 fluid	 of	 the	mice	were	measured	 by	ELISA.	 	 Three	 were	 6	 mice	 per	 group,	 and	 results	 are	 presented	 as	 mean	 +/-	 SEM	 and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.		 	
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In	lung	homogenates	the	cytokine	pattern	was	quite	different	(figure	3.20).		TNF	levels	were	low	 in	 all	 groups	 except	 with	 wild-type	 bacteria	 in	 liposome	 treated	 mice	 at	 4	 hours,	suggesting	that	macrophage	responses	to	encapsulated	S.	pneumoniae	are	 important	 in	 this	compartment.		IL1β	levels	were	much	higher	in	lungs	than	BALF,	with	only	a	trend	towards	greater	levels	with	encapsulated	bacteria.		There	was,	however,	a	significant	decrease	in	IL1β	levels	 after	macrophage	 depletion	with	 complete	 abrogation	 of	 the	 difference	 between	 the	strains.	 	 This	 suggests	 that	 AM	 are	 important	 in	 inducing	 inflammatory	 responses	 in	 lung	parenchyma,	 possibly	 by	 crosstalk	 with	 epithelium.	 	 IL6	 levels	 were	 also	 increased	 after	exposure	 to	 wild-type	 bacteria	 compared	 to	 unencapsulated,	 with	 macrophage	 depletion	attenuating	 these	differences,	 in	particular	 reducing	 IL6	 secretion	 in	 response	 to	wild-type	bacteria.	 	
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Figure	3.20	Cytokines	in	lung	homogenate	after	low	inoculum	intranasal	infection	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×105	 CFU	 bacteria	 under	isoflurane	anaesthesia.	 	The	cytokine	levels	in	lung	homogenate	of	the	mice	were	measured	by	 ELISA.	 	 There	were	 6	mice	 per	 group,	 and	 results	 are	 presented	 as	mean	 +/-	 SEM	 and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.		 	
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3.9	Effects	of	capsule	on	septic	shock	in	rats	To	see	 if	 the	physiological	difference	between	wild-type	and	unencapsulated	bacteria	were	maintained	in	other	disease	states,	a	model	of	rat	septic	shock	was	used,	with	the	help	of	Dr	Alex	 Dyson,	 from	 Professor	 Mervyn	 Singer’s	 lab.	 	 To	 account	 for	 differences	 in	 clearance	between	wild-type	and	unencapsulated	bacteria,	non-replicating	bacteria	were	used.	 	These	had	 a	 mutation	 in	 the	 pabB	 gene,	 meaning	 that	 the	 bacteria	 cannot	 replicate	 in	 organic	environments	unless	supplemented.	 	As	clearance	from	blood	is	rapid,	high	inoculums	were	required	to	induce	a	septic	shock	phenotype	(figure	3.21).		Although	there	was	no	significant	difference	between	the	bacterial	strains,	there	was	a	trend	towards	a	greater	drop	in	systolic	blood	 pressure	 and	 rise	 in	 lactate	 with	 the	 wild-type	 strain,	 suggesting	 that	 the	 greater	inflammatory	response	to	encapsulated	organisms	may	also	be	replicated	in	this	model.			
There	was	great	variability	in	cytokine	levels,	possibly	due	to	the	instrumentation	required	to	insert	the	indwelling	catheters.	 	With	this	in	mind	there	is	a	trend	towards	greater	TNF	and	IL6	levels	induced	by	wild-type	organisms,	reflecting	in	vitro	data	and	the	mouse	pneumonia	data.			
Overall	 the	 data	 using	 this	model	 lack	 significance	 and	 specific	 conclusions	 should	 not	 be	drawn	from	them.		With	more	biological	replicates,	a	clearer	picture	may	have	developed.	 	
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Figure	3.21	Bacterial	counts	and	physiological	data	of	intravenous	infection	of	rats		Male	Wistar	 rats	 (5	 per	 group)	 were	 injected	 intravenously	 with	 non-replicating	 bacteria.		Panel	A	shows	bacterial	counts	in	blood	taken	at	specified	timepoints.		Panel	B	shows	systolic	blood	 pressure	 measure	 by	 arterial	 line,	 and	 panel	 C	 shows	 lactate	 level	 as	 measured	 by	arterial	 blood	 gas	 analysis.	 	 CFU	 data	 are	 shown	 as	 median	 and	 IQR,	 analysed	 by	 Mann-Whitney	U	test.		Physiological	data	are	shown	as	mean	+/-	SEM,	and	analysed	by	t-test.		There	were	no	signifcant	differences	seen.	 	
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Figure	3.22	Cytokine	levels	in	serum	from	intravenous	infection	of	rats		Male	Wistar	 rats	 (5	 per	 group)	 were	 injected	 intravenously	 with	 non-replicating	 bacteria.		Cytokine	levels	were	measured	by	ELISA	in	serum	obtained	at	specified	timepoints.		Data	are	presented	as	mean	+/-	SEM	and	analysed	by	2	was	ANOVA	and	Tukey’s	multiple	comparison	test,	with	no	significant	differences	seen.		 	
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3.10	Chapter	Summary	This	 chapter	 has	 explored	 the	 role	 of	S.	 pneumoniae	 capsule	 on	 the	 inflammatory	 cytokine	response	 in	 cell	 culture	 models	 using	 monocyte	 derived	 macrophages	 and	 an	 alveolar	epithelial	 cell	 line.	 	This	data	was	extended	 to	 in	 vivo	models	of	mouse	pneumonia	and	 rat	septic	 shock	 to	 ensure	 there	 are	 physiological	 effects	 correlating	 with	 the	 inflammatory	cytokines	seen	in	the	tissue	culture	model.	
The	pro-inflammatory	cytokine	response	to	purified	capsule	 is	abolished	by	the	addition	of	polymyxin	 B,	 suggesting	 that	 this	 is	 due	 to	 LPS	 contamination.	 	 The	 effect	 of	 polymyxin	 B	could	 have	 had	 unanticipated	 effects,	 for	 example	 on	 any	 anionic	 charge	 from	 the	 capsule.		Despite	this,	encapsulated	TIGR4	induces	more	pro-inflammatory	cytokine	transcription	and	secretion	 than	 the	 isogenic	 unencapsulated	 mutant.	 Bacterial	 stimulation	 of	 pro-inflammatory	cytokine	release	from	alveolar	epithelial	cells	is	limited,	whereas	the	products	of	macrophages	exposed	to	bacteria	 induce	significant	cytokine	release,	particularly	CXCL8.		This	reflects	the	differences	in	macrophage	stimulation	due	to	the	presence	of	capsule.	
The	capsule	 is	known	to	have	an	 important	role	 in	 inhibiting	opsonophagocytosis,	and	 it	 is	clear	 from	MDM	 internalisation	data	 that	 the	 capsule	 inhibits	 internalisation	 in	 this	model.		Similarly	capsule	 inhibited	bacterial	clearance	by	MDM	from	cell	culture	supernatant.	 	Both	may	contribute	to	explaining	the	difference	in	inflammatory	responses	between	strains.	
It	was	also	noted	that	the	difference	between	inflammatory	responses	to	TIGR4	and	Δcps	was	not	so	marked	in	some	experiments,	particularly	evident	in	later	chapters	(e.g.	figure	5.1	and	6.7).	 	 The	 data	 had	 large	 inter-donor	 variation	 noted,	 and	 this	 may	 explain	 the	 lack	 of	significant	difference.		This	is	likely	due	to	variation	in	between	experiments,	possibly	due	to	variation	 in	 MDM	 numbers,	 activation	 state	 perhaps	 due	 to	 differences	 in	 plasticware,	different	batches	of	AB	serum	and	RPMI	used	during	the	course	of	my	PhD.		In	addition	there	could	be	variation	in	bacterial	virulence	(though	this	was	minimised	by	using	bacteria	grown	form	 animal	 passaged	 archived	 master	 stocks).	 	 There	 is	 undoubtedly	 donor	 variation	 in	
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responses	 to	 bacteria	 and	 so	 conclusions	would	 ideally	 be	 drawn	 from	 greater	 number	 of	replicates.	 	 Ideally	 I	 would	 have	 made	 greater	 efforts	 to	 confirm	 MDM	 expression	 of	 cell	surface	markers	 to	 ensure	 consistency.	 	 To	 account	 for	 this	 all	TIGR4	v	Δcps	 cytokine	data	obtained	at	MOI	10	for	6	hours	were	combined	(60	experiments	in	total)	and	can	be	seen	in	figure	3.23.		Overall	there	was	a	significant	difference	seen	by	t-test	giving	confidence	to	the	overall	pattern	that	capsule	contributes	to	pro-inflammatory	inflammation.	
In	 a	 mouse	 pneumonia	 model	 wild-type	 encapsulated	 S.	 pneumoniae	 also	 induced	 greater	inflammatory	cytokine	release	than	unencapsulated.		The	unencapsulated	bacteria	were	also	cleared	more	quickly	from	lavage	fluid.		While	removal	of	AM	reduced	bacterial	clearance,	the	effect	was	 similar	 in	 both	 strains.	 	 Similarly	 inflammatory	 cytokine	 levels	were	 reduced	 in	macrophage-depleted	mice	but	the	difference	between	strains	largely	persisted	(except	IL1β,	though	 levels	 were	 very	 low	 so	 is	 of	 doubtful	 significance).	 	 However	 in	 a	 low	 inoculum	infection	model,	where	macrophages	are	thought	to	play	a	more	pivotal	role,	it	was	clear	that	clearance	 of	 encapsulated	 organisms	 is	 more	 dependent	 on	 macrophages	 than	unencapsulated	organisms.	 	 Inflammatory	 cytokine	 levels	were	much	 lower,	 but	 there	was	still	more	cytokine	secretion	seen	with	encapsulated	S.	pneumoniae,	 though	 the	differences	were	less	impressive.		When	AM	were	depleted	the	cytokine	profile	between	both	strains	was	very	similar,	suggesting	that	macrophages	are	key	to	the	difference	in	inflammatory	response	noted	both	in	vitro	and	in	vivo.		The	presence	of	capsule	magnifies	the	inflammatory	response	at	the	transcriptional	and	secreted	cytokine	level.		It	is	difficult	to	draw	conclusions	from	the	lung	homogenate	data,	mainly	because	the	lung	compartment	is	complex.		Lung	homogenate	includes	lung	parenchyma,	blood	vessels,	and	also	what	is	left	in	the	airways	after	the	lavage	was	taken.		Although	there	are	clear	differences	from	the	alveolar	lavage,	it	is	difficult	to	pick	apart	the	causes	of	those	differences	with	such	a	heterogeneous	population	of	cells.		It	is	clear	that	 TNF	 is	 the	 dominant	 cytokine	 in	 the	 alveolar	 compartment,	 and	 IL1β	 is	 much	 more	prominent	in	the	lungs,	but	these	data	cannot	discern	which	cell	type	is	responsible	for	this.	
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A	 rat	 septic	 shock	model	with	 intravenous	 infection	of	 non-replicating	bacteria	 showed	no	significant	 differences	 between	 the	 strains,	 but	 there	 was	 a	 trend	 towards	 more	inflammatory	 cytokine	 release	with	wild-type	bacteria	and	physiological	 sequelae	of	 sepsis	such	as	hypotension	and	lactataemia.	
In	summary,	the	data	indicate	that	unexpectedly	the	macrophage	inflammatory	response	to	S.	
pneumoniae	was	greater	to	encapsulated	than	unencapsulated	bacteria.		 	
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Figure	3.23	Combined	cytokine	response	of	MDM	to	TIGR4	and	unencapsulated	mutant	MDM	 were	 incubated	 with	 TIGR4	 or	 TIGR4Δcps	 in	 tissue	 culture	 plates,	 at	 MOI	 10.		Supernatant	was	aspirated	at	6	hours	and	later	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6.		The	data	from	60	different	donors	are	analysed	by	t-test.			 	
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4	Mechanisms	of	pro-inflammatory	effects	of	capsule	After	establishing	that	capsule	had	pro-inflammatory	effects	in	vitro	and	in	vivo,	I	carried	out	a	series	of	experiments	to	try	and	explore	the	mechanisms	by	which	they	occur.		
4.1	Transcriptional	response	of	monocyte	derived	macrophages	To	further	explore	the	response	of	MDM	to	S.	pneumoniae	and	how	the	capsule	modifies	this	response,	 I	 undertook	 whole	 genome	 transcriptional	 analysis.	 	 Some	 of	 the	 datasets	 were	obtained	 by	 Gillian	 Tomlinson	 (from	 the	 Noursadeghi	 lab),	 who	 performed	 the	 LPS	 and	PAM2CSK4	 control	 experiments	 as	 well	 as	 obtained	 data	 for	 TIGR4	 and	 Δcps	 infection	experiments	from	3	donors	each.	 	However	I	extracted	and	analysed	the	data.	 	I	carried	out	the	microarray	 experiments	with	 unstimulated	 controls,	 and	 the	 TIGR4	 and	Δcps	 infection	experiments	 for	 an	 additional	 three	 donors.	 	 In	 total	 there	 were	 3	 replicates	 each	 for	unstimulated,	LPS	and	PAM2CSK4	 incubated	MDM,	and	6	each	 for	TIGR4	and	Δcps	 infected	MDM.	These	 data	were	 obtained	 at	 the	 same	 time	 as	 the	 transcriptional	 data	 presented	 in	chapters	4.4,	7.1	and	7.3.	 	The	data	were	analysed	by	T	 tests	on	MultiExperiment	Viewer	v	4.6.0	and	significance	was	set	at	p<0.05.		A	false	discovery	rate	was	not	used	as	the	number	of	biological	replicates	was	 low	(3	to	6),	and	confidence	was	built	by	comparison	to	historical	group	data	and	bioinformatic	analysis	confirmation	with	other	experimental	data.	
Figure	4.1	A	shows	all	 the	genes	on	the	microarray,	with	relative	expression	values	plotted	for	 MDM	 incubated	 with	 TIGR4	 versus	 unstimulated	 MDM.	 	 As	 relatively	 few	 points	 lie	outside	the	red	lines,	this	indicates	that	a	small	proportion	of	recognised	genes	are	altered	by	incubation	 with	 TIGR4.	 	 The	 Venn	 diagram	 in	 panel	 C	 indicates	 that	 after	 infection	 with	TIGR4,	298	genes	are	differentially	expressed	by	more	than	2	fold	compared	to	unstimulated	controls,	and	294	genes	with	Δcps.		Of	these	genes	showing	differential	expression	compared	to	 unstimulated	 controls,	 194	 genes	 were	 shared	 between	 the	 two	 bacterial	 strains.	Stimulation	of	MDMs	with	the	TLR2	agonist	PAM2CSK4	caused	two-fold	changes	in	expression	of	2863	genes,	135	of	which	were	also	affected	by	MDM	infection	with	TIGR4	and	/	or	Δcps	S.	
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pneumoniae.	 	 Figure	 4.2,	 panel	 A	 compares	 the	 gene	 expression	 between	MDM	exposed	 to	TIGR4	and	the	Δcps	mutant.		Here,	only	50	genes	were	differentially	expressed	by	more	than	2	 fold.	 	Panel	B	 shows	 the	20	genes	 that	were	most	overexpressed	by	TIGR4	 in	 relation	 to	Δcps,	 with	 log2	 difference	 in	 gene	 expression	 displayed.	 	 Pro-inflammatory	 cytokines	 are	prominent	 in	 this	 gene	 list,	 supporting	 the	 previous	 data	 that	 the	 encapsulated	 bacteria	promote	 increases	 in	 the	 inflammatory	 responses	 at	 the	 transcriptional	 level.	 Figure	 4.3	illustrates	 the	 top	 20	 genes	 upregulated	 by	 TIGR4,	 and	 how	 the	 mean	 expression	 values	compare	to	the	other	conditions.		Again	pro-inflammatory	genes	are	prominent,	and	the	heat	map	shows	 that	 the	Δcps	strain	upregulated	 similar	genes,	but	 to	a	 lesser	extent.	 	The	 fold	change	column	shows	a	direct	comparison	of	the	two	strains	for	this	gene	signature.	 	While	the	differences	were	modest,	pro-inflammatory	cytokines	such	as	ILβ,	 IL6,	and	IL23	as	well	as	chemokines	such	as	CXCL1,	2,	&	8	were	more	upregulated	by	MDMs	after	 infection	with	the	wild-type	strain	in	comparison	to	the	unencapsulated	strain.	
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Figure	4.1	Comparative	transcriptome	response	of	MDMs	to	S.	pneumoniae	and	Δcps	Panel	 A	 plots	 expression	 values	 of	 all	 genes	 on	 a	 microarray	 comparing	 TIGR4	 v	unstimulated,	 whereas	 B	 compares	 TIGR4	 v	 Δcps.	 	 In	 both,	 the	 red	 lines	 indicate	 2	 fold	differences.	 	Each	gene	on	 the	microarray	 is	 expressed	as	 a	data	point.	 	Data	points	 falling	outside	these	lines	indicate	significantly	different	gene	expression	between	conditions.	
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Figure	 4.2	 Comparative	 transcriptome	 response	 of	
MDM	to	TIGR4	and	Δcps	–	most	upregulated	genes	Panel	 A	 is	 a	 Venn	 diagram	 showing	 the	 number	 of	 genes	upregulated	 by	 more	 than	 2	 fold	 compared	 to	unstimulated	 for	 the	 two	 strains	 and	 the	positive	 control.		Panel	 B	 shows	 the	 genes	 most	 upregulated	 when	comparing	 the	 response	 of	 TIGR4	with	 Δcps	 directly;	 the	values	indicating	log2	of	the	difference	in	expression	values	between	the	conditions.		 	
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Figure	4.3	Comparison	of	genes	upregulated	by	PAM2CSK4,	TIGR4	and	Δcps		This	 heat	map	 shows	mean	 relative	 expression	 values	 of	 the	 top	 20	 genes	 upregulated	 by	wild-type	 TIGR4	 when	 compared	 to	 unstimulated	 MDM.	 	 The	 results	 displayed	 are	 from	experiments	of	6	donors.	 	 	The	most	upregulated	genes	are	displayed	as	relative	expression	with	the	most	upregulated	in	red,	and	the	least	upregulated	in	blue.		The	last	column	shows	a	direct	comparison	of	gene	upregulation	of	these	genes	between	TIGR4	and	the	Δcps	mutant,	displayed	as	 log2	 fold	change	 (FC)	with	green	being	 the	most	upregulated	genes,	 and	black	the	most	downregulated.	 	
6	 	 	 				16					 -2	 							2	
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Analysis	of	the	same	data	by	non-biased	principle	component	analysis	(PCA)	was	confounded	as	 the	 experiments	 carried	out	by	 colleagues	were	performed	on	an	older	microarray	 chip	platform	with	differences	in	the	genes	included	as	well	as	the	oligonucleotides	spotted	on	the	membranes.	 	 As	 a	 consequence	PC1	 (accounting	 for	45%	of	 variation)	 primarily	 separated	the	 data	 by	 differences	 between	 the	 two	 microarray	 chips.	 	 PC2	 (accounting	 for	 24%	 of	variation)	mostly	separated	the	LPS	control	 from	the	other	conditions,	but	PC3	(accounting	for	19%	of	 variation)	 is	 composed	primarily	 of	 pro-inflammatory	 genes.	The	 results	 of	 the	PCA	indicated	that	both	LPS	and	PAM2CSK4	induced	a	greater	inflammatory	response	than	S.	
pneumoniae,	 and	 that	 wild-type	 bacteria	 induced	 higher	 transcriptional	 responses	 of	 pro-inflammatory	genes	than	unencapsulated	bacteria	(figure	4.4).	
Bioinformatic	 analysis	 of	 the	 transcriptome	 with	 oPOSSUM	 software	 extracts	 information	about	 predicted	 transcription	 factor	 binding	 sites	 on	 upregulated	 genes.	 	 Analysis	 of	 the	genes	differentially	upregulated	by	TIGR4	over	Δcps	 is	illustrated	in	figure	4.5.	 	A	z-score	of	>10	is	considered	to	be	significant,	and	panel	A	shows	the	transcription	factors	predicted	to	be	 activated	 by	 TIGR4	 and	 Δcps	 compared	 to	 unencapsulated,	whereas	 panel	 B	 shows	 the	transcription	 factors	 predicted	 to	 be	 activated	 by	 TIGR4	 compared	 to	 Δcps	 in	 rank	 order.		These	largely	involved	the	NFκB	complex	and	stimulation	of	interferon	stimulated	response	elements	 (e.g.	 IRF1),	 as	 well	 as	 response	 to	 cytokines	 and	proliferation/differentiation/apoptosis	 responses	 (e.g.	 AP1).	 	 The	 Innate	 DB	 database	 of	genes,	 proteins,	 and	 signalling	 pathways	 is	 a	 curated	 resource	 of	 experimentally	 verified	interactions.	 	 Innate	 DB	 analysis	 of	 the	 difference	 in	 upregulated	 genes	 identified	overrepresented	 functional	pathways.	 	The	most	 significantly	overrepresented	pathways	 in	MDM	 exposed	 to	 TIGR4	 compared	 to	 unstimulated	MDM	are	 shown	 in	 figure	 4.6,	 panel	 A.		They	 include	 PRR	 signalling,	 and	 inflammatory	 cytokine	 recognition.	 Pathways	overrepresented	during	infection	with	encapsulated	wild-type	compared	to	Δcps	bacteria	are	shown	in	panel	B.	 	
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Figure	 4.4	 Principle	 component	 analysis	 of	 transcriptome	 of	 MDM	 incubated	 with	
TIGR4	or	Δcps	The	 transcriptome	 of	MDM	 exposed	 to	wild-type,	 unencapsulated	 TIGR4,	 or	 controls	 for	 4	hours	was	analysed	by	non-biased	principle	component	analysis	illustrating	expression	of	co-correlated	genes	in	the	global	gene	expression	profile.	 	Panel	A	shows	mean	+/-	SEM	scores	of	principle	components	2	and	3,	for	3	donors	of	controls,	and	6	each	of	TIGR4	and	Δcps.		The	top	 20	 genes	 contributing	 the	 most	 towards	 the	 negative	 deflection	 of	 PC3	 are	 shown	 in	panel	B.	 	
PC3	negative	IL6	TNF	CCL20	CSF3	CXCL1	TNFAIP6	IL1B	IL23A	CCL5	PTGS2	VCPIP1	CSF2	CCR7	TNIP3	KGFLP2	SOCS3	PTX3	CXCL3	IL1A	CCL4	
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Figure	4.5	Bioinformatic	analysis	–	transcription	factor	binding	sites	Panel	 A	 shows	 oPOSSUM	 analysis	 of	 the	most	 upregulated	 genes	 in	MDM	when	 incubated	with	TIGR4	or	Δcps	compared	to	unstimulated	cells,	which	predict	 the	transcription	factors	activated	in	those	conditions.	 	Z-score	indicating	significantly	overrepresented	transcription	factor	binding	sites	are	illustrated;	the	darker	the	panel	the	more	genes	upregulated	that	are	activated	 by	 the	 transcription	 factor	 in	 question.	 	 Panel	 B	 shows	 the	 transcription	 factors	most	differentially	activated	between	wild-type	and	unencapsulated	in	rank	order.				 	
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Figure	4.6	Bioinformatic	analysis	of	transcriptome	–	overrepresented	pathways	This	 shows	 the	 10	 most	 significantly	 overrepresented	 pathways	 analysis	 by	 innateDB	software.	 	This	shows	the	pathways	predicted	to	be	activated	by	analysing	clusters	of	genes	more	expressed	in	one	group	than	the	other.	 	Panel	A	shows	the	pathways	overrepresented	by	 incubation	 with	 wild-type	 over	 unstimulated	 cells	 whereas	 B	 shows	 the	 pathways	overrepresented	by	incubation	with	wild-type	over	incubation	with	unencapsulated	cells.	
TIGR4	>	Unstimulated	 p	value	IL23-mediated	signalling	events	 1.14-4	TLR	signalling	pathway	 3.17-4	
Staphylococcus	aureus	infection	 3.52-4	IL12-mediated	signalling	events	 3.68-4	Cytokine-cytokine	receptor	interaction	 9.36-4	IFN	α/β	signalling	 0.0012	Chemokine	receptors	bind	chemokines	 0.0013	Cytosolic	DNA-sensing	pathway	 0.0016	IFNγ	signalling	 0.0016	NOD-like	receptor	signalling	 0.0025	
TIGR4	>	Δcps	 p	value	NOD-like	receptor	signalling	pathway	 8.24-6	IL23-mediated	signalling	events	 5.04-5	Signal	transduction	through	IL1R	 4.93-4	Validated	transcriptional	targets	of	AP1	family	members	Fra1	and	Fra2	 5.96-4	CD40/CD40L	signalling	 0.0017	Cytokine	–cytokine	receptor	interaction	 0.0021	NFκB	activation	by	nontypeable	
Haemophilus	influenzae	 0.0022	TNFR2	signalling	pathway	 0.0023	AP-1	transcription	factor	network	 0.0041	Chagas	disease	pathways	 0.0041	
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4.2	 Effect	 of	 opsonisation	 and	 on	 the	 inflammatory	 response	 to	
capsule	As	 the	primary	 role	of	 the	 capsule	appears	 to	be	 to	 inhibit	phagocytosis,	 I	 investigated	 the	effect	of	phagocytosis	on	MDM	inflammatory	responses.		The	media	MDM	were	incubated	in	contained	 10%	 pooled	 human	 serum,	 which	 contains	 enough	 human	 antibody	 to	 cause	detectable	IgG	binding	to	S.	pneumoniae	(figure	4.7).		Figure	4.7	also	demonstrates	that	there	was	increased	binding	of	human	antibody	to	unencapsulated	mutants	in	MDM	media	as	well	as	 with	 pooled	 human	 immunoglobulin	 (IVIG)	 compared	 to	 wild-type.	 This	 may	 have	indicated	 that	 serum	 in	 media	 could	 confound	 the	 inflammatory	 responses	 from	 MDM,	particularly	as	Fcγ	receptors	are	known	to	play	a	role	in	inflammatory	signalling	(Clatworthy	and	Smith,	2004).	 	However,	repeating	the	MDM	infection	experiments	in	serum-free	media	(removing	the	effects	of	antibody)	showed	that	wild	bacteria	still	induced	more	inflammatory	cytokine	than	unencapsulated	mutants	when	assessed	using	qPCR	at	3	hours	(Figure	4.8).		In	contrast,	 pre-opsonisation	 of	 bacteria	 before	 incubating	 with	 MDMs	 to	 increase	 bacterial	phagocytosis	 reduced	 the	 inflammatory	 response	 to	 S.	 pneumoniae	 and	 abrogated	 the	differences	between	the	TIGR4	and	Δcps	strains.			
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Figure	4.7	IgG	binding	to	bacteria	Bacteria	were	suspended	in	PBS,	10%	IVIG	in	media	or	5%	AB	serum	media	for	30	minutes.		Fixed	bacteria	were	stained	for	PE	conjugated	to	an	anti	human	IgG	antibody.		Panel	A	shows	the	number	of	bacteria	that	bound	IgG	and	panel	B	display	the	fluorescence	index,	a	product	of	the	amount	of	bacteria	that	fluoresce,	with	degree	of	fluorescence	(measured	by	geometric	mean	of	fluorescence),	indicating	the	quantity	of	antibody	binding	to	each	bacterium.		Results	displayed	are	mean	+/-	SEM	of	3	separate	experiments,	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test.			 	
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Figure	4.8	MDM	cytokine	responses	to	bacteria	in	serum	free	media	MDM	were	 incubated	 with	 controls	 or	 bacteria	 at	 MOI	 10	 in	 RPMI	 supplemented	 with	 L-glutamine	 only	 for	 3	 hours.	 	 RNA	was	 extracted	 from	 cells	 after	 3	 hours	 and	 results	 of	 3	experiments	are	depicted	as	mean	+/-SEM,	with	panel	A	showing	TNF,	B,	showing	IL1β,	and	C,	IL6.		Data	were	analysed	by	1	way	ANOVA,	and	Tukey’s	multiple	comparison	test	with	no	significant	differences	found.	 	
	 191	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.9	Effect	of	opsonisation	on	inflammatory	response	Bacteria	were	opsonised	in	pooled	human	serum	for	30	minutes	before	being	diluted	to	the	required	concentration	and	added	to	MDM.		Analysis	from	3	experiments	with	supernatants	6	hours	after	infection	are	shown	as	mean	+/-	SEM.	 	Panel	A	is	TNF,	B	is	IL1β,	and	C	is	IL6.		Statistical	analysis	was	with	2	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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4.3	Effect	of	phagocytosis	on	the	inflammatory	response	to	capsule	The	above	results	indicated	that	the	increase	in	inflammatory	responses	to	TIGR4	compared	to	the	Δcps	strain	was	driven	by	non-phagocytosed	bacteria.	To	further	establish	whether	the	effect	 of	 capsule	 on	 the	 inflammatory	 response	 to	 S.	 pneumoniae	was	 driven	 by	 bacteria	external	 to	 the	host	cell,	phagocytosis	was	 inhibited	by	pre-incubation	of	MDM	with	10	μM	cytochalasin	 D,	 an	 actin	 polymerisation	 inhibitor,	 for	 30	minutes.	 	 Pre-incubation	 of	MDM	with	 cytochalasin	 D	 reduced	 internalisation	 of	 S.	 pneumoniae	 (figure	 4.10,	 panel	 A)	 as	measured	 by	 internalised	 bacteria	 in	 an	 antibiotic	 protection	 assay.	 	 Similarly	 fluorescent	microscopy	with	labelled	bacteria	and	anti	IgG	to	label	external	bacteria,	showed	fewer	green	internalised	bacteria	with	 cytochalasin	D	 (figure	4.10,	panel	B&C).	 	 Inhibiting	phagocytosis	had	relatively	limited	effects	on	the	cytokine	response	to	S.	pneumoniae,	with	a	trend	towards	increasing	 responses	 (most	 evident	 with	 IL1β)	 especially	 for	 encapsulated	 organisms	although	 this	 did	 not	 achieve	 statistical	 significance	 (p=0.07	 for	 IL1β)	 (figure	 4.11).		Importantly,	the	increased	inflammatory	response	due	to	encapsulated	organisms	compared	to	 unencapsulated	 was	 preserved,	 best	 seen	 by	 qPCR	 (figure	 4.12).	 	 	 Interestingly	cytochalasin	D	appeared	to	reduce	the	inflammatory	effect	of	PAM2CSK4.		While	this	was	not	significant,	it	potentially	suggests	that	cytochalasin	D	has	off	target	effects	that	may	effect	the	generation	 of	 an	 inflammatory	 response,	 as	 TLR2	 stimulation	 does	 not	 require	 actin	polymerisation	or	phagocytosis.	
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Figure	4.10	The	effect	of	cytochalasin	D	on	bacterial	internalisation	Panel	A	 shows	 the	percentage	of	 bacteria	 internalised	using	 an	 antibiotic	protection	 assay.		Data	were	 analysed	 by	Mann	Whitney	U	 test,	with	 no	 significant	 differences	 seen.	 Panel	 B	shows	 MDM	 in	 a	 culture	 plate	 incubated	 with	 FAM-SE	 labelled	 TIGR4	 Δcps	 (in	 green).		Bacteria	 external	 to	 the	 cells	 are	 also	 labelled	 with	 PE	 conjugated	 anti	 IgG	 (in	 red),	colocalisation	 leads	 to	 a	 yellow	 colour.	 	 Panel	 C	 shows	 MDM	 pre-treated	 with	 10μM	cytochalasin	D.			
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Figure	4.11	Effects	of	inhibiting	phagocytosis	on	the	inflammatory	response	MDM	were	 incubated	with	controls	or	bacteria	at	MOI	10,	and	supernatants	were	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6	after	6	hours.	 	The	presented	results	are	mean	+/-	SEM	of	3	experiments,	 analysed	 by	 2	 way	 ANOVA	 and	 Tukey’s	 multiple	 comparison	 test,	 with	 no	significant	differences	seen.	
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Figure	 4.12	 Effects	 of	 inhibiting	 phagocytosis	 on	 transcription	 of	 inflammatory	
cytokines	MDM	were	incubated	with	bacteria	at	MOI	10	for	4	hours,	and	then	RNA	extracted	from	cells.		Data	from	3	experiments	is	presented	as	mean	+/-	SEM	and	analysed	by	2	way	ANOVA	and	Tukey’s	 multiple	 comparison	 test.	 	 Panel	 A	 is	 TNF,	 B	 is	 IL1β,	 and	 IL6	 is	 seen	 in	 panel	 C.		GAPDH	was	used	as	a	housekeeping	gene.	 	
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4.4	Effects	of	inhibiting	phagocytosis	on	the	transcriptome		The	genome	wide	microarray	analyses	of	MDM	responses	to	incubation	with	TIGR4	or	Δcps	were	 examined	 with	 and	 without	 pre-incubation	 with	 cytochalasin	 D	 to	 prevent	phagocytosis.	 These	 data	 were	 obtained	 at	 the	 same	 time	 as	 the	 transcriptional	 data	presented	 in	chapters	4.1,	7.1,	and	7.3.	 	Cytochalasin	D	had	some	effect	on	MDM	incubated	with	S.	pneumoniae,	and	this	was	more	marked	for	TIGR4	than	the	Δcps	strains	(figure	4.13).		Incubation	 with	 cytochalasin	 D	 increased	 the	 number	 of	 genes	 differentially	 regulated	 by	TIGR4	 compared	 to	Δcps	 (figure	4.13C,	 compare	 to	 figure	4.1	panel	B).	 	Of	note,	 there	was	very	little	effect	of	cytochalasin	D	on	gene	expression	in	unstimulated	cells.	
Figure	4.14	and	4.15	demonstrate	that	pro-inflammatory	genes	are	more	highly	upregulated	by	both	wild-type	and	unencapsulated	bacteria	in	the	presence	of	cytochalasin	D.		In	addition,	while	inhibiting	phagocytosis	increased	the	inflammatory	response	of	MDM,	the	difference	in	scale	of	inflammatory	response	is	maintained	between	wild-type	and	unencapsulated	strains.		Interestingly	 more	 genes	 are	 upregulated	 with	 the	 encapsulated	 wild-type,	 than	unencapsulated	with	inhibition	of	phagocytosis.	 	 	However	the	genes	that	were	upregulated	did	not	map	to	any	specific	pathways,	many	of	them	had	unknown	functions.		
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Figure	4.13	Gene	expression	of	MDM	by	genome	wide	analysis	Relative	gene	expression	is	plotted	by	condition	for	all	genes	on	a	microarray.		The	mean	of	3	experiments	for	each	condition	is	plotted.		The	red	lines	indicated	log2	of	2	fold	differences	in	expression.	
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Gene	Symbol	 Unstim	 TIGR4	 Δcps	 TIGR4	+			Cyt	D	 Δcps+	Cyt	D	TNF	 	 	 	 	 	IL23A	 	 	 	 	 	CXCL2	 	 	 	 	 	IL6	 	 	 	 	 	IL1B	 	 	 	 	 	CCL4	 	 	 	 	 	C11orf96	 	 	 	 	 	CCL20	 	 	 	 	 	CXCL1	 	 	 	 	 	CXCL2	 	 	 	 	 	IL8	 	 	 	 	 	CXCL3	 	 	 	 	 	CSF2	 	 	 	 	 	CCL3L3	 	 	 	 	 	ZFP36L1	 	 	 	 	 	PTX3	 	 	 	 	 	CXCL10	 	 	 	 	 	PTGS2	 	 	 	 	 	G0S2	 	 	 	 	 	IFNG	 	 	 	 	 	
	
	
Figure	4.14	Heat	map	of	gene	expression	of	top	20	genes	upregulated	byTIGR4	Mean	 gene	 expression	 of	 MDM	 incubated	 with	 TIGR4	 or	 Δcps	 (3	 donors	 each),	 with	 least	expressed	 in	blue,	and	most	expressed	 in	red.	 	Gene	order	by	most	upregulated	genes	with	TIGR4	 compared	 to	 unstimulated.	 	 In	 the	 relevant	 experiments,	 MDM	were	 pre-incubated	with	 10μM	 cytochalasin	 D	 for	 30	 minutes,	 which	 was	 washed	 off,	 before	 the	 addition	 of	bacteria	at	MOI	10.	 	
6	 	 	 	 	 	 	 	 							16	
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Gene	Symbol	 FC	T4>	Δcps	 FC	T4+	cytD-	Δcps	+	cytD	 FC	T4	+	CytD	>	T4	 FC	Δcps	+	Cyt	D	>	Δcps	TNF	 	 	 	 	IL23A	 	 	 	 	CXCL2	 	 	 	 	IL6	 	 	 	 	IL1B	 	 	 	 	CCL4	 	 	 	 	C11orf96	 	 	 	 	CCL20	 	 	 	 	CXCL1	 	 	 	 	CXCL2	 	 	 	 	IL8	 	 	 	 	CXCL3	 	 	 	 	CSF2	 	 	 	 	CCL3L3	 	 	 	 	ZFP36L1	 	 	 	 	PTX3	 	 	 	 	CXCL10	 	 	 	 	PTGS2	 	 	 	 	G0S2	 	 	 	 	IFNG	 	 	 	 	
	
	
	
Figure	 4.15	 Fold	 change	 in	 relative	 gene	 expression	 of	 top	 20	 upregulated	 genes	 by	
TIGR4	Heat	map	of	relative	differences	in	expression	between	MDM	incubated	with	TIGR4	or	Δcps	+/-	 pre-incubation	 with	 cytochalasin	 D.	 	 Values	 expressed	 as	 log2	 differences	 in	 gene	expression	(fold	change,	FC),	colour	coded	such	that	the	most	upregulated	are	in	green,	and	most	downregulated	in	black.		Mean	of	3	experiments	displayed.				
	 	
-4	 	 	 	 	 	 	 	 									4	
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4.5	Effects	of	capsule	on	Transcription	factors	NFκB	 is	 a	 key	 transcription	 factor	 that	 coordinates	 pro-inflammatory	 gene	 transcription.	NFκB	 is	 induced	 to	 translocate	 into	 the	 nucleus	 to	 engage	 promoter	 sequences	 as	 a	culmination	 of	 multiple	 different	 signalling	 pathways,	 such	 as	 TLR	 signalling	 and	 MAPK	signalling.	 I	 therefore	 investigated	 whether	 MDM	 NFκB	 location	 after	 infection	 with	 S.	
pneumoniae	was	affected	by	the	presence	of	 the	capsule	using	single	cell	analysis	 in	optical	tissue	culture	plates	read	on	a	high	throughput	fluorescent	microscope	(figure	4.16	&	4.17).		Surprisingly	NFκB	activation	in	MDMs	at	one	hour	after	incubation	with	bacteria	was	greater	with	 the	 unencapsulated	 bacteria	 than	 wild-type,	 although	 by	 2	 hours	 the	 difference	 was	minimal.			
A	 commercially	 available	 transcription	 factor	 array	 (Panomics)	 was	 used	 to	 assess	 which	other	 transcription	 factors	 were	 engaged	 with	 gene	 promoters	 at	 a	 protein/DNA	 level	 in	MDMs	 infected	 with	 S.	 pneumoniae.	 	 These	 data	 were	 obtained	 from	 a	 single	 analysis	 of	pooled	 DNA	 extracts.	 	 Visual	 inspection	 of	 the	 protein/DNA	 arrays	 shows	 that	 far	 more	transcription	 factors	were	actively	bound	to	DNA	 in	Δcps	 infected	MDM	than	TIGR4	(figure	4.18).		This	was	further	analysed	by	Imagequant	analysis	software,	and	differences	between	membranes	 accounted	 for	 by	 normalising	 data	 by	 using	 the	 placement	 dots.	 The	 effect	 of	TIGR4	 appears	 to	 be	 largely	 downregulation	 of	 transcription	 factors	 that	 are	 active	 in	unstimulated	 cells	 (i.e.	 metabolic	 and	 cell	 function	 pathways),	 with	 the	 Δcps	 upregulating	more	transcription	 factors	than	wild-type	(figure	4.19).	 	However,	key	transcription	 factors	such	as	NFκB	and	IRF1,	which	were	predicted	to	be	activated	from	the	microarray	data,	were	not	detected,	suggesting	this	array	system	lacked	sensitivity.			
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Figure	4.16	Nuclear:	Cytoplasm	ratio	of	NFκB	in	MDM	after	stimulation	with	bacteria	
or	controls			Panels	A	&	B	show	the	ratio	of	NFκB	between	the	nucleus	and	cytoplasm	in	MDM,	with	the	data	 from	3	different	donors	at	1	and	2	hours	 respectively,	 analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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Figure	4.17	NFκB	translocation	1	hour	after	infection				Microscopy	 images	 of	 high	 throughput	 optical	 96	 well	 plates	 with	 MDM	 incubated	 with	bacteria.		Panel	A	(Unstimulated),	B	(PAM2CSK4),	C	(TIGR4),	and	D	(Δcps)	are	representative	images	 of	 MDM.	 	 Here	 the	 nucleus	 is	 DAPI	 stained,	 in	 blue,	 and	 NFκB	 is	 in	 green.	 	 High	amounts	 of	 nuclear	 translocation	 are	 indicated	 by	 colocalisation	 of	 blue	 and	 green,	 an	example	is	indicated	by	the	white	arrow.		 	
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Figure	4.18	Transcription	Factor	Array	MDM	were	 incubated	with	media	or	bacteria	at	MOI	10	 for	1	hour.	 	 	Nuclear	extracts	were	isolated,	 then	 combined	 between	 4	 donors,	 and	 transcription	 factors	 bound	 to	 DNA	 were	bound	 to	 oligonucleotide	 spotted	 membranes.	 Panel	 A	 is	 of	 unstimulated	 MDM,	 B,	 MDM	incubated	with	TIGR4,	and	C,	Δcps.	
Unstimulated 
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Figure	4.19	Active	Transcription	Factors	After	quantification	of	chemiluminescence	on	protein/DNA	membranes	(figure	3.20),	relative	activity	of	transcription	factors	was	estimated.		Panel	A	shows	transcription	factors	that	are	>2	 fold	upregulated	compared	to	unstimulated	MDM,	and	panel	B,	 the	 transcription	 factors	that	are	<2	fold	downregulated.	 	
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4.6	Effect	of	capsule	on	MAPK	signalling	response	of	macrophages		As	 MAPK	 signalling	 is	 critical	 in	 multiple	 responses	 downstream	 of	 PRR	 activation	 and	cytokine-cytokine	 receptor	 interaction,	 western	 blotting	was	 used	 to	 assess	 the	 activity	 of	these	 pathways.	 	 Although	 there	 was	more	 pro-inflammatory	 cytokine	 production	 at	 both	transcriptional	 and	 secretion	 level	 with	 the	 TIGR4	 strain,	 there	 appears	 to	 be	much	more	activation	of	all	3	MAPK	cascades	with	 the	Δcps	mutant	compared	 to	TIGR4	by	60	minutes	(figure	 4.20	 &	 4.21)	 suggesting	 greater	 PRR	 activation	 by	 the	 Δcps	 strain.	 	 In	 contrast,	 a	phosphoarray	 at	 30	minutes	 after	 incubation	 of	 bacteria	with	MDM	 showed	 no	 significant	differences	between	the	strains	across	a	range	of	kinase	pathways	(figure	4.22	&	4.23).		This	timepoint	was	chosen	because	there	was	significant	NFκB	activation	evident	by	1	hour	and	to	avoid	 confounding	 by	 any	 autocrine	 activation	 by	 pro-inflammatory	 cytokines,	 so	 that	 the	initial	 engagement	 of	 MDM	 with	 bacteria	 would	 be	 the	 most	 important	 factor	 in	 the	phosphorylation	 events	 detected.	Overall,	 the	 data	 shows	no	 suggestion	 that	 the	 increased	inflammatory	 response	 seen	 by	 encapsulated	 organisms	 can	 be	 attributed	 to	 increases	 in	MAPK	 signalling.	 	 Rather	 the	 data	 indicate	 there	 might	 be	 greater	 MAPK	 signalling	 in	response	to	the	unencapsulated	strain.	 	
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Figure	4.20	Western	blot	of		MDM	for	MAPK	Western	blot	of	4	pooled	MDM	lysates	with	TIGR4	or	Δcps,	with	zymosan	as	a	positive	control	and	 media	 only	 as	 an	 unstimulated	 negative	 control.	 	 Lysates	 were	 probed	 for	 phospho-MAPK	and	GAPDH	was	used	as	a	 loading	control.	 	One	example	of	2	separate	western	blots	shown.	
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Figure	4.21		Quantification	of	MAPK	Western	blots	Western	 blots	 from	 figure	 4.20	 were	 quantified	 by	 Imagequant	 and	 presented	 as	 relative	density	normalised	to	GAPDH.		A)	phospho-p38,	B)	phospho–JNK,	and	C)	phospho-ERK.	
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Figure	4.22	Analysis	of	phosphoarray	Panel	A	shows	relative	pixel	density	analysed	by	ImageJ	of	a	phosphoarray	of	4	pooled	MDM	lysates	at	30	minutes	of	incubation.				
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Figure	4.23	Phosphoarray	of	MDM	at	30	minutes	of	incubation		Images	 of	 phosphoarray	 membranes	 of	 exposed	 for	 45	 seconds	 of	 MDM	 lysates	 after	incubation	with:	A)	media	only,	B)	TIGR4,	and	C)	Δcps	are	shown.		 	
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4.7	 Effect	 of	 capsule	 on	 TLR2	 stimulation,	 lectin	 stimulation,	 and	
scavenger	receptors	As	 inhibiting	 phagocytosis	 preserved	 the	 difference	 between	 TIGR4	 and	 Δcps,	 specific	 cell	surface	PRR	that	might	explain	this	difference	were	investigated	to	see	if	they	could	explain	the	difference	between	strains.	
TLR2	 is	 recognised	 as	 an	 important	 PRR	 that	 recognises	 lipoproteins	 of	 S.	 pneumoniae	(Tomlinson,	Chimalapati	et	al,	2014).		Purified	capsule,	even	at	very	high	concentrations,	did	not	 induce	 TLR2	 activation	 in	 a	 reporter	 cell	 assay	 (figure	 4.24,	 A).	 	 Interestingly	 after	incubation	with	whole	bacteria	there	was	less	TLR2	activation	with	TIGR4	compared	to	Δcps	strains	at	MOI	10,	with	no	significant	differences	seen	at	other	MOI	(figure	4.24,	B).		However,	transfected	HEK	cells	may	not	 represent	TLR2	 function	 in	professional	phagocytic	 immune	cells	such	as	macrophages.	
Lectins	are	a	group	of	receptors	that	recognise	carbohydrate	motifs,	some	of	which	serve	as	PRRs,	 for	 example	 in	 the	 recognition	 of	 fungal	 cell	 wall	 products,	 and	 could	 potentially	recognise	S.	pneumoniae	 capsular	polysaccharide.	 	Lectins	are	a	diverse	group	of	receptors,	but	 they	 largely	 signal	 through	 either	 the	 Syk	 or	 c-Raf	 pathways.	 	 Syk	 is	 also	 activated	downstream	of	 immunoglobulin	recognising	Fc	receptors,	as	well	as	B	and	T	cell	receptors.		As	the	media	used	for	MDM	culture	is	usually	supplemented	with	human	serum,	which	would	contain	 antibodies,	 the	 experiments	 looking	 for	 phosphorylation	 events	 in	 these	 pathways	were	 performed	 in	 serum	 free	 conditions.	 	 Immunoblots	 showed	 constitutive	phosphorylation	of	both	Syk	and	c-RAF,	with	no	evidence	of	differential	activation	between	TIGR4	and	Δcps	(figure	4.25	&	4.26).		Furthermore	Syk	inhibition	had	no	inhibitory	effect	on	the	 inflammatory	 response	 to	 either	TIGR4	or	Δcps	 (figure	4.27).	 	 It	was	a	 surprise	 to	 find	marked	 basal	 activation	 of	 both	 these	 signalling	 molecules.	 	 This	 suggests	 that	 the	experimental	setup	or	processing	of	the	lysates	induced	some	lectin	activation	or	that	there	was	poor	specificity	of	the	antibodies	to	the	phosphorylated	kinases.		This	means	that	these	
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data	 may	 require	 more	 parallel	 experiments	 to	 confirm	 no	 lectin	 involvement	 in	 capsule	recognition.	
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Figure	4.24	HEK	TLR2	activation	HEK	 cells,	 transfected	with	TLR2	 linked	 to	 a	NFκB	 SEAP	 reporter,	were	 incubated	with	A)	purified	capsular	polysaccharide	at	varying	concentrations,	positive	control,	or	B)	bacteria	at	varying	MOI.		Supernatant	removed	and	analysed	on	a	microplate	reader.		Mean	+/-SEM	of	5	experiments	shown	and	analysed	by	1	way	ANOVA	with	Tukey’s	multiple	comparison	test.	
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Figure	4.25	Western	blots	of	MDM	lysates	for	lectin	signalling		Western	blot	of	4	MDM	lysates	with	TIGR4	or	Δcps,	with	zymosan	as	a	positive	control	and	media	only	as	an	unstimulated	negative	control.	 	Lysates	were	probed	for	phospho-SYK	and	c-RAF,	 with	 total	 SYK	 and	 c-RAF	 used	 as	 loading	 controls.	 	 Representative	 blot	 of	 2	experiments	shown.		 	
Unstim			Zym							Zym					TIGR4				TIGR4					Δcps					Δcps																											15										60											15											60										15										60											 
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Figure	4.26	Westerns	of	SYK	and	c-RAF	phosphorylation	Western	blot	of	4	MDM	lysates	with	TIGR4	or	Δcps,	with	zymosan	as	a	positive	control	and	media	only	as	an	unstimulated	negative	control	shown	in	panel	A.	 	Lysates	were	probed	for	phosphorylated	SYK	(at	525)	and	total	SYK,	phosphorylated	c-RAF	and	total	c-RAF.		This	was	quantified	by	Imagequant;	phospho-SYK	presented	in	panel	A,	and	phospho-c-RAF	presented	in	panel	B.	
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Figure	4.27	The	effect	of	Syk	inhibition	of	MDM	cytokine	secretion	Mean	+/-	SEM	of	3	MDM	experiments	with	cytokines	measured	in	cell	culture	supernatants	6	hours	after	stimulation	with	positive	control	or	bacteria	at	MOI	10.		Cells	pre-incubated	with	Syk	 inhibitor	 (Oxindole,	 Sigma	Aldrich,	Gillingham	at	2μM)	 for	1hour.	 	Panel	A	 shows	TNF,	panel	B	shows	IL1β,	and	panel	C	shows	IL6.		Analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test	with	no	significant	differences	seen.	
Unstimulated
PAM2 CSK4
TIGR4 Δcps0
20004000
60008000
TNF	(p
g/ml)
NilSyki
Unstimulated
PAM2 CSK4
TIGR4 Δcps0
50100
150200
IL1β	(p
g/ml)
NilSyki
Unstimulated
PAM2 CSK4
TIGR4 Δcps0
200400
600800
1000
IL6	(pg
/ml)
NilSyki
A
B
C
	 216	
Similarly	scavenger	receptors	are	a	heterogeneous	group	of	receptors	that	recognise	anionic	structures.	 	 Previous	 work	 has	 shown	 that	 MARCO	 in	 particular	 is	 important	 for	 the	recognition	 of	 S.	 pneumoniae	 capsule,	 and	 that	 it	 facilitates	 non-opsonic	 phagocytosis.	 	 In	addition,	 MARCO	 recognition	 of	 components	 of	 other	 organisms	 such	 as	 Mycobacterium	
tuberculosis	 cord	 factor,	 have	 been	 shown	 to	 increase	 TLR2	 responses.	 	 However,	neutralisation	of	MARCO	with	antibody	failed	to	reduce	the	inflammatory	response	of	MDM	(figure	4.28).		Similarly,	competitive	blockade	of	all	type	A	scavenger	receptors	with	dextran	sulphate	 failed	 to	 significantly	 reduce	 the	 inflammatory	 response	 to	either	encapsulated	or	unencapsulated	strains	(figure	4.29).	
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Figure	4.28	Effect	of	MARCO	blockade	on	MDM	cytokine	secretion	Mean	+/-	SEM	of	3	MDM	experiments	with	cytokines	measured	in	cell	culture	supernatants	6	hours	after	stimulation	with	positive	control	or	bacteria	at	MOI	10.		Cells	pre-incubated	with	mouse	anti-human	monoclonal	MARCO	antibody	(eBioscience)	or	isotype	control	(both	at	25	μg/ml)	for	1hour.		Panel	A	shows	TNF,	panel	B	shows	IL1β,	and	panel	C	shows	IL6.		Analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test	with	no	significant	differences	seen.	
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Figure	4.29	The	effect	of	scavenger	receptor	blockade	on	MDM	cytokine	secretion	Mean	+/-	SEM	of	4	MDM	experiments	with	cytokines	measured	in	cell	culture	supernatants	6	hours	after	stimulation	with	positive	control	or	bacteria	at	MOI	10.		Some	cells	pre-incubated	with	dextran	sulphate	at	100μg/ml	for	1hour	to	block	class	A	scavenger	receptors.	 	Panel	A	shows	 TNF,	 panel	 B	 shows	 IL1β,	 and	 panel	 C	 shows	 IL6.	 	 Analysed	 by	 2	way	 ANOVA	 and	Tukey’s	multiple	comparison	test	with	no	significant	differences	seen.	 	
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4.8	Chapter	Summary	Whole	 genome	 transcriptional	 analysis	 indicates	 that	 the	most	 upregulated	 genes	 in	MDM	incubated	 with	 S.	 pneumoniae	 involve	 pro-inflammatory	 cytokines	 and	 chemokines.	 	 The	wild-type	 strain	 induced	 a	 very	 similar	 upregulated	 gene	 signature	 to	 the	 unencapsulated	mutant,	 but	 to	 a	 greater	 extent.	 	 Bioinformatic	 analysis	 suggests	 that	 NFκB	 and	 IFN	stimulating	transcription	factors	are	the	most	active	on	MDM	exposure	to	S.	pneumoniae,	and	that	 TLR,	 NOD,	 and	 cytokine	 signalling	 pathways	 are	 the	 most	 stimulated	 intracellular	signalling	pathways.					
The	best-recognised	role	of	capsule	is	to	evade	phagocytosis,	and	this	was	confirmed	in	both	human	 and	 mouse	 macrophages.	 Pre-opsonisation	 of	 bacteria	 reduced	 the	 inflammatory	sequelae,	more	evident	in	the	wild-type	encapsulated	organism.	 	The	reduced	inflammatory	response	 to	 unencapsulated	 bacteria	 is	 not	 solely	 due	 to	 more	 rapid	 internalisation,	 as	complete	 inhibition	 of	 phagocytosis	 with	 an	 actin	 polymerisation	 inhibitor	 preserved	 the	differences	between	the	strains.	These	observations	suggest	 that	 the	presence	of	capsule	at	the	 host	 cell	 surface	 could	modify	 the	 inflammatory	 response	 to	 other	 components	 of	 the	bacteria,	as	without	phagocytosis	the	bacteria	would	remain	at	the	cell	surface,	and	thus	able	to	 stimulate	more	 prolonged	 activation	 of	 cell	 surface	 receptors	 (frustrated	 phagocytosis).		The	 genome-wide	 transcriptional	 response	 to	 bacteria	 after	 inhibition	 of	 phagocytosis	supports	 this,	 as	 the	 differences	 between	 wild-type	 and	 unencapsulated	 strains	 were	minimally	 affected	 by	 cytochalasin	 D.	 	 Cytochalasin	 D	 could	 have	 other	 effects	 on	 the	inflammatory	response:	bacterial	uptake	and	subsequent	bacterial	breakdown	may	stimulate	inhibitory	pathways	that	would	not	been	seen	with	phagocytosis	inhibition,	it	is	also	known	to	cause	p53	mediated	cell	cycle	arrest	therefore	may	affect	inflammatory	signalling	directly,	and	its	effects	on	actin	polymerisation	could	have	unintended	pro-inflammatory	effects	as	the	cell	 continues	 to	signal	 the	cell	 to	move.	 	These	are	potential	confounders	 for	 the	effects	of	cytochalasin	D	on	MDM	responses	to	S.	pneumoniae.	
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NFκB,	a	critical	 transcription	 factor	 that	regulates	pro-inflammatory	cytokine	 transcription,	is	 activated	 by	S.	 pneumoniae.	 	 Despite	 this	 the	 unencapsulated	 strain	 induced	more	NFκB	translocation	 and	 also	 stimulated	 the	 activation	 of	more	 transcription	 factors	 than	 TIGR4.		The	unencapsulated	strain	also	 induced	more	activation	of	MAPK	than	wild-type	within	60	minutes	of	incubation	with	MDM.		It	should	be	noted	that	GAPDH	has	been	used	as	a	control	to	account	for	total	protein,	but	this	does	not	account	for	upregulation	of	unphosphorylated	proteins,	 and	 it	 can	 be	 argued	 that	 total	 amount	 of	MAPK	 is	 a	 better	 control.	 	 These	 data	indicate	 that	 the	 recognition	 of	 polysaccharide	 capsule	may	 inhibit	multiple	 pathways	 that	culminate	in	transcription	factor	activation.	However	this	transcription	factor	activation	did	not	 correlate	 with	 pro-inflammatory	 gene	 transcription,	 possibly	 reflecting	 the	 complex	interplay	 between	 transcription	 factors,	 some	 of	 which	 may	 inhibit	 the	 downstream	consequences	 of	 NFκB	 activation.	 	 This	 discordance	 could	 also	 be	 explained	 by	 longer	duration	 of	 or	 amplification	 of	 transcription	 factor	 action	 within	 the	 nucleus	 driven	 by	alternative	signalling	pathways.		The	transcription	factor	array	assay	had	poor	sensitivity	so	strong	conclusions	should	not	be	drawn	from	the	results.			
TLR2,	 lectin,	 and	 scavenger	 receptor	 activation	was	 similar	 between	 strains,	 so	 it	 is	 as	 yet	unclear	if	a	cell	surface	PRR	actively	recognises	capsular	polysaccharide	to	cause	this	effect.		It	 should	 be	 noted	 that	 the	 transfected	 HEK	 cell	 line,	 while	 effective	 for	 simple	 TLR2	stimulation,	may	not	be	generalizable	in	the	context	of	complex	infection.		These	cells	do	not	phagocytose	 bacteria	 and	 therefore	 there	 is	 less	 dynamic	 effect	 on	 bacterial	 cell	 numbers,	which	would	only	be	restricted	by	the	nutrient	content	of	the	media.		In	addition,	the	length	of	the	incubation	required	to	generate	a	colorimetric	change	(16	hours),	may	result	in	some	cell	death	that	could	confound	the	results.		I	did	not	assess	bacterial	counts	for	adherence	or	invasion,	 which	 could	 additionally	 have	 confounded	 the	 data.	 	 So	 they	 are	 a	 blunt	 tool	 to	assess	 TLR2	 activation,	 and	 may	 not	 be	 reflective	 of	 what	 happens	 in	 MDM,	 and	 ore	particularly	 in	 vivo.	 	 The	 immunoblots	 of	 Syk	 and	 cRAF	 activation	 showed	 no	 difference	between	negative	and	positive	controls.		This	means	that	they	are	very	difficult	to	interpret.		
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It	may	be	that	 there	 is	constitutional	 lectin	activation	 in	MDM	in	sugar	containing	media	 in	tissue	culture	plates.		However,	non-specificity	of	the	antibody	to	phospho	Syk	and	c-Raf	(i.e.	off	 target	 binding	 to	 total	 Syk	 and	 Raf)	 could	 also	 explain	 the	 lack	 of	 difference	 between	negative	and	positive	control.		As	such,	more	supportive	data	is	required	to	definitively	state	there	is	no	difference	in	lectin	signalling	due	to	capsule.	
It	 remains	 unclear	 how	 the	 capsule	 is	 recognised	 to	 have	 this	 effect,	 and	 an	 alternative	hypothesis	 is	 that	 capsule	may	 rather	 act	 as	 a	 physical	 barrier	 to	 recognition	 of	 other	 cell	surface	ligands,	which	then	have	inhibitory	effects	on	the	inflammatory	response.	
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5	 Effects	 of	 serotype	 4	 capsule	 expression	 on	 other	 S.	
pneumoniae	serotypes	and	Streptococcus	mitis		
5.1	Effect	of	capsule	on	inflammatory	response	to	various	serotypes	To	ensure	the	difference	in	 inflammatory	response	between	TIGR4	and	Δcps	strain	was	not	serotype	specific,	 the	experiments	were	repeated	with	3	other	serotypes	and	their	 isogenic	unencapsulated	mutant	 strain	 derivatives.	 	 For	 all	 three	 serotypes,	MDM	 supernatant	 pro-inflammatory	 cytokine	 levels	 were	 not	 significantly	 different	 between	 encapsulated	 and	unencapsulated	 strains.	 There	 were	 relatively	 large	 differences	 in	 some	 pro-inflammatory	cytokine	 responses	 to	 wild	 type	 serotype2	 and	 23F	 compared	 to	 their	 isogenic	unencapsulated	 mutants,	 but	 inter	 donor	 variability	 prevented	 the	 results	 from	 being	statistically	 significant	 (figure	 5.1).	 	 For	 the	 serotype	 3	 strain	 the	 presence	 of	 the	 capsule	showed	a	trend	towards	reduction	in	the	levels	of	pro-inflammatory	cytokines,	perhaps	as	a	consequence	of	its	heavily	mucoid	phenotype.		
The	absence	of	capsule	affected	TLR2	stimulation,	with	increased	TLR2	activation	for	TIGR4	and	 serotype	 2,	 but	 less	 with	 serotype	 3	 (figure	 5.2).	 	 There	 were	 variations	 between	serotypes	 in	 TLR2	 stimulation	 with	 serotypes	 2,	 3,	 and	 23F	 showing	 increased	 TLR2	stimulation	 compared	 to	 the	 serotype	 4	 strain.	 	 Interestingly	 these	 differences	 were	 no	longer	evident	between	unencapsulated	strains.		As	data	in	chapter	4	indicated	that	capsular	material	 does	 not	 directly	 induce	 TLR2	 stimulation,	 this	 is	 more	 evidence	 that	 capsule	 is	likely	 to	 modify	 how	 bacterial	 surface	 components	 interact	 with	 TLR2	 on	 host	 cell	membranes.	
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Figure	 5.1	 MDM	 cytokine	 response	 to	 different	 serotypes	 and	 their	 isogenic	
unencapsulated	mutants	MDM	were	incubated	with	4	different	serotypes	and	their	isogenic	unencapsulated	mutants	at	MOI	10	for	6	hours.		Supernatants	were	removed	and	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6.	 	Data	are	presented	as	mean	+/-	SEM.	 	No	results	were	significantly	different	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test.	
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Figure	 5.2	 TLR2	 reporter	 cell	 responses	 to	 different	 serotypes	 and	 their	 isogenic	
unencapsulated	mutants	HEK	293	 cells	 transfected	with	 TLR2	 and	NFκB	 linked	 to	 a	 SEAP	 reporter	were	 incubated	with	 several	 wild-type	 (WT)	 S.	 pneumoniae	 serotypes	 and	 their	 isogenic	 unencapsulated	mutants	 at	 MOI	 10	 for	 20	 hours.	 	 Supernatant	 colorimetric	 change	 is	 expressed	 as	absorbance.	 	Data	are	presented	as	the	mean	+/-	SEM	of	3	separate	experiments.	 	Analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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5.2	Inflammatory	response	of	capsule	switch	S.	pneumoniae	strains		To	investigate	whether	capsular	serotype	directly	affected	MDM	inflammatory	response	to	S.	
pneumoniae,	 capsule	 switch	 strains	 based	 on	 the	 TIGR4	 background	 were	 incubated	 with	MDM.		Again	donor	variation	made	data	interpretation	difficult.		When	comparing	results	for	non-isogenic	strains	there	was	a	significantly	increased	IL6	release	by	MDMs	in	response	to	a	serotype	6A	strain	compared	to	TIGR4	(figure	5.3),	with	a	trend	towards	more	TNF	from	6A	compared	 to	 the	other	serotypes.	 	While	other	differences	were	not	statistically	significant,	both	 6A	 and	 14	 appeared	 to	 induce	 more	 IL1β	 than	 TIGR4.	 	 23F	 appeared	 to	 generate	relatively	 similar	 inflammatory	 responses	 to	 TIGR4.	 	 This	 may	 suggest	 that	 serotype	differences	 influence	 specific	 cytokines	 differentially,	 so	 multiple	 PRR	 are	 likely	 to	 be	involved	to	account	for	variation	in	response	to	serotype.	
There	 were	 differences	 between	 TIGR4	 strains	 expressing	 different	 capsular	 serotypes,	showing	 that	 the	 capsule	 itself	 affects	 inflammatory	 responses	 (figure	 5.4),	 and	 that	 non-capsular	differences	between	serotypes	do	not	account	for	all	the	variation	in	inflammatory	response	between	serotypes.		TIGR4	+	6A	induced	more	TNF	and	IL6	than	TIGR4,	and	TIGR4	+	23F	induced	more	IL6	than	TIGR4,	though	IL1β	levels	were	again	quite	variable.	
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Figure	5.3	MDM	cytokine	response	to	varied	serotypes		MDM	were	 incubated	with	 different	 serotypes.	 	 Supernatants	were	 removed	 after	 6	 hours	and	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6.		Data	are	presented	as	mean	+/-	SEM.		Results	were	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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Figure	5.4	MDM	cytokine	response	to	capsule	switch	strains	MDM	were	incubated	with	capsule	switch	strains	where	the	other	serotype	is	expressed	on	TIGR4	bacteria.		Supernatants	were	removed	after	6	hours	and	analysed	for	A)	TNF,	B)	IL1β,	and	C)	 IL6.	 	Data	are	presented	as	mean	+/-	SEM.	 	Results	were	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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The	 HEK	 TLR2	 reporter	 assay	 was	 used	 to	 assess	 whether	 the	 differences	 in	 MDM	inflammatory	 responses	 identified	 above	were	 due	 to	 differences	 between	 strains	 in	 TLR2	stimulation.	 Sian	 Hutchings,	 a	 BSc	 student,	 performed	 these	 experiments	 under	 my	supervision.		The	data	from	HEK	TLR2	cells	incubated	with	TIGR4,	other	clinical	isolates	and	the	 TIGR4	 capsular	 serotype	 switched	 strains	 showed	 differences	 in	 TLR2	 responses	between	wild-type	strains	but	none	between	the	TIGR4	capsular	switch	strains	(figure	5.5).	These	results	indicate	that	expression	of	varying	capsule	does	not	alter	TLR2	recognition	of	TIGR4.	The	differences	in	TLR2	stimulation	between	clinical	strains	did	not	correlate	with	the	results	from	MDM	pro-inflammatory	cytokine	release	e.g.	despite	reduced	TLR2	responses	to	the	 serotype	23F	 strain,	 infection	of	MDMs	with	 this	 strain	 resulted	 in	higher	 levels	 of	 IL6	compared	to	infection	with	the	TIGR4	strain	(figures	5.3	and	5.5).			 	
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Figure	5.5	TLR2	reporter	cell	responses	to	varied	serotypes	and	capsule	switch	strains		HEK	 293	 cells	 transfected	with	 TLR2	 and	NFκB	 linked	 to	 a	 SEAP	 reporter	were	 incubated	with	several	S.	pneumoniae	 serotypes	(panel	A)	and	capsule	switch	strains	where	the	other	serotype	 is	 expressed	 on	 TIGR4	 bacteria	 (panel	 B)	 at	 MOI	 10	 for	 20	 hours.	 	 Supernatant	colorimetric	change	is	expressed	as	absorbance.		Data	are	presented	as	the	mean	+/-	SEM	of	4	separate	experiments	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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5.3	Effect	of	capsule	on	the	inflammatory	response	to	S.	mitis		To	 extend	 the	 data	 on	 capsule,	 with	 collaborators	 from	 Oslo,	 we	 used	 the	 closely	 related	bacteria	Streptococcus	mitis	to	assess	the	effect	of	its	capsule	on	the	inflammatory	response.		In	 addition	 to	 assess	 whether	 the	 S.	 pneumoniae	 serotype	 4	 capsule	 is	 directly	 pro-inflammatory	we	compared	 the	MDM	response	 to	wild-type	S.	mitis	 (expressing	 its	natural	polysaccharide	capsule)	to	an	S.	mitis	strain	expressing	the	TIGR4	cps	 locus	(Rukke,	Kalluru	et	al.	2014).		Data	from	our	group	also	show	that	S.	mitis	is	taken	up	into	RAW	macrophages,	that	 its	 naturally	 expressed	 capsule	 is	 protective	 against	 uptake,	 and	 that	 expression	 of	TIGR4	capsule	provides	even	greater	protection	(Rukke,	Kalluru,	et	al.	2014)	as	evidenced	by	association	with	fluorescent	cells,	intracellular	bacterial	numbers,	and	electron	micrography.	
The	data	were	heterogeneous,	but	the	most	obvious	difference	was	that	all	the	S.	mitis	strains	induced	more	TNF	and	IL6	than	S.	pneumoniae,	though	again	the	IL1β	response	was	muted	in	this	model	(figure	5.6).		There	was	no	significant	difference	between	S.	mitis	and	S.	mitis	Δcps	except	 in	 IL1β,	 although	 the	 levels	 were	 so	 low	 that	 this	 difference	 is	 unlikely	 to	 have	functional	significance.		Importantly,	expression	of	the	S.	pneumoniae	serotype	4	capsule	by	S.	
mitis	did	not	increase	the	inflammatory	response,	with	in	fact	a	significantly	increased	IL6	in	response	 to	 S.	 mitis	 compared	 to	 S.	 mitis	 +	 TIGR4	 capsule.	 	 This	 suggests	 that	 the	 pro-inflammatory	effect	of	TIGR4	capsule	lies	in	modification	of	a	response	to	another	component	of	S.	pneumoniae	rather	than	a	direct	effect	of	the	capsule	material.			
The	 HEK	 TLR2	 reporter	 assay	 showed	 no	 difference	 between	 TIGR4	 and	 S.	 mitis,	 and	 no	difference	between	S.	mitis	and	either	the	capsule	deficient	mutant	or	the	mutant	expressing	the	TIGR4	capsule	(figure	5.7).	 	
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Figure	5.6	MDM	cytokine	response	to	TIGR4	and	S.	mitis	strains	MDM	were	incubated	with	TIGR4,	and	S.	mitis	wild-type,	capsule	deficient	strains,	and	S.	mitis	expressing	the	TIGR4	capsule.	Supernatants	were	removed	after	6	hours	and	analysed	for	A)	TNF,	 B)	 IL1β,	 and	 C)	 IL6.	 	 Data	 are	 presented	 as	 mean	 +/-	 SEM.	 	 Analysis	 was	 by	 1	 way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	5.7	TLR2	reporter	cell	responses	to	TIGR4	and	S.	mitis	strains		HEK	 293	 cells	 transfected	with	 TLR2	 and	NFκB	 linked	 to	 a	 SEAP	 reporter	were	 incubated	with	TIGR4	and	S.	mitis	wild-type,	capsule	deficient	strains,	and	S.	mitis	expressing	the	TIGR4	capsule,	and	capsule	switch	strains	where	the	other	serotype	is	expressed	on	TIGR4	bacteria	at	MOI	10	for	20	hours.	 	Supernatant	colorimetric	change	is	expressed	as	absorbance.	 	Data	are	 presented	 as	 the	mean	 +/-	 SEM	 and	 analysed	 by	 1	 way	 ANOVA	 and	 Tukey’s	 multiple	comparisons	test,	with	no	significant	differences	seen.		
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5.4	 Effects	 of	 S.	 mitis	 expressing	 TIGR4	 capsule	 in	 a	 mouse	
pneumonia	model	To	assess	the	role	of	capsule	of	S.	mitis	in	vivo	we	used	S.	mitis,	its	isogenic	capsule	deficient	mutant,	 and	 S.	 mitis	 expressing	 the	 TIGR4	 capsule	 in	 a	 pneumonia	model,	 and	mice	 were	culled	at	4	hours	to	evaluate	inflammatory	responses	in	early	infection.		
In	 the	 first	 set	 of	 experiments,	 mice	 were	 treated	 with	 empty	 liposomes	 as	 a	 control	 for	liposomal	clodronate	used	in	the	experiments	in	chapter	5.6.	 	By	4	hours	there	was	already	significantly	more	S.	mitis	+	TIGR4cps	than	S.	mitis	in	both	lavage	fluid	and	lung	homogenate	(figure	 5.8).	 	 However,	 TIGR4	 caused	 significantly	 more	 neutrophil	 recruitment	 to	 lavage	fluid	 than	 the	 S.	 mitis	 strains,	 but	 the	 expression	 of	 TIGR4	 capsule	 had	 little	 effect	 on	 the	inflammatory	 cell	 infiltrate	 caused	 by	 S.	mitis	 (figure	 5.9).	 	 Similarly,	while	 TIGR4	 induced	similar	TNF	levels	in	lavage	fluid	to	the	S.	mitis	strains,	it	induced	significantly	more	IL1β	and	a	trend	to	more	IL6	than	all	the	S.	mitis	strains	(figure	5.10).		In	lung	homogenate,	TNF	levels	were	similar	between	strains	but	there	was	significantly	more	IL6	and	a	trend	to	more	IL1β	with	TIGR4	(figure	5.11).	 	Again,	the	TIGR4	capsule	had	little	bearing	when	expressed	on	S.	
mitis	in	both	lavage	fluid	and	lung	homogenate.			
These	 data	 support	 the	 in	 vitro	 data	 that	 TIGR4	 capsule	 has	 little	 effect	 on	 inflammatory	response	in	the	context	of	S.	mitis.		This	provides	more	evidence	that	the	TIGR4	capsule’s	pro-inflammatory	 effects	must	 be	 driven	 by	modification	 of	 host	 cell	 interaction	with	 other	 S.	
pneumoniae	components.	 	
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Figure	5.8	Mouse	lavage	and	lung	homogenate	bacterial	counts	4	hours	after	infection	5	 week	 old	 female	 CD1	 mice	 had	 intranasal	 liposomes	 administered	 72	 hours	 before	intranasal	infection	with	5×106	CFU	bacteria;	either	TIGR4,	S.	mitis,	S.	mitis	Δcps,	or	S.	mitis	+	TIGR4cps.		Mice	were	culled	at	4	hours	and	bronchoalveolar	lavage	and	lung	homogenate	was	obtained	 and	plated	 to	 assess	bacterial	 counts,	 shown	 in	panel	A	 and	B	 respectively.	 	Data	from	 individual	 mice	 and	medians	 values	 are	 presented.	 	 Analysed	 by	 Kruskal-Wallis	 and	Dunn’s	multiple	comparisons	test.		 	
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Figure	5.9	Mouse	lavage	cell	counts	4	hours	after	infection	5	 week	 old	 female	 CD1	 mice	 had	 intranasal	 liposomes	 administered	 72	 hours	 before	intranasal	infection	with	5×106	CFU	bacteria;	either	S.	mitis	Δcps,	S.	mitis,	S.	mitis	+	TIGR4cps	or	 TIGR4.	 	 Mice	 were	 culled	 at	 4	 hours	 and	 cell	 count	 and	 neutrophil	 numbers	 in	bronchoalveolar	lavage	fluid	determined	by	haemocytometer	and	cytospin,	shown	in	panel	A	and	B	respectively.		Data	shown	as	mean	+/-SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
	 236	
S.	mitis	Δcps
S.	mitis
S.	mitis	+	TIGR4
TIGR4
10002000
30004000
50006000
7000
TNF	(p
g/ml)
S.	mitis	Δcps
S.	mitis
S.	mitis	+	TIGR4
TIGR40
200400
600800
IL1β	(p
g/ml)
**
**
S.	mitis	Δcps
S.	mitis
S.	mitis	+	TIGR4
TIGR40
100200
300400
500600
IL6	(pg
/ml)
**
A
B
C
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 5.10	 Mouse	 lavage	 cytokine	 levels	 4	 hours	 after	 infection	 in	 mice	 given	
liposomes	5	 week	 old	 female	 CD1	 mice	 had	 intranasal	 liposomes	 administered	 72	 hours	 before	intranasal	infection	with	5×106	CFU	bacteria;	either,	S.	mitis	Δcps,	S.	mitis,	S.	mitis	+	TIGR4cps	or	TIGR4.		Mice	were	culled	at	4	hours	and	cytokine	levels	in	lavage	fluid	were	determined	by	ELISA.	TNF,	IL1β,	and	IL6	shown	in	panels	A,	B	and	C	respectively.		Data	are	shown	as	mean	+/-SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	5.11	Mouse	lung	homogenate	cytokine	levels	4	hours	after	infection	5	 week	 old	 female	 CD1	 mice	 had	 intranasal	 liposomes	 administered	 72	 hours	 before	intranasal	infection	with	5×106	CFU	bacteria;	either,	S.	mitis	Δcps,	S.	mitis,	S.	mitis	+	TIGR4cps	or	 TIGR4.	 	 Mice	 were	 culled	 at	 4	 hours	 and	 cytokine	 levels	 in	 lung	 homogenate	 were	determined	by	ELISA.	TNF,	IL1β,	and	IL6	shown	in	panels	A,	B	and	C	respectively.	 	Data	are	shown	as	mean	+/-SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparison	test.	 	
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5.5	Effect	of	macrophage	depletion	on	S.	mitis	strains	This	 series	 of	 experiments	 was	 then	 repeated	 in	 mice	 that	 had	 been	 pre-treated	 with	intranasal	clodronate	to	deplete	AM.	 	After	clodronate,	there	were	no	longer	any	significant	differences	 in	 bacterial	 counts	 between	 strains	 in	 either	 lavage	 fluid	 or	 lung	 homogenate	(figure	5.12).	 	While	it	 is	difficult	to	compare	directly	with	the	liposome	treated	mice,	there	appears	 to	 be	 a	 similar	 order	 of	 bacteria	 found	 in	 lavage	 fluid,	 but	 more	 bacteria	 in	 lung	homogenate	in	clodronate	treated	mice.	 	This	suggests	 increased	invasion	in	the	absence	of	AM,	 though	 the	 effect	 may	 be	 minimised	 because	 of	 the	 high	 inoculum,	 as	 previous	 data	indicates	 that	 the	 role	 of	 the	AM	 is	more	 important	 in	bacterial	 clearance	 in	 low	 inoculum	models	(Dockrell,	Marriott	et	al.	2003).			
Despite	 the	 similarities	 in	 bacterial	 counts,	 again	 TIGR4	 induced	 a	 greater	 leucocytosis	(figure	5.13),	though	S.	mitis	Δcps	counts	also	increased	in	this	system,	suggesting	that	S.	mitis	capsule	 may	 have	 a	 role	 like	 S.	 pneumoniae	 capsule	 in	 inhibiting	 macrophage	 mediated	bacterial	clearance	(Camberlein,	Cohen	et	al.	2015,	Rukke,	Kalluru	et	al.	2014).	
Interestingly,	 macrophage	 depletion	 appeared	 to	 have	 a	 larger	 effect	 on	 lavage	 fluid	cytokines	 in	 the	 S.	 mitis	 strains.	 	 There	 was	 now	 a	 trend	 to	 greater	 TNF	 production	 with	TIGR4	(figure	5.14)	although	differences	were	preserved	for	IL1β	and	IL6	the	magnitudes	of	cytokine	 response	were	 reduced.	 	 This	 reduction	 in	 cytokine	 responses	 has	 been	 noted	 in	other	 clodronate	 experiments	within	 the	 Brown	 laboratory.	 	Within	 lung	 homogenate,	 AM	depletion	had	 little	effect	on	 the	pattern	of	 responses,	 though	 levels	of	TNF	and	 IL1β	were	somewhat	 reduced	 overall	 (figure	 5.15).	 	 A	 direct	 comparison	 of	 the	 liposome	 treated	 and	clodronate	treated	mice	can	be	seen	in	figures	5.16	(CFU	and	neutrophil	counts),	5.17	(BALF	cytokines)	and	5.18	(Lung	homogenate	cytokines).	
These	data	suggest	 that	while	macrophages	are	 important	 in	cytokine	responses	 to	 inhaled	bacteria,	 other	 tissue	 such	 as	 epithelial	 cells	 can	 take	 over	 some	 of	 this	 role.	 	 They	 also	
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suggest	 that	 while	 macrophage	 depletion	 has	 effects	 on	 the	 inflammatory	 response	 to	 S.	
pneumoniae,	there	is	little	effect	in	the	context	of	S.	mitis.	 	
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Figure	 5.12	 Mouse	 lavage	 and	 lung	 homogenate	 bacterial	 counts	 at	 4	 hours	 in	
macrophage	depleted	mice	5	 week	 old	 female	 CD1	 mice	 had	 intranasal	 clodronate	 administered	 72	 hours	 before	intranasal	infection	with	5×106	CFU	bacteria;	either,	S.	mitis	Δcps,	S.	mitis,	S.	mitis	+	TIGR4cps	or	TIGR4.		Mice	were	culled	at	4	hours	and	bronchoalveolar	lavage	and	lung	homogenate	was	obtained	 and	plated	 to	 assess	bacterial	 counts,	 shown	 in	panel	A	 and	B	 respectively.	 	Data	from	 individual	 mice	 and	medians	 values	 are	 presented.	 	 Analysed	 by	 Kruskal-Wallis	 and	Dunn’s	multiple	comparisons	test	with	no	significant	difference	found.		 	
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Figure	 5.13	 Mouse	 bronchoalveolar	 lavage	 cell	 counts	 4	 hours	 after	 infection	 in	
clodronate	treated	mice	5	 week	 old	 female	 CD1	 mice	 had	 intranasal	 clodronate	 administered	 72	 hours	 before	intranasal	infection	with	5×106	CFU	bacteria;	either,	S.	mitis	Δcps,	S.	mitis,	S.	mitis	+	TIGR4cps	or	 TIGR4.	 	 Mice	 were	 culled	 at	 4	 hours	 and	 cell	 count	 and	 neutrophil	 numbers	 in	bronchoalveolar	lavage	fluid	determined	by	haemocytometer	and	cytospin,	shown	in	panel	A	and	 B	 respectively.	 	 Data	 are	 shown	 as	mean	 +/-SEM	 and	 analysed	 by	 1	way	 ANOVA	 and	Tukey’s	multiple	comparisons	test.		 	
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Figure	 5.14	Mouse	 bronchoalveolar	 lavage	 cytokine	 levels	 4	 hours	 after	 infection	 in	
clodronate	treated	mice	5	 week	 old	 female	 CD1	 mice	 had	 intranasal	 clodronate	 administered	 72	 hours	 before	intranasal	infection	with	5×106	CFU	bacteria;	either,	S.	mitis	Δcps,	S.	mitis,	S.	mitis	+	TIGR4cps	or	TIGR4.		Mice	were	culled	at	4	hours	and	cytokine	levels	in	lavage	fluid	were	determined	by	ELISA.		TNF,	IL1β,	and	IL6	shown	in	panels	A,	B	and	C	respectively.		Data	are	shown	as	mean	+/-SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	5.15	Mouse	lung	homogenate	cytokine	levels	4	hours	in	clodronate	treated	mice	5	 week	 old	 CD1	 mice	 had	 intranasal	 clodronate	 administered	 72	 hours	 before	 intranasal	infection	with	5×106	CFU	bacteria;	either,	S.	mitis	Δcps,	S.	mitis,	S.	mitis	+	TIGR4cps	or	TIGR4		Mice	were	culled	after	4	hours	and	cytokine	levels	in	lung	homogenate	were	determined	by	ELISA.	TNF,	IL1β,	and	IL6	shown	in	panels	A,	B	and	C	respectively.		Data	are	shown	as	mean	+/-SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.		 	
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Figure	5.16	Mouse	lavage	&	lung	bacterial	counts,	and	lavage	neutrophil	numbers	after	
infection	in	liposome	or	liposomal	clodronate	treated	mice	These	data	 are	 a	 combination	 of	 figures	 5.8,	 5.9,	 5.12,	 and	5.13.	 	 CFU	data	 from	 individual	mice	and	medians	values	are	presented	and	analysed	by	Dunn’s	multiple	comparisons	 test.		Panel	 C	 shows	BALF	neutrophil	 numbers	 as	 determined	by	 haemocytometer	 and	 cytospin.		Data	 are	 shown	 as	 mean	 +/-SEM	 and	 analysed	 by	 1	 way	 ANOVA	 and	 Tukey’s	 multiple	comparisons	test.			
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Figure	 5.17	Mouse	 bronchoalveolar	 lavage	 cytokine	 levels	 4	 hours	 after	 infection	 in	
liposome	or	liposomal	clodronate	treated	mice	These	data	are	a	combination	of	figures	5.10	&	5.14.		BALF	levels	of	TNF,	IL1β,	and	IL6	shown	in	panels	A,	B	and	C	respectively.	 	Data	are	shown	as	mean	+/-SEM	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	5.18	Mouse	lung	homogenate	cytokine	levels	4	hours	after	infection	in	liposome	
or	liposomal	clodronate	treated	mice	These	data	are	a	combination	of	figures	5.11	&	5.15.	 	Lung	homogenate	levels	of	TNF,	IL1β,	and	IL6	are	shown	in	panels	A,	B	and	C	respectively.	 	Data	are	shown	as	mean	+/-SEM	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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5.6	Chapter	Summary	This	 chapter	 explored	 the	 effect	 of	 the	 capsule	 role	 in	 inflammatory	 response	 in	 other	 S.	
pneumoniae	serotypes,	the	effect	of	capsule	on	a	closely	related	species,	S.	mitis.	and	to	assess	how	 much	 individual	 serotypes’	 capsule	 contributes	 to	 differences	 in	 the	 inflammatory	response.		
The	initial	experiments	suggested	that	the	effect	of	capsule	is	not	restricted	to	TIGR4,	though	serotype	3	with	its	unusual	mucoid	capsule	behaves	differently.	 	Interestingly	the	serotypes	examined	 had	 different	 propensities	 to	 induce	 TLR2	 stimulation,	 but	 the	 unencapsulated	forms	 were	 all	 similar.	 	 This	 suggests	 that	 different	 capsule	 structure	 may	 modify	 how	common	cell	wall	 ligands	 interact	with	host	PRR.	 	The	use	of	capsule	switch	strains,	where	TIGR4	expressed	the	capsule	of	other	serotype,	was	aimed	at	assessing	how	much	capsular	differences	 accounted	 for	 variation	 in	 inflammatory	 responses	 by	 serotype.	 	 However,	 a	detailed	 accounting	 for	 confounding	variables	 such	as	how	capsule	 affects	 adhesion	 to	 and	phagocytosis	by	MDM	was	not	carried	out,	and	could	explain	some	of	the	variation.	
Interestingly	 when	 the	 closest	 relative	 of	 S.	 pneumoniae,	 S.	 mitis,	 is	 examined,	 its	 native	capsule	does	not	consistently	promote	inflammatory	responses	from	MDM	in	vitro.		If	TIGR4	capsule	 was	 expressed	 on	 S.	 mitis,	 there	 was	 no	 increase	 in	 inflammatory	 response,	 if	anything	 there	was	a	 trend	 to	 reduced	 inflammatory	response.	 	Both	 the	native	and	TIGR4	capsule	had	no	obvious	effect	on	TLR2	stimulation.		Intriguingly,	S.	mitis	strains	appeared	to	cause	more	inflammatory	responses	than	TIGR4	from	MDM.		
In	 the	 context	of	mouse	pneumonia,	native	 capsule	has	no	effect	on	 leukocyte	 recruitment,	and	no	significant	effect	in	cytokine	levels	in	lavage	fluid.		The	addition	of	TIGR4	capsule	to	S.	
mitis,	was	not	sufficient	 to	make	 it	as	virulent	as	TIGR4.	 	 	At	4	hours,	despite	having	 fewer	bacteria	 than	 S.	 mitis	 +	 TIGR4cps,	 the	 inflammatory	 cytokine	 response	 was	 convincingly	higher	 in	 response	 to	 TIGR4.	 	 The	 inflammatory	 response	 to	 S.	 mitis	 strains	 compared	 to	TIGR4	 in	 vivo	 was	 in	 the	 opposite	 direction	 to	 that	 of	 MDM	 in	 vitro	 data,	 which	 may	 be	
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explained	 by	 human/murine	 differences,	 or	 more	 likely	 that	 the	 exposure	 of	 bacteria	 to	macrophages	in	vitro	does	not	reflect	the	complexities	of	the	cell-cell	interaction	in	vivo	and	that	greater	changes	 in	bacterial	dynamics	may	play	a	more	 important	 role	 in	 the	cytokine	responses	seen	in	vivo.				
At	4	hours	in	vivo,	in	mouse	pneumonia,	TIGR4	induced	significantly	more	neutrophilia	than	the	S.	mitis	strains.		This	was	accompanied	by	greater	IL1β	and	in	particular	IL6.		This	pattern	was	 preserved	 when	 alveolar	 macrophages	 were	 depleted	 by	 the	 use	 of	 liposomal	clodronate,	though	overall	cytokine	levels	were	marginally	lower.	
In	 general,	 it	may	 be	 expected	 that	 pneumococcal	 capsule	 expression	 on	 S.	mitis	 does	 not	have	 similar	effects	 to	 that	 seen	 in	S.	pneumoniae;	despite	 the	 close	genetic	 ancestry,	 there	are	many	differences	in	protein	expression	that	may	bear	on	inflammation	and	virulence.		As	such,	 if	a	positive	effect	of	TIGR4	capsule	on	S.	mitis	had	been	noted,	 this	would	have	been	strong	evidence	of	its	effect,	but	the	lack	of	effect	merely	confirms	the	phenotypic	difference	between	a	largely	avirulent	bacterium	and	its	pathogenic	cousin.	
In	summary,	the	pro-inflammatory	effect	of	S.	pneumoniae	capsule	largely	persists	for	other	strains.	 	 However,	 differences	 in	 inflammatory	 response	 between	 serotypes	 are	 largely	driven	by	non-capsular	factors.	 	The	capsule	of	S.	mitis	does	not	promote	pro-inflammatory	responses,	and	neither	does	TIGR4	capsule	expressed	on	S.	mitis.			 	
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6	Effects	of	pneumolysin	on	 the	 inflammatory	response	 to	
S.	pneumoniae	Ply	is	a	cytosolic	protein	that	can	localise	to	the	bacterial	cell	wall	and	is	best	known	as	pore-forming	 toxin.	 In	addition	pleiotropic	pro-inflammatory	effects	have	been	described	 for	Ply	(Davis,	 Nakamura	 et	 al.	 2011,	Malley,	 Henneke	 et	 al.	 2003,	Witzenrath,	 Pache	 et	 al.	 2011).		However	many	of	these	effects	were	defined	using	purified	Ply	or	occur	late	during	infection.	For	 this	 work	 I	 have	 investigated	 the	 early	 Ply	 dependent	 effects	 on	 the	 macrophage	inflammatory	 response	 using	 infection	 of	 MDM	 cultures	 with	 wild-type	 and	 Ply	 deficient	bacteria	and	an	in	vivo	model	of	mouse	infection.	
6.1	Haemolysis	assays		Ply	 activity	 is	measure	 by	 ability	 to	 haemolyse	 red	 blood	 cells,	 and	 this	 assay	was	 used	 to	confirm	the	Ply	phenotype	of	the	proteins	and	strains	used	in	this	chapter.		Purified	Ply	(kind	gift	from	Prof	Tim	Mitchell)	induces	significant	haemolysis	down	to	125	ng/ml	(figure	6.1,	A).		Purified	 non-haemolytic	 Ply	 (also	 gift	 from	 Professor	 Tim	 Mitchell)	 with	 an	 amino	 acid	substitution	that	allows	the	toxin	to	be	inserted	into	cholesterol	containing	membranes	but		prevents	oligomerisation	 to	 form	pores,	does	not	 induce	haemolysis	unless	present	at	very	high	 concentrations	 (>5	 µg/ml).	 	 Whole	 bacteria,	 including	 TIGR4	 cause	 haemolysis,	 but	isogenic	 Δply	 strains	 do	 not	 (figure	 6.1,	 B).	 	 Bacterial	 supernatants	 also	 cause	 haemolysis,	indicating	some	liberation	of	Ply	from	S.	pneumoniae	during	normal	log	phase	growth	(figure	6.1	 C).	 Haemolysis	 occurs	 in	 the	 presence	 of	 other	 S.	 pneumoniae	 serotypes	 such	 as	 D39	(figure	6.2,	A),	serotype	3	and	serotype	23F	(figure	6.2,	B)	with	varying	efficacy,	but	not	with	their	isogenic	Δply	strains.	The	ply	complemented	D39	strain	regained	its	haemolytic	ability.		Some	 serotype	 1clinical	 isolates	 express	 a	 variant	 of	 Ply	 that	 is	 non-haemolytic	 (03.3038,		306)	and	some	that	do	not	express	Ply	at	all	(NCTC7465,	ST615)	(figure	6.2,	C).	 	
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Figure	6.1	Haemolysis	assays:	TIGR4	strains	Bacteria	and	pneumolysin	at	different	 concentrations	were	assessed	 for	haemolysis	 ability.		Liberated	 pigments	 from	 haemolysed	 red	 blood	 cells	 were	 measured	 by	 microplate	spectrophotometer.	 	Panel	A	shows	purified	Ply	and	a	non-haemolytic	mutant	Ply.	 	Panel	B	shows	saponin	as	a	positive	control	as	well	as	TIGR4	strains	with	isogenic	strains	deficient	in	capsule	and	Ply.	Panel	C	shows	whole	bacteria	and	supernatant	from	whole	bacteria.	
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Figure	6.2	Haemolysis	assays:	other	serotypes	Haemolysis	assays	with	other	strains,	panel	A)	D39,	panel	B)	serotype	3	and	23F,	panel	C)	1.	 	
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6.2	 Effect	 of	 pneumolysin	 on	 inflammatory	 response	 of	
macrophages	To	assess	 the	effects	of	Ply	on	macrophage	 inflammatory	responses,	MDMs	were	 incubated	with	 the	 TIGR4	 wild-type	 and	 Δply	 strains	 and	 the	 levels	 of	 pro-inflammatory	 cytokines	measured	 in	 the	 culture	 supernatants.	 Surprisingly,	 when	 whole	 TIGR4	 bacteria	 were	incubated	 with	 MDM	 the	 wild-type	 strains	 induced	 less	 inflammatory	 responses	 than	isogenic	 Δply	 bacteria.	 	 This	was	 particularly	 evident	with	 TNF	 and	 IL6,	 especially	 at	 later	timepoints	(figure	6.3)	and	across	a	range	of	multiples	of	infection	(figure	6.4).		However	data	at	24	hours	may	have	been	confounded	by	significant	cell	death	 in	wild-type	 infected	MDM	(figure	 2.1).	 	 These	 data	 suggest	 that	 despite	 the	 large	 body	 of	 literature	 showing	 that	 Ply	induces	 pro-inflammatory	 responses,	 during	 early	macrophage	 infection	with	 live	 bacteria	Ply	might	actively	inhibit	pro-inflammatory	cytokine	responses.	
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Figure	6.3	Timecourse	of	cytokine	response	of	MDM	to	TIGR4	and	Δply	mutant	MDM	were	incubated	with	TIGR4	or	TIGR4Δply	in	tissue	culture	plates,	with	10	bacteria	per	cell.		Supernatant	was	aspirated	at	6	hours	and	later	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6.		The	data	are	presented	as	mean	+/-	SEM,	with	results	from	4	different	donors,	with	results	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	6.4	MDM	cytokine	response	to	varying	numbers	of	bacteria	MDM	 were	 incubated	 with	 TIGR4	 or	 Δcps	 at	 varying	 concentrations;	 from	 0.625	 to	 40	bacteria	per	cell.		After	6	hours,	supernatant	was	removed,	and	later	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6.		The	data	obtained	are	from	3	different	donors,	presented	as	mean	+/-	SEM,	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	
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6.3	 Effects	 of	 pneumolysin	 on	 inflammatory	 response	 of	 epithelial	
cells	Previous	 studies	 have	 indicated	 that	 purified	 Ply	 induces	 epithelial	 cell	 damage	 in	 mouse	pneumonia,	 and	 that	 this	 was	 due	 to	 its	 pore-forming	 ability	 inducing	 an	 inflammatory	response	(Kadioglu,	Taylor	et	al.	2002,	Maus,	Srivastava	et	al.	2004).	 	To	establish	whether	there	was	a	pro-inflammatory	response	to	whole	bacteria	containing	Ply,	I	incubated	TIGR4	wild-type	 and	 Δply	 bacteria	with	 A549	 cells.	 	 The	 presence	 of	 Ply	 did	 not	 affect	 how	well	bacteria	 adhered	 to	 epithelial	 cells	 (figure	 6.5).	 	 As	 shown	 in	 chapter	 4,	 whole	 bacteria	induced	 very	 little	 in	 the	 way	 of	 inflammatory	 cytokine	 response	 with	 no	 significant	difference	between	 the	wild-type	 and	Δply	 strains	 (figure	6.6	 and	 figure	6.7),	 though	 there	was	 a	 trend	 towards	 increased	 CXCL8	 at	 high	 MOI	 with	 wild-type	 compared	 to	 Δply.		Unstimulated	 MDM	media	 induced	 similar	 cytokine	 responses	 to	 conditioned	 media	 from	MDMs	incubated	with	wild-type	TIGR4,	and	the	chemokine	CXCL8	responses	were	similar	for	conditioned	 media	 from	 unstimulated	 MDM	 and	 those	 incubated	 with	 wild	 type	 or	Δply	bacteria.	 	 This	 very	 high	 basal	 release	 of	 CXCL8	 from	MDM	 conditioned	media	may	 be	 an	artefact	 due	 to	 the	 effect	 of	 the	 MDM	 media	 or	 basally	 secreted	 factors	 on	 A549	 cells.	However	 conditioned	media	 from	MDM	 incubated	with	Δply	 induced	greater	TNF	and	 IL6	responses	than	conditioned	media	from	MDM	incubated	with	wild-type	TIGR4	(figure	6.8).			
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Figure	6.5	Adhesion	of	bacteria	to	A549	cells	This	 compares	 the	 number	 of	 TIGR4	 and	 Δply	 adhering	 to	 an	 A549	 cell	 layer	 after	 1	 hour	expressed	as	percentage	of	all	bacteria	present	in	the	well.		A	representative	experiment	of	3	is	shown,	presented	as	mean	+/-SEM,	with	no	significant	differences	by	paired	t	test.		 	
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Figure	6.6	Timecourse	of	cytokine	release	by	A549	alveolar	epithelial	cells	incubated	
with	bacteria	A549	 were	 incubated	 with	 approximately	 1	 bacterium	 per	 cell,	 at	 various	 timepoints	supernatant	was	 analysed	 for	 cytokine	 secretion.	 	 Panel	A	 shows	TNF,	B	 shows	 IL6,	 and	C	shows	CXCL8	 (IL1β	 levels	were	 undetectable).	 	 	 Data	 are	 presented	 as	mean	+/-	 SEM	of	 3	experiments	 and	were	 analysed	 by	 2	 way	 ANOVA	 and	 Tukey’s	multiple	 comparisons	 test,	with	no	significant	differences	noted.		Controls	are	also	shared	with	figure	3.5	 	
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Figure	6.7	Cytokine	release	by	A549	cells	in	response	to	different	numbers	of	bacteria	A549	cells	were	incubated	with	positive	controls	and	varying	multiple	infections	of	TIGR4	or	Δply.	Supernatant	was	analysed	for	cytokines	after	6	hours.		Mean	+/-	SEM	of	3	experiments	shown.	 	Panel	A	 shows	TNF,	B	 shows	 IL6,	 and	C	 shows	CXCL8.	 	There	were	no	differences	between	 wild-type	 and	 Δply	 when	 analysed	 by	 1	 way	 ANOVA	 and	 Tukey’s	 multiple	comparisons	test.	 	
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Figure	6.8	Cytokine	release	by	A549	cells	in	response	to	conditioned	media	from	MDM	A549	 cells	were	 incubated	with	 pooled	 conditioned	media	 from	MDM	 incubated	 TIGR4	 or	Δply	(4	separate	experiments	were	pooled)	at	MOI	10.		The	conditioned	media	was	diluted	1	in	 5	 in	media	 before	 adding	 to	 A549	 cells.	Supernatant	was	 analysed	 for	 cytokines	 after	 6	hours.		Mean	+/-	SEM	of	3	experiments	shown.		Panel	A	shows	TNF,	B	shows	IL6,	and	C	shows	CXCL8.		The	data	was	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	
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6.4	Effects	of	purified	pneumolysin	The	effect	of	purified	Ply	was	measured	to	establish	whether	extracellular	Ply	had	different	effects	 from	cytosolic	Ply	 in	 the	context	of	a	whole	bacterium.	 	Purified	Ply	 induced	a	dose	related	 increase	 in	 pro-inflammatory	 cytokine	 secretion	 from	 MDM	 (figure	 6.9),	 although	cytokine	 release	was	only	 seen	 at	 high	 concentrations	of	 Ply.	 	 This	was	more	 evident	with	high	concentrations	of	non-haemolytic	Ply,	though	this	may	be	due	to	the	cytotoxic	effects	of	very	 high	 concentrations	 of	 purified	 Ply	 causing	 cell	 death;	 in	 these	 experiments	 10μg/ml	caused	 significant	 numbers	 of	 MDM	 to	 become	 non-adherent	 within	 6	 hours	 (data	 not	shown).		The	experiments	were	replicated	in	the	presence	of	polymyxin	B	to	ensure	that	the	inflammatory	responses	were	not	caused	by	contaminating	endotoxin.		There	appeared	to	be	a	significant	effect	of	polymyxin	B	on	the	MDM	TNF	response	to	Ply	and	a	trend	towards	an	effect	 with	 IL6	 (figure	 6.10),	 suggesting	 that	 there	 may	 be	 an	 effect	 of	 endotoxin	contamination	at	high	concentrations	of	Ply	contributing	to	its	inflammatory	effect.		This	was	not	 evident	 in	 CXCL8	 responses,	 and	 a	 trend	 towards	 the	 opposite	 response	 in	 IL1β	suggested	 that	 high	 concentrations	 of	 Ply	 have	 an	 intrinsic	 pro-inflammatory	 effect	 on	 the	inflammasome	 as	 previously	 described	 (McNeela,	 Burke	 et	 al.	 2010).	 	 The	 inflammatory	response	 from	 epithelial	 cells	 was	 again	 limited,	 and	 IL1β	 remained	 undetectable	 (figure	6.11).		 	
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Figure	6.9	Inflammatory	response	to	purified	pneumolysin	Purified	 Ply	 and	 a	 non-haemolytic	 variant	 were	 incubated	 with	 MDM	 at	 various	concentrations	 and	 supernatant	 analysed	 for	 A)	 TNF,	 B)	 IL1β,	 and	 C)	 IL6	 after	 6	 hours.		Results	are	presented	as	mean	+/-	SEM,	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	6.10	Effect	of	polymyxin	B	on	purified	pneumolysin	In	 panels	 A,	 B,	 C,	 and	D	MDM	were	 incubated	with	 purified	 Ply	with	 or	without	 30	 μg/ml	polymyxin	 B	 (PMxB),	 and	 TNF,	 IL1β,	 and	 IL6	 measured	 respectively.	 	 Both	 sets	 of	experiments	 are	 represented	 as	means	 +/-	 SEM	of	 3	 experiments.	 	 Analysis	was	 by	 2	way	ANOVA	and	Tukey’s	multiple	comparisons	test.		
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Figure	6.11	Inflammatory	response	of	epithelial	cells	to	purified	pneumolysin	Purified	 Ply	 and	 a	 non-haemolytic	 variant	 was	 incubated	 with	 A549	 at	 various	concentrations	and	supernatant	analysed	for	A)	TNF,	B)	IL6	and	C)	CXCL8	(IL1β	levels	were	undetectable)	after	6	hours.		Results	are	presented	as	mean	+/-	SEM,	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparison	test.		 	
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6.5	 Effect	 of	 pneumolysin	 on	 S.	 pneumoniae	 survival	 and	
macrophage	internalisation	As	Ply	is	thought	to	be	important	in	virulence,	the	effect	on	bacterial	viability	was	assessed.		As	phagocytosis	is	the	main	mechanism	by	which	S.	pneumoniae	is	killed	by	the	host,	and	this	could	affect	 the	 inflammatory	response,	 the	effect	of	Ply	on	bacterial	phagocytosis	was	also	ascertained.	TIGR4	and	Δply	CFU	in	MDM	supernatant	were	similar,	indicating	similar	growth	in	 media	 and	 rate	 of	 killing	 by	 MDM	 in	 culture	 (figure	 6.12,	 panel	 A).	 	 The	 gentamicin	protection	assay	demonstrated	similar	levels	of	bacterial	adherence	and	uptake	to	MDM	for	both	strains	(figure	6.12,	panel	B),	i.e.	no	differences	in	internalisation.		So	the	differences	in	inflammatory	 response	 between	 the	 strains	were	 not	 explained	 by	 differences	 in	 bacterial	numbers.	 	 This	 was	 supported	 by	 data	 in	 mouse	 AM	 after	 intranasal	 infection	 with	fluorescently	 labelled	 bacteria	 and	 flow	 cytometry	 of	 AM	 in	 recovered	 BALF,	 with	 similar	numbers	of	bacteria	associated	with	cells	4	hours	after	inoculation	(figure	6.12,	panels	C	and	D).	 	
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Figure	6.12	The	effect	of	pneumolysin	on	bacterial	numbers	Bacterial	counts	(CFU/ml)	of	MDM	supernatants	at	6	hours	are	shown	in	panel	A	as	median	+/-	 IQR	of	4	experiments	and	analysed	by	Mann-Whitney	U	 test.	 	Panel	B	shows	growth	of	wild-type	and	mutant	bacteria	(CFU/ml)	in	media	in	tissue	culture	plates	containing	no	cells	as	median	+/-	IQR	of	4	experiments.		These	data	are	analysed	by	Kruskal-Wallis	and	Dunn’s	multiple	comparisons	test.		No	significant	differences	were	noted.		 	
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Figure	6.13	The	effect	of	pneumolysin	on	bacterial	uptake	and	association	Panel	A	shows	numbers	of	bacteria	adherent	and	internalised	in	MDM	after	1	hour,	measured	by	gentamicin	protection	assay,	presented	as	mean	+/-	SEM	of	3	experiments.	 	Panel	B	&	C	show	 recovered	 mouse	 AM	 association	 with	 FAM-SE	 labelled	 bacteria	 after	 4	 hours,	presented	as	mean	+/-	SEM	and	analysed	by	t-test.	 	
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6.6	Effect	of	pneumolysin	in	other	serotypes		To	 ensure	 that	 the	 pro-inflammatory	 effect	 of	 Ply	 on	 MDM	 was	 replicated	 across	 other	serotypes,	MDM	responses	were	assessed	by	3	other	serotypes	along	with	their	isogenic	Ply	deficient	mutants.	 	The	effects	on	TNF,	 IL1β,	and	 IL6	 for	 the	serotype	2,	3,	 and	23F	strains	were	 broadly	 similar	 to	 those	 seen	with	 the	 TIGR4	 stains,	with	 the	Δply	mutants	 causing	increased	TNF	and	IL6	levels	for	all	three	strains	and	increased	IL1β	levels	for	the	serotype	2	and	3	strains	(figure	6.14).	
MDM	 cytokine	 responses	 to	 naturally	 occurring	 non-isogenic	 Ply	 expressing	 and	 deficient	serotype	1	strains	also	suggested	that	Ply	also	dampens	TNF	and	IL6	secretion	in	this	context	(figure	 6.15).	 	 In	 addition	 serotype	 1	 strains	 expressing	 a	 non-haemolytic	 Ply	 caused	 an	intermediate	 phenotype,	 suggesting	 that	 both	 insertion	 of	 Ply	 into	 cell	 membranes	 and	oligomerisation	 to	 form	 pores	 are	 important	 for	 the	 anti-inflammatory	 this	 response	 on	MDMs	(Korchev,	Bashford	et	al,	1998).	
Using	 isogenic	D39	strains,	 these	effects	of	Ply	were	confirmed	(figure	6.16),	with	 the	non-haemolytic	Ply	having	 a	 similar	partial	 phenotype	as	 that	 seen	with	 the	 serotype	1	 clinical	isolates.	 	 In	 addition,	 a	 complemented	 strain	 recapitulated	 the	 effects	 of	 wild-type	 D39,	linking	the	phenotype	directly	to	the	Ply	mutation.	 	
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Figure	 6.14	 MDM	 cytokine	 response	 to	 different	 serotypes	 and	 their	 isogenic	
pneumolysin	deficient	mutants	MDM	were	 incubated	with	4	different	serotypes	and	their	 isogenic	Ply	deficient	mutants	at	MOI	10	 for	6	hours.	 	Supernatants	were	removed	and	analysed	 for	A)	TNF,	B)	 IL1β,	and	C)	IL6.	 	 Data	 are	 presented	 as	mean	 +/-	 SEM.	 	 Results	 were	 analysed	 by	 2	 way	 ANOVA	 and	Tukey’s	multiple	comparisons	test.	
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Figure	6.15	MDM	cytokine	response	to	Serotype	1	strains	MDM	were	 incubated	with	serotype	1	strains	at	MOI	10	for	6	hours.	 	The	3	clinical	 isolates	express	Ply	normally,	express	non-haemolytic	Ply,	or	no	Ply	at	all	respectively.		Supernatants	were	removed	and	analysed	for	A)	TNF,	B)	IL1β,	and	D)	IL6.		Data	are	presented	as	mean	+/-	SEM.		Results	were	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	 6.16	 MDM	 cytokine	 response	 to	 D39,	 D39	 expressing	 no	 pneumolysin,	 D39	
expressing	non-haemolytic	pneumolysin,	and	a	complemented	strain	MDM	were	incubated	with	a	D39	strain,	its	isogenic	Ply	deficient	mutant,	a	mutant	expressing	non-haemolytic	Ply,	 and	a	 complemented	strain	 (i.e.	 the	Ply	gene	has	been	reinserted	after	removal)	 at	MOI	10	 for	6	hours.	 	 Supernatants	were	 removed	and	analysed	 for	A)	TNF,	B)	IL1β,	C)	IL6,	and	D)	CXCL8.		Data	are	presented	as	mean	+/-	SEM.		Results	were	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	
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6.7	Effect	of	capsule	and	pneumolysin	together	on	inflammation	The	data	from	chapter	3	and	6	indicate	that	capsule	is	pro-inflammatory,	and	that	Ply	is	anti-inflammatory.	 	 To	 establish	 if	 these	 two	 components	 affect	 each	 other,	 a	 double	 mutant	lacking	capsule	and	Ply	was	created	and	incubated	with	MDM	to	obtain	supernatant	cytokine	levels.	 	 The	 results	 showed	 that	 the	 effect	 of	 Ply	 deletion	 largely	 eclipsed	 the	 pro-inflammatory	effect	of	capsule	with	similar	levels	of	TNF,	IL6	and	IL1β	in	the	supernatants	of	MDMs	incubated	with	the	Δply	and	ΔcpsΔply	mutant	strains	(figure	6.17).		Similar	changes	were	seen	for	TNF,	IL6	and	IL1β	gene	expression	levels	(figure	6.18).		It	is	not	clear	why	the	difference	between	TIGR4	and	Δcps	 is	not	evident	 in	 this	data	set	(compared	to	 figure	3.3).		Potential	explanations	include	differential	MDM	numbers	and	their	activation	status,	as	well	as	differences	in	individual	host	responses.	 	The	data	are	not	easily	combinable	with	that	of	figure	3.3	with	different	CT	values,	partially	due	to	the	use	of	an	alternative	qPCR	reader	in	this	 experiment	due	 to	 refurbishment	of	 the	 lab.	 	However,	 the	data	does	 support	 that	 the	anti-inflammatory	effects	of	Ply	are	greater	than	the	pro-inflammatory	effects	of	capsule.	 	
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Figure	6.17	MDM	cytokine	response	to	TIGR4,	Δcps,	Δply,	and	ΔcpsΔply	double	mutants	MDM	were	incubated	with	TIGR4,	an	isogenic	capsule	deficient	strain,	a	Ply	deficient	strain,	and	a	mutant	deficient	in	both	capsule	and	Ply.		They	were	incubated	at	MOI	10	for	6	hours.		Supernatants	 were	 removed	 and	 analysed	 for	 A)	 TNF,	 B)	 IL1β,	 and	 D)	 IL6.	 	 Data	 are	presented	as	mean	+/-	SEM.	 	Results	were	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	 6.18	 MDM	 cytokine	 gene	 expression	 in	 response	 to	 TIGR4,	 Δcps,	 Δply,	 and	
ΔcpsΔply	double	mutants	MDM	were	incubated	with	TIGR4,	an	isogenic	capsule	deficient	strain,	a	Ply	deficient	strain,	and	a	mutant	deficient	in	both	capsule	and	Ply.		They	were	incubated	at	MOI	10	for	4	hours.		RNA	was	extracted	from	cell	 lysates	and	analysed	for	A)	TNF,	B)	IL1β,	and	D)	IL6	by	qPCR.		Data	are	presented	as	mean	+/-	SEM.	 	Results	were	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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6.8	Effect	of	pneumolysin	in	mouse	pneumonia		The	mouse	pneumonia	model	was	used	to	establish	whether	the	in	vitro	findings	had	in	vivo	correlates.		By	4	hours	after	intranasal	infection	there	was	a	log10	more	TIGR4	CFU	recovered	from	 BALF	 than	 Δply	 CFU	 (figure	 6.19)	 reflecting	 increased	 virulence.	 	 There	 were	 no	statistically	significant	differences	 in	 lung	homogenate	CFU	at	4	hours,	or	 in	BALF	and	 lung	CFU	at	24	hours	by	which	time	both	strains	bacteria	had	largely	been	cleared.			
At	 4	 hours	 there	 were	 similar	 numbers	 of	 neutrophils	 found	 in	 lavage	 fluid,	 despite	 the	differences	 in	bacterial	numbers	(figure	6.20).	 	By	24	hours	 in	mice	 infected	with	 the	wild-type	TIGR4	there	were	significantly	more	recruited	neutrophils	and	increased	alveolar	leak,	as	measured	by	albumin	concentrations.	 	BALF	TNF	levels	at	4	hours	reflected	 in	vitro	data,	with	significantly	lower	TNF	levels	for	mice	infected	with	the	TIGR4	strain	compared	to	those	infected	 with	 the	 Δply	 strain.	 	 By	 24	 hours	 BALF	 TNF	 levels	 were	 much	 lower	 with	 no	differences	between	mice	infected	with	the	TIGR4	and	Δply	strains	(figure	6.21).	In	contrast	to	the	TNF	data,	BALF	IL1β	levels	at	4	and	24	hours	were	greater	 in	mice	infected	with	the	TIGR4	wild-type	strain	compared	to	those	infected	with	the	Δply	strain.		BALF	IL6	levels	were	not	 significantly	different	between	 the	2	 strains.	 	 Levels	of	TNF	 in	 lung	homogenates	were	much	 lower,	 and	 similar	 between	 the	 2	 strains,	 whereas	 lung	 levels	 of	 IL1β	 were	 much	greater	than	BALF,	with	higher	levels	in	mice	infected	with	Δply	compared	to	those	infected	with	 TIGR4	 the	 strain	 (figure	 6.22),	 opposing	 the	 IL1β	 patterns	 in	 BALF.	 	 Lung	 IL6	 levels	opposed	this	pattern,	with	higher	levels	in	mice	infected	with	the	TIGR4	strain	compared	to	those	 infected	 with	 Δply	 strain	 at	 4	 hours.	 	 Overall,	 these	 data	 suggest	 there	 is	 an	 anti-inflammatory	effect	of	Ply	during	early	lung	infection	with	marked	suppression	of	early	BALF	TNF	responses,	but	that	there	was	also	a	pro-inflammatory	effect	in	increasing	IL1β	in	some	compartments	 compatible	 with	 the	 described	 data	 on	 Ply	 activation	 of	 the	 inflammasome	(McNeela,	Burke	et	al.	2010).	 	
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Figure	6.19	Bacterial	 counts	 in	BALF	and	 lung	homogenate	after	 intranasal	 infection	
with	TIGR	4	or	Δply	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia.		Mice	were	culled	at	specified	timepoints,	bronchoalveolar	lavage	was	performed	(panel	A),	and	lungs	removed	and	homogenised	(panel	B).		Both	were	then	plated	to	 ascertain	 bacterial	 numbers.	 	 There	 were	 6	 mice	 per	 group.	 Data	 presented	 as	 per	individual	mouse	and	medians;	analysed	by	Kruskal-Wallis	and	Dunn’s	multiple	comparisons	test.		 	
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Figure	 6.20	 Neutrophil	 counts	 and	 albumin	 in	 BALF	 after	 intranasal	 infection	 with	
TIGR4	or	Δply	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia.		Mice	were	culled	at	specified	timepoints,	bronchoalveolar	lavage	was	performed	 and	 neutrophil	 numbers	 were	 determined	 (panel	 A),	 as	 well	 as	 albumin	 levels	(panel	B).		There	were	6	mice	per	group.	Data	presented	as	mean	+/-	SEM;	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	6.21	Cytokine	levels	in	BALF	after	intranasal	infection	with	TIGR	4	or	Δply	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia.		Mice	were	culled	at	specified	timepoints,	bronchoalveolar	lavage	was	performed	and	TNF	(panel	A),	IL1β	(panel	B),	and	IL6	(panel	C)	levels	were	measured.		There	were	6	mice	per	group.	Data	are	presented	as	mean	+/-	SEM;	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	6.22	Cytokine	levels	 in	 lung	homogenate	after	 intranasal	 infection	with	TIGR4	
or	Δply	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia.		Mice	were	culled	at	specified	timepoints,	lung	homogenate	retrieved,	and	TNF	(panel	A),	 IL1β	(panel	B),	and	 IL6	(panel	B)	 levels	were	measured.	 	There	were	6	mice	per	group.	Data	are	presented	as	mean	+/-	SEM;	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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6.9	Effects	of	pneumolysin	in	D39	in	mouse	pneumonia	To	ensure	the	effects	of	Ply	 in	vivo	were	not	serotype	specific,	the	mouse	pneumonia	model	was	used	 to	assess	D39,	D39Δply,	 and	complemented	D39.	 	For	 these	strains,	4	hours	after	inoculation	there	were	similar	numbers	of	bacteria	recovered	in	BALF	and	lung	homogenate.		The	 complemented	 D39	 induced	 higher	 BALF	 neutrophil	 infiltrate,	 with	 no	 differences	between	D39	and	D39Δply	strains	(figure	6.25).		Similar	to	the	TIGR4	experiments,	compared	to	the	results	for	D39	there	was	an	increase	in	BALF	TNF	levels	in	mice	infected	with	the	Δply	strain	 and	 lower	 BALF	 IL1β	 levels.	 These	 differences	 were	 lost	 between	 D39	 and	 the	complemented	 Δply	 strain.	 There	 were	 no	 differences	 in	 BALF	 IL6	 levels	 (figure	 6.26)	between	 the	 strains.	 	 There	 were	 no	 significant	 differences	 in	 TNF	 or	 IL1β	 in	 lung	homogenate,	but	complemented	D39	induced	significantly	more	IL6	than	Δply	(figure	6.27).		 	
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Figure	 6.23	 Bacterial	 and	 neutrophil	 counts	 in	 BALF	 and	 bacterial	 numbers	 in	 lung	
homogenate,	and	after	intranasal	infection	with	TIGR4	or	Δply	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia.		Mice	were	culled	at	specified	timepoints,	bronchoalveolar	lavage	was	performed	(panel	A),	and	lungs	removed	(panel	B).	 	Both	were	plated	to	ascertain	bacterial	numbers.	 	 Neutrophil	 numbers	 were	measured	 in	 BALF.	 Data	 presented	 as	 per	 individual	mouse	and	medians;	analysed	by	Kruskal-Wallis	with	Dunn’s	multiple	comparisons	 test	 for	bacterial	counts,	and	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test	for	neutrophil	numbers	(*=p<0.05).	 	
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Figure	 6.24	 Cytokine	 levels	 in	 BALF	 after	 intranasal	 infection	 with	 D39,	 Δply,	 or	
complemented	strain	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	Mice	were	 culled	 at	 specified	 timepoints,	 BALF	 retrieved,	 and	TNF	(panel	A),	 IL1β	(panel	B),	and	 IL6	(panel	C)	 levels	were	measured.	 	There	were	6	mice	per	group.	 Data	 are	 presented	 as	mean	 +/-	 SEM	 and	 analysed	 by	 1	way	 ANOVA	with	 Tukey’s	multiple	comparisons	test.	 	
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Figure	 6.25	 Cytokine	 levels	 in	 lung	 homogenate	 after	 intranasal	 infection	with	 D39,	
Δply,	or	complemented	strain	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia.		Mice	were	culled	at	specified	timepoints,	lung	homogenate	obtained,	and	TNF	(panel	A),	 IL1β	(panel	B),	and	 IL6	(panel	B)	 levels	were	measured.	 	There	were	6	mice	 per	 group.	 Data	 are	 presented	 as	 mean	 +/-	 SEM;	 analysed	 by	 1	 way	 ANOVA	 with	Tukey’s	multiple	comparisons	test.	 	
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6.10	Chapter	Summary	Ply	is	an	important	virulence	factor	in	S.	pneumoniae	pathogenesis	with	pleiotropic	effects	on	the	host	 immune	response.	 	Previous	data	have	 largely	held	 that	Ply	has	pro-inflammatory	effects,	 particularly	 through	 activation	 of	 TLR4,	 the	 inflammasome,	 and	 the	 delivery	 of	bacterial	breakdown	products	to	cytosolic	PRR.	 	Much	of	 these	data	had	been	derived	from	models	using	purified	Ply.	
Purified	Ply	 induced	 significant	 cell	 death	 at	 high	 concentration,	 and	did	 induce	MDM	pro-inflammatory	responses,	albeit	at	quite	high	concentrations	(which	could	be	directly	due	to	the	pore-induced	cell	death),,	in	line	with	other	investigators.		Not	all	of	this	inflammation	can	be	explained	my	contamination	by	endotoxin,	suggesting	high	concentrations	of	purified	Ply	in	the	external	environment	of	cells	are	indeed	pro-inflammatory.	
The	 rest	 of	 the	data	presented	 above,	 using	whole	bacteria	 and	 isogenic	mutants,	 suggests	that	Ply	has	 important	 anti-inflammatory	 effects.	 	Human	macrophages	produced	 less	pro-inflammatory	cytokine	response	to	Ply	containing	wild-type	bacteria	than	Δply.		At	this	same	early	timepoint,	alveolar	epithelial	cells	secrete	little	pro-inflammatory	cytokine	in	response	to	 bacteria,	 but	 conditioned	 media	 from	 macrophages	 indicates	 that	 the	 Ply	 driven	macrophage-phenotype	 increased	 the	 release	 of	 inflammatory	 cytokines	 by	 epithelial	 cells.		The	 most	 contentious	 section	 of	 these	 data	 are	 the	 increased	 IL1β	 levels	 seen	 with	 Δply	strains,	suggesting	that	Ply	inhibits	the	inflammasome.		This	phenomenon	may	be	explained	by	 the	 early	 timepoint,	meaning	 less	 exogenous	Ply	 both	 in	 cell	 culture	 and	 in	 vivo	 so	 less	pore	formation	and	so	less	inflammasome	activation.		The	release	of	IL1β	without	Ply	could	be	explained	by	more	pro-IL1β	synthesis	due	to	other	components	of	the	bacteria,	and	then	inflammasome	activation	by	DAMPs	such	as	ATP,	or	bacterial	DNA	activation	of	AIM.		That	is,	the	 Ply	 does	 not	 inhibit	 the	 inflammasome	 directly,	 rather	 it	 inhibits	 production	 of	 the	inflammasome	 components	 and	 IL1β,	 so	 taking	 longer	 for	 any	K+	 shifts	 due	 to	 Ply-related	pore	formation	to	have	an	effect.	
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Mutation	 of	 ply	 does	 not	 appear	 to	 affect	 rates	 of	 bacterial	 adhesion	 to	 epithelial	 cells,	phagocytosis	by	MDM,	or	growth	rates	 in	cell	culture	supernatant,	suggesting	that	different	bacterial	numbers	between	strains	were	unlikely	to	be	a	confounding	factor.		
The	phenotype	of	increased	inflammatory	responses	by	MDM	to	the	Ply	strain	was	preserved	across	 four	 other	 S.	 pneumoniae	 strains,	 and	 complementation	 replicated	 the	 wild-type	phenotypes.		These	data	suggest	the	differences	seen	were	not	due	to	genetic	manipulation	of	the	bacteria	but	directly	linked	to	the	inflammatory	phenotype.		The	effect	of	non-haemolytic	Ply	 seemed	 to	 be	 half	 that	 of	 haemolytic	 Ply	 suggesting	 that	 the	 pore-forming	 effect	 is	partially	 implicated	 in	 the	 mechanism	 by	 which	 Ply	 alters	 early	 MDM	 inflammatory	responses.	possibly	due	 to	membrane	 insertion	of	Ply	either	singly	or	 in	oligomers	 to	 form	pores.	
Using	a	double	capsule/Ply	deficient	mutant,	I	confirmed	that	capsule	had	little	effect	on	Ply	driven	anti-inflammatory	responses,	and	indeed	the	effect	of	capsule	on	inflammation	was	on	a	much	smaller	scale	than	that	of	Ply.	
In	 an	 in	 vivo	 mouse	 pneumonia	 model	 some	 of	 the	 anti-inflammatory	 effects	 of	 Ply	 were	replicated,	specifically	increases	in	BALF	TNF	levels.	 	TNF	is	the	quickest	cytokine	response	seen	and	important	in	protection	against	S.	pneumoniae	infection.		The	increased	IL1β	levels	in	wild-type	BALF	probably	reflect	 the	pore-forming	effect	of	Ply,	which	may	be	seen	more	quickly	in	vivo	with	more	cell	types	and	tissues	involved	in	host	response.		Similar	data	was	obtained	using	mice	infected	with	the	D39	strains.		 	
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7	 Mechanisms	 of	 anti-inflammatory	 functions	 of	
pneumolysin	Once	 I	had	established	 the	surprising	anti-inflammatory	effects	of	Ply	 in	vitro	 and	 in	vivo,	 I	carried	out	a	series	of	experiments	to	try	and	explore	the	mechanisms	by	which	they	occur.		
7.1	Transcriptional	response	of	monocyte	derived	macrophages		I	 carried	out	whole	 genome	 transcriptional	 analysis	of	MDM	responses	 to	wild-type	TIGR4	and	 Δply	 to	 explore	 potential	 mechanisms	 that	 explain	 the	 differential	 inflammatory	responses	between	the	strains.	 	Again	the	positive	control,	PAM2CSK4	data	was	obtained	by	Gillian	 Tomlinson.	 	 These	 data	were	 obtained	 at	 the	 same	 time	 as	 the	 transcriptional	 data	presented	 in	 chapters	 4.1,	 4.4,	 and	 7.3.	 	 The	 data	 were	 analysed	 by	 T	 tests	 on	MultiExperiment	Viewer	 v	 4.6.0	 and	 significance	was	 set	 at	 p<0.05.	 	 A	 false	 discovery	 rate	was	 not	 used	 as	 the	 number	 of	 biological	 replicates	was	 low	 (3	 to	 6),	 and	 confidence	was	built	 by	 comparison	 to	 historical	 group	 data	 and	 bioinformatic	 analysis	 confirmation	with	other	experimental	data.	
Figure	7.1	shows	all	the	genes	on	the	microarray,	with	relative	expression	values	plotted	for	MDM	 incubated	 with	 TIGR4	 versus	 Δply.	 	 The	 red	 lines	 indicate	 2	 fold	 gene	 changes.	 	 A	relatively	small	proportion	of	genes	were	differentially	expressed	between	MDM	incubated	with	 either	 strain,	 but	 more	 genes	 were	 downregulated	 in	 the	 presence	 of	 Ply	 than	upregulated,	and	to	a	greater	extent.	
A	Venn	diagram	of	upregulated	genes	indicates	that	after	infection	with	TIGR4	or	Δply,	294	or	314	 genes	 respectively	 were	 upregulated	 compared	 to	 unstimulated	 controls	 (figure	 7.2,	panel	A).		102	of	these	genes	were	shared	between	the	two	bacterial	strains.		Figure	7.2	panel	B	 shows	 the	 20	 genes	 that	 were	 most	 overexpressed	 by	 TIGR4	 in	 relation	 to	 Δply,	 with	difference	 log2	 in	gene	expression	displayed.	 	The	most	prominent	genes	 in	this	 list	 include	IL12,	important	in	stimulating	Th1	responses,	as	well	as	genes	stimulated	as	a	consequence	
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of	 interferon	 signalling	 e.g.	 IFIT2,	 CXCL9,	 10	 &	 11.	 	 Pro-inflammatory	 cytokines	 and	chemokines	were	also	upregulated	by	incubation	with	Δply	e.g.	IL6	and	CCL2.	
When	 gene	 upregulation	 was	 ranked	 by	 the	 genes	 most	 upregulated	 by	 wild-type	 TIGR4,	comparison	 of	 the	 top	 20	 upregulated	 genes,	 shows	 that	many	were	more	 upregulated	 by	Δply.	 	 In	 particular,	 pro-inflammatory	 genes	 such	 as	 TNF,	 IL6,	 and	 chemokines	 such	 as	CXCL10	were	all	upregulated	in	the	absence	of	Ply	(figure	7.4).			 	
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Figure	7.1	Transcriptome	Response	of	MDMs	to	TIGR4	and	Δply	The	graph	plots	expression	values	of	all	genes	on	a	microarray	comparing	TIGR4	v	Δply.	 	In	both,	the	red	lines	indicate	2	fold	differences.		Each	gene	on	the	microarray	is	expressed	as	a	data	 point.	 	 Data	 points	 falling	 outside	 these	 lines	 indicate	 significantly	 different	 gene	expression	 between	 TIGR4	 and	 Δply,	 with	 greater	 expression	 after	 incubation	 with	 Δply	above	the	superior	line	and	greater	expression	after	incubation	with	TIGR4	below	the	lower	line.		
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Figure	 7.2	 Comparative	 transcriptome	 response	 of	
MDM	to	TIGR4	and	Δply	–	most	upregulated	genes	Panel	 A	 is	 a	 Venn	 diagram	 showing	 the	 number	 of	 genes	upregulated	by	more	than	2	fold	compared	to	unstimulated	MDM	for	the	two	strains	and	the	positive	 control.	 	 Panel	 B	 shows	 the	 genes	 most	 upregulated	 when	 comparing	 the	 MDM	responses	to	the	Δply	strain	with	TIGR4	directly;	the	values	indicating	log2	of	the	difference	in	expression	values	between	the	conditions.	
Gene	Symbol	 Δply	-	TIGR4	IL12B	 6.00	SERPINB2	 4.06	CCL5	 4.00	CLCF1	 3.79	CCR7	 3.76	RSAD2	 3.73	ISG20	 3.69	IFITM1	 3.68	CXCL10	 3.62	CD38	 3.51	SLAMF1	 3.31	CXCL9	 3.26	CCL2	 3.23	EDN1	 3.20	IL6	 3.14	IFIT2	 3.04	CSF3	 3.02	CXCL11	 3.00	IFI44L	 2.95	LAMP3	 2.93	
Δply	
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Gene	Symbol	 Unstim	 PAM2CSK4	 TIGR4	 Δply	 FC	Δply-TIGR4	TNF	 	 	 	 	 	IL23A	 	 	 	 	 	CXCL2	 	 	 	 	 	IL6	 	 	 	 	 	IL1B	 	 	 	 	 	CCL4	 	 	 	 	 	C11orf96	 	 	 	 	 	CCL20	 	 	 	 	 	CXCL1	 	 	 	 	 	CXCL2	 	 	 	 	 	IL8	 	 	 	 	 	CXCL3	 	 	 	 	 	CSF2	 	 	 	 	 	CCL3L3	 	 	 	 	 	ZFP36L1	 	 	 	 	 	PTX3	 	 	 	 	 	CXCL10	 	 	 	 	 	PTGS2	 	 	 	 	 	G0S2	 	 	 	 	 	IFNG	 	 	 	 	 	
	
Figure	7.3	Comparison	of	genes	upregulated	by	PAM2CSK4,	TIGR4	and	Δply		This	 heat	map	 shows	mean	 relative	 expression	 values	 of	 the	 top	 20	 genes	 upregulated	 by	wild-type	 TIGR4	 when	 compared	 to	 unstimulated	 MDM.	 	 The	 results	 displayed	 are	 from	experiments	of	3	donors.	 	 	The	most	upregulated	genes	are	displayed	as	relative	expression	with	the	most	upregulated	in	red,	and	the	least	upregulated	in	blue.		The	last	column	shows	a	direct	comparison	of	gene	upregulation	of	these	genes	between	TIGR4	and	the	Δply	mutant,	displayed	 as	 log2	 fold	 change	with	 green	 being	 the	most	 upregulated	 genes,	 and	 black	 the	most	downregulated.		
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A	non-biased	principle	component	analysis	of	the	data	shows	that	the	Δply	strain	 induces	a	similar	 pattern	 of	 gene	 transcription	 to	 PAM2CSK4	 by	 PC2	 and	 3	 (as	 previously,	 PC1	segregates	data	by	the	specific	array	used)	(figure	7.4,	panel	A).		As	mentioned	in	chapter	4.1,	PC1	accounts	for	45%	of	variation	seen,	PC2	for	24%,	and	PC3	for	19%.	 	This	suggests	that	Ply	 acts	 to	 inhibit,	 mask,	 or	 counteract	 the	 transcriptional	 response	 to	 bacterial	 TLR2	activation,	in	the	context	of	whole	bacteria.		In	particular	Ply	inhibits	inflammatory	cytokine	transcription,	as	shown	by	the	genes	that	contribute	to	a	negative	deflection	in	PC	3	(figure	7.4,	panel	B).	
oPOSSUM	 bioinformatics	 analysis	 of	 differentially	 upregulated	 genes	 reveals	 that	 the	predicted	transcription	factors	activated	in	response	to	Δply	compared	to	unstimulated	MDM	were	 largely	 from	 the	 NFκB	 family	 (figure	 7.5,	 panel	 A).	 	 In	 addition,	 the	 presence	 of	 Ply	appeared	to	restrict	 the	number	of	pathways	upregulated	by	TIGR4.	 	On	direct	comparison	between	 the	 2	 strains,	 again	 the	 NFκB	 family	 followed	 by	 IRE	were	 the	most	 upregulated	transcription	factors	stimulated	by	Δply	(figure	7.5,	panel	B).			
Innate	DB	software	analysis	of	 the	pathways	most	upregulated	by	Δply	 compared	to	TIGR4	(figure	7.6)	indicated	that	cytokine	and	IFN	signalling	pathways	were	prominent	followed	by	innate	immune	signalling	pathways.			 	
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Figure	 7.4	 Principle	 component	 analysis	 of	 transcriptome	 of	 MDM	 incubated	 with	
TIGR4	or	Δply	The	 transcriptome	 of	 MDM	 exposed	 to	 wild-type,	 TIGR4Δply,	 or	 controls	 for	 4	 hours	 was	analysed	by	non-biased	principle	component	analysis	illustrating	expression	of	co-correlated	genes	 in	 the	 global	 gene	 expression	 profile.	 	 Panel	 A	 shows	 individual	 donor	 scores	 of	principle	components	2	and	3	for	unstimulated	cells,	PAM2CSK4,	TIGR4	and	Δply.		The	top	20	genes	contributing	the	most	towards	the	negative	deflection	of	PC3	are	shown	in	panel	B.		
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Figure	7.5	Bioinformatic	analysis–	transcription	factor	binding	sites	Panel	 A	 shows	 oPOSSUM	 analysis	 of	 the	most	 upregulated	 genes	 in	MDM	when	 incubated	with	TIGR4	or	Δply	 compared	to	unstimulated	cells,	which	predict	 the	 transcription	 factors	activated	in	those	conditions.	 	Z-score	indicating	significantly	overrepresented	transcription	factor	 binding	 sites	 are	 illustrated.	 	 Panel	 B	 shows	 the	 transcription	 factors	 most	differentially	activated	between	wild-type	and	Δply	in	order.			
		 TIGR4	 Δply	Egr1	 	 	ELF5	 	 	ELK1	 	 	EWSR1-FLI1	 	 	FEV	 	 	GABPA	 	 	HIF1A::ARNT	 	 	IRF1	 	 	IRF2	 	 	Klf4	 	 	MZF1_1-4	 	 	MZF1_5-13	 	 	NF-kappaB	 	 	NFKB1	 	 	NFYA	 	 	NHLH1	 	 	PAX4	 	 	REL	 	 	RELA	 	 	RUNX1	 	 	Sox2	 	 	SP1	 	 	SPI1	 	 	SPIB	 	 	Tcfcp2l1	 	 	TP53	 	 	Zfp423	 	 	ZNF354C	 	 	
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Figure	7.6	Bioinformatic	analysis	of	transcriptome		This	 shows	 the	 10	 most	 significantly	 overrepresented	 pathways	 analysis	 by	 innateDB	software.	 	This	shows	the	pathways	predicted	to	be	activated	by	analysing	clusters	of	genes	more	expressed	in	one	group	than	the	other.	 	This	list	shows	the	top	pathways	significantly	overrepresented	by	incubation	with	Δply	over	incubation	with	wild-type.			
	
	 	
Δply	–	TIGR4	 p	value	Cytokine	signalling	in	immune	system	 5.28-23	Cytokine-cytokine	receptor	interaction	 1.72-19	Interferon	alpha/beta	signalling	 9.41-17	Interferon	signalling	 3.98-17	Immune	system	 1.19-16	Interferon	gamma	signalling	 6.66-11	JAK	STAT	pathway	and	regulation	 7.10-10	Toll-like	receptor	signalling	pathway	 4.72-9	Jak-STAT	signalling	pathway		 1.93-7	IL23-mediated	signalling	events	 1.79-7	
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7.2	 Effect	 of	 opsonisation	 and	 phagocytosis	 on	 the	 inflammatory	
response	to	pneumolysin	The	 effect	 of	 bacterial	 opsonisation	 and	 uptake	 by	 macrophages	 on	 the	 differential	inflammatory	 response	 to	 wild-type	 S.	 pneumoniae	 and	 Δply	 was	 investigated.	 	 Pre-opsonisation	of	bacteria	in	human	serum,	which	would	serve	to	increase	engagement	with	Fc	receptors	as	well	as	increase	bacterial	uptake,	caused	a	reduction	in	TNF	responses	to	wild-type	and	Δply	(figure	7.7).	 	 	There	was	a	trend	to	reduction	in	IL6,	but	a	trend	to	 increased	IL1β.	 	 Pre-incubation	 of	 MDM	 with	 cytochalasin	 D	 interestingly	 increased	 TNF	 and	 IL6	responses	from	wild-type	bacteria,	but	decreased	the	same	cytokines	with	Δply	(figure	7.8)	at	least	partially	abrogating	the	differences	between	the	2	strains.	These	data	suggest	that	the	effect	of	Ply	on	pro-inflammatory	cytokine	release	is	dependent	on	bacterial	uptake.	 	
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Figure	7.7	Effect	of	opsonisation	on	inflammatory	response	Bacteria	were	opsonised	in	pooled	human	serum	for	30	minutes	before	being	diluted	to	the	required	concentration	and	added	to	MDM.		Analysis	from	3	experiments	with	supernatants	6	hours	after	infection	are	shown	as	mean	+/-	SEM.	 	Panel	A	is	TNF,	B	is	IL1β,	and	C	is	IL6.		Statistical	 analysis	was	with	 2	way	 ANOVA	 and	 Tukey’s	multiple	 comparisons	 test.	 	 These	experiments	were	run	at	the	same	time	as	figure	4.9.	
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Figure	7.8	Effects	of	inhibiting	phagocytosis	on	the	inflammatory	response	MDM	were	 incubated	with	controls	or	bacteria	at	MOI	10,	and	supernatants	were	analysed	for	A)	TNF,	B)	IL1β,	and	C)	IL6	after	6	hours.	 	The	presented	results	are	mean	+/-	SEM	of	3	experiments,	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	
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7.3	Effect	of	inhibiting	phagocytosis	on	transcriptional	response	As	 the	 data	 above	 indicated	 that	 phagocytosis	 was	 key	 to	 the	 effects	 on	 inflammatory	cytokine	 release,	 the	effect	of	phagocytosis	 inhibition	on	 the	 response	 to	wild-type	and	Ply	deficient	 bacteria	 was	 explored	 by	 whole	 genome	 transcription	 analysis.	 	 MDM	 were	incubated	 with	 either	 media	 or	 10μM	 cytochalasin	 D	 for	 an	 hour	 prior	 to	 the	 addition	 of	bacteria.		These	data	were	obtained	at	the	same	time	as	the	transcriptional	data	presented	in	chapters	4.1,	4.4,	and	7.1.	
The	number	of	genes	 that	were	upregulated	after	4	hours	by	more	 than	2	 fold	due	 to	Δply	was	reduced	by	the	addition	of	cytochalasin	D	(figure	7.9	panel	A).		In	addition	the	number	of	genes	differentially	expressed	between	wild-type	and	Δply	was	reduced	when	both	were	 in	the	presence	of	cytochalasin	D	(figure	7.9,	panel	B).		Heat	map	representation	(ranked	by	the	most	expressed	genes	induced	by	TIGR4	over	unstimulated	controls)	suggests	that	inhibition	of	phagocytosis	greatly	inhibited	the	transcriptional	response	to	Δply,	whereas	there	was	an	increase	in	responses	to	wild-type	TIGR4	(figure	7.10).		In	a	direct	comparison	of	MDM	genes	expression	 between	 Δply	 and	 TIGR4	 in	 the	 presence	 of	 cytochalasin	 D,	 inhibition	 of	phagocytosis	considerably	reduced	the	difference	between	the	2	strains	(figure	7.11).	 	
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Figure	7.9	Gene	expression	of	MDM	by	genome	wide	analysis	Relative	gene	expression	is	plotted	by	condition	for	all	genes	on	a	microarray.		The	mean	of	3	experiments	 for	each	condition	 is	plotted.	 	Panel	A	plots	 the	effect	of	cytochalasin	D	on	the	Δply	 strain,	and	panel	B	compares	TIGR4	v	Δply	once	phagocytosis	had	been	 inhibited	with	cytochalasin	D.		The	red	lines	indicated	log2	of	2	fold	differences	in	expression		
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Gene	Symbol	 Unstim	 TIGR4	 Δply	 T4	+	cyt	D	 Δply	+	cyt	D	TNF	 	 	 	 	 	IL23A	 	 	 	 	 	CXCL2	 	 	 	 	 	IL6	 	 	 	 	 	IL1B	 	 	 	 	 	CCL4	 	 	 	 	 	C11orf96	 	 	 	 	 	CCL20	 	 	 	 	 	CXCL1	 	 	 	 	 	CXCL2	 	 	 	 	 	IL8	 	 	 	 	 	CXCL3	 	 	 	 	 	CSF2	 	 	 	 	 	CCL3L3	 	 	 	 	 	ZFP36L1	 	 	 	 	 	PTX3	 	 	 	 	 	CXCL10	 	 	 	 	 	PTGS2	 	 	 	 	 	G0S2	 	 	 	 	 	IFNG	 	 	 	 	 		
	
Figure	7.10	Heat	map	of	gene	expression	of	top	20	genes	upregulated	byTIGR4	Mean	 gene	 expression	 of	 MDM	 incubated	 with	 TIGR4	 or	 Δply	 (3	 donors	 each),	 with	 least	expressed	 in	blue,	and	most	expressed	 in	red.	 	Gene	order	by	most	upregulated	genes	with	TIGR4	 compared	 to	 unstimulated.	 	 In	 the	 relevant	 experiments,	 MDM	were	 pre-incubated	with	 10μM	 cytochalasin	 D	 for	 30	 minutes,	 which	 was	 washed	 off,	 before	 the	 addition	 of	bacteria	at	MOI	10.		 	
6	 	 	 	 	 	 	 													16	
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Gene	Symbol	 FC	 Δply	 -	TIGR4	 FC	Δply	-	Δply	+	cyt	D	 FC	Δply	+	 cyt	D	-	T4	+	cyt	D	TNF	 	 	 	IL23A	 	 	 	CXCL2	 	 	 	IL6	 	 	 	IL1B	 	 	 	CCL4	 	 	 	C11orf96	 	 	 	CCL20	 	 	 	CXCL1	 	 	 	CXCL2	 	 	 	IL8	 	 	 	CXCL3	 	 	 	CSF2	 	 	 	CCL3L3	 	 	 	ZFP36L1	 	 	 	PTX3	 	 	 	CXCL10	 	 	 	PTGS2	 	 	 	G0S2	 	 	 	IFNG	 	 	 		
	
Figure	 7.11	 Fold	 change	 in	 relative	 gene	 expression	 of	 top	 20	 upregulated	 genes	 by	
TIGR4	Heat	map	of	relative	differences	in	expression	between	MDM	incubated	with	TIGR4	or	Δply	+/-	 pre-incubation	 with	 cytochalasin	 D.	 	 Values	 expressed	 as	 log2	 differences	 in	 gene	expression,	 colour	 coded	 such	 that	 the	 most	 upregulated	 are	 in	 green,	 and	 most	downregulated	in	black.		Mean	of	3	experiments	displayed.		
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7.4	Effect	of	pneumolysin	on	MAPK	signalling	Western	blotting	of	important	components	of	MAPK	signalling	was	used	to	assess	differences	in	signalling	activation	in	MDM	as	a	consequence	of	Ply.		There	did	seem	to	be	differences	in	signalling	cascades	activated,	as	Δply	appeared	to	induce	greater	phosphorylation	of	p38	and	to	 a	 lesser	 extent	 ERK	 (figure	 7.12	 &	 7.13).	 	 Whereas	 JNK	 phosphorylation	 was	 broadly	similar	between	the	MDM	incubated	with	either	strain.		This	suggests	that	Ply	may	selectively	inhibit	some	pro-inflammatory	pathways	that	are	triggered	by	specific	MAPK	cascades.	 	
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Figure	7.12	Western	blot	of	MDM	for	MAPK	Western	blot	of	4	pooled	MDM	lysates	with	TIGR4	or	Δply,	with	zymosan	as	a	positive	control	and	 media	 only	 as	 an	 unstimulated	 negative	 control.	 	 Lysates	 were	 probed	 for	 phospho-MAPK	 and	 GAPDH	 was	 used	 as	 a	 loading	 control.	 	 A	 representative	 immunoblot	 of	 2	replicates	 is	 shown.	 	These	experiments	were	run	at	 the	same	 time	as	 those	 in	 figure	4.20,	though	the	Western	blots	were	run	separately.		
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Figure	7.13	Quantification	of	Western	blots	Western	 blots	 from	 figure	 7.13	 were	 quantified	 by	 Imagequant	 and	 presented	 as	 relative	density	normalised	to	GAPDH.		A)	phospho-p38,	B)	phospho–JNK,	and	C)	phospho-ERK.	 	
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7.5	Effect	of	pneumolysin	on	transcription	factors	As	NFκB	is	central	to	how	multiple	PRR	and	cytokine-receptor	interaction	pathways	impact	on	 the	 regulation	 of	 pro-inflammatory	 cytokine	 transcription,	 the	 translocation	 of	NFκB	 to	the	nucleus	was	measured	as	a	marker	of	activation	in	MDM.	This	was	measured	using	high	throughput	microscopy	techniques	and	analysed	on	software	to	look	at	the	intensity	of	NFκB	protein	in	nucleus	compared	to	cytoplasm.	
NFκB	translocation	was	greater	at	both	1	and	2	hours	when	MDM	were	incubated	with	Δply	in	 comparison	 to	 TIGR4	 (figure	 7.14	 &	 7.15).	 	 This	 indicates	 that	 the	 presence	 of	 Ply	significantly	 decreases	NFκB	 activation.	 	 As	 previous	 investigators	 have	 suggested	 that	 Ply	engages	with	 TLR4	 (Malley,	 Henneke	 et	 al.	 2003),	 I	 also	 looked	 at	 the	 transcription	 factor	IRF3,	 which	 is	 activated	 by	 phagolysosomal	 TLR4	 activation	 (Moynagh	 2005).	 	 IRF3	translocated	into	the	nucleus	significantly	more	in	MDM	incubated	with	TIGR4	than	Δply	at	1	hour	(though	they	were	similar	by	2	hours)	possibly	indicating	that	phagolysosomal	release	of	Ply	may	engage	with	TLR4,	which	could	conceivably	inhibit	pathways	that	activate	NFκB.	 	
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Figure	7.14	Nuclear:	Cytoplasm	ratio	of	NFκB	in	MDM	after	stimulation	with	bacteria	
or	controls			Panels	A	&	B	show	the	ratio	of	NFκB	between	the	nucleus	and	cytoplasm	in	MDM,	with	the	data	 from	3	different	donors	at	1	and	2	hours	respectively,	analysed	by	1	way	ANOVA,	and	Tukey’s	multiple	comparisons	test.			These	experiments	were	run	at	the	same	time	as	those	in	figure	4.16.	 	
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Figure	7.15	NFκB	translocation	Microscopy	 images	 of	 high	 throughput	 optical	 96	 well	 plates	 with	 MDM	 incubated	 with	bacteria.		Panel	A	(unstimulated),	B	(TIGR4	1	hour),	C	(TIGR4	2	hours),	D	(Δply	1	hour),	and	E	(Δply	2	hours)	are	representative	images	of	MDM.		Here	the	nucleus	is	DAPI	stained,	in	blue,	and	NFκB	is	in	green.		 	
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Figure	7.16	Nuclear:	Cytoplasm	ratio	of	IRF3	in	MDM	after	stimulation	with	bacteria	or	
controls			Panels	A	&	B	show	the	ratio	of	 IRF3	between	 the	nucleus	and	cytoplasm	 in	MDM,	with	 the	data	 from	 3	 different	 donors	 at	 1	 and	 2	 hours	 respectively	 shown	 as	 mean	 +/-SEM,	 and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.		
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Figure	7.17	IRF3	translocation	Microscopy	 images	 of	 high	 throughput	 optical	 96	 well	 plates	 with	 MDM	 incubated	 with	bacteria.		Panel	A	(Unstimulated),	B	(LPS),	C	(TIGR4),	and	D	(Δply)	are	representative	images	of	MDM	after	1	hour.		Here	the	nucleus	is	DAPI	stained,	in	blue,	and	IRF3	is	in	red.		
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7.6	 Effect	 of	 pneumolysin	 on	 apoptosis,	 inflammasome	 and	 TLR4	
mediated	signalling	Other	 authors	 have	 shown	 that	 Ply	 has	 multiple	 effects	 on	 inflammatory	 pathways,	 pre-eminent	 amongst	 these	 are	 induction	 of	 apoptosis	 (Marriott,	 Ali	 et	 al.	 2004),	 activation	 of	inflammasome	 pathways	 (McNeela,	 Burke	 et	 al.	 2010),	 and	 interaction	with	 TLR4	 (Malley,	Henneke	 et	 al.	 2003).	 	 	 By	 24	hours,	 incubation	with	 live	wild-type	TIGR4	 (or	 the	 positive	control	staurosporin)	induces	nuclear	condensation,	but	Δply	strains	do	not,	confirming	that	Ply	 is	 involved	 in	 inducing	macrophage	apoptosis	 (figure	7.18,	panel	A),	but	at	6	hours	 the	differences	between	the	strains	were	not	significant	(figure	7.18,	panel	B).		This	indicates	that	apoptosis	 is	 not	 morphologically	 evident	 at	 6	 hours,	 analagous	 to	 the	 early	 stages	 	 of	infection.		However	this	does	not	exclude	pathways	upstream	of	apoptosis	being	involved	in	cross	talk	with	inflammatory	pathways.	
To	 explore	 specific	 pathways	 in	 the	 in	 vitro	 model	 of	 human	 MDM	 responses	 to	 S.	
pneumoniae,	 specific	 inhibitors	 were	 employed.	 	 ZVAD-FMK	 (Invivogen),	 a	 pan	 caspase	inhibitor	and	so	 inhibitor	of	apoptosis,	did	not	affect	 inflammatory	cytokine	release	 (figure	7.19)	 suggesting	 Ply-dependent	 inhibition	 of	 inflammation	 does	 not	 depend	 on	 increasing	apoptosis.	 	 Similarly,	 YVAD-FMK	 (Invivogen),	 a	 caspase	 1	 inhibitor	 that	 inhibits	 the	inflammasome	reduced	IL1β	release	due	to	LPS	and	calcium	pyrophosphate	crystals,	but	had	no	impact	on	the	release	of	pro-inflammatory	cytokines	induced	by	TIGR4,	irrespective	of	the	presence	of	Ply	(figure	7.20).	
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Figure	7.18	MDM	apoptosis	after	incubation	with	bacteria	MDM	in	optical	plates	were	incubated	with	controls	or	bacteria	at	MOI	10	for	24	(panel	A)	or	6	hours	(panel	B).		Cells	were	fixed	and	stained	with	DAPI	to	assess	nuclei.		Nuclear	area	was	used	as	a	proxy	 for	apoptosis	mediated	nuclear	condensation.	 	Data	are	presented	as	mean	+/-SEM	of	3	experiments,	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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Figure	7.19	MDM	cytokine	response	after	apoptosis	inhibition	MDM	were	 incubated	with	20μM	ZVAD	FMK,	 a	pan	 caspase	 inhibitor,	 or	media	 for	1	hour,	then	bacteria	or	controls	were	added.		Supernatants	were	removed	at	6	hours	and	analysed	for	pro-inflammatory	cytokine	levels.		Data	are	presented	as	mean	+/-	SEM	of	3	experiments	and	 analysed	 by	 2	way	 ANOVA	 and	 Tukey’s	multiple	 comparisons	 test	with	 no	 significant	differences	seen.	 	
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Figure	7.20	MDM	cytokine	response	after	inflammasome	inhibition	MDM	were	incubated	with	50μM	YVAD	FMK,	a	caspase	1	inhibitor,	or	media	for	1	hour,	then	bacteria	or	 controls	were	added.	 	 Supernatants	were	 removed	at	6	hours	 and	analysed	 for	pro-inflammatory	cytokine	levels.	Data	are	presented	as	mean	+/-	SEM	of	3	experiments	and	analysed	 by	 2	 way	 ANOVA	 with	 Tukey’s	 multiple	 comparisons	 test,	 with	 no	 significant	differences	seen.	 	
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As	 data	 from	 transcription	 factor	 translocation	 indicated	 that	 IRF3	 was	 more	 rapidly	activated	by	the	Ply	containing	wild-type	strain,	and	this	pathway	is	stimulated	by	lysosomal	TLR4	activation,	potential	 crosstalk	between	 these	pathways	was	 investigated.	 	TBK1	 is	 an	adaptor	 protein	 that	 is	 an	 important	 intermediary	 between	 TLR4	 activation	 and	 IRF3	activation.		A	small	molecule	inhibitor	BX795	(Invivogen)	was	used	to	inhibit	TBK1,	to	see	if	this	would	increase	the	inflammatory	response	to	wild-type	TIGR4.			BX795	slightly	reduced	IFNβ,	 and	 significantly	 reduced	 CXCL10,	 which	 is	 induced	 by	 interferon	 signalling	 (figure	7.21).		However,	MDM	secretion	of	pro-inflammatory	cytokines	was	not	affected,	in	particular	the	response	 to	wild-type	TIGR4	was	not	decreased	by	BX795	(figure	7.22).	 	 	Similarly,	 the	converse	 approach	 of	 addition	 of	 poly	 I:C	 (Invivogen),	 a	 TLR3	 agonist	 that	 also	 stimulates	TRIF-mediated	 signalling	 cascades	 that	 act	 via	 TBK1	 to	 stimulate	 IRF3,	 did	 not	 reduce	 the	inflammatory	response	to	Δply	bacteria	(figure	7.23).		Interpretation	of	this	experiment	may	have	been	confounded	by	the	direct	pro-inflammatory	properties	of	poly	I:C.	
As	data	from	S.	pneumoniae	expressing	non-haemolytic	Ply	suggested	that	the	pore-forming	functions	 of	 Ply	 were	 at	 least	 partially	 involved	 in	 inhibiting	 the	 inflammatory	 response,	inhibition	of	voltage	gated	calcium	channels	was	performed	with	SKF96365	(Sigma	Aldrich,	Gillingham).	 	Blockade	of	these	channels	 inhibits	the	early	membrane	depolarisation	effects	of	 Ply,	 and	 if	 Ply	 insertion	 into	 membrane	 was	 involved	 in	 inhibiting	 the	 inflammatory	response,	 SKF96365	 would	 be	 expected	 to	 increase	 the	 MDM	 inflammatory	 cytokine	response	 to	 wild-type	 bacteria.	 	 However,	 there	 was	 a	 trend	 to	 reduced	 inflammatory	cytokine	release	across	all	strains	(figure	7.24).	 	
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Figure	7.21	MDM	IFN	response	to	TBK1	inhibitor	MDM	 were	 incubated	 with	 1μM	 BX-795,	 a	 TBK1	 inhibitor,	 or	 media,	 then	 bacteria	 and	controls	were	added	and	supernatant	removed	after	6	hours.		These	were	analysed	for	IFNβ	(panel	 A)	 and	 CXCL10	 (panel	 B),	 which	 are	 downstream	 of	 TBK1.	 	 Mean	 +/-	 SEM	 of	 3	experiments	 are	 shown.	 	 Results	 were	 analysed	 by	 2	 way	 ANOVA	 and	 Tukey’s	 multiple	comparisons	test.	 	
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Figure	7.22	MDM	cytokine	response	to	TBK1	inhibitor	MDM	were	incubated	with	1μM	BX-795,	a	TBK1	inhibitor,	or	media	for	1	hour,	then	bacteria	and	controls	were	added	and	supernatant	removed	after	6	hours.	 	These	were	analysed	for	pro-inflammatory	 cytokines.	 	 Data	 are	 presented	 as	 mean	 +/-	 SEM	 of	 3	 experiments	 and	analysed	 by	 2	 was	 ANOVA	 and	 Tukey’s	 multiple	 comparisons	 test,	 with	 no	 significant	differences	seen.	
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Figure	7.23	MDM	cytokine	response	after	the	addition	of	Poly	I:C	MDM	 were	 incubated	 with	 bacteria	 or	 controls	 +/-	 10μg/ml	 poly	 I:C	 (Invivogen)	 and	supernatant	 removed	 after	 6	 hours.	 	 These	were	 analysed	 for	 pro-inflammatory	 cytokines.		Data	are	presented	as	mean	+/-	SEM	of	3	experiments	and	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparisons	test	with	no	significant	differences	seen.	 	
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Figure	7.24	MDM	cytokine	response	after	voltage	gated	calcium	channel	blocker	MDM	 were	 incubated	 with	 40μM	 SKF96365,	 a	 voltage	 gated	 calcium	 channel	 blocker,	 or	media	 for	1	hour,	 then	bacteria	and	controls	were	added	and	supernatant	 removed	after	6	hours.		These	were	analysed	for	pro-inflammatory	cytokines.		Mean	+/-	SEM	of	3	experiments	are	shown.		Data	were	analysed	by	2	way	ANOVA	and	Tukey’s	multiple	comparisons	test.		 	
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7.7	Effects	of	TNF	blockade	on	pneumolysin	in	mouse	pneumonia	In	 the	 murine	 intranasal	 infection	 model,	 wild-type	 TIGR4	 reduced	 TNF	 secretion	 in	 the	bronchoalveolar	compartment	in	comparison	to	Δply.		To	see	if	this	reduction	in	TNF	release	had	 physiological	 effects,	 TNF	 activity	 was	 inhibited	 in	 the	 bronchoalveolar	 compartment	with	a	neutralising	antibody	(Biolegend).		The	antibody	was	administered	intranasally	at	the	same	time	as	bacteria	to	only	inhibit	TNF	secreted	locally	as	a	result	of	bacterial	infection.			
Bacterial	counts	in	BALF	show	that	TNF	inhibition	abrogated	the	difference	between	TIGR4	and	 Δply	 (figure	 7.25),	 suggesting	 Ply	 mediated	 reduction	 of	 early	 TNF	 release	 in	 the	bronchoalveolar	 compartment	 is	 important	 in	 controlling	 bacterial	 numbers.	 	 This	abrogation	of	difference	was	also	seen	in	neutrophil	counts	(figure	7.25,	panel	C).			
Cytokines	in	BALF	show	that	TNF	blockade	had	little	effect	on	IL1β,	but	that	it	may	attenuate	the	difference	in	IL6	between	the	strains,	though	this	was	not	statistically	significant	(figure	7.26).	 	 Interestingly	 TNF	 blockade	 reduced	 the	 Ply	 dependent	 release	 of	 IL1β	 in	 lung	homogenate	 (figure	 7.27).	 	 Similarly,	 there	was	 a	 reduction	 in	 Ply	 dependent	 TNF	 and	 IL6	release	in	this	compartment	suggesting	that	the	other	cytokines	may	compensate	somewhat	for	Ply	mediated	TNF	inhibition.	 	
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Figure	7.25	 	Bacterial	 counts	 at	 4	 hours	 in	mouse	pneumonia	with	 and	without	TNF	
blocking	antibody	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia,	mixed	with	either	20μg	TNF	blocking	antibody	(Biolegend)	or	isotype	control	 (Biolegend).	 	BALF	and	 lung	homogenates	were	obtained	after	4	hours	with	6	mice	per	group.	 	CFU	are	presented	as	 individual	mouse	results	with	medians	 in	BALF	(panel	A)	and	 lung	 homogenate	 (panel	 B)	 and	 analysed	 by	 Kruskal-Wallis	 with	 Dunn’s	 multiple	comparison	test.	 	Neutrophil	counts	are	presented	as	mean	+/-	SEM	and	analysed	by	2	way	ANOVA	with	Tukey’s	multiple	comparisons	test.		 	
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Figure	7.26	Cytokines	in	BALF		with	TNF	blockade	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	 The	 cytokine	 levels	 in	 lavage	 fluid	 of	 the	 mice	 at	 4	 hours	 were	measured	by	ELISA.	 	Three	were	6	mice	per	group,	 and	 results	 are	presented	as	mean	+/-	SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	
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Figure	7.27	Cytokines	in	lung	homogenate	with	TNF	blockade		5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	 The	 cytokine	 levels	 in	 lavage	 fluid	 of	 the	 mice	 at	 4	 hours	 were	measured	by	ELISA.	 	Three	were	6	mice	per	group,	 and	 results	 are	presented	as	mean	+/-	SEM	and	analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.		
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7.8	Early	timepoint	mouse	pneumonia	As	the	neutrophil	infiltrate	was	similar	between	the	2	strains	at	4	hours,	an	earlier	timepoint	was	 assessed	 to	 ascertain	 whether	 the	 Δply	 strain	 caused	 more	 early	 inflammation,	potentially	facilitating	early	neutrophil	ingress	and	bacterial	clearance.		By	2	hours	there	was	already	a	small	but	significant	difference	in	bacterial	numbers	in	BALF,	with	greater	numbers	seen	with	the	wild-type	(figure	7.28).		There	were	significantly	more	neutrophils	recruited	in	response	 to	 the	 Δply	 strain	 by	 this	 stage.	 	 Cytokine	 levels	 were	 not	 significantly	 different	between	 the	 strains	 (figure	 7.29),	 though	 the	 trends	 replicated	 those	 seen	 by	 the	 4	 hour	timepoint	with	wild-type	inducing	lower	BALF	TNF	and	greater	IL1β	levels.		 	
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Figure	 7.28	 Bacterial	 and	 neutrophil	 counts	 in	 BALF	 and	 bacterial	 numbers	 in	 lung	
homogenate,	and	after	intranasal	infection	with	TIGR	4	or	Δply	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	 anaesthesia.	 	 Mice	 were	 culled	 after	 2	 hours,	 bronchoalveolar	 lavage	 was	performed	(panel	A),	and	lungs	removed	(panel	B).	 	Both	were	plated	to	ascertain	bacterial	numbers.	 	 Neutrophil	 numbers	 were	measured	 in	 BALF.	 Data	 presented	 as	 per	 individual	mouse	 and	medians;	 analysed	by	Mann	Whitney	 test	 for	 bacterial	 counts,	 and	by	 t-test	 for	neutrophil	numbers.	 	
	 324	
TIGR4 Δply0
2000
4000
6000
8000
TNF	(p
g/ml)
TIGR4 Δply0
50
100
150
200
IL1β	(p
g/ml)
TIGR4 Δply0
200
400
600
IL6	(pg
/ml)
TIGR4 Δply0
1000
2000
3000
TNF	(p
g/ml)
TIGR4 Δply0
500
1000
1500
IL1β	(p
g/ml)
TIGR4 Δply0
500
1000
1500
2000
IL6	(pg
/ml)
A B
C D
E F
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 7.29	 Cytokine	 levels	 in	 BALF	 or	 lung	 homogenate	 2	 hours	 after	 intranasal	
infection	with	TIGR4	or	Δply	5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia.		Mice	were	culled	after	2	hours.		BALF	was	obtained,	and	TNF	(panel	A),	 IL1β	 (panel	 C),	 and	 IL6	 (panel	 E)	 levels	were	measured.	 	 TNF,	 IL1β,	 and	 IL6	were	 also	measured	 in	 lung	 homogenate	 (panels	 B,	 D,	 and	 F	 respectively).	 	 There	 were	 6	 mice	 per	group.	Data	are	presented	as	mean	+/-	SEM	and	analysed	by	paired	t-test	with	no	significant	differences	seen.	 	
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7.9	 Effects	 of	 neutrophil	 depletion	 on	 pneumolysin	 in	 mouse	
pneumonia	As	 there	 was	 a	 rapid	 neutrophil	 influx	 into	 BALF	 at	 2	 hours	 after	 infection	 with	 Δply	compared	 to	wild-type,	and	TNF	 induced	a	neutrophil	 influx,	 I	explored	 the	possibility	 that	Ply’s	 impact	 on	 bacterial	 numbers	 and	 thus	 virulence	 was	 due	 to	 the	 effect	 of	 TNF	 on	neutrophil	 recruitment	 to	BALF.	 	 This	was	 carried	 out	 by	 depleting	 neutrophils	 from	mice	prior	 to	 intranasal	 infection	 with	 600μg	 Ly6G	 (clone	 1A8)	 antibody	 (BioXcell)	 or	 isotype	control	 administered	 intraperitoneally	 24	 hours	 prior	 to	 infection,	 which	 reduced	 BALF	neutrophil	 numbers	 by	 80%	 (figure	 7.30,	 panel	 A).	 	 However,	 despite	 this	 differences	 in	TIGR4	and	Δply	BALF	and	lung	CFU	at	4	hours	were	similar	after	neutrophil	depletion	(figure	7.30,	panel	B	&	C),	indicating	neutrophils	were	not	required	for	Ply	dependent	differences	in	bacterial	CFU	in	BALF.	 	TNF	and	IL1β	levels	 in	BALF	were	increased	with	both	strains	after	neutrophil	depletion,	possibly	reflecting	increased	bacterial	numbers	(figure	7.31,	panel	A	&	B).		Interestingly	IL6	levels	were	increased	after	Δply	infection,	but	not	wild-type	(figure	7.31,	panel	 C).	 	 TNF	 levels	 in	 lung	 homogenate	 were	 increased	 after	 neutrophil	 depletion	 with	wild-type	 but	 not	 Δply	 infection,	 however	 there	were	 no	 differences	 in	 IL1β	 or	 IL6	 (figure	7.32).	 	
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Figure	 7.30	 Neutrophil	 and	 bacterial	 counts	 in	 BALF	 and	 bacterial	 numbers	 in	 lung	
homogenate,	after	neutrophil	depletion	5	week	old	female	CD1	mice	were	inoculated	intranasally	with	5×106	CFU	bacteria	24	hours	after	 intraperitoneal	 Ly6G	 antibody.	 	 After	 4	 hours,	 neutrophil	 depletion	was	 confirmed	 in	bronchoalveolar	lavage	(panel	A),	and	bacterial	counts	measured	in	BALF	(panel	B),	and	lung	homogenate	(panel	C).	Neutrophil	numbers	presented	as	mean	+/-	SEM,	and	CFU	presented	as	 per	 individual	 mouse	 and	 medians;	 analysed	 by	 1	 way	 ANOVA	 and	 Tukey’s	 multiple	comparisons	 test	 for	 neutrophil	 numbers	 and	 Kruskal-Wallis	 with	 Dunn’s	 multiple	comparisons	test	for	CFU.	 	
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Figure	7.31	Cytokines	in	BALF	with	neutrophil	depletion		5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia,	some	had	been	pre-depleted	of	neutrophils	with	Ly6G	antibody.		The	cytokine	 levels	 in	 lavage	fluid	of	 the	mice	after	4	hours	were	measured	by	ELISA.	 	Data	are	presented	 as	 mean	 +/-	 SEM	 and	 analysed	 by	 1	 way	 ANOVA	 and	 Tukey’s	 multiple	comparisons	test.	
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Figure	7.32	Cytokines	in	lung	homogenate	after	neutrophil	depletion		5	week	 old	 female	 CD1	mice	were	 inoculated	 intranasally	 with	 5×106	 CFU	 bacteria	 under	isoflurane	anaesthesia,	some	had	been	pre-depleted	of	neutrophils	with	Ly6G	antibody.		The	cytokine	 levels	 in	 the	 lung	homogenate	of	 the	mice	after	4	hours	were	measured	by	ELISA.		Data	 are	presented	 as	mean	+/-	 SEM	and	 analysed	by	1	way	ANOVA	and	Tukey’s	multiple	comparisons	test.	 	
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7.10	Effects	of	TNF	in	vitro	and	in	vivo	To	further	characterise	the	role	of	TNF	in	early	host	defence	against	S.	pneumoniae,	TNF	was	directly	instilled	intranasally	into	mice	and	the	BALF	recovered.		The	administration	of	50ng	of	 TNF	 per	 mouse	 had	 little	 inflammatory	 effects	 (data	 not	 shown).	 	 However,	 after	administration	of	200ng	of	TNF	in	50μl	per	mouse	a	significant	leucocytosis	was	induced,	in	particular	 a	 BALF	 neutrophilia	 (figure	 7.33	 panels	 A,	 C,	 and	 E).	 	 Similarly	 there	 was	 an	increase	in	pro-inflammatory	cytokines	(figure	7.33	panels	B,	D,	and	F),	suggesting	that	TNF	by	itself	induces	other	cytokine	release.		This	could	be	an	early	host	protective	response	that	is	subverted	by	the	actions	of	Ply.	
As	 TNF	 is	 thought	 to	 activate	macrophages	 and	 increase	 killing	 of	 intracellular	 organisms	(Bekker,	Freeman	et	al.	2001	et	al)	and	is	known	to	increase	oxidative	burst	mediated	killing	of	S.	pneumoniae	by	neutrophils	(Kragsbjerg	and	Fredlund	2001).	 	10μg/ml	TNF	(similar	to	the	 concentrations	 produced	 by	 MDM	 after	 incubation	 with	 Δply)	was	 added	 to	 media	 of	MDM	 and	 the	 effect	 on	 S.	 pneumoniae	 growth	 assessed.	 	 At	 a	 variety	 of	 bacterial	concentrations	 there	was	 no	 significant	 increase	 in	 restriction	 of	S.	 pneumoniae	 growth	 by	the	addition	of	TNF	(figure	7.34).	
To	investigate	whether	TNF	induces	release	of	soluble	factors	into	BALF	that	could	inhibit	S.	
pneumoniae	survival	or	growth,	BALF	from	PBS	or	TNF	treated	mice	were	passed	through	a	cell	strainer	and	pooled.	BALF	from	PBS	treated	mice	supported	growth	of	TIGR4.	In	contrast,	at	all	timepoints	TIGR4	CFU	in	BALF	from	TNF	treated	mice	was	at	least	one	log10	lower	that	in	BALF	from	PBS	treated	mice	and	there	was	no	increase	over	time	(figure	7.35).		These	data	indicate	 that	 TNF	 stimulates	 soluble	 immunity	 to	 S.	 pneumoniae	 and	 the	 TNF	 inhibiting	properties	of	Ply	may	thus	allow	bacterial	proliferation	and	thus	contribute	to	virulence	of	S.	
pneumoniae.			
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Figure	7.33	Mouse	Lavage	fluid	4	hours	after	instillation	of	200ng	TNF	5	 week	 old	 female	 CD1	 mice	 were	 given	 PBS	 or	 200ng	 murine	 TNF	 (Miltenyi	 Biotech)	intranasally.	 	4	hours	later,	 lavage	was	retrieved	and	analysed	for	total	cell	count	(panel	A),	neutrophil	percentage	(panel	C)	and	neutrophil	numbers	(panel	E).		BALF	was	then	analysed	for	TNF	(panel	B),	IL1β	(panel	D),	and	IL6	(panel	F).		There	were	6	mice	in	each	group,	with	data	presented	as	mean	+/-	SEM	and	analysed	by	t-test.		 	
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Figure	7.34	TIGR4	survival	in	the	presence	of	macrophages	with	TNF	MDM	were	incubated	with	various	concentrations	of	TIGR4,	and	bacterial	numbers	counted	in	 culture	 supernatant	 after	 1	 hour.	Data	 presented	were	 representative	 of	 3	 experiments,	and	displayed	as	mean	+/-	SEM.	 	
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Figure	7.35	TIGR4	growth	in	BALF	from	PBS	treated	or	TNF	treated	mice	BALF	from	CD1	mice	(5	per	group)	was	retrieved	4	hours	after	intranasal	administration	of	PBS	or	200ng	TNF.		The	samples	were	centrifuged,	pooled	and	passed	through	a	cell	strainer.		Then	 TIGR4	 was	 added	 to	 both	 pooled	 BALF	 samples	 and	 bacterial	 counts	 measured	 at	various	timepoints.		Data	presented	is	a	representative	of	3	experiments	(one	performed	by	Gabriella	Szylar),	and	analysed	by	Kruskal-Wallis	and	Dunn’s	multiple	comparisons	test.	
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7.11	Chapter	Summary	Whole	genome	 transcriptional	 analysis	of	MDM	after	 exposure	 to	wild-type	or	Δply	 strains	suggest	 that	 Ply	 downregulates	 immune	 gene	 expression,	 including	 IL12,	 interferon	stimulated	 genes	 and	 pro-inflammatory	 cytokines.	 	 Principle	 component	 analysis	 suggests	that	without	Ply	MDM	responses	to	S.	pneumoniae	segregate	more	closely	with	those	to	the	TLR2	agonist	PAM2CSK4,	suggesting	that	Ply	suppresses	some	of	the	inflammatory	responses	that	are	induced	by	S.	pneumoniae	surface	lipoproteins.		Bioinformatic	analysis	suggests	that	wild-type	bacteria	induce	less	NFκB	and	interferon	regulated	pathways	than	Δply.			
S.	 pneumoniae	 clearance	 is	 dependent	 on	 phagocytosis,	 and	 opsonisation	 (which	 facilitates	bacterial	 uptake)	 reduced	 inflammatory	 responses	 from	 MDM	 suggesting	 that	 improving	bacterial	clearance,	and	thereby	reducing	external	bacterial	numbers,	reduces	inflammatory	responses.	 	 Interestingly	 inhibition	 of	 phagocytosis	 with	 cytochalasin	 D	 increased	 the	inflammatory	response	to	wild-type	bacteria	but	reduced	the	response	to	Δply.	This	suggests	that	Ply-dependent	inhibition	of	inflammation	is	dependent	on	bacterial	uptake.		In	addition	these	 data	 indicate	 a	 role	 for	 intracellular	 PRR	 to	 amplify	 inflammatory	 responses	 to	 S.	
pneumoniae.	 	 Whole	 genome	 analysis	 of	 MDM	 responses	 to	 both	 strains	 suggested	 that	inhibition	of	 phagocytosis	 reduced	 the	upregulation	of	 pro-inflammatory	 genes	 to	 the	Δply	strain,	decreasing	 the	differences	with	 the	wild-type	 strain	and	 further	 supporting	 that	 the	effects	of	Ply	are	dependent	on	bacterial	uptake.	
Signalling	 events	 upstream	 of	 transcription	 were	 also	 inhibited	 by	 Ply,	 with	 wild-type	inducing	 less	 p38	 and	 ERK	 phosphorylation	 and	 translocation	 of	 NFκB	 to	 the	 nucleus,	indicating	 that	 the	 effects	 of	 Ply	 inhibit	 NFκB	 activation.	 	 Interestingly,	 wild-type	 bacteria	induced	more	 IRF3	 activation	 than	Δply,	 suggesting	 that	 Ply	 actively	 induces	 this	 pathway.	This	 could	 be	 explained	 by	 lysosomal	 TLR4	 stimulation	 that	 induces	 TBK1	 mediated	pathways,	which	may	also	inhibit	NFκB.		However,	inhibition	of	TBK1	does	not	replicate	the	pro-inflammatory	phenotype	of	the	Δply	strain.		Another	explanation	for	the	IRF3	data	could	
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be	 Ply	 allowing	 bacterial	 DNA	 to	 enter	 the	macrophage	 cytoplasm	 and	 stimulate	 cytosolic	PRR.	
Similarly	 inhibition	 of	 apoptosis	 and	 inflammasome	 did	 not	 impact	 on	 the	 6	 hour	inflammatory	 response	 from	 MDM.	 	 Though	 further	 evidence	 would	 have	 provided	 more	support,	for	example	with	intracellular	stains	for	apoptosis	markers.		However,	while	caspase	1,	an	important	step	in	the	apoptosis	pathway	was	inhibited	with	no	effect	on	inflammation,	opposing	the	data	seen	by	Littman	et	al	(Littman,	Albiger	et	al.	2009),	this	does	not	preclude	earlier	points	in	the	signalling	cascade	that	stimulate	apoptosis	being	involved.	 	In	addition,	though	the	cytolytic	component	of	Ply	may	contribute	to	inhibition	of	inflammation,	voltage	gated	calcium	channels	were	not	implicated.			
In	 vivo,	 in	 a	 mouse	model	 of	 pneumonia,	 the	 Δply	 strain	 caused	 increased	 BALF	 TNF	 and	neutrophil	 levels	 and	 was	 more	 rapidly	 cleared	 that	 the	 wild	 type	 strain.	 	 Inhibiting	 TNF	abrogated	 the	 differences	 in	 bacterial	 CFU	 at	 6	 hours,	 suggesting	 that	 TNF	 in	 BALF	 is	important	in	control	of	bacterial	numbers	early	in	infection.		It	is	not	clear	why	TNF	blockade	reduced	the	amount	of	bacteria	in	BALF;	possible	reasons	include	a)	TNF	blockade	allowing	greater	invasion	and	movement	of	bacteria	into	lungs	and	blood	and	b)	the	pleiotropic	effects	of	TNF	making	direct	inferences	difficult.	
Although	 at	 very	 early	 timepoints	 the	 Δply	 strain	 induced	 an	 early	 neutrophil	 influx,	neutrophil	depletion	did	not	alter	 the	differences	 in	bacterial	BALF	CFU	indicating	that	 this	was	 not	 the	 main	 mechanism	 of	 bacterial	 control.	 	 The	 addition	 of	 TNF	 to	 MDM	 did	 not	increased	bacterial	killing	suggesting,	suggesting	the	difference	in	survival	between	the	Δply	and	wild-type	 strains	was	 not	 due	 to	 TNF	 effects	 on	 phagocytes.	 	 Rather,	 BALF	 recovered	from	mice	treated	with	TNF	restricted	S.	pneumoniae	growth,	implicating	TNF	driven	soluble	factors	 such	 as	 antimicrobial	 peptides,	 lysozyme	 or	 lactoferrin	 in	 the	 early	 control	 of	bacterial	 numbers	 in	 the	 bronchoalveolar	 compartment.	 	 Hence,	 inhibition	 of	 early	
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inflammatory	responses	to	S.	pneumoniae	by	Ply	would	allow	increased	bacterial	replication	in	the	bronchoalveolar	space	thereby	supporting	virulence.		 	
	 336	
8	Discussion	
S.	pneumoniae	causes	an	enormous	amount	of	morbidity	and	mortality	worldwide.		Since	Sir	William	Osler	 used	 Bunyan’s	 phrasing	 to	 refer	 to	 pneumonia	 as	 the	 captain	 of	 the	men	 of	death	(Osler	1904),	antibiotics	and	vaccination	programmes	have	 improved	the	outlook	for	long-term	 disease	 control.	 	 However	 despite	 antibiotics	 and	 vaccination	 programmes	 S.	
pneumoniae	 is	 still	 a	 common	 cause	 of	 infectious	 disease,	 and	 a	 proportion	 of	 people	who	develop	 infection	 go	 on	 to	 develop	 severe	 disease	 characterised	 by	 local	 and	 systemic	infection.		It	is	likely	that	the	pattern	of	excessive	inflammation	is	established	early	within	the	course	 of	 infection,	 which	 manifests	 as	 consolidation	 and	 lung	 injury,	 septic	 shock	 or	meningitis.		Thus	elucidating	the	pathogenesis	of	the	inflammatory	response	and	the	reason	for	its	propagation	remain	key	targets	in	tackling	S.	pneumoniae	related	morbidity.	
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8.1	 Effect	 of	 Capsule	 on	 Inflammatory	 Response	 to	 Streptococcus	
pneumoniae	The	 capsule	 has	 been	 long	 recognised	 as	 the	 most	 important	 virulence	 factor	 for	 S.	
pneumoniae	 but	 the	 primary	 characterised	 functions	 have	 been	 to	 reduce	 recognition	 and	thus	engagement	with	the	host	immune	system.	 	Unencapsulated	S.	pneumoniae	are	cleared	quickly	by	the	innate	immune	response	so	are	rarely	found	as	a	cause	of	invasive	infections,	although	 they	 are	 present	 as	 colonisers	 of	 the	 nasopharynx	 and	 can	 cause	 conjunctivitis	(Haas,	Hesje	et	al.	2011)	and	otitis	media	(Keller,	Robinson	et	al.	2016).			
Variation	 in	 capsular	makeup	 has	 resulted	 in	 over	 90	 serotypes,	 some	 of	 which	 are	more	likely	 to	 cause	 invasive	 disease	 than	 others	 (Brueggemann,	 Griffiths	 et	 al.	 2003,	 Hanage,	Kaijalainen	et	al.	2005,	Sandgren,	Albiger	et	al.	2005).	 	 Interestingly	 the	different	serotypes	also	 seem	 to	 have	 differing	 propensities	 to	 cause	 inflammation	 in	 terms	 of	 septic	 shock	(Garcia-Vidal,	 Ardanuy	 et	 al.	 2010),	 and	meningitis	 (Geldhoff,	Mook-Kanamori	 et	 al.	 2013).		Similarly	in	animal	models,	there	is	serotype	dependent	variation	in	inflammatory	response	(Engelhard,	Pomeranz	et	al.	1997,	Seyoum,	Yano	et	al.	2011).		This	suggests	that	the	capsule	certainly	plays	a	role	in	modifying	the	inflammatory	response	to	S.	pneumoniae.	
Previous	work	 has	 shown	 that	 purified	 capsule	 itself	 is	 not	 pro-inflammatory	 (Tuomanen,	Tomasz	 et	 al.	 1985),	 and	 considerable	 human	 and	 animal	 data	 demonstrates	 that	inflammation	is	necessary	for	host	immunity	to	S.	pneumoniae.		Hence,	it	would	follow	that	a	physical	 barrier	 such	 as	 the	 capsule	 that	 reduces	 engagement	 of	 host	 PRR	 with	 bacterial	PAMPs	 should	 reduce	 inflammation,	 and	 this	 might	 allow	 greater	 bacterial	 survival.	 I	therefore	set	out	to	assess	how	the	capsule	affects	inflammatory	responses	to	S.	pneumoniae	using	MDMs.	
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8.1.1	 Streptococcus	 pneumoniae	 capsule	 promotes	 inflammatory	
responses	in	vitro	and	in	vivo	I	have	investigated	how	the	presence	of	capsule	in	live	S.	pneumoniae	affected	inflammatory	responses	in	vitro	and	in	vivo	using	macrophage	cell	culture	and	murine	models	of	infection.			
When	 primary	 human	 MDM	 were	 incubated	 with	 live	 S.	 pneumoniae,	 unexpectedly	encapsulated	 wild-type	 strains	 induced	 greater	 pro-inflammatory	 cytokine	 secretion	 than	isogenic	 capsule	 deficient	 strains.	 	 Despite	 significant	 variation	 in	 individual	 responses,	overall	 there	was	a	strong	pro-inflammatory	signal	due	to	encapsulated	strains.	 	While	 this	variation	may	well	have	been	due	to	variations	in	individual	response	to	bacteria,	more	time	and	 effort	 should	 have	 gone	 into	 ensuring	 standardisation	 across	 experiments,	 e.g.	 by	ensuring	 similar	 cell	 numbers	 and	 activation	 states,	 ensuring	 no	 contaminating	 T	 cells,	perhaps	by	more	regular	cell	surface/intracellular	marker	staining.		Additionally,	MDM	were	differentiated	with	M-CSF,	and	a	more	regulatory	phenotype	(perhaps	more	similar	 to	AM)	could	 have	 been	 investigated	 using	 GM-CSF	 differentiated	 cells.	 	 While	 it	 is	 likely	 that	exposure	to	pathogens	does	induce	a	more	M1	phenotype,	initial	responses	that	I	examined	during	 this	 thesis	may	be	different	using	differently	differentiated	MDM.	 	 Ideally	a	 few	key	experiments	could	have	been	performed	with	primary	human	alveolar	macrophages.	
This	 effect	was	 also	 seen	 at	 transcriptional	 level	 as	measured	by	 qPCR	 and	whole	 genome	transcriptional	 analysis.	 The	whole	 genome	 transcriptional	microarrays	 of	 primary	 human	MDM	 responses	 to	 S.	 pneumoniae	 showed	 that	 a	 relatively	 small	 proportion	 of	 the	 whole	genome	was	differentially	expressed	by	the	addition	of	TIGR4.	 	The	differentially	expressed	genes	were	 largely	 pro-inflammatory	 genes	 and	 chemokines,	 and	 transcription	 of	many	 of	these	was	reduced	in	response	to	the	unencapsulated	strain.		While	these	data	were	obtained	from	 relatively	 few	 individuals,	 they	 support	 the	 secreted	 cytokine	 data,	 and	 suggest	 a	transcriptionally	 regulated	 difference	 between	 encapsulated	 and	 unencapsulated	 strains.		These	data	reflect	epithelial	transcription	responses	to	TIGR4	and	TIGR4Δcps,	with	similarly	greater	 gene	 upregulation	 in	 response	 to	 wild-type	 strains,	 and	 more	 pro-inflammatory	
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signalling	 (Bootsma,	 Egmont-Petersen,	 et	 al.	 2007).	 	 Additionally	 the	 genes	 commonly	upregulated	by	the	strains	examined	are	similar	to	that	of	my	data.	
The	 results	 seen	with	MDMs	were	partially	 replicated	 in	 a	mouse	pneumonia	model.	 	 TNF	production	 in	 the	bronchoalveolar	compartment	was	evident	within	2	hours,	 and	 IL1β	and	IL6	 within	 4	 hours.	 	 Wild-type	 TIGR4	 induced	 greater	 pro-inflammatory	 cytokine	 release	than	unencapsulated	TIGR4.	However,	 these	results	were	confounded	by	bacterial	numbers	as	bacterial	clearance	is	heavily	influence	by	the	presence	of	capsule	(Camberlein,		Cohen	et	al.	2015).	 	These	differences	were	also	partially	reflected	in	physiological	effects	and	serum	cytokine	levels	in	a	rat	septic	shock	model,	although	these	data	were	largely	statistically	non-significant	due	 to	 few	biological	 replicates	and	 large	error	bars.	 	The	early	mouse	 infection	model	 used	 is	 relevant	 as	 inflammation	 is	 induced,	 bacteria	 are	 not	 entirely	 cleared,	 and	previous	data	from	the	Brown	laoratory	have	shown	that	left	longer,	many	of	the	mice	would	succumb	 to	 bacteraemia	 and	 often	 die.	 Hence	 the	 unencapsulated	 strain	 induced	 weaker	proinflammatory	 responses	 when	 measured	 at	 the	 protein	 and	 gene	 level,	 with	 some	evidence	of	this	effect	being	relevant	in	murine	models	of	infection.		
Similar	 to	 others	 (Tuomanen,	 Tomasz	 et	 al.	 1998),	 I	 found	 that	 the	 relatively	 pro-inflammatory	effect	of	encapsulated	bacteria	compared	to	unencapsulated	S.	pneumoniae	was	not	 caused	 directly	 by	 capsular	 material,	 as	 inhibiting	 contaminating	 endotoxin	 abolished	pro-inflammatory	 cytokine	 release	 due	 to	 high	 concentrations	 of	 capsular	 material.	 	 LPS	contamination	 could	 also	 explain	 the	 cytokine	 response	 seen	 in	 response	 to	 high	concentrations	 of	 purified	 polysaccharide	 seen	 in	 others’	 work	 (Jagger,	 Huo	 et	 al.	 2002,	Simpson,	Singh	et	al.	1994).	
In	 the	 in	 vitro	 model,	 capsule	 inhibited	 phagocytosis	 corroborating	 previous	 data	 (Hyams,	Camberlein	et	al.	2010).		Phagocytosis	by	MDM	restricted	bacterial	replication	in	media,	and	CFU	 of	 the	 unencapsulated	 strains	 were	 therefore	 restricted	 more	 effectively	 than	encapsulated	strains.		As	a	result	by	6	hours	there	were	significantly	more	TIGR4	than	Δcps	in	
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media	which	could	confound	the	results	reflecting	MDM	inflammatory	responses.		However,	when	 penicillin	 was	 added	 to	 the	 MDMs,	 although	 the	 cytokine	 response	 was	 vastly	diminished,	differences	between	wild-type	and	unencapsulated	strains	were	preserved.		At	4	hours,	 when	 there	 was	 already	 a	 non-signifcant	 smaller	 difference	 in	 bacterial	 counts	between	 the	 strains,	 again	 the	 cytokine	 response	 was	 blunted	 but	 the	 difference	 between	strains	 was	 preserved.	 	 These	 data	 suggest	 that	 while	 bacterial	 numbers	may	 account	 for	some	of	the	difference	in	inflammatory	response	between	strains,	they	do	not	explain	all	of	the	pro-inflammatory	effect	of	the	encapsulated	bacteria	versus	unencapsulated	bacteria.		In	addition,	unpublished	data	 from	the	Brown	group	with	non-replicating	bacteria	 in	a	mouse	pneumonia	 model	 suggests	 that	 the	 difference	 in	 early	 lung	 TNF	 inflammatory	 responses	between	encapsulated	and	unencapsualted	bacteria	is	preserved	when	differential	bacterial	bacterial	numbers	are	accounted	for.			
During	pneumonia	the	two	main	resident	cell	populations	that	encounter	S.	pneumoniae	are	the	respiratory	epithelium	and	alveolar	macrophages.	As	the	cytokine	response	from	alveolar	epithelial	cells	was	limited	with	direct	exposure	to	S.	pneumoniae,	macrophages	are	likely	to	be	 the	predominant	cell	 type	 that	 initiate	early	 inflammatory	responses	during	pneumonia.		Conditioned	 media	 from	 macrophages	 induced	 a	 slightly	 greater	 cytokine	 response	 from	epithelial	cells,	but	even	this	was	at	a	much	lower	level	than	that	of	macrophages	themselves.		This	 supports	 a	 model	 of	 AM	 being	 key	 sensors	 of	 pathogens,	 initiating	 inflammatory	responses,	and	activating	nearby	epithelial	cells	to	amplify	this	response	until	pathogens	are	dealt	with.		Depletion	of	AM	in	a	low	inoculum	model	of	infection	in	mice	by	the	instillation	of	lysosomal	clodronate	diminshed	 inflammatory	responses,	confirming	 that	macrophages	are	the	 key	 cell	 type	 involved	 in	 capsule-dependent	 inflammatory	 responses	 in	 vivo.	 	However	the	difference	between	TIGR4	and	Δcps	was	preseved	with	respect	to	TNF	in	high	inoculum	infection.	 	 At	 lower	 inocula,	 the	 pro-inflammatory	 effects	 of	 encapsulated	 bacteria	 were	diminshed	 somewhat.	 	 The	 patterns	 of	 inflammatory	 responses	 were	 different	 in	 lung	homogenate,	in	particular	while	TNF	and	IL6	levels	were	slightly	lower,	IL1β	levels	were	an	
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order	of	magnitude	greater,	suggesting	differential	responses	by	compartment.		Importantly	the	pro-inflammatory	effects	of	the	capsule	were	preserved	in	both	compartments	overall.			
Thus	both	in	vitro	and	in	vivo	models	suggest	that	the	presence	of	capsule	on	S.	pneumoniae	has	 pro-inflammatory	 effects	 early	 during	 host-pathogen	 interaction.	 	 While	 bacterial	numbers	may	contribute	to	this,	they	are	not	the	sole	reason	for	the	effect	seen.		
8.1.2	 Exploration	 of	 mechanisms	 underpinning	 the	 pro-inflammatory	
effects	of	S.	pneumoniae	capsule	There	are	multiple	potential	explanations	as	to	why	capsule	exerts	a	pro-inflammatory	effect.		My	hypotheses	included:	
(i) The	capsule	allows	greater	exposure	of	pro-inflammatory	bacterial	ligands	to	cell	surface	PRRs	by	preventing	bacterial	phagocytosis	(ii) Capsule	 recognition	 by	 cell	 surface	 PRRs	 amplifies	 the	 inflammatory	 response	driven	by	other	bacterial	ligands	such	as	lipoproteins	(iii) Antibody	 binding	 to	 the	 capsule	 increases	 inhibitory	 signalling	 due	 to	engagement	with	Fcγ	receptors	on	the	cell	surface	(iv) Increased	activation	of	intracellular	PRR	by	internalised	bacteria	with	inhibitory	effect	
Further	interrogation	of	the	whole	genome	transcriptional	responses	showed	that	the	TLR2	agonist	PAM2CSK4	 induced	 far	more	differential	 gene	 expression	 than	bacteria,	 though	 this	may	have	been	distorted	by	the	differences	in	platforms	used	between	the	positive	controls	and	 the	 unstimulated	 cells.	 	 The	 most	 upregulated	 genes	 in	 response	 to	 PAM2CSK4	 were	largely	an	inflammatory	gene	set	but	the	levels	of	upregulation	were	greater	and	more	genes	were	upregulated	by	more	 than	2	 fold	 (data	not	 shown	 in	 thesis).	 	The	difference	between	wild-type	 and	 unencapsulated	 strains	 was	 limited	 to	 an	 even	 smaller	 gene	 set,	 and	 the	difference	 in	 gene	 expression	 was	 surprisingly	 small	 given	 the	 effects	 seen	 in	 culture	supernatant	 and	 in	 vivo.	 	 Bioinformatic	 analysis	 suggested	 that	 the	 transcription	 factors	
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involved	 in	 generating	 this	 gene	 signature	were	 largely	 restricted	 to	 the	 NFκB	 family	 and	some	 interferon	response	genes,	which	would	be	predicted	 to	occur	as	a	result	of	PRR	and	cytokine	 receptor	 stimulation.	 	 Interestingly	 the	 pathway	 predicted	 to	 be	 most	overrepresented	by	TIGR4	compared	to	unencapsulated	bacteria	was	the	NOD-like	receptor	signalling	 pathway.	 	 This	 pathway	 is	 stimulated	 by	 cytosolic	 recognition	 of	 PAMPs,	 which	would	be	unexpected	as	the	capsule	reduces	rates	of	S.	pneumoniae	phagocytosis.			
Nuclear	NFκB	translocation	was	greater	with	unencapsulated	bacteria	compared	to	wild-type	at	 1	 hour,	 but	 there	was	 little	 difference	 by	 2	 hours.	 	 This	may	 indicate	 a	 slightly	 delayed	kinetic	 of	 signalling	 responses	 with	 encapsulated	 bacteria,	 possibly	 due	 to	 slower	engagement	of	cell	surface	host	PRR	with	bacterial	ligands	due	to	the	shielding	effect	of	the	capsule.		These	data	were	strengthened	by	the	single	cell	nature	of	the	analysis,	and	had	little	variation	 between	 donors,	 suggesting	 a	 conserved	 response.	 	 Importantly,	 this	 was	discordant	 with	 the	 transcriptional	 findings	 at	 4	 hours	 or	 protein	 data	 at	 subsequent	timepoints.		This	implicates	capsule	driven,	non-NFκB	mediated	pathways	affecting	cytokine	transcription	 and	 secretion.	 	 The	 phosphoarray	 and	 MAPK	 data	 suggested	 that	 similar	activation	 patterns	 between	 the	 strains,	 indicating	 that	 the	 capsule	 did	 not	 affect	 these	pathways,	although	there	was	greater	signalling	seen	with	Δcps.	 	Although	the	transcription	factor	array	was	not	necessarily	sensitive	enough	to	detect	all	transcription	factor	effects	(for	example,	 this	 array	did	not	 identify	NFκB),	 there	was	 the	 suggestion	of	more	 transcription	factors	 being	 activated	 by	 the	 unencapsulated	 strain,	 possibly	 indicating	 that	 the	unencapsulated	organism	activates	more	pathways	than	wild-type	bacteria.		Indeed	much	of	the	 effect	 of	S.	 pneumoniae	 appeared	 to	be	 to	downregulate	 transcription	 factor	 activation.	This	may	be	the	macrophage	responding	to	pathogen	by	amplifying	anti-pathogen	functions	while	 reducing	 regulatory	 functions.	 Conclusions	 from	 this	 array	 must	 be	 viewed	 with	caution	given	the	lack	of	sensitivity,	and	may	reflect	that	some	transcription	factors	can	have	profound	effects	despite	a	lack	of	abundance,	although	could	also	reflect	timepoint	issues	or	the	effect	of	transcription	regulators	magnifying	small	effects.	
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The	media	used	 to	culture	MDM	contained	pooled	human	serum,	which	 is	 likely	 to	contain	anti-pneumococcal	 antibodies.	 	 Both	 wild-type	 and	 unencapsulated	 bacteria	 bound	 to	antibodies	 in	 serum,	 but	 unencapsulated	 bacteria	 had	 a	 greater	 mean	 fluorescence	 index,	indicating	 that	 on	 average	 more	 antibodies	 bound	 to	 each	 unencapsulated	 bacterium.		Antibody	responses	can	have	an	effect	on	inflammation	over	and	above	that	on	the	effect	on	phagocytosis	as	Fc	receptor	engagement	are	implicated	in	inflammatory	signalling	pathways	(Clatworthy	and	Smith,	2004).	 	However,	 in	serum	free	media	at	early	timepoints	wild-type	bacteria	 still	 induced	 a	 trend	 to	 more	 inflammatory	 cytokine	 transcription	 than	unencapsulated	 bacteria.	 Deliberately	 opsonising	 bacteria	 in	 higher	 concentration	 pooled	serum	reduced	 inflammatory	 cytokine	 responses,	 and	 reduced	 the	differences	between	 the	two	 strains,	 likely	 due	 to	 increased	 phagocytosis	 and	 enhanced	 clearance	 of	 bacteria	 by	opsonisation.		Given	the	strength	of	this	correlation,	it	may	well	be	that	the	largest	part	of	the	difference	in	inflammatory	response	seen	between	encapsulated	and	unencapsulated	strains	is	due	to	variation	in	bacterial	uptake.		This	is	logical	as	lack	of	adherent	bacteria	would	serve	to	reduce	external	PRR	engagement,	and	successful	phagocytosis	could	therefore	switch	off	pro-inflammatory	signalling.	
Hence	 I	 examined	 the	 effect	 on	 inflammatory	 responses	 of	 phagocytosis	 using	 the	 actin	polymerisation	 inhibitor,	 cytochalasin	D,	 to	 inhibit	 phagocytosis.	 	 The	 antibiotic	 protection	assay	 and	 fluorescent	microscopy	 data	 indicated	 that	 phagocytosis	was	 almost	 completely	abrogated	by	the	use	of	10μM	cytochalasin	D.	 	Interestingly,	 inhibition	of	phagocytosis	with	cytochalasin	D	 increased	the	 inflammatory	responses	to	TIGR4,	and	to	a	 lesser	extent	Δcps,	with	 increases	 in	the	number	of	genes	differential	expressed	by	MDM	after	 incubation	with	wild-type	 and	 unencapsulated	 bacteria.	 	 However,	 the	 relative	 expression	 of	 inflammatory	cytokines	 and	 supernatant	 cytokine	 levels	 was	 very	 similar	 to	 those	 seen	with	MDMs	 not	treated	with	cytochalasin	D,	and	with	preserved	differences	between	the	strains.		Hence	the	differences	 in	 inflammation	 were	 not	 due	 to	 differences	 in	 ratios	 of	 internal	 to	 external	bacteria	 for	 encapsulated	 and	 unencapsulated	 S.	 pneumoniae.	 Rather	 as	 inhibition	 of	
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phagocytosis	maintained	 the	 difference	 in	 inflammatory	 cytokine	 production,	 this	 suggests	that	cell	surface	receptors	are	responsible	for	the	difference	seen.		
These	 data	 would	 be	 compatible	 with	 the	 hypothesis	 that	 capsule	 modifies	 and	 amplifies	external	 PRR	 signalling	 due	 to	 other	 components	 of	 bacteria	 although	 TLR2,	 probably	 the	most	 important	 cell	 surface	 PRR,	 activation	 was	 similar	 between	 the	 two	 strains.	Alternatively	 the	 capsule	 could	be	 relatively	 selective	 in	 inhibiting	engagement	of	bacterial	cell	 surface	 ligands	 with	 host	 surface	 PRR	 that	 are	 anti-inflammatory	 compared	 to	 pro-inflammatory	PRRs.	 	However,	there	was	no	difference	seen	in	lectin-mediated	signalling	or	after	 scavenger	 receptor	 blockade,	 suggesting	 that	 although	 several	 members	 of	 these	receptor	families	have	been	linked	to	recognition	of	S.	pneumoniae,	they	are	not	implicated	in	capsule-mediated	pro-inflammatory	signalling.		Hence	the	increase	in	inflammatory	cytokine	release	 attributable	 to	 capsule	 is	 not	 explained	 by	 differences	 in	 phagocytosis,	 TLR2	activation,	 Fc	 receptor,	 lectin,	 or	 scavenger	 receptor	 activation,	 so	 the	mechanism	 remains	unexplained.	 	 Alternative	 mechanisms	 that	 need	 investigation	 include	 capsule	 induced	amplification	 of	 pro-inflammatory	 signals	 or	 reductions	 in	 inhibitory	 signals	 at	 the	 cell	surface	(figure	8.1)	perhaps	due	to	non-NFκB	mediated	transcriptionally	regulated	events.	
8.1.3	Serotype	affects	inflammatory	responses	of	human	macrophages	to	
S.	pneumoniae	Expression	of	 a	 capsule	 saw	a	 trend	 towards	 increased	 inflammatory	 cytokine	 from	MDMs	after	 incubation	 with	 a	 number	 of	 different	 S.	 pneumoniae	 serotypes.	 The	 exception	 was	serotype	 3,	 which	 expresses	 a	 particularly	 mucoid	 capsule.	 	 These	 data	 indicate	 that	 the	presence	of	a	capsule	affects	inflammation	across	a	variety	of	strains,	usually	increasing	the	inflammatory	 response.	 	 For	 encapsulated	 wild-type	 strains	 there	 were	 differences	 in	inflammatory	 responses	 between	 serotypes,	 with	 for	 example	 serotype	 6A	 inducing	 more	TNF	 and	 IL6	 than	 TIGR4.	 	 Interestingly	 while	 TLR2	 simulation	 varied	 between	 serotypes,	there	 was	 little	 difference	 between	 different	 capsule	 deficient	 strains.	 	 This	 suggests	 that	
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while	 the	capsule	does	not	directly	activate	TLR2,	 it	may	modify	how	TLR2	 ligands	such	as	bacterial	surface	lipoproteins	engage	with	this	surface	PRR.	
As	the	inflammatory	phenotype	differed	between	S.	pneumoniae	strains	expressing	different	capsular	 serotypes,	 I	used	 isogenic	 capsule	 switch	 strains	 to	determine	how	much	of	 these	differences	 were	 due	 to	 variations	 in	 the	 capsule	 rather	 than	 non-capsular	 differences	between	strains.		Similar	to	wild-type	strains	the	expression	of	6A	capsule	on	TIGR4	induced	more	 IL6	 and	 TNF	 than	 serotype	 4	 capsule.	 	 These	 data	 suggest	 that	 at	 least	 part	 of	 the	difference	in	inflammatory	response	between	strains	is	driven	directly	by	capsular	structure.		However,	 the	 TLR2	 activation	 did	 not	 vary	 between	 isogenic	 capsule	 switch	 variants	suggesting	that	these	serotype	effects	are	not	TLR2	dependent.			
8.1.4	The	expression	of	S.	pneumoniae	capsule	on	S.	mitis	does	not	affect	
inflammatory	responses	
S.	mitis	 is	closely	related	to	S.	pneumoniae,	and	has	been	suggested	to	be	a	descendent	 that	has	lost	multiple	virulence	factors.	 	It	is	a	successful	coloniser	of	the	oropharynx	that	rarely	causes	disease.		Recently	it	has	been	established	that	some	strains	express	a	capsule,	and	the	capsule	genetic	 locus	has	been	manipulated	so	that	the	S.	pneumoniae	serotype	4	capsule	is	expressed	by	S.	mitis	 (Rukke,	Hegna	et	al.	2012).	 	This	enabled	me	to	assess	 the	effect	of	S.	
pneumoniae	capsule	on	inflammatory	responses	to	another	organism.	 	MDM	responses	to	S.	
mitis	strains	(perhaps	surprisingly)	showed	that	they	induced	more	TNF	and	IL6	than	TIGR4	strains.		Importantly	the	addition	of	TIGR4	capsule	did	not	appear	to	affect	the	inflammatory	response.	 	 Along	 with	 the	 data	 that	 showed	 capsular	 polysaccharide	 does	 not	 induce	inflammation	 by	 itself,	 these	 results	 suggest	 that	 the	 capsule	 modifies	 how	 macrophages	interact	with	another	pneumococcal	virulence	factor	not	shared	with	S.	mitis.		
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Figure	8.1	Possible	pro-inflammatory	mechanisms	of	S.	pneumoniae	capsule	Pro-inflammatory	 components	 of	 S.	 pneumoniae	 stimulate	 PRR,	 and	 largely	 converge	 via	NFκB	 to	 induce	pro-inflammatory	cytokine	 transcription.	 	Capsule	does	not	directly	 induce	inflammation,	 but	 as	 yet	 unrecognised	 PRR	may	 allow	 signalling	 such	 that	 transcription	 is	amplified,	 but	 not	 via	 NFκB.	 	 Alternatively,	 as	 the	 surface	 and	 internal	 constituents	 of	 S.	
pneumoniae	 may	 engage	 more	 PRR,	 which	 could	 either	 compete	 with	 or	 directly	 inhibit	NFκB,	 so	 effectively	 the	 capsule	 may	 streamline	 macrophage	 responses	 through	 the	 pro-inflammatory	pathways.	 	
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In	a	mouse	pneumonia	model,	the	addition	of	the	TIGR4	capsule	to	S.	mitis	reduced	bacterial	clearance,	confirming	the	effect	of	TIGR4	capsule	on	inhibiting	phagocytosis.		However,	there	was	no	effect	on	neutrophil	infiltrate	or	cytokine	levels	in	lavage	fluid	or	lung	homogenate.		In	contrast	 to	human	MDM	cytokine	 levels,	during	murine	pneumonia	S.	mitis	 strains	 induced	similar	 levels	of	BAL	TNF	but	 far	 less	 IL1β	and	 IL6	 than	 infection	with	S.	pneumoniae.	 	The	reasons	 for	 these	 differences	 are	 not	 known,	 but	 the	 mouse	 pneumonia	 model	 involves	bacterial	interactions	with	multiple	cell	types	and	a	very	active	innate	immune	response,	and	is	a	much	more	complex	situation	than	cell	culture	infection.			
8.1.5	Summary	The	most	 important	 role	of	S.	 pneumoniae	 capsule	 is	 clearly	 the	 inhibition	of	phagocytosis,	which	 is	 the	 main	 mechanism	 of	 bacterial	 clearance.	 	 The	 data	 presented	 in	 this	 thesis	indicates	 that	 the	 capsule	 also	 has	 pro-inflammatory	 effects	 which	 may	 contribute	 to	 the	morbidity	and	mortality	associated	with	the	over-exuberant	inflammatory	response	seen	in	disease	 caused	 by	 S.	 pneumoniae.	 	 Many	 other	 major	 bacterial	 pathogens	 express	 a	polysaccharide	capsule,	including	Neisseria	meningitides,	Klebsiella	pneumoniae,	Haemophilus	
influenzae,	and	Streptococcus	pyogenes.		In	addition	Cryptococcus	neoformans,	a	bacteria-sized	yeast	expresses	a	capsule.	In	all	these	species	the	capsule	is	a	virulence	factor	that	primarily	inhibits	 opsonophagocytosis.	 	 When	 the	 inflammatory	 properties	 of	 the	 capsule	 in	 other	species	have	been	studied,	 in	contrast	 to	my	data	 for	S.	pneumoniae	generally	they	dampen	the	response	to	the	organism	(Yoshida,	Matsumoto	et	al.	2000;	Ellerbroek,	Walenkamp	et	al.	2004;	Regueiro,	Campos	et	al.	2006;	Raffatellu,	Santos	et	al.	2007;	Frank,	Reguerio	et	al.	2013;	Monari	 et	 al.	 2005),	 presumably	 improving	 evasion	 of	 host	 immune	 responses.	 	 The	exceptions	 are	 purified	 Staphylococcus	 aureus	 and	 Neisseria	 meningitidis	 capsular	polysaccharide	that	induced	pro-inflammatory	cytokines	secretion	from	PBMC	(Soell,	Diab	et	al.	1995)	or	human	macrophages	in	a	TLR2	and	TLR4	dependent	manner	(Zughaier,	Tzeng	et	al.	 2004)	 respectively,	 producing	 a	 similar	 functional	 effect	 to	 the	 S.	 pneumoniae	 capsule	effects	but	by	a	different	mechanism.		As	loss	of	the	capsule	has	multiple	other	effects	on	host	
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-	bacterial	interactions	the	biological	significance	of	the	effect	of	the	capsule	on	inflammatory	responses	to	S.	pneumoniae	during	actual	infection	remains	unclear.		The	in	vitro	data	would	suggest	 that	 it	 maybe	 partially	 responsible	 for	 the	 marked	 inflammatory	 response	 that	 is	characteristic	of	acute	S.	pneumoniae	infections.	
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8.2	 Effect	 of	 Pneumolysin	 on	 Inflammatory	 Response	 to	
Streptococcus	pneumoniae	Ply	 is	 an	 important	 virulence	 factor	 expressed	 by	 the	 majority	 of	 virulent	 S.	 pneumoniae	strains.	 	 There	 is	 little	 variation	 in	 Ply	 proteins	 between	 strains,	 though	 some	 serotypes	express	 a	 form	 that	 does	 not	 induce	 pore	 formation	 and	 therefore	 do	 not	 cause	 cytolysis.		This	particularly	occurs	in	some	serotype	1	strains	(Kirkham,	Jefferies	et	al.	2006);	serotype	1	has	an	unusual	capsular	structure	(Mertens,	Fabri	et	al.	2009),	possibly	accounting	for	the	loss	 of	 Ply	 as	 a	 compensatory	 measure.	 	 Ply	 has	 no	 recognised	 export	 sequence,	 and	 is	thought	 to	 be	 released	 extracellularly	 by	 bacterial	 lysis	 although	 it	 has	 recently	 been	reported	to	also	be	cell	wall	associated	(Price,	Greene	et	al.	2012).			
Since	its	 initial	discovery,	Ply	has	proven	to	have	pleiotropic	effects	on	the	immune	system,	mostly	pro-inflammatory	(Malley,	Henneke	et	al.	2003)	and	often	linked	to	its	pore-forming	function	(Davis,	Nakamura	et	al.	2011,	McNeela,	Burke	et	al.	2010).		As	initiation	of	the	innate	immune	 response	 and	 inflammation	 is	 important	 in	 host	 defence	 to	 S.	 pneumoniae,	 it	 is	unclear	why	 if	 Ply	 is	 strongly	 pro-inflammatory	 it	 has	 been	 retained	 in	 the	 S.	 pneumoniae	genome.	In	contrast	to	the	data	on	pro-inflammatory	effects	of	Ply,	at	least	one	group	suggest	that	 human	DCs	 incubated	with	wild-type	 bacteria	 secrete	 less	 pro-inflammatory	 cytokine	than	Δply	(Littman,	Albiger	et	al.	2009).	
8.2.1	Pneumolysin	inhibits	inflammatory	responses	I	 investigated	whether	 the	 early	macrophage	 inflammatory	 response	 to	 live	 S.	 pneumoniae	was	affected	by	Ply	by	 incubating	primary	human	MDM	with	wild-type	and	Ply	deficient	S.	
pneumoniae.	 	 Contrary	 to	most	 of	 the	 existing	 Ply	 literature	 (Davis,	 Nakamura	 et	 al.	 2011,	Malley,	Henneke	et	al.	2003,	McNeela,	Burke	et	al.	2010),	wild-type	strains	induced	less	pro-inflammatory	cytokine	release	than	Δply	 strains.	 	This	 finding	was	quite	striking,	and	much	more	 obvious	 than	 the	 difference	 seen	 with	 capsule.	 	 Δply	 strains	 were	 found	 in	 similar	numbers	 in	 culture	 supernatant	 with	 similar	 bacterial	 uptake	 suggesting	 adhesion	 and	
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phagocytosis	 by	macrophages	 are	 not	 affected	 by	 Ply,	 so	 differences	 in	 bacterial	 numbers	were	not	likely	to	confound	the	results.			
Whole	genome	transcriptome	analysis	suggested	quite	a	significant	 increase	 in	upregulated	genes	with	Δply	 over	wild-type,	 supporting	 an	 inhibitory	 role	 for	Ply	 at	 the	 transcriptional	level.		Direct	comparison	of	the	genes	upregulated	showed	that	Δply	increased	expression	of	IL12,	 chemokines,	 interferon	 stimulated	 genes	 and	 pro-inflammatory	 cytokines.	 	 NFκB	translocation	was	 increased	 in	 the	presence	of	Δply	 compared	 to	wild-type,	 confirming	 the	predicted	 transcription	 factor	 activation	 from	 the	 genome	 wide	 transcriptional	 data.			Interestingly	others	have	examined	transcriptional	responses	of	THP-1	cells,	a	monocytic	cell	line,	 to	 D39	 and	 D39Δply	 (Rogers,	 Thornton	 et	 al.)	 and	 found	 much	 less	 effect	 on	inflammation	 and	 no	 striking	 pattern	 that	 Ply	 inhibits	 inflammation	 despite	 a	 similar	timepoint.		The	differences	could	be	explained	by	the	effects	of	differentiation	of	my	cells	into	macrophages,	alternatively	they	could	be	a	function	of	cell	line	versus	primary	cells.	
In	a	mouse	pneumonia	model,	the	Δply	strain	was	clearly	less	virulent	by	4	hours	but	by	24	hours	both	 strains	had	 largely	been	 cleared.	 	At	 this	 timepoint	neutrophil	 recruitment	 and	albumin	 leak	 were	 similar	 despite	 a	 log10	 less	 Δply	 suggesting	 that	 each	 individual	 Δply	bacterium	induced	more	 inflammatory	response	than	wild-type.	 	Despite	 there	being	 fewer	bacteria,	 early	TNF	 responses	 in	BALF	were	 significantly	 greater	with	Δply	 suggesting	 that	Ply	inhibits	TNF	release	from	AM,	the	primary	cell	type	that	initiate	inflammatory	responses	in	 the	 bronchoalveolar	 compartment.	 	 Ideally	 the	 central	 role	 of	 the	 AM	 to	 this	 response	could	 have	 been	 confirmed	 with	 a	 clodronate-mediated	 macrophage	 depletion.	 	 Although	clodronate	 also	 appears	 to	 induce	 neutrophil	 infiltrate	 directly,	which	 could	 confound	 any	data.	
The	 effects	 of	 Ply	 on	 MDM	 inflammatory	 responses	 were	 conserved	 across	 a	 number	 of	different	 serotypes	and	 their	 isogenic	Δply	mutants,	 as	well	 as	naturally	occurring	variants	within	 serotype	 1,	 suggesting	 that	 this	 effect	 is	 not	 serotype	 dependent,	 and	 therefore	
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unlikely	 to	 be	 due	 to	 bacterial	 uptake	 or	 affected	 by	 bacterial	 association	 with	 the	 cell	surface.	 	The	data	from	D39	strains	in	vivo	suggests	that	the	virulence	effects	of	Ply	are	less	pronounced	in	this	strain	background.		Despite	this,	the	effects	of	loss	of	Ply	on	TNF	and	IL1β	levels	were	 similar	 to	 those	 seen	 for	 the	TIGR4	data.	 	 Importantly,	 the	 complemented	D39	strain	had	similar	effects	to	wild-type	suggesting	that	the	antibiotic	resistance	cassette	alone	was	 not	 responsible	 for	 differences	 in	 cytokine	 response	 seen.	 	 Much	 larger	 cytokine	responses	were	also	obtained	 from	epithelial	 cells	 incubated	with	MDM	conditioned	media	obtained	 using	 the	 Δply	 strain	 compared	 to	MDM	 conditioned	media	 obtained	 using	wild-type	 bacteria.	 	 Again,	 this	 reflects	 the	 primary	 importance	 of	 the	 AM	 in	 generating	inflammatory	 responses.	 	 A	 double	 deletion	 ΔcpsΔply	 mutant	 showed	 similar	 effects	 on	inflammatory	cytokines	as	Δply.		This	suggests	that	the	effect	of	Ply	outweighs	that	of	capsule,	and	that	there	was	no	obvious	effect	of	one	component	on	the	response	to	the	other,	though	in	 these	 experiments	 the	pro-inflammatory	 effects	 of	 capsule	were	blunted	 so	perhaps	not	generalisable.	
One	reason	that	 the	data	described	 in	 this	 thesis	 is	at	odds	with	 the	bulk	of	published	data	may	be	the	use	of	live	bacteria	rather	than	purified	Ply.		Purified	Ply	induced	dose-dependent	pro-inflammatory	cytokine	release,	which	in	the	case	of	TNF	and	IL6	was	greatly	reduced	by	removing	endotoxin	contamination,	though	it	may	be	that	polymyxin	B	could	have	been	off-target	effects.	However,	at	the	highest	concentrations	of	purified	Ply	there	was	still	significant	TNF	 and	 IL6	 secretion	 in	 the	 presence	 of	 polymyxin	 B	 indicating	 some	 direct	 Ply	 pro-inflammatory	effects,	though	with	higher	concentrations,	IL1β	levels	fell	with	probably	due	to	significant	 cell	 death.	 	More	 experiments	 to	 confirm	 this	 cell	 death,	 and	 its	manner,	would	have	been	useful	to	build	confidence	in	this	narrative.	 	Purified	non-haemolytic	Ply	induced	inflammatory	 cytokine	 release	 in	a	dose-dependent	manner.	 	These	data	 confirm	 that	 IL1β	release	 is	 stronger	 upon	 exposure	 to	 the	 pore-forming	 effects	 of	 extracellular	 Ply,	 which	would	 be	 consistent	 with	 inflammasome	 activation	 (McNeela,	 Burke	 et	 al.	 2010)	 but	 that	some	of	the	inflammatory	responses	to	extracellular	Ply	occur	independently	of	this	function.			
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Another	important	reason	for	the	discrepancy	in	my	data	compared	to	previous	publications	were	the	early	timepoints	I	used	to	examine	initial	host-pathogen	interaction.		Furthermore,	most	previous	data	were	largely	derived	from	murine	models	and	cell	lines,	whereas	my	data	involved	primary	human	macrophages	similar	to	the	data	from	primary	human	DCs	that	also	suggested	an	anti-inflammatory	effect	of	Ply	(Littman,	Albiger	et	al.	2009).	 	This	paper	used	Δcps	 and	 ΔcpsΔply	 to	 facilitate	 uptake,	 and	 used	monocyte-derived	 DCs,	 which	 only	 differ	from	MDMs	in	that	monocyte	differentiation	was	induces	with	GM-CSF	and	IL4.		Interestingly	they	noted	that	expression	of	Ply	affected	bacterial	uptake	in	the	context	of	unencapsulated	bacteria.	 	This	may	have	not	been	apparent	 in	my	data	as	the	capsule	has	a	more	profound	effect	on	bacterial	uptake.		They	looked	at	IL12	and	CXCL8	with	similar	effects	to	my	dataset,	as	well	as	similar	effects	on	apoptosis.		Secreted	IL1β	levels	were	also	similar,	and	differences	clearer	at	later	timepoints.		They	also	showed	that	Ply	murine	DCs	had	the	opposite	pattern	in	respect	to	IL1β	secretion,	further	suggesting	that	murine	responses	to	Ply	may	be	different	from	humans’.	
Principle	component	analysis	of	the	whole	genome	transcriptome	showed	that	Δply	induced	similar	 upregulation	 patterns	 to	 PAM2CSK4,	 a	 lipoprotein	 that	 signals	 via	 TLR2,	 suggesting	that	 Ply	 inhibits	 the	 host	 response	 to	 bacterial	 TLR2	 ligands.	 	 Transcription	 factor	enrichment	 binding	 analysis	 predicted	 increased	 NFκB-dependent	 gene	 transcription	 in	response	to	the	Δply	strain,	which	is	also	consistent	with	signalling	via	TLR2	(but	not	limited	to	 this	 PRR).	 	 The	 other	 group	 of	 transcription	 factors	 that	 Δply	 induced	 were	 the	 IRFs,	suggesting	increased	interferon	responses.		Previous	data	suggests	that	Ply	is	instrumental	in	inducing	IFN	responses	by	allowing	bacterial	DNA	to	enter	the	cytosol	(Parker,	Martin	et	al.	2011).		This	function	of	Ply	seems	to	occur	later	in	infection,	as	there	are	data	suggesting	that	Ply	only	enters	the	cytosol	of	macrophages	after	8	hours	(Bewley,	Naughton	et	al.	2014).		As	interferon	 responses	may	 also	 be	 induced	 by	 phagolysosomal	membrane	 PRR	 stimulation,	e.g.	TLR9	(Moretti	and	Blander	2014),	Ply	could	conceivably	interfere	with	the	engagement	of	bacterial	DNA	with	these	PRR.	
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Of	 the	MAPK	signalling	molecules	upstream	of	 inflammatory	 transcriptional	 responses,	 the	Δply	 strain	 induced	more	ERK	and,	 in	particular,	p38	phosphorylation,	but	had	 little	effects	on	JNK	phosphorylation	compared	to	wild-type.		ERK	is	stimulated	by	lectins,	growth	factors,	and	calcium	signalling,	whereas	p38	 is	stimulated	by	TLRs,	 IL1β,	and	TNF.	 	This	 is	 likely	 to	mean	greater	responses	to	external	PRR	signalling,	possibly	TLR2,	after	exposure	to	Δply.		
In	the	mouse	pneumonia	model,	while	there	were	clear	anti-inflammatory	effects	of	Ply	at	4	hours,	by	24	hours	 there	was	significantly	more	neutrophil	 infiltrate	and	corollary	albumin	leak	after	wild-type	 infection.	 	This	may	reflect	 the	persistence	of	wild-type	bacteria	or	 the	pore	 forming	 pro-inflammatory	 effects	 of	 Ply	 may	 be	 becoming	 evident	 at	 this	 later	timepoint.		
TNF	 is	 the	 quickest	 responder	 of	 the	 pro-inflammatory	 cytokines,	which	may	 explain	why	transcriptional	 inhibition	 of	 release	 by	 Ply	 in	 vivo	 may	 most	 easily	 be	 seen	 with	 TNF	compared	to	IL6.	 	Unlike	MDM,	IL1β	levels	were	also	reduced	in	response	to	the	Δply	strain	during	lung	infection.		This	may	be	because	of	increased	Ply	liberation	in	the	context	of	other	host	 defence	mechanisms	 such	 as	 antibacterial	 peptides,	 but	 also	may	 reflect	 the	 interplay	between	macrophages	 and	 epithelial	 cells	 being	 key	 for	 the	 two	 step	 process	 required	 for	IL1β	secretion.			
Interestingly	in	lung	homogenate	the	differences	in	cytokine	responses	between	the	Δply	and	wild-type	strains	were	not	so	clear.		The	process	of	obtaining	lung	homogenates	means	that	the	 tissues	 involved	 include	 alveolar	 and	 parenchymal	 cells,	 but	 also	 includes	 cells	 in	 the	vasculature	including	circulating	immune	cells.		Compared	to	BALF,	TNF	levels	were	lower	in	lung	 homogenate,	 whereas	 IL1β	 responses	 were	 much	 greater,	 and	 IL6	 of	 a	 similar	magnitude.	 	 IL1β	 levels	were	 raised	 after	 infection	with	 Δply	 infection	 suggesting	 that	 the	pro-inflammatory	 effects	 in	 the	 alveolus	 may	 cause	 enough	 of	 a	 stimulus	 to	 induce	 IL1β	without	requiring	the	pore-forming	functions	of	Ply.	 	 IL6	 levels	were	greater	after	 infection	with	wild-type,	which	is	at	odds	with	the	other	cytokine	data.	
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Overall,	 the	data	show	that	Ply	 inhibits	 inflammation	when	live	bacteria	are	incubated	with	MDM,	and	has	 similar	effects	 in	a	mouse	pneumonia	model	particularly	 in	 respect	 to	BALF	TNF	levels.				
8.2.2	 Exploration	 of	 mechanisms	 underpinning	 the	 anti-inflammatory	
effects	of	pneumolysin	To	investigate	the	possible	mechanisms	by	which	Ply	may	exert	its	anti-inflammatory	effects,	I	 investigated	 bacterial	 and	 cellular	mechanisms	using	 the	 in	 vitro	model,	 and	 investigated	the	downstream	sequelae	in	the	mouse	pneumonia	model.			
The	 expression	 of	 non-haemolytic	 Ply	 by	 S.	 pneumoniae	 induced	 more	 TNF	 and	 IL6	 from	MDM	than	wild-type	bacteria	but	less	than	Ply	deficient	strains,	suggesting	that	Ply	inhibition	of	macrophage	 inflammation	 is	 partially	mediated	 by	 pore	 formation.	 	 This	would	 suggest	that	 insertion	 into	 the	 cell	 membrane	 is	 key	 to	 triggering	 the	 inhibitory	 effects	 on	inflammation,	with	a	more	obvious	effect	once	pores	are	formed.	
Opsonisation	 of	 bacteria,	 which	 facilitates	 more	 rapid	 phagocytosis,	 largely	 reduced	inflammatory	cytokine	release,	 indicating	 that	external	PRR	are	probably	more	responsible	for	 induction	 of	 pro-inflammatory	 cytokines	 than	 phagolysosomal	 and	 cytosolic	 PRR.		However,	 inhibition	 of	 phagocytosis	 with	 cytochalasin	 D	 had	 divergent	 effects	 on	 the	inflammatory	 response	 to	 the	 two	 strains;	 it	 increased	 the	 response	 to	 wild-type	 and	decreased	the	response	to	Δply,	with	the	differences	between	the	strains	largely	abolished	in	the	presence	of	cytochalasin	D.	 	Genome	wide	transcriptional	responses	confirmed	that	 the	difference	 in	 gene	 expression	 was	 reduced	 between	 the	 two	 strains	 in	 the	 presence	 of	cytochalasin	 D,	 and	 in	 particular	 that	 differences	 between	 inflammatory	 cytokines	 were	abrogated.		This	suggests	that	the	anti-inflammatory	effects	of	Ply	are	dependent	on	bacterial	phagocytosis.			
Although	 the	 wild-type	 bacteria,	 but	 not	 the	 Δply	 strain,	 induced	 nuclear	 condensation	reflecting	Ply’s	 ability	 to	 cause	 apoptosis	 (Marriott,	 Ali	 et	 al.	 2004),	 these	differences	were	
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not	 evident	 at	 6	 hours.	 	Hence	 the	 inflammation	dampening	 effects	 of	 Ply	were	not	 due	 to	downstream	effects	of	 apoptosis.	 	This	was	 confirmed	when	 inhibition	of	 all	 caspases	with	ZVAD	FMK	made	little	difference	to	inflammatory	cytokine	release,	in	contrast	to	Littman	et	
al	 (Littman,	 Albiger	 et	 al.	 2009).	 	 Inhibition	 of	 caspase-1,	 which	 functions	 downstream	 of	inflammasome	activation,	also	made	little	difference	to	cytokine	release.		This	is	surprising	as	Ply	is	known	to	activate	the	inflammasome	after	pore-formation;	however	these	experiments	involved	relatively	early	timepoints	and	this	may	be	before	the	IL1β	response	is	evident.		
As	TLR4	 is	 thought	 to	be	activated	by	Ply	 (Malley,	Henneke	et	al.	2003),	and	TLR4	acts	via	different	 adaptors	 proteins	 and	 signalling	 pathways	 when	 situated	 on	 the	 phagolysosome	compared	 to	 cell	 surface,	 I	 investigated	 IRF3	 translocation	 which	 occurs	 downstream	 of	endosomal	TLR4	activation,	and	subsequent	engagement	with	TRIF	and	TRAM	(Newton	and	Dixit	2012).	 	At	1	hour	 there	was	more	 IRF3	activation	by	wild-type	 than	Δply,	 though	 this	was	 similar	 by	 2	 hours.	 	 This	 suggested	 that	 Ply	 might	 indeed	 activate	 TLR4	 (or	 TLR3)	directly,	 and	 that	 this	 might	 cause	 inhibition	 of	 pro-inflammatory	 pathways.	 	 	 However	inhibition	 of	 TBK1,	 an	 adaptor	 protein	 that	 is	 activated	 by	 lysosomal	 TLR4,	 reduced	 IFN-dependent	 responses	 but	 did	 not	 affect	 inflammatory	 cytokine	 release.	 	 Similarly	 co-stimulation	of	TLR3	did	not	 reduce	 the	 inflammatory	 cytokine	 responses	 to	bacteria.	 	 This	suggests	that	while	IRF3	activation	may	be	induced	by	Ply,	this	does	not	have	a	downstream	inhibitory	 effect	 on	 pro-inflammatory	 cytokine	 release.	 	 This	 may	 be	 due	 to	 alternative	mechanisms	by	which	IRF3	is	stimulated,	e.g.	cytosolic	DNA	sensors,	being	affected	by	TBK1	inhibition,	rather	than	TLR4.	
As	 the	pore-forming	effects	partially	 affected	 inflammatory	 cytokine	 release,	 I	 assessed	 the	effects	of	insertion	of	Ply	into	the	cell	membrane.		As	both	haemolytic	and	non-haemolytic	Ply	inserts	 into	 cholesterol-containing	 membranes	 to	 cause	 membrane	 depolarisation	 very	quickly,	 this	 may	 be	 the	 mechanism	 mediating	 the	 inhibitory	 effects	 of	 Ply	 on	 pro-inflammatory	responses.		Voltage-gated	calcium	channels	are	activated	within	minutes	of	Ply	inserting	into	a	cell	membrane	(Iliev,	Djannatien	et	al.	2006),	and	their	blockade	attenuates	
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calcium	influx	and	consequent	actin	polymerisation	responses	to	Ply.		However,	inhibition	of	voltage	 gated	 calcium	 channels	 did	 not	 increase	 inflammatory	 cytokine	 responses	 to	wild-type	 strains.	 	 Rather,	 it	 decreased	 IL1β	 responses	 to	wild-type,	 suggesting	 that	membrane	destabilisation	 and	 calcium	 flux	 is	 important	 in	 driving	 Ply-mediated	 inflammasome	activation.	 	 Better	 understanding	 of	 whether	 calcium	 channels	 were	 inhibited	 would	strengthen	these	negative	data.	
As	 TNF	 responses	 in	 bronchoalveolar	 lavage	 fluid	 of	mice	were	 diminished	 after	 infection	with	 wild-type	 bacteria	 compared	 to	 Δply,	 I	 assessed	 the	 functional	 effects	 of	 TNF	 during	early	 infection.	 	 Blockade	 of	 TNF	 in	 the	 bronchoalveolar	 space	 abrogated	 the	 difference	 in	bacterial	 counts	 recovered	 in	 lavage	 fluid	 between	wild-type	 and	Δply,	 indicating	 that	TNF	plays	 an	 important	 role	 in	 protection	 in	 early	 infection.	 	 Unexpectedly	 the	 effect	 of	 TNF	blockade	was	to	decrease	the	virulence	of	wild-type,	rather	than	as	expected	increasing	the	virulence	of	Δply.	 	The	explanation	 for	 this	 is	not	clear.	 	 In	addition,	TNF	blockade	reduced	levels	of	TNF	and	IL6	in	lavage	fluid,	and	TNF,	IL1β,	and	IL6	in	lung	homogenate,	indicating	that	 TNF	 has	 important	 secondary	 inflammatory	 effects	 that	 promote	 inflammation.	 	 This	was	confirmed	by	the	direct	administration	of	intranasal	TNF	to	mice,	which	also	induced	a	neutrophil	 influx	as	well	as	pro-inflammatory	cytokine	secretion.	 	Clearly	the	effects	of	TNF	do	 not	 directly	 reflect	 the	 complex	 effects	 of	 inflammatory	 bacterial	 infection,	 but	 the	downstream	effects	of	TNF	may	be	to	stimulate	inflammatory	effects	from	macrophages	and	epithelial	cells	that	then	somewhat	replicate	the	early	stages	of	infection.	
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Figure	8.2	Mechanisms	of	anti-inflammatory	effects	of	Ply	A)	 The	 insertion	 of	 Ply	 in	 the	 phagolysosomal	membrane	 inhibits	 inflammatory	 signalling,	possibly	downstream	of	surface	TLR	activation.		This	inhibits	NFκB	mediated	transcription	of	pro-inflammatory	 cytokines.	 	 Ply	 also	 induces	 inflammasome	 activation	 and	 IRF3,	 though	these	do	not	directly	impact	on	early	inflammation.			B)	 Ply	 inhibits	 AM	 release	 of	 TNF	 in	 early	 infection	 in	 response	 to	 S.	 pneumoniae.	 	 TNF	induces	epithelial	derived	release	of	soluble	antibacterial	compounds,	which	 in	 turn	 inhibit	early	bacterial	replication.	
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As	TNF	was	a	driver	of	neutrophil	influx,	and	neutrophil	numbers	in	lavage	fluid	were	similar	between	 strains	at	4	hours	despite	 there	being	 log10	more	wild-type	bacteria	 than	Δply,	 an	earlier	 timepoint	was	 examined.	 	 This	was	 to	 ascertain	whether	 the	 greater	TNF	 secretion	Δply	 induced	 caused	 a	 brisker	 neutrophil	 influx	 that	 allowed	 more	 rapid	 clearance	 of	bacteria.	 	Indeed,	at	2	hours	there	was	already	more	rapid	bacterial	clearance	of	Δply,	along	with	a	significant	neutrophil	infiltrate,	suggesting	that	the	elevated	TNF	levels	did	contribute	to	 quicker	 leucocyte	 recruitment.	 	 	 To	 confirm	 the	 role	 of	 neutrophils	 in	 early	 bacterial	clearance,	4	hour	experiments	were	repeated	in	neutrophil	depleted	mice.	 	After	neutrophil	depletion	the	difference	in	virulence	between	the	2	strains	was	preserved,	indicating	that	at	this	 early	 timepoint	 the	differences	 in	neutrophil	 numbers	do	not	 explain	 the	difference	 in	bacterial	 clearance.	 	 Interestingly	 there	was	 greater	TNF	 and	 IL6	 release	 in	 the	 absence	 of	neutrophils,	 indicating	 that	 without	 increased	 phagocytic	 capacity,	 pro-inflammatory	signalling	was	increased.		This	may	mean	simply	that	macrophages	were	being	overwhelmed,	causing	 them	 to	 send	 more	 ‘help’	 signals,	 and	 could	 also	 mean	 that	 non-cellular	 defence	mechanisms	were	more	upregulated	in	response	to	the	increased	cytokine	secretion.	
Other	 potential	 downstream	 effects	 of	 TNF	 that	 could	 promote	 host	 defence	 include	activating	 macrophages	 to	 increase	 phagocytic	 and/or	 killing	 capacity.	 	 However	 TNF	administration	did	not	improve	MDM	mediated	S.	pneumoniae	killing	in	vitro.		Whilst	in	vitro,	mouse	lavage	fluid	recovered	from	mice	after	administration	of	TNF	was	less	able	to	support	TIGR4	 growth	 in	 comparison	 to	 PBS	 treated	 mice.	 	 This	 suggests	 that	 non-cellular	mechanisms	are	upregulated	by	TNF	that	may	account	for	host	defence	improvements	early	infection.	 	 This	 may	 include	 soluble	 antimicrobial	 compounds,	 such	 as	 defensins	 or	lactoferrin.	
Overall,	my	data	show	that	Ply	inhibits	early	macrophage-dependent	inflammatory	responses	to	 S.	 pneumoniae	 by	 phagocytosis	 dependent	mechanism(s),	 and	 partially	 due	 to	 its	 pore-forming	 abilities.	 	 This	 inhibition	 of	 TNF	 secretion	 in	 the	 bronchoalveolar	 compartment	seems	 to	 reduce	 the	 efficacy	 of	 secreted	 antibacterial	 factors	 that	would	otherwise	usually	
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inhibit	 bacterial	 growth	 during	 early	 lung	 infection.	 Hence	 Ply	 contributes	 to	 virulence	 by	inhibiting	inflammation-dependent	mucosal	soluble	immune	mechanisms	(figure	8.2).	
8.2.3	Summary	Understanding	 how	 Ply	 inhibits	 inflammatory	 responses,	 and	 dissection	 of	 the	 cellular	mechanisms	 could	 have	 implications	 beyond	 that	 of	 understanding	 the	 pathogenesis	 of	 S.	
pneumoniae.	 	 Anti-inflammatory	 treatments	 with	 fewer	 side	 effects	 are	 needed	 for	 a	multitude	of	chronic	diseases,	and	the	ability	to	selectively	inhibit	inflammatory	pathways	in	phagocytes	could	be	an	attractive	therapeutic	strategy.	
Pore	forming	toxins	are	relatively	common	among	bacteria,	and	are	known	to	cause	a	variety	of	different	functions.		Several	aid	immune	evasion	by	causing	death	of	immune	cells.		Group	A	Streptococci	(i.e.	Streptococcus	pyogenes),	group	B	Streptococci	(Streptococcus	agalectiae),	
Staphylococcus	 aureus,	 and	 Mycobacterium	 tuberculosis	 possess	 toxins	 (streptolysin	 O,	 β-haemolysin,	 α-toxin,	 and	 ESAT-6	 respectively)	 that	 induce	 programmed	 cell	 death	 (Los,	Randis	 et	 al.	 2013),	 whereas	 streptolysin	 S	 from	 group	 B	 Streptococci	 causes	 direct	neutrophil	 toxicity.	 	 Many	 of	 the	 toxins	 are	 also	 described	 to	 induce	 barrier	 dysfunction,	which	 allows	 bacterial	 invasion	 and	 dissemination	 into	 deeper	 tissues.	 	 While	 this	 causes	host	damage,	and	in	some	bacteria	allows	them	to	access	their	preferred	ecological	niche,	S.	
pneumoniae‘s	preferred	home	is	the	nasopharynx.	 	This	 is	easily	accessed	without	 invasion,	and	 inducing	host	cell	damage	may	be	counter-productive	as	this	 initiates	and/or	amplifies	host	 innate	 immune	 responses.	 	 Innate	 immune	 signalling	 is	 important	 in	 protection	 from	invasive	pneumococcal	disease.	 	The	data	presented	in	this	thesis	shows	that	S.	pneumoniae	possesses	 anti-inflammatory	 properties	 that	 allow	 bacterial	 replication,	 and	 so	 allows	bacterial	 dissemination.	 	 In	 evolutionary	 terms,	 this	 would	 allow	 horizontal	 transmission	from	 the	 nasopharynx,	 but	 has	 the	 unintended	 effect	 of	 increasing	 bacterial	 replication	 at	other	body	sites	and	so	increasing	pathogenicity.			
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Previous	 studies	 have	 indicated	 that	 Ply	 is	 important	 in	 virulence	 and	 ascribed	pleiotropic	functions	 that	 promote	 disease.	 	Many	 of	 these	 functions	 are	 pro-inflammatory,	 and	while	they	explain	how	Ply	contributes	to	the	negative	consequences	of	infection,	they	don’t	explain	why	 Ply	 is	 a	 ubiquitous	 S.	 pneumoniae	 virulence	 factor.	 	 The	 data	 presented	 in	 this	 thesis	suggests	 that	Ply	has	anti-inflammatory	properties	during	early	 infection	with	downstream	consequences	 for	 epithelial	 innate	 immunity,	 and	 this	 may	 explain	 its	 persistence	 in	 the	majority	of	S.	pneumoniae	genomes.	 	
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8.3	Limitations	The	main	limitations	of	the	data	presented	in	this	thesis	are	the	inherent	weaknesses	of	the	models	used.	 	 In	vitro	 cell	 culture	work	 is	useful	 for	 teasing	out	cell-specific	 responses	and	cellular	mechanisms	but	 can	miss	 the	 complexities	 of	 cell-cell	 interactions	 and	may	not	 be	physiologically	relevant	as	 it	cannot	replicate	how	organs	function;	 for	example	cell	culture	models	of	interactions	between	macrophages	and	respiratory	epithelial	immune	mechanisms	such	 as	 cilia	 and	 antimicrobial	 peptides	 have	 not	 yet	 been	 properly	 developed.	 	 Largely,	primary	cells	from	healthy	volunteers	were	used,	which	helps	account	for	the	heterogeneity	in	 human	 responses	 and	 that	 primary	 cells	 are	 less	 likely	 to	 have	 changed	 the	 way	 they	interact	with	pathogens.		However,	the	inherent	variety	of	responses	for	primary	cells	meant	that	finding	significant	consistent	differences	between	conditions	was	sometimes	difficult.			
Murine	models	 are	 useful	when	 trying	 to	model	 disease	 states,	 but	 S.	 pneumoniae	 is	 not	 a	natural	coloniser	or	pathogen	of	mice	or	rats,	suggesting	that	there	are	important	differences	in	the	ecological	niches	explored	such	as	the	nasopharynx	and	lungs.	 	In	addition	it	 is	 likely	that	 there	 are	 significant	differences	 in	how	both	 the	 innate	 and	 adaptive	 immune	of	mice	respond	 to	 S.	 pneumoniae	 compared	 to	 humans.	 	 Despite	 this,	 the	 introduction	 of	 bacteria	into	 the	 respiratory	 tract	 of	mice	 does	 induce	 a	 neutrophil	 infiltrate	 and	 consolidation,	 as	well	as	causing	bacteraemia	and	eventually	death,	which	is	a	similar	pattern	to	severe	human	pneumonia.	 	 Obtaining	 data	 from	 the	 rat	 sepsis	 model	 was	 made	 difficult	 by	 the	 rapid	clearance	 of	 S.	 pneumoniae	 after	 intravenous	 inoculation,	 especially	 when	 non-replicating	bacteria	were	used	to	overcome	differences	in	bacterial	uptake	due	to	the	capsule.	As	a	result	very	high	inocula	were	necessary	to	generate	an	inflammatory	response,	and	even	then	there	was	only	a	relatively	narrow	window	of	effect.		
The	 use	 of	 isogenic	 deficient	 mutants	 is	 an	 advantage	 in	 that	 it	 ensures	 that	 the	 role	 of	specific	bacterial	components	can	be	studied	in	the	context	of	a	whole	bacterium	rather	than	purified	 components,	which	are	often	 contaminated.	 	However,	unexpected	effects	of	 these	
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mutations	may	affect	the	interactions	studied.		The	antibiotic	resistance	cassette	may	exert	a	burden	 that	 affects	 bacterial	 growth,	 and	 the	 lack	 of	 capsule	 or	 Ply	 could	 result	 in	compensatory	gene	expression	that	may	affect	the	interaction	between	host	and	bacteria	and	confound	the	data	obtained.	 	
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8.4	Future	Work	The	 data	 in	 this	 thesis	 points	 towards	 several	 conclusions,	 but	more	work	 is	 necessary	 to	support	these	conclusions.		In	addition,	some	intriguing	points	came	up	that	warrant	further	investigation.	
To	improve	the	link	between	the	in	vitro	and	in	vivo	data,	I	carried	out	preliminary	work	on	a	neutrophil	 migration	 model,	 where	 I	 was	 investigating	 whether	 the	 pro-inflammatory	cytokine	release	of	MDM	had	functional	correlates	in	increasing	human	neutrophil	migration	across	an	epithelial	 layer	seeded	onto	 transwells.	 	This	work	needed	more	 time	 to	develop	fully,	and	ideally	would	 incorporate	a	dual	 layer	of	endothelial	and	epithelial	cells	 to	mimic	the	alveolar	interface	with	blood	vessels.	 	Similarly	I	had	carried	out	preliminary	studies	on	mouse	 lung	 slices	where	whole	mouse	 lungs	were	 sliced	and	placed	 in	 tissue	 culture	wells	but	maintaining	 a	 complex	mix	 of	 cell	 types	 and	 some	 tissue	 structure.	 	 Ideally	 this	 work	would	be	extended	to	human	lung	biopsy	cores	to	mimic	complex	human	tissue	responses	to	
S.	pneumoniae.		Potentially	ex	vivo	human	lungs	that	were	not	usable	for	transplant	could	be	a	more	advanced	model	for	lung	infection.	
The	mechanism	by	which	capsule	exerts	its	pro-inflammatory	effects	still	need	defining.		The	effect	of	capsule	in	its	structured	form	needs	exploring,	perhaps	by	layering	capsular	material	on	inert	beads,	as	3	dimensional	recognition	of	capsule	may	trigger	PRR	when	a	suspension	does	not.	 	 If	 contamination	was	possible	 to	 eradicate,	 the	 serial	 addition	of	 other	 bacterial	components	could	identify	how	capsule	modifies	interaction	with	other	virulence	factors.		It	is	 also	 possible	 that	 some	 of	 the	 methods	 I	 used	 did	 not	 completely	 eliminate	 possible	mechanisms,	i.e.	there	are	many	PRR	belonging	to	the	lectin	and	scavenger	groups	that	have	not	been	fully	explored,	which	may	not	signal	via	Syk	or	be	inhibited	by	dextran	respectively.		There	are	also	other	classes	of	PRR	that	could	conceivably	recognise	capsular	polysaccharide.	Immunopreciptation	 experiments	 with	 macrophages	 and	 labelled	 capsular	 polysaccharide	(in	 the	 context	 of	 live	 bacteria)	 may	 allow	 greater	 exploration	 of	 other	 receptors	 that	
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recognise	 capsule,	 and	 then	 phosphoproteomic	 approaches	 could	 be	 used	 to	 understand	which	signalling	molecules	are	activated	to	further	explore	the	mechanisms	underpinning	the	pro-inflammatory	effects	of	capsule.			
The	differences	between	strains	within	the	same	serotype	also	merit	exploration.		Significant	differences	would	 lend	 support	 to	 non-capsular	 factors	 being	 the	 dominant	 explanation	 of	variation	 in	 inflammation.	 	 These	 data	 could	 also	 be	 correlated	with	 in	 vivo	 differences	 in	inflammation	between	serotypes	and	capsule	switch	strains.	
The	murine	Ply	data	indicated	that	TNF	release	increase	non-cellular	mechanisms	that	limit	bacterial	replication.		Protein	expression	in	lavage	fluid	and/or	mRNA	of	lung	tissue	would	be	useful	 in	 identifying	the	specific	components	that	are	upregulated	 in	response	to	TNF.	 	The	identified	 elements	 could	 then	 be	 tested	 to	 establish	 if	 they	 effectively	 inhibit	 bacterial	growth,	so	confirming	one	mechanism	by	which	Ply	contributes	to	virulence.	
The	Ply	data	 from	 the	microarray	pointed	 to	 important	differences	between	wild-type	 and	Δply	that	I	did	not	get	the	chance	to	follow	up.		Some	of	the	differences	involved	IL12,	which	is	 important	 in	 the	 generation	 of	 Th1	 responses,	 suggesting	 that	 Ply	 may	 play	 a	 role	 in	inhibiting	 the	 adaptive	 immune	 response	 as	well	 as	 the	 innate.	 	 In	 addition	 IFN	 responses	were	much	increased	in	response	to	Δply,	and	exploring	the	mechanisms	by	which	this	occur	would	also	be	interesting.			
Further	 work	 is	 also	 required	 to	 establish	 the	 molecular	 mechanism	 by	 which	 Ply	 exerts	these	 effects.	 	 This	 could	 be	 carried	 out	 by	 creating	 mutants	 where	 Ply	 is	 expressed	 and	produced	 but	 does	 not	 insert	 into	 cell	 membranes.	 	 The	 effect	 of	 Ply	 within	 the	phagolysosome	 on	 S.	 pneumoniae	 needs	 exploring,	 as	 one	 hypothesis	 that	may	 explain	 the	findings	 in	 the	 thesis	 could	 be	 that	 Ply	 modifies	 bacterial	 components	 so	 that	 they	 have	reduced	 affinity	 for	 phagolysosomal	 or	 cytosolic	 PRR.	 	 From	 the	 host	 perspective,	 a	phosphoproteomic	approach	may	establish	key	cell	signalling	differences	between	wild-type	and	Δply,	to	further	examine	which	host	cell	pathways	are	differentially	activated.		If	the	host	
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pathways	 involved	 were	 identified,	 this	 may	 allow	 therapeutic	 anti-inflammatory	manipulation,	which	could	be	useful	over	a	spectrum	of	inflammatory	disorders.	
In	terms	of	larger	scale	investigations	of	S.	pneumoniae,	and	the	importance	of	inflammation	in	disease,	I	think	multiple	important	gaps	bear	more	detailed	investigation:	
A	fuller	understanding	of	the	place	of	inflammation	in	disease	pathogenesis	is	required.		This	should	 include	 both	 bacterial	 components,	 but	 also	 host	 elements	 that	were	 not	 examined	during	 the	 course	 of	 this	 thesis.	 	 This	 includes	 the	 interplay	 between	 innate	 and	 adaptive	responses,	 for	 example	 how	 inflammation	 affects	 the	 development	 of	 mature	 T	 cells	 and	antibodies,	 the	 role	 of	 innate-like	 immune	 cells,	 as	 well	 as	 in	 vivo	 examination	 of	 soluble	components	of	the	host	immune	response.		In	terms	of	more	clinically	applicable	elements,	I	think	more	 time	 and	money	 could	 be	 spent	 investigating	 how	 inflammation	 is	 affected	 in	chronic	 disease	 states	 such	 as	 COPD	 and	 bronchiectasis,	 and	 potentially	 expanded	 to	 the	effect	 of	 age	 in	 general,	 and	 how	 this	 impacts	 on	morbidity	 and	mortality.	 	 This	 could	 be	extended	 to	 further	 disease	 categories	 such	 as	meningitis	 and	 septic	 shock,	 and	 also	 how	inflammation	impacts	on	nasopharyngeal	colonisation.			 	
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8.5	Summary	
Streptococcus	pneumoniae	 is	an	important	pathogen,	and	the	host	 inflammatory	response	is	important	in	both	preventing	disease	and	causing	collateral	host	tissue	damage.		This	thesis	presents	 data	 that	 allow	 further	 understanding	 of	 how	 specific	 virulence	 factors	 affect	 the	inflammatory	response.	
The	extracellular	capsule	 increases	the	 inflammatory	response	of	human	monocyte	derived	macrophages,	 as	well	 as	 in	 a	mouse	pneumonia	model.	 	While	 the	 capsular	polysaccharide	itself	does	not	induce	inflammation,	it	appears	to	modify	interactions	between	host	cells	and	other	bacterial	components.		These	effects	are	not	dependent	on	phagocytosis,	TLR2,	MAPK,	NFκB,	 or	 recognition	 by	 Fc	 receptors,	 lectins,	 and	 scavenger	 receptors.	 	 More	 signalling	pathways	 appear	 to	 be	 stimulated	 by	 unencapsulated	 bacteria,	 possibly	 including	 some	inhibitory	signals.			
Cytosolic	 pneumolysin	 inhibits	 inflammatory	 responses	 in	 human	 monocyte	 derived	macrophages	 and	 in	 the	 bronchoalveolar	 compartment	 of	 mice.	 	 This	 is	 dependent	 on	bacterial	 uptake	 and	 partially	 on	 pore-forming	 function.	 	 While	 pneumolysin	 induces	apoptosis,	caspase	 inhibition	does	not	affect	 the	 inflammatory	response.	 In	mice,	early	TNF	release	 in	 particular	 is	 inhibited	 by	 pneumolysin.	 	 Inhibition	 of	 TNF	 release	 reduces	 non-cellular	host	defence	factors,	allowing	more	bacterial	replication,	and	so	increased	virulence.		 	
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The	pro-inflammatory	effects	of	Streptococcus	pneumoniae’s	capsule.	J	 Periselneris,	 G	 Tomlinson,	 T	 Pollard,	 S	 Chimalapati,	 R	 José,	 A	 Dyson,	 M	 Singer,	 M	Noursadeghi,	J	Brown.	
Streptococcus	 pneumoniae	 is	 the	 second	 commonest	 cause	 of	 bacterial	 death	 world-wide,	causing	 a	 variety	 of	 infections	 such	 as	 community	 acquired	 pneumonia,	 meningitis,	 and	septicaemia.	 	 Many	 of	 the	 most	 serious	 consequences	 of	 infection	 are	 due	 to	 an	 over-exuberant	inflammatory	response.		The	bacterium	is	surrounded	by	a	polysaccharide	capsule	that	 plays	 a	 role	 in	 inhibiting	 opsonophagocytosis.	 	 While	 this	 is	 recognised	 as	 its	 most	important	 virulence	 factor	 it	 has	 not	 previously	 been	 thought	 to	 play	 a	 role	 in	 inducing	inflammation.	We	have	data	 that	 shows	 that	 the	encapsulated	wildtype	 strain,	TIGR4,	provokes	a	 greater	inflammatory	 response	 than	 an	 unencapsulated	mutant	 of	 S.	 pneumoniae,	P1672.	 	 In	 vitro	infection	of	human	monocyte	derived	macrophages	showed	increased	TNF,	IL1β,	IL6,	and	IL8	in	response	to	TIGR4	versus	P1672	(see	figure).	 	This	is	despite	the	unencapsulated	mutant	activating	more	NFKB	translocation.	 	Microarray	analysis	of	macrophage	responses	suggest	that	a	wider	range	of	intracellular	signalling	pathways	are	stimulated	by	the	unencapsulated	mutant.	 	 Inhibition	 of	 phagocytosis	 with	 cytochalasin	 D	 did	 not	 reduce	 this	 difference,	suggesting	that	the	inflammatory	effects	of	capsule	are	not	due	to	reduced	phagocytosis.	 	In	vivo	 modelling	 of	 mouse	 pneumonia	 by	 intranasal	 inoculation	 reproduces	 the	 difference	between	TIGR4	and	P1672,	in	terms	of	neutrophil	infiltrate	into	the	lungs,	albumin	leak	and	cytokine	 levels	 in	 bronchoalveolar	 fluid	 and	 lung	 homogenate.	 	 Depleting	 alveolar	macrophages	with	 clodronate	 diminished	 some	 but	 not	 all	 of	 the	 differences.	 	 Using	 a	 rat	sepsis	 model	 of	 infection	 with	 non-replicating	 bacteria	 we	 have	 again	 shown	 that	 TIGR4	elicits	more	pro-inflammatory	cytokine	release	in	serum	than	P1672.			Further	 work	 is	 required	 to	 characterise	 how	 the	 unencapsulated	 mutant	 causes	 a	 more	varied	 transcriptional	 response.	 	 By	 identifying	 the	 mechanisms	 by	 which	 the	 capsule	induces	 inflammation	 we	 may	 be	 able	 to	 find	 ways	 of	 inhibiting	 it	 and	 thus	 ameliorating	disease.		 	
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The	inflammatory	response	to	Streptococcus	pneumoniae	is	exaggerated	by	the	polysaccharide	capsule		J	N	Periselneris,	S	Chimalapati,	G	Tomlinson,	A	Dyson,	C	Hyams,	H	Rukke,	F	Peterson,	M	Singer,	M	Noursadeghi,	J	S	Brown	
Streptococcus	 pneumoniae	infections	 characteristically	 cause	 a	 high	 degree	 of	inflammation.		The	S.	pneumoniae	polysaccharide	capsule	prevents	opsonophagocytosis	and	is	 essential	 for	 virulence.	 	 The	 capsule	 might	 also	 be	 expected	 to	 reduce	 the	 host’s	inflammatory	response	by	inhibiting	bacterial	interactions	with	pro-inflammatory	signalling	proteins	 eg	 toll-like	 receptors	 (TLR),	 but	 this	 has	 not	 previously	 been	 investigated.	 Using	isogenic	 unencapsulated	 strains	 and	 in	 vitro	 and	 in	 vivo	 models	 of	 infection	 we	 have	characterised	capsule	effects	on	the	inflammatory	response	to	S.	pneumoniae.	Surprisingly,	 although	 the	 unencapsulated	 (Δcps)	 S.	 pneumoniae	 strain	 was	 much	 more	sensitive	to	phagocytosis	by	macrophages	and	induced	a	stronger	NFκB	response	by	human	monocyte	 derived	 macrophages	 (MDMs)	 it	 caused	 similar	 levels	 of	 stimulation	 of	 a	 TLR2	reporter	 cell	 line	 as	 the	 encapsulated	 strain	TIGR4.	 In	 addition,	microarrays	 demonstrated	increased	 transcription	 of	 pro-inflammatory	 cytokines	 by	 MDMs	 in	 response	 to	 TIGR4	compared	to	the	Δcps	strain,	and	quantitative	PCR	and	ELISAs	confirmed	stronger	TNF,	IL1β,	and	IL6	responses	by	MDMs	to	TIGR4.		Furthermore,	compared	to	the	Δcps	strain	the	TIGR4	strain	 caused	 greater	 neutrophil	 recruitment	 and	 higher	 cytokine	 levels	 in	 the	 lungs	 in	 a	mouse	model	of	pneumonia,	as	well	as	higher	serum	cytokine	levels	with	worse	hypotension	in	 a	 rat	 model	 of	 sepsis.	Additional	 in	 vitro	 experiments	 excluded	 antibody,	 complement,	pneumolysin,	 the	 inflammasome,	 and	 lectin-mediated	 signalling	 as	 mechanisms	 driving	differences	 in	 inflammatory	 responses	 between	 TIGR4	 and	 Δcps.	 Expression	 of	 the	 TIGR4	capsule	 in	 Streptococcus	 mitis	 did	 not	 increase	 MDM	 or	 murine	 inflammatory	 responses.	Notably,	 preventing	 phagocytosis	 with	 cytochalasin	 D	 did	 not	 alter	 differences	 in	 the	inflammatory	response	between	TIGR4	and	the	Δcps	strains,	and	in	silico	analysis	suggested	the	Δcps	strain	activated	a	wider	range	of	transcription	factors.	Overall,	the	data	indicate	that	unencapsulated	S.	pneumoniae	stimulate	a	wider	range	of	host	cell	 signalling	 pathways	 than	 encapsulated	 bacteria,	 some	 of	 which	 are	 likely	 to	 be	 anti-inflammatory.	Hence	the	capsule,	rather	 than	reducing	 inflammation,	causes	 increased	pro-inflammatory	 responses	 and	 subsequent	 disturbances	 to	 host	 physiology	 during	 S.	
pneumoniae	 infection.	 Targeting	the	 mechanisms	 responsible	 for	 capsule-dependent	inflammation	could	offer	novel	 treatment	options	 for	 reducing	 the	morbidity	and	mortality	associated	with	S.	pneumoniae	infections.		 	
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The	inflammatory	response	to	Streptococcus	pneumoniae	is	exaggerated	by	the	polysaccharide	capsule		J	N	Periselneris,	S	Chimalapati,	G	Tomlinson,	C	Hyams,	A	Dyson,	M	Singer,	M	Noursadeghi,	J	S	Brown	The	 inflammatory	 response	 to	 bacteria	 requires	 the	 interaction	 of	 pattern	 recognition	receptors	with	bacterial	surface	constituents.	Streptococcus	pneumoniae	has	a	polysaccharide	capsule,	an	essential	virulence	factor	that	would	be	expected	to	inhibit	these	interactions,	so	reducing	inflammatory	responses.	We	tested	this	hypothesis	by	characterising	the	effect	of	S.	
pneumoniae	 capsule	 on	 the	 inflammatory	 response	 using	 the	 TIGR4	 strain	 and	 its	unencapsulated	 derivative	 TIGR4cps.	 	 Despite	 being	 more	 sensitive	 to	 phagocytosis	 by	human	macrophages	 than	TIGR4,	RNA	transcripts	and	supernatant	 levels	of	TNF,	 IL1β,	and	IL6	 were	 reduced	 in	 response	 to	 TIGR4cps.	 Furthermore,	 TIGR4	 generated	 greater	neutrophilic	 infiltrate	 in	 a	 mouse	 pneumonia	 model	 than	 TIGR4cps.	 Whole	 genome	transcriptome	analysis	demonstrated	a	generally	reduced	pro-inflammatory	response	to	the	TIGR4cps	 strain.	 Notably,	 preventing	 phagocytosis	 preserved	 these	 differences.	 In	 vitro	experiments	 excluded	 differences	 in	 TLR2	 signalling,	 antibody	 recognition,	 the	inflammasome,	 and	 lectin	 signalling	 as	 mechanisms	 driving	 differences	 in	 inflammatory	responses	 between	 TIGR4	 and	 Δcps.	 However,	 a	 transcription	 factor	 array	 suggested	 that	TIGR4cps	 activated	more	 transcription	 factors	 than	TIGR4.	 These	 data	 demonstrate	 that	S.	
pneumoniae	 capsule	 causes	 increased	pro-inflammatory	 responses	 that	 are	 relevant	during	infection,	 perhaps	 by	 restricting	 macrophage	 cell	 signalling	 responses.	 Identifying	mechanisms	 responsible	 for	 capsule-dependent	 inflammation	 may	 offer	 opportunities	 for	adjuvant	treatment	of	S.	pneumoniae	infections.		 	
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Inflammation	dampening	effects	of	pneumolysin	J	Periselneris,	T	Pollard,	T	James,	M	Noursadeghi,	J	Brown	
Streptococcus	 pneumoniae	 interactions	 with	 alveolar	 macrophages	 are	 important	 for	protective	 inflammatory	 responses	 during	 early	 lung	 infection.	 Pneumolysin	 is	 a	 well-recognised	 virulence	 factor	 for	 Streptococcus	 pneumoniae	 that	 has	multiple	 effects	 on	 the	host	 immune	 response	 that	 are	 primarily	 thought	 to	 be	 pro-inflammatory.	 We	 have	investigated	the	effects	of	pneumolysin	on	the	early	macrophage	response	to	S.	pneumoniae	using	 in	 vitro	 culture	 and	 an	 animal	 model	 of	 early	 pneumonia.	 	 Wildtype	 and	 non-haemolytic	 purified	 pneumolysin	 induced	 dose	 dependent	 inflammatory	 cytokine	 release	from	 human	monocyte	 derived	macrophages	 (MDMs),	 as	 expected.	 	 However,	 in	 contrast,	when	MDMs	were	incubated	with	TIGR4	S.	pneumoniae,	higher	levels	of	TNF	and	IL6	mRNA	and	 protein	 were	 induced	 in	 response	 to	 pneumolysin	 deficient	 bacteria	 than	 wildtype.	Transcriptome	 analysis	 of	 MDMs	 after	 S.	 pneumoniae	 infection	 confirmed	 increased	expression	 of	 a	 range	 of	 pro-inflammatory	 genes	 in	 response	 to	 the	 pneumolysin	mutant.		Despite	 differential	 cell	 death	 in	 response	 to	 wildtype	 and	 pneumolysin	 deficient	 TIGR4,	inhibition	of	 apoptosis	or	 the	 inflammasome	also	had	no	effect	on	 the	early	MDM	cytokine	response.	Instead,	the	increase	in	transcription	of	pro-inflammatory	genes	and	TNF	and	IL6	supernatant	 levels	 in	 response	 to	 the	 pneumolysin	 deficient	 strain	 were	 abrogated	 by	inhibition	 of	 S.	 pneumoniae	 phagocytosis	 with	 cytochalasin	 D.	 In	 a	murine	model	 of	 early	pneumonia	 despite	more	 rapid	 clearance	 of	 the	 pneumolysin	mutant	 from	 BALF	 and	 lung	compared	to	wildtype	TIGR4	at	4	and	24	hours,	BALF	leukocyte	recruitment	was	increased	at	4	hours.		These	data	indicate	an	unexpected	role	for	pneumolysin	as	an	initial	suppressor	of	macrophage	 inflammatory	 responses,	 which	 is	 dependent	 on	 phagocytosis.	 The	 early	inflammation	dampening	effects	of	pneumolysin	released	within	the	phagolysosome	may	be	an	 important	 contribution	 to	 S.	 pneumoniae	 virulence,	 allowing	 increased	 bacterial	replication	early	during	the	course	of	infection.				 	
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Inflammation	dampening	effects	of	pneumolysin	J	Periselneris,	T	James,	M	Noursadeghi,	J	Brown.	The	 inflammatory	 response	 to	 bacteria	 requires	 the	 interaction	 of	 pattern	 recognition	receptors	 with	 bacterial	 surface	 constituents,	 and	 humans	 deficient	 in	 components	 of	inflammatory	 signalling	 pathways	 such	 as	 IRAK4	 are	 prone	 to	 invasive	 pneumococcal	disease.	Pneumolysin	is	a	well-recognised	virulence	factor	for	Streptococcus	pneumoniae	that	has	 multiple	 effects	 on	 the	 host	 immune	 response	 that	 are	 primarily	 thought	 to	 be	 pro-inflammatory;	including	causing	IL1β	release	due	to	pore	formation,	and	epithelial	cell	layer	breakdown.	We	hypothesised	that	pneumolysin	deficient	TIGR4	(a	serotype	4	strain)	would	induce	 less	 inflammatory	 cytokines	 than	 wildtype	 from	 human	 monocyte	 derived	macrophages.	While	both	pore	forming	and	non-cytolytic	purified	pneumolysin	induced	dose	dependent	 inflammatory	 cytokine	 release,	 the	 pneumolysin	 deficient	 bacteria	 induced	greater	TNF	 and	 IL6	 than	wildtype,	 by	qPCR	and	ELISA	measurement	 of	 protein.	 This	was	reduced	by	inhibition	of	phagocytosis	with	cytochalasin	D.		Given	the	pore	forming	effects	of	pneumolysin	we	 assessed	whether	 differential	 cell	 death	 contributed	 to	 the	 differences	 in	inflammatory	 response.	 While	 wildtype	 bacteria	 caused	 more	 cell	 death	 at	 24	 hours,	inhibition	 of	 caspases	 had	 no	 effect	 on	 the	 cytokine	 response	 suggesting	 that	 apoptosis	pathways	don’t	directly	 influence	 the	early	 inflammatory	 response.	Transcriptome	analysis	confirmed	increased	pro-inflammatory	and	interferon	gene	signalling	with	the	mutant	strain,	with	reduction	of	the	inflammatory	and	interferon	signature	with	inhibition	of	phagocytosis.		Wildtype	bacteria	 induced	 less	NFκB	 translocation,	 but	more	 IRF3	 translocation	 than	Δply.	An	 in	 vivo	 intranasal	 mouse	 infection	 showed	 wildtype	 was	 more	 virulent,	 with	 more	bacteria	 recovered	 from	 bronchoalveolar	 lavage	 fluid	 at	 4	 hours.	 	 However,	 this	 was	associated	with	reduced	TNF	compared	to	Δply.	Neutralising	TNF	intranasally	abrogated	the	difference	 in	 bacteria	 recovered	between	wildtype	 and	Δply.	 	 Thus,	 the	 early	 inflammation	dampening	effects	of	pneumolysin	released	within	the	phagolysosome	may	be	an	important	contribution	to	its	virulence	by	allowing	bacterial	replication	at	mucosal	surfaces.		This	may	be	 due	 to	 IRF3	 mediated	 inhibition	 of	 inflammatory	 cytokine	 transcription.	 	 Better	understanding	 of	 the	 biology	 of	 pneumolysin	 may	 aid	 in	 adjuvant	 treatment	 of S.	
pneumoniae.		 	
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Anti-inflammatory	effects	of	Streptococcus	pneumoniae	toxin	pneumolysin	Jimstan	Periselneris,	Mahdad	Noursadeghi,	Jeremy	Brown			
Background	Streptococcus	pneumoniae	is	the	second	commonest	cause	of	bacterial	mortality	worldwide.	 Interactions	 of	S	 pneumoniae	with	 alveolar	macrophages	 are	 important	 for	 the	protective	 inflammatory	 responses	 during	 early	 lung	 infection.	 Pneumolysin	 is	 a	 well-recognised	 virulence	 factor	 for	 S	 pneumoniae;	 the	 toxin	 has	 multiple	 effects	 on	 the	 host	immune	 response	 that	 are	 primarily	 thought	 to	 be	 proinflammatory.	 Our	 aim	 was	 to	characterise	the	inflammatory	effects	of	pneumolysin	on	macrophages.	
Methods	We	used	in-vitro	culture	of	primary	human	monocyte-derived	macrophages	(MDM)	with	 S	 pneumoniae	 and	 an	 isogenic	 mutant	 lacking	 pneumolysin.	 We	 measured	 cytokine	production	(including	tumour	necrosis	factor	[TNF]	and	interleukin	6)	at	transcriptional	and	protein	 level,	 as	well	 as	 transcription	 factor	 function,	 to	 look	 at	mechanisms	of	 interaction	between	 MDM	 and	 bacteria.	 We	 extended	 these	 data	 with	 epithelial	 cell	 line	 work	 and	neutrophil	 transmigration	 models.	 Then	 we	 used	 a	 murine	 intranasal	 infection	 model	 to	assess	functional	effects	in	vivo.	
Findings	Higher	mean	concentrations	of	TNF	and	interleukin	6	were	induced	from	MDM	in	response	 to	 pneumolysin-deficient	 bacteria	 than	 in	 response	 to	 wild-type	 bacteria	 (6014	pg/ml	[SD	970]	vs	2295	[SD	470]	and	821	[SD	374]	vs	89	[SD	28],	respectively).	This	finding	was	reflected	in	TNF	mRNA	(change	in	cycle	threshold	4·3	vs	2·4)	and	interleukin	6	mRNA	(3·5	
vs	 0·4).	 	Transcriptome	analysis	of	MDMs	after	S	pneumoniae	 infection	confirmed	 increased	expression	of	a	range	of	proinflammatory	genes,	including	IL12,	IL27,	CCR7,	IL5,	and	CCL5,	in	response	to	the	pneumolysin	mutant.	The	increase	in	transcription	of	proinflammatory	genes	and	concentrations	of	TNF	and	interleukin	6	in	supernatant	in	response	to	the	pneumolysin-deficient	strain	were	abrogated	by	inhibition	of	phagocytosis.	In	a	murine	pneumonia	model,	despite	more	rapid	clearance	of	 the	pneumolysin-deficient	mutant	 (1	×	104	 colony-forming	units	[CFU]/mL)	compared	with	the	wild	type	strain	(1×	105	CFU/ml)	from	bronchoalveolar	lavage	fluid	(BALF)	by	4	h,	mean	concentrations	of	TNF	were	elevated	in	BALF	fluid	with	the	mutant	(1336	pg/mL	[SD	130	]	vs	6164	[SD	632]).	This	 increase	was	associated	with	more	rapid	neutrophil	influx	with	the	pneumolysin-deficient	mutant	than	with	the	wild-type	strain	into	BALF	seen	at	2	h	(107	neutrophils	per	mL	[SD	39]	vs	3303	[SD	1624]).	Blockade	of	TNF	abrogated	 the	 differences	 in	 clearance	 between	 the	 pneumolysin	 mutant	 and	 wild-type	strain.			
Interpretation	 These	 data	 indicate	 an	 unexpected	 role	 for	 pneumolysin	 as	 an	 initial	suppressor	 of	 macrophage	 inflammatory	 responses,	 which	 is	 dependent	 on	 phagocytosis.	The	 early	 inflammation	 dampening	 effects	 of	 pneumolysin	 released	 within	 the	phagolysosome	might	 be	 an	 important	 contribution	 to	 the	 virulence	 of	 S	 pneumoniae.	 The	inhibition	 of	 TNF	 release	 allows	 increased	 bacterial	 replication	 early	 during	 the	 course	 of	infection,	and	presumably	is	an	evolutionary	advantage.		
